

SA BCS

SAN ANTONIO
BREAST
CANCER
SYMPOSIUM®

POCKET PROGRAM

December 6-10, 2022

SABCS.ORG



NOW APPROVED ACROSS MULTIPLE INDICATIONS

See how ENHERTU is transforming the treatment landscape

Explore the latest data at
booths 100 & 607 and [ENHERTUhcp.com](https://www.enherthu.com)



Please see Important Safety Information and full Prescribing Information, including Boxed WARNINGS for Interstitial Lung Disease/Pneumonitis and Embryo-Fetal Toxicity, and Medication Guide at booths 100 & 607, at [ENHERTUhcp.com](https://www.enherthu.com), or by scanning here.

 **ENHERTU**[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

 Daiichi-Sankyo

| AstraZeneca 

ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
© 2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-2049 10/22

WHAT'S INSIDE

SCHEDULES

Registration and Information	2
------------------------------------	---

SCHEDULE OVERVIEW



Tuesday, December 6	7
Wednesday, December 7	12
Thursday, December 8	18
Friday, December 9	22
Saturday, December 10	25

PROGRAM

Detailed Program	26–60
Product Theatre Schedule	62–63

SESSIONS

Spotlight Poster Discussion Sessions	64–93
Poster Sessions	95–252

AWARDS

2022 Award Recipients	253–258
-----------------------------	---------

EXHIBITS

Exhibit List	263
--------------------	-----

SABCS INFORMATION

We are looking forward to the 2022 San Antonio Breast Cancer Symposium.

SABCS continues to provide a forum for interaction, communication, and education. SABCS attracts thought-leaders, academic and private physicians and researchers, as well as other health care professionals focused on curing breast cancer. SABCS facilitates discussion and education about new and late-breaking research including experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and pre-malignant breast disease, as well as new findings from clinical trials. The Symposium also attracts young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.

As you review the program you will see that our Program Planning Committee has worked with the breast cancer research community to put together a particularly strong program this year.

International attendance is a key component of the symposium. More than half of our attendees come from more than 90 different countries outside the USA. We continue to offer substantial virtual attendance and online resources for free to those who cannot attend the symposium in person, wherever they may be based. Our supporters make all of this possible, for which we are sincerely grateful.

If you are attending the SABCS virtually, to ensure that you have a great experience and to avoid any potential attendance issues, we are providing the following technical directions.

Accessing the Virtual SABCS

Just click the link in your Know Before You Go email to log onto the site with your username (email) and contact ID and you will enter the meeting. The meeting begins Tuesday, December 6, 8:00 am Central Time (CT). Please note that all session times for the 2022 SABCS are in U.S. Central Time (CT). Please be aware of this when planning your participation.

On-Demand Session Availability

Recordings of daily sessions will be available for on-demand viewing if the presenter has given SABCS permission on the virtual platform at the end of that day's programming.

Technical Support

If you require assistance with accessing the 2022 SABCS site, please email SABCS@uthscsa.edu.

Support

If you are not yet registered, click [here](#). You must register to attend the 2022 SABCS. Should you require assistance with your login information, please contact [SABCS](#).

Wi-Fi.

SABCS will offer wireless service throughout the symposium. Connection setting information and support specialist will be available onsite. Sponsored by Lilly.

Social Media #SABCS22

Blog: <https://www.sabcs.org/2022-SABCS-sup-sup/Blogs>

Facebook: <https://www.facebook.com/SABCSSanAntonio/>

Twitter: <https://twitter.com/SABCSSanAntonio>
#SABCS22

Download the 2022 SABCS Mobile App.

With the mobile app you can view the program and build your own personalized schedule. Stay organized with up-to-the-minute event information, speakers and exhibitors. On the events list, select the 2022 show.

On the next screen, select "Download."

To download the app go to the App Store or Google Play and search for "SABCS".

Sponsored by AstraZeneca

CONVENTION CENTER

Symposium events & services are located on three levels of the convention center.

Street (1st) level (Main Lobby, Hall 1, Hall 2, Hall 3, Hall 4)

Entrance (Main Lobby)

Registration, Market Place, Mobile Charging Stations

Hall 1

Poster Sessions, Continental Breakfast, Reception (Tuesday-Friday)

Hall 2

First Aid station, Housing Desk, Lounge, Information Desk, Exhibits, Product Theatre, Loading Dock (for exhibitors), Continental Breakfast (Saturday), Mobile Charging Stations

Hall 3

General Sessions, Award Lectures, Plenary Lectures, Mini-Symposium, Debate, Year in Review, Special Session

Meeting Level

Press Room, Speaker Lounge

Ballroom Level (Stars at Night Ballrooms, Hemisfair Ballroom, Room 304)

Educational Sessions, Career Development Forum, Workshops, Forums, Mini-Symposium, Case Discussions, Spotlight Sessions, Special Sessions, Molecular Tumor Board, View from the Trenches

REGISTRATION DESK HOURS

Symposium events & services are located on three levels of the convention center.

Monday, December 5	12:00 PM – 5:00 PM
Tuesday, December 6	8:00 AM – 5:15 PM
Wednesday, December 7	6:45 AM – 5:15 PM
Thursday, December 8	6:45 AM – 5:15 PM
Friday, December 9	6:45 AM – 4:00 PM
Saturday, December 10	7:30 AM – 9:00 AM

POSTER SESSIONS COLOR KEY

To help you navigate the poster sessions, the poster board sections are color coded as shown below.

	DETECTION/DIAGNOSIS		PSYCHOSOCIAL, QUALITY OF LIFE AND EDUCATIONAL ASPECTS
	TUMOR CELL AND MOLECULAR BIOLOGY		TREATMENT
	PROGNOSTIC AND PREDICTIVE FACTORS		ONGOING CLINICAL TRIALS
	EPIDEMIOLOGY, RISK AND PREVENTION		

SYMPOSIUM HOTEL SHUTTLE

Shuttle buses will operate December 6 through December 10 between official symposium hotels and the convention center at no charge.

- Buses will drop off and pick up at the Market Street Entrance of the Henry B. Gonzalez Convention Center.
- Buses will only stop at the official symposium hotels.
- A wheelchair accessible bus will be available during the listed days and times.
- SABCS does not provide transportation from the airport to hotels

DATE	SERVICE TIMES	PEAK TIMES
Tuesday, December 6, 2022	6:00 am - 9:30 am 4:00 pm - 8:00 pm	15-20 Minute Service
Wednesday, December 7, 2022	6:00 am - 9:30 am 4:00 pm - 8:00 pm	15-20 Minute Service
Thursday, December 8, 2022	6:00 am - 9:30 am 4:00 pm - 8:00 pm	15-20 Minute Service
Friday, December 9, 2022	6:00 am - 9:30 am 4:00 pm - 8:00 pm	15-20 Minute Service
Saturday, December 10, 2022	6:00 am - 10:30 am	15-20 Minute Service

PROPOSED ROUTES	HOTEL SERVICED	PICK UP / DROP OFF
Route 1 – Green	Holiday Inn RW	St. Mary's Street
	Hotel Valencia	Just past Houston on St. Mary's
	Omni La Mansion	Walk to Holiday Inn Riverwalk
	Courtyard by Marriott	Walk to Holiday Inn Riverwalk
	Mokara	Walk to Holiday Inn Riverwalk

PROPOSED ROUTES	HOTEL SERVICED	PICK UP / DROP OFF
Route 2 – Yellow	The Menger	Walk from the hotel to Commerce at Alamo
	Embassy Suites	Front Entrance
	St. Anthony	Motor Lobby
	Hyatt Regency Riverwalk	Front Entrance
Route 3 – Pink	Hampton Inn	Bowie Street
	Fairfield Inn & Suites	Walk to Sonesta
	Springhill Suites	Walk to Hampton Inn
	Emily Morgan	Avenue E across from the Emily Morgan
	Sonesta	Front Entrance
Route 4 – Blue	Westin Riverwalk	Front Entrance
	Hotel Contessa	Walk to the Westin Riverwalk

ONSITE DINING

If you are looking for a quick snack or a nice dining experience, you do not have to go far. We welcome you to sit and relax in between events or sessions at one of the onsite dining locations throughout the Henry B. Gonzalez Convention Center. Each location has items deliciously prepared by the highly acclaimed The RK Culinary Group.

SABCS Bistro

Stop here to get coffee, snacks and meals. Conveniently located in Hall 2 next to the exhibit hall.

Market Cafe

The Market Cafe is conveniently located in the Main Lobby. Stop here to get coffee, snacks and meals on your way into the Convention Center. You can also easily access the Market Cafe from any of the Exhibit Hall entrances.

El Puente Cafe

The El Puente Cafe is located in the West Lobby bridge overlooking the River Walk. It also offers coffee, snacks and meals. Enjoy your snack as you look out onto the River Walk through our floor to ceiling windows.

Keep track of your badge.

Your conference badge allows you admission to all sessions. Past and current events have heightened security awareness around the world. Although no one can predict world events, incidents or situations, we are working to help ensure a safe and a successful Symposium. To this end, to ensure easy access throughout the conference.

We require attendees to wear the Symposium Name Badge to ALL Symposium activities (sessions, exhibits, etc.) at the convention center.

Accreditation

The Joe R. Teresa Lozano Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Long School of Medicine designates this live activity up to a maximum of 86 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Healthcare professionals receiving a certificate of attendance should consult their licensing board for information on applicability and acceptance.

Certificate of Attendance/CME Certificate

Physicians seeking CME credit for this live continuing medical education activity must complete the online surveys. Survey opens on December 6, 2022 and closes on January 31, 2023. Certificates may be printed online after completing the surveys.

Certificates of Attendance are available for attendees who need a record of their attendance at the Symposium but do not require or qualify for CME through the online survey. The online survey opens on December 6, 2022, and closes on January 31, 2023. Certificates may be printed online after completing the survey.

After the Symposium Complete the session evaluations and the post conference survey.

Please take a few minutes to let the planning committee know about your experience. The SABCS 2023 committee will carefully review survey responses as it plans for next year.

Patient Advocate Lounge

SABCS will have room 225C reserved exclusively for Patient Advocates. Refreshments will be provided. SABCS will have a Zoom room reserved exclusively for Patient Advocates. The Patient Advocate Lounge sponsored by Lilly Oncology serves as a designated space where advocates can gather in a relaxed environment to take a break, catch up on work and network with others.

Exhibits

Make sure you schedule time to visit the Exhibit Hall. SABCS has over 40 exhibitors that will be on display Wednesday, December 7 - Friday, December 9.

Charging Stations

SABCS has five conveniently located charging stations to recharge your mobile device, and laptop. Charging Stations are located in the Lobby and Hall 2. Charging stations are sponsored by AstraZeneca, Daiichi Sankyo, Lilly, and Pfizer.

SCHEDULE AT A GLANCE

To view the full schedule, see the daily schedule and sessions list

TUESDAY, DECEMBER 6, 2022

8:00 am - 9:45 am CT

Clinical Research Workshop - Stars at Night Ballroom 1&2

Moderator: Aditya Bardia, MD, MPH

Massachusetts General Hospital
Boston, MA

Use of the postneoadjuvant setting to accelerate drug development

Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

How to measure and improve drug adherence in clinical trials

Dawn L. Hershman, MD, MS
Columbia University Medical Center
New York, NY

Statistical considerations for precision medicine

Nabihah Tayob, PhD
Dana-Farber Cancer Institute
Boston, MA

Bringing trials to all patients: A patient's perspective

Thelma Perry Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

8:00 am - 9:45 am CT

Basic Science Workshop - Stars at Night Ballroom 3&4

Moderator: Alana L. Welm, PhD

University of Utah
Salt Lake City, UT

APOBEC and genome evolution in mBC

Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX

Therapy-induced senescence: Friend or foe?

Sheila Stewart, PhD
Washington University
St. Louis, MO

Drug-tolerant persister cells in cancer

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Clinical implications of tumor heterogeneity single cell genomics

Nnennaya Kanu, PhD
University College London, Cancer Institute
London, United Kingdom

9:45 am - 10:00 am CT

Break

10:00 am - 12:00 pm CT

EDUCATIONAL SESSION BLOCK #1

EDUCATIONAL SESSION BLOCK #1A - Stars at Night Ballroom 3&4

Living with Metastatic Breast Cancer

Moderator: Anne Blaes, MD, MSc

University of Minnesota

Minneapolis, MN

Early palliative care

Tara L. Kaufmann, MD, MSCE
Dell Medical School, University Of Texas at Austin
Austin, TX

Support for patients with MBC

Abbey Kaler, NP
UT MD Anderson Cancer Center
Houston, TX

Financial Toxicity

Fumiko Chino, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Patient Perspective

Christine Hodgdon, MS
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
Baltimore, MD

Stephanie Walker, BSN

MBC Alliance

Tarboro, NC

EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2

Local Therapy - Best Breast Practice

Moderator: Peter Dubsy, MD, PhD

Breast Center Hirslanden Klinik St. Anna
Luzern, Switzerland

Contralateral mastectomy in patients with germline mutations

Katharine A. Yao, MD
Northshore University HealthSystem
Evanston, IL

RT: How short can it be

David Krug, Dr Med
Universitätsklinikum Schleswig-Holstein
Kiel, Germany

How to reconcile novel reconstructive techniques with the need to radiate

Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany

EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3

New Agents Targeting HRD in Breast Cancer

Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL

Pol-theta inhibitors in HRD tumors

Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA

Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond

Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom

ATR inhibitors and PARP1 selective PARP inhibitors

Andrew Tutt, MB ChB, PhD
Institute of Cancer Research
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2

Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy

Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

ER therapies

Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO

HER2

Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy

Triple Negative

Peter Schmid, MD, PhD, FRCP
Bart's Cancer Institute
London, United Kingdom

12:00 pm - 2:00 pm CT

SPECIAL SESSION #1 - Stars at Night Ballroom 1&2

Big Data and Health Equity

Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA

Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

Keynote Speakers:

Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Panelists:

Rhea Blakey
FDA
Silver Spring, MD

Martin Mendoza, PhD
National Institute of Health
Bethesda, MD

Thelma Perry Brown, BSc
University of Alabama at
Birmingham
Birmingham, AL

Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA

Michael Crawford, MBA, MHLA
Howard University
Washington, DC

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Andrea Downing
The Light Collective
Shoreline, WA

Jasmine Souers, BSc
The Missing Pink Breast Cancer
Alliance
Jackson, FL

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

SPECIAL SESSION #2 - Hall 3

Overcoming the Big Obstacles to Find Solutions for Breast Cancer

Chairs:

Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX



Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Panelists:

Christine Ambrosone, PhD
Roswell Park Comprehensive
Cancer Center
Buffalo, NY

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

Regina Barzilay, PhD
Massachusetts Institute of
Technology
Cambridge, MA

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Matthew J. Ellis, MD, PhD
AstraZeneca
Gaithersburg, MD

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, South Korea

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

Patty Spears, BS
UNC Patient Advocates For
Research Council
Chapel Hill, NC

Eric Winer, MD
Yale Cancer Center
New Haven, CT

2:00 pm - 5:00 pm CT
GENERAL SESSION #1 - Hall 3

5:00 pm - 6:15 pm
POSTER SESSION #1 - Hall 1

5:00 pm - 6:15 pm
**SPOTLIGHT POSTER DISCUSSION SESSION #1 Racial Outcomes and Disparities
- Hemisfair Ballroom 1&2**

**SPOTLIGHT POSTER DISCUSSION SESSION #2 Tumor Immunology and Novel
Immune Therapy Strategies - Stars at Night Ballroom 1&2**

**SPOTLIGHT POSTER DISCUSSION SESSION #3 New Radiation Techniques -
Stars at Night Ballroom 3&4**

7:00 pm - 10:00 pm
OPEN SATELLITE EVENTS - Marriott Rivercenter

**Expanding the Spectrum of HER2-Positivity for Precision Breast Cancer Care:
Clinical Implications of HER2-Low Status presented by Clinical Care Options,
LLC, <https://www.clinicaloptions.com/BreastHER2Low2022>**

**Clarifying the Complexities and Augmenting the Options in the Treatment of
HR+/HER2- Breast Cancer: How to Build Better Skills to Make the Most of
Existing and Emerging Therapies for the Benefit of Patients With HR+/HER2-
MBC and EBC presented by PVI, PeerView Institute for Medical Education, [www.
PeerView.com/SanAntonio2022-Live](http://www.PeerView.com/SanAntonio2022-Live)**

**Medical Crossfire®: Clinical Decision Making Under New Paradigms for HR+/
HER2-Breast Cancer presented by Physicians' Education Resource, LLC**

WEDNESDAY, DECEMBER 7

7:00 am - 8:15 am

POSTER SESSION #2 - Hall 1

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #4 Single Cell Approaches for Translational Research and Biomarker Discovery - Hemisfair Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #5 Advances in TNBC Biology - Stars at Night Ballroom 3&4

SPOTLIGHT POSTER DISCUSSION SESSION #6 Special Populations: Male Breast Cancer/Geriatrics - Stars at Night Ballroom 3&4

8:30 am - 9:00 am

WILLIAM L. MCGUIRE MEMORIAL LECTURE - Hall 3

Leveraging Preclinical Models for Translational Breast Cancer Research

Jeffrey Rosen, PhD

Baylor College of Medicine

Houston, TX

9:00 am - 9:45 am CT

GENERAL SESSION #2 - Hall 3

9:45 am - 11:00 am CT

HER2 Low: A Separate Entity Special Session - Hall 3

Chairs: Adam Brufsky, MD, PhD

University of Pittsburgh

Pittsburgh, PA

Kalliopi Siziopikou, MD, PhD

Northwestern University

Chicago, IL

10:00 am - 5:00 pm CT

EXHIBITS - Hall 2

11:00 am - 12:00 pm CT

MINI-SYMPOSIUM #1 - Hall 3

C. Kent Osborne HER2 and ER Crosstalk: Signaling Mechanisms and Clinical Implications Symposium

Moderator: Carlos Arteaga, MD

UT Southwestern Medical Center

Harold C. Simmons Comprehensive Cancer Center

Dallas, TX

Virginia G. Kaklamani, MD

UT Health San Antonio

San Antonio, TX

Special Guest: C. Kent Osborne, MD

Baylor College of Medicine

Houston, TX

HER2 signaling the ER cistrome

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Oncogene signal transduction and antiestrogen resistance

Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Treatment of ER+/HER2+ breast cancer

Stephen Johnston, MBBS
The Royal Marsden Hospital
London, United Kingdom

12:00 PM - 12:30 PM

PLENARY LECTURE #1 - Hall 3

**Lineage-defined Metabolism of Normal Mammary Cells and Origins of Cancer
Metabolic Heterogeneity**

Rama Khokha, PhD
University Health Network
Toronto, Canada

12:30 pm - 1:00 pm

AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3

12:30 pm - 1:30 pm CT

CAREER DEVELOPMENT FORUM - Room 304

1:00 pm - 2:00 pm CT

CLINICAL CASE DISCUSSION SESSION - Stars at Night Ballroom 1&2

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:

Michael Gnant, MD, FACS,
FEBSHon
Medical University of Vienna
Vienna, Austria

Celina Kleer, MD
University of Michigan Medical
School
Ann Arbor, MI

Julia Maues
GRASP
Washington, DC

George Sledge, Jr, MD
Stanford University
Stanford, CA

Jonathan Strauss, MD
Northwestern
Chicago, IL

1:00 pm - 2:00 pm CT

**FORUM #1 - Stars at Night Ballroom 3&4
Molecular Aspects of DCIS Progression**

Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Tumor stroma in DCIS progression

Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA

Clonal evolution of DCIS to invasion

Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Defining clinical risk: How do we tailor therapy

Kimberly J. Van Zee, MS, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

2:00 pm - 3:00 pm CT

CLINICAL CONTROVERSIES - Hall 3

Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC

To clip or not to clip

Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX

Viviana E. Galimberti, MD, MPH
European Institute of Oncology
Milan, Italy

Duration of endocrine therapy

Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN

Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL

Post Neoadjuvant therapy in TNBC

Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX

Susan Domchek, MD

University of Pennsylvania School of Medicine
Philadelphia, PA

2:00 pm - 3:00 pm CT

MINI-SYMPOSIUM #2 - Stars at Night Ballroom 1&2

Late Recurrence and Tumor Dormancy

Moderator: Alana Welm, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN

NK cell induced dormancy

Ana Luisa Correia, PhD
Champalimaud Research
Lisboa, Portugal

Extra cellular matrix and dormancy

Javier Bravo-Cordero, PhD
Icahn School of Medicine
New York, NY

Implications for clinical care

Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

2:00 pm - 3:00 pm CT

FORUM #2 New Targets and Strategies for Immunotherapy - Stars at Night Ballroom 3&4

Moderator: Justin Balko, PhD
Vanderbilt University Medical Center
Nashville, TN

Activating a collaborative innate-adaptive immune response to control metastasis

Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Neutrophil elastase and anti-tumor effects

Lev Becker, PhD
University of Chicago
Chicago, IL

Immunosuppressive macrophages and PARP inhibitor resistance

Jennifer Guerriero, PhD
Brigham and Women's Hospital
Boston, MA

3:00 pm - 5:00 pm CT

EDUCATIONAL SESSION BLOCK #2

**EDUCATIONAL SESSION BLOCK #2A - Hemisfair Ballroom 1&2
Digital Health and PROs in Breast Cancer Research and Care**

Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA

What are PROs and evidence for benefit?

Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY

How to incorporate PROs into clinical care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Where are we going with digital interventions and PROs

Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France

Patient Advocate Perspective

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

EDUCATIONAL SESSION BLOCK #2B - Stars at Night Ballroom 1&2
Antibody Drug Conjugates: Future Directions and Opportunities

Moderator: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT

Bioengineering and mechanism of action of ADC

Puja Sapra, PhD
AstraZeneca
New York, NY

ADCs in breast oncology: Present and future

Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Mechanisms of resistance

Leif Ellisen, MD, PhD
Massachusetts General Hospital
Boston, MA

EDUCATIONAL SESSION BLOCK #2C - Stars at Night Ballroom 3&4
Spatial and Single Cell Characterization of Breast Cancer - Progression

Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

Single cell profiling

Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia

Multiplex spatial proteomic profiling

David Rimm, MD, PhD
Yale University
New Haven, CT

Imaging mass cytometry of breast cancer

Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom

Beyond the lab: Clinical implications

Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

EDUCATIONAL SESSION BLOCK #2D - Hemisfair Ballroom 3

Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know

Moderators: Carmen Bergom, MD, PhD

Washington University in St. Louis
St. Louis, MO

Susan Dent, MD
Duke
Durham, NC

Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents

Susan Dent, MD
Duke
Durham, NC

Radiation therapy and cardiovascular disease in breast cancer

Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO

Cardiovascular toxicity and breast cancer: Detection and prevention strategies

Dinesh Thavendiranathan, MD, MSc
Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto
Toronto, Canada

Cardiac problems secondary to chemotherapy

Alexea Gaffney, MD
Stony Brook Medicine
Stony Brook, NY

5:00 pm - 6:15 pm CT

POSTER SESSION #3 - Hall 1

5:00 pm - 6:15 pm CT

SPOTLIGHT POSTER DISCUSSION SESSION #7 - Brain Metastasis - Stars at Night Ballroom 3&4

SPOTLIGHT POSTER DISCUSSION SESSION #8 - Symptom Management and Associated Toxicities - Stars at Night Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #9 - Immune Landscape and Microenvironments - Hemisfair Ballroom 1&2



7:00 pm - 10:00 pm CT

OPEN SATELLITE EVENTS - Marriott Rivercenter

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research To Practice, <http://www.researchtopractice.com/Meetings/SA2022>

Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy presented by Clinical Care Options, LLC, <https://www.clinicaloptions.com/BreastEBCSanAntonio2022>

THURSDAY, DECEMBER 8

7:00 am - 8:15 am CT

POSTER SESSION #4 - Hall 1

7:00 am - 8:15 am CT

SPOTLIGHT POSTER DISCUSSION SESSION #10 Endocrine Therapy and Resistance - Stars at Night Ballroom 3&4

SPOTLIGHT POSTER DISCUSSION SESSION #11 Improving Outcome for TNBC: New Directions in Immunotherapy - Stars at Night Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #12 Obesity and Breast Cancer- Hemisfair Ballroom 1&2

8:30 am - 11:00 am CT

GENERAL SESSION #3 - Hall 3

10:00 am - 5:00 pm CT

EXHIBITS - Hall 2

11:00 am - 12:00 pm CT

DEBATE Are all of CDK4/6 Inhibitors the Same or Different?- Hall 3

12:00 pm - 12:30 pm CT

PLENARY LECTURE #2 - Hall 3

Premenopausal ER+ Breast Cancer: Past, Present, and Future

Prudence Francis, MD

Peter MacCullum Cancer Centre

Victoria, Australia

12:30 pm - 1:00 pm CT

BRINKER AWARD LECTURE #1

Geoffrey M. Wahl, PhD

Salk Institute for Biological Studies

La Jolla, CA

1:00 pm - 2:00 pm CT

MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2

Moderator: Giuseppe Curigliano, MD, PhD

European Institute of Oncology

Milano, Italy

Panelists:

Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada

Amy L. Delson, AIA
University of California San
Francisco
Atherton, CA

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Sara Hurvitz, MD, FACP
University of California San
Francisco
Los Angeles, CA

Antonio Marra, MD
Memorial Sloan Kettering Cancer
Center,
New York, NY

Alex Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

Daniel Stover, MD
Ohio State University
Comprehensive Cancer Center
Columbus, OH

1:00 pm - 2:00 pm CT

FORUM #3 - Stars at Night Ballroom 3&4

Modifying Tumor Response: Microbiome, Diet, and Fasting

Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX

Fungal regulation of breast tumor radiation response

Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA

Microbiome and response to immunotherapy

Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX

Fasting and Microbiotic

Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France

2:00 pm - 3:00 pm CT

TRANSLATIONAL CONTROVERSIES - Stars at Night Ballroom 1&2

Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY

RIP MTD

Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA

Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Randomized trials vs real world evidence

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY

Ki 67

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada

2:00 pm - 3:00 pm CT

FORUM #4 - Stars at Night Ballroom 3&4

Demystifying CDKs in Breast Cancer: Beyond CDK4/6

Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches

Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX

Current status of CDK2 inhibitors in (pre-)clinical development

Sarat Chandarlapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Inhibiting transcriptional CDKs in breast cancer

Charles Coombes, MD, PhD
Imperial College
London, United Kingdom

3:00 pm - 5:00 pm CT

EDUCATIONAL SESSION BLOCK #3

EDUCATIONAL SESSION BLOCK #3A - Hemisfair Ballroom 1&2

Management of Hereditary Risk: Moderate-Risk Genes and New Approaches

Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL

Cancer risks in patients with moderate penetrance gene mutations

Payal D. Shah, MD
Penn Medicine
Philadelphia, PA

Screening for high-risk patients: Does everyone need annual MRI with mammogram?

Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Hormonal exposure and risk in BRCA1/2 carriers

Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada

EDUCATIONAL SESSION BLOCK #3B - Stars at Night Ballroom 1&2
Challenging Types of Breast Cancer

Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX

Pathologic aspects

Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Metaplastic

Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Inflammatory

Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA

Lobular/pleomorphic

Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, Germany

EDUCATIONAL SESSION BLOCK #3C - Stars at Night Ballroom 3&4
What ctDNA Can Tell Us

Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom

Which is the best technique

Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Can ctDNA substitute tissue testing

Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom

Using ctDNA in detecting disease

Minetta C. Liu, MD

Natera

Austin, TX

5:00 pm - 6:15 pm CT

POSTER SESSION #5 - Hall 1

SPOTLIGHT POSTER DISCUSSION SESSION #13 Therapeutic Approaches for HR+/Her2- Breast Cancer - Stars at Night Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #14 Breast Cancer Risk Modeling - Stars at Night Ballroom 3&4

SPOTLIGHT POSTER DISCUSSION SESSION #15 Local Regional/Management of the Axilla - Hemisfair Ballroom 1&2

7:00 pm - 10:00 pm CT

OPEN SATELLITE EVENTS - Marriott Rivercenter

Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments presented by Society of Nuclear Medicine and Molecular Imaging, <https://www.snmml.org/sanantonio22>

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research To Practice, <http://www.researchtopractice.com/Meetings/SA2022>

FRIDAY, DECEMBER 9

7:00 am - 8:15 am CT

POSTER SESSION #6 - Hall 1

SPOTLIGHT POSTER DISCUSSION SESSION#16 Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How? - Hemisfair Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #17 Endocrine Therapy New Insights - Stars at Night Ballroom 1&2

SPOTLIGHT POSTER DISCUSSION SESSION #18 Updates and New Therapies for HER2 Positive Disease - Stars at Night Ballroom 3&4

8:30 am - 9:00 am CT

AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH - Hall 3

9:00 AM - 11:30 AM CT

GENERAL SESSION #4 - Hall 3

10:00 am - 5:00 pm CT

EXHIBITS - Hall 2

11:30 am - 12:00 pm CT

BRINKER AWARD LECTURE #2

Norman Wolmark, MD, FACS, FRCSC
University of Pittsburgh
Pittsburgh, PA

12:00 pm - 3:00 pm CT

GENERAL SESSION #5 - Hall 3

3:00 pm - 5:00 pm CT

EDUCATIONAL SESSION BLOCK #4

**EDUCATIONAL SESSION BLOCK #4A - Stars at Night Ballroom 1&2
Advances in Pregnancy Associated Breast Cancer (PABC)**

Moderator: Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Updates in the pathology of PABCS

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Special treatment issues in this young patient population

Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Oncofertility and other quality of life issues

Matteo Lambertini, MD, PhD
University of Genova - San Martino Hospital
Genova, Italy

**EDUCATIONAL SESSION BLOCK #4B - Stars at Night Ballroom 3&4
State of the Art Radiotherapy: Reducing Toxicity and Increasing Options**

Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

The role of advanced radiation technology in reducing toxicity

Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA

**Overview of the current state of the art - what patients and oncologists
need to know**

Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Evidence for ablative radiation in metastatic breast cancer

Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

EDUCATIONAL SESSION BLOCK #4C - Hemisfair Ballroom 1&2
Targeting the Tumor Microenvironment for Clinical Impact

Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO

Influence of bone microenvironment on metastasis

Igor Bado, PhD
Baylor College of Medicine
Houston, TX

The contribution of the tumor microenvironment to cancer dormancy

J. Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Effects of age on the tumor microenvironment

Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA

Can inflammation be targeted?

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

5:00 pm - 5:15 pm CT
REFRESHMENT BREAK

5:15 pm - 7:15 pm CT

View from the Trenches: What will You do on Monday Morning - Stars at Night
Ballroom 1&2

Moderators: Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Panelists

Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger
Cancer Institute
Mooresville, NC

Mariana Chavez-MacGregor, MD,
MSC, FASCO
UT MD Anderson Cancer Center
Houston, TX

Tanja N. Fehm, MD
University Hospital
Düsseldorf
Düsseldorf, Germany

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Mediget Teshome, MD, MPH,
FACS
UT MD Anderson Cancer Center
Houston, TX

Cynthia Villareal Garza, MD, DSc
Tecnológico de Monterrey
Monterrey, Mexico

Richard C. Zellars, MD
Indiana University
Indianapolis, IN

SATURDAY, DECEMBER 10

8:00 am - 10:00 am

YEAR IN REVIEW - Hall 3

Moderators: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Basic science

Andrei Goga, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Translational research

Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia

Early breast cancer

Marleen Kok, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Advanced breast cancer

Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA

DETAILED PROGRAM

TUESDAY, DECEMBER 6, 2022

8:00 am - 9:45 am CT

Clinical Research Workshop - Stars at Night Ballroom 1&2

Moderator: Aditya Bardia, MD, MPH
Massachusetts General Hospital
Boston, MA

Use of the postneoadjuvant setting to accelerate drug development

Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

How to measure and improve drug adherence in clinical trials

Dawn L. Hershman, MD, MS
Columbia University Medical Center
New York, NY

Statistical considerations for precision medicine

Nabihah Tayob, PhD
Dana-Farber Cancer Institute
Boston, MA

Bringing trials to all patients: A patient's perspective

Thelma Perry Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

8:00 am - 9:45 am CT

Basic Science Workshop - Stars at Night Ballroom 3&4

Moderator: Alana L. Welm, PhD
University of Utah
Salt Lake City, UT

APOBEC and genome evolution in mBC

Reuben S. Harris, PhD
UT Health San Antonio
San Antonio, TX

Therapy-induced senescence: Friend or foe?

Sheila Stewart, PhD
Washington University
St. Louis, MO

Drug-tolerant persister cells in cancer

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Clinical implications of tumor heterogeneity single cell genomics

Nnennaya Kanu, PhD
University College London, Cancer Institute
London, United Kingdom

9:45 am - 10:00 am CT

Break

10:00 am - 12:00 pm CT

EDUCATIONAL SESSION BLOCK #1

EDUCATIONAL SESSION BLOCK #1A - Stars at Night Ballroom 3&4

Living with Metastatic Breast Cancer

Moderator: Anne Blaes, MD, MSc

University of Minnesota

Minneapolis, MN

Early palliative care

Tara L. Kaufmann, MD, MSCE

Dell Medical School

University Of Texas at Austin

Austin, TX

Support for patients with MBC

Abbey Kaler, NP

UT MD Anderson Cancer Center

Houston, TX

Financial Toxicity

Fumiko Chino, MD

Memorial Sloan Kettering Cancer Center

New York, NY

Patient Perspective

Christine Hodgdon, MS

GRASP - Guiding Researchers & Advocates to Scientific Partnerships

Baltimore, MD

Stephanie Walker, BSN

MBC Alliance

Tarboro, NC

EDUCATIONAL SESSION BLOCK #1B - Hemisfair Ballroom 1&2

Local Therapy - Best Breast Practice

Moderator: Peter Dubsy, MD, PhD

Breast Center Hirslanden Klinik St. Anna

Luzern, Switzerland

Contralateral mastectomy in patients with germline mutations

Katharine A. Yao, MD

Northshore University HealthSystem

Evanston, IL

RT: How short can it be

David Krug, Dr Med

Universitätsklinikum Schleswig-Holstein

Kiel, Germany

How to reconcile novel reconstructive techniques with the need to radiate

Christine Solbach, MD, PhD
University Hospital Frankfurt
Frankfurt, Germany

EDUCATIONAL SESSION BLOCK #1C - Hemisfair Ballroom 3

New Agents Targeting HRD in Breast Cancer

Moderator: Erica Stringer-Reasor, MD
University of Alabama at Birmingham
Birmingham, AL

Pol-theta inhibitors in HRD tumors

Alan D. d'Andrea, MD
Dana-Farber Cancer Institute
Boston, MA

Mechanisms of sensitivity and resistance to HRD targeting agents in breast cancer - PARPi and beyond

Christopher Lord, DPhil
Institute of Cancer Research
London, United Kingdom

ATR inhibitors and PARP1 selective PARP inhibitors

Andrew Tutt, MB ChB, PhD
Institute of Cancer Research
London, United Kingdom

EDUCATIONAL SESSION BLOCK #1D - Stars at Night Ballroom 1&2

Predictive Value of Treatment Response and Residual Disease After Neoadjuvant Therapy

Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

ER therapies

Cynthia X. Ma, MD, PhD
Washington University in St. Louis
St. Louis, MO

HER2

Luca Gianni, MD
Fondazione Michelangelo
Milano, Italy

Triple Negative

Peter Schmid, MD, PhD, FRCP
Bart's Cancer Institute
London, United Kingdom

12:00 pm - 2:00 pm CT

SPECIAL SESSION #1 - Stars at Night Ballroom 1&2

Big Data and Health Equity

Moderators: Thelma Brown, BSc
University of Alabama at Birmingham
Birmingham, AL

Maimah Karmo, BS
Tigerlily Foundation
Aldie, VA

Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

Keynote Speakers:

Martin Mendoza, PhD
National Institutes of Health
Bethesda, MD

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Panelists:

Rhea Blakey
FDA
Silver Spring, MD

Martin Mendoza, PhD
National Institute of Health
Bethesda, MD

Michael Crawford, MBA, MHLA
Howard University
Washington, DC

Charlotte Owens, MD
Takeda Pharmaceutical Company
Cambridge, MA

Andrea Downing
The Light Collective
Shoreline, WA

Barbara Seggara, D.H.Sc
University of Puerto Rico
San Juan, Puerto Rico

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Jasmine Souers, BSc
The Missing Pink Breast Cancer
Alliance
Jackson, FL

SPECIAL SESSION #2 - Hall 3

Overcoming the Big Obstacles to Find Solutions for Breast Cancer

Chairs:

Carlos Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Panelists:

Christine Ambrosone, PhD
Roswell Park Comprehensive
Cancer Center
Buffalo, NY

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

Regina Barzilay, PhD
Massachusetts Institute of
Technology
Cambridge, MA

Joan S. Brugge, PhD
Harvard Medical School
Boston, MA

Matthew J. Ellis, MD, PhD
AstraZeneca
Gaithersburg, MD

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Yeon Hee Park, MD, PhD
Samsung Medical Center
Seoul, South Korea

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

Patty Spears, BS
UNC Patient Advocates For
Research Council
Chapel Hill, NC

Eric Winer, MD
Yale Cancer Center
New Haven, CT

2:00 pm - 5:00 pm

GENERAL SESSION #1 - Hall 3

Moderators: Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Shom Goel
Peter MacCallum Cancer Centre
Melbourne, VIC, Australia

2:00 pm - 2:15 pm

GS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)

Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delalogue S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Puzstai L, Hortobagyi GN, Kalinsky K.

2:15 pm - 2:30 pm

GS1-02 Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy

Karadal B, Kim G, Sharma V, Pastoriza J, Oktay I, Lin Y, Ye X, Qin J, Cheng E, Ladak N, Condeelis J, Adler E, Ginter P, D'Alfonso T, Xue X, Enterberg D, Sparano J, Oktay M.

2:30 pm - 2:45 pm

GS1-03 Discussant for GS1-01 and GS1-02

Lori Pierce, MD
University of Michigan
Ann Arbor, MI

2:45 pm - 3:00 pm CT

GS1-04 Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status

Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Puzstai L, Hortobagyi GN, Kalinsky K, Henry NL.

3:00 pm - 3:15 pm

GS1-05 Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates

Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson Jr JA, Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge Jr GW.

3:15 pm - 3:30 pm

GS1-06 Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

O'Regan R, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Lang I, Bellet Ezquerra M, Bonnefoi HR, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM.

3:30 pm - 3:45 pm

GS1-07 Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207

Chavez-MacGregor M, Miao J, Pusztaí L, Goetz MP, Rastogi P, Ganz PA, Mamounas EP, Paik S, Bandos H, Razaq W, O'Dea A, Kaklamani V, Silber ALM, Flaum LE, Andreopolu E, Baar J, Wendt AG, Careny JF, Sharma P, Gralow JR, Lew DL, Barlow WE, Hortobagyi GN.

3:45 pm - 4:00 pm CT

GS1-08 Discussant for GS1-06 and GS1-07

Polly Niravath, MD
Houston Methodist Hospital
Houston, TX

4:00 pm - 4:15 pm

GS1-09 Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Johnston S, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, Andre V, Harbeck N, Martín M.

4:15 pm - 4:30 pm

GS1-10 Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy

Lu Y-S, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap Y-S, Im S-A, Rihani J, Bowles J, Delgar Alfaro T, Wu J, Gao M, Slimane K, El Saghir N

5:00 pm - 6:15 pm

POSTER SESSION #1 - Hall 1

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #1 - Hemisfair Ballroom 1&2

Racial Outcomes and Disparities

Chair: Vanessa Sheppard, PhD
Virginia Commonwealth University
Richmond, VA

Disparities in screening and outcomes

David Haynes, PhD
University of Minnesota
Minneapolis, MN

Biology Race and Outcomes

Elena Martinez, PhD
UC San Diego
La Jolla, CA

Patient Perspective

Tammie Denyse
Carrie's Touch
Sacramento, CA

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #2 - Stars at Night Ballrooms 1&2

Tumor Immunology and Novel Immune Therapy Strategies

Chair: Cesar A. Santa-Maria, MD
Johns Hopkins Medicine
Baltimore, MD

Sangeetha Reddy, MD
UT Southwestern
Dallas, TX

Justin M. Balko, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #3 - Stars at Night Ballrooms 3&4

New Radiation Techniques

Chair: Richard Zellars, MD
Indiana University School of Medicine
Indianapolis, IN

Is timing everything?

Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

PBI- Post, Pre and Primary

Ryan M. Rhome, MD, PhD
Indiana University
Indianapolis, IN

7:00 pm - 10:00 pm

OPEN SATELLITE EVENTS

Expanding the Spectrum of HER2-Positivity for Precision Breast Cancer Care: Clinical Implications of HER2-Low Status presented by Clinical Care Options, LLC

Clarifying the Complexities and Augmenting the Options in the Treatment of HR+/HER2- Breast Cancer: How to Build Better Skills to Make the Most of Existing and Emerging Therapies for the Benefit of Patients With HR+/HER2-MBC and EBC presented by PVI, PeerView Institute for Medical Education

Medical Crossfire®: Clinical Decision Making Under New Paradigms for HR+/HER2-Breast Cancer presented by Physicians' Education Resource, LLC

WEDNESDAY, DECEMBER 7, 2022

7:00 am - 8:15 am

POSTER SESSION #2 - Hall 1

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #4 - Hemisfair Ballroom 1&2

Single Cell Approaches for Translational Research and Biomarker Discovery

Chair: Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Single cell genomics for breast cancer outcomes

Christine Desmedt, PhD
Catholic University Of Leuven
Leuven, Belgium

Spatial imaging and the importance of localization

Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #5 - Stars at Night Ballroom 3&4

Advances in TNBC Biology

Chair: Ratna K. Vadlamudi, PhD
UT Health San Antonio
San Antonio, TX

Celina Kleer, MD, PhD
University of Michigan
Ann Arbor, MI

Brian Lehmann, PhD
Vanderbilt University Medical Center
Nashville, TN

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #6 - Stars at Night Ballroom 1&2

Special Populations: Male Breast Cancer/Geriatrics

Chair: Anne Blaes, MD, MSc

University of Minnesota

Minneapolis, MN

Geriatric Breast Cancer

Rachel A. Freedman, MD, MPH

Dana-Farber Cancer Institute

Boston, MA

Male Breast Cancer

Jose P. Leone, MD

Dana-Farber Cancer Institute

Boston, MA

8:30 am - 9:00 am

William L. McGuire Memorial Lecture - Hall 3

Leveraging Preclinical Models for Translational Breast Cancer Research

Jeffrey Rosen, PhD

Baylor College of Medicine

Houston, TX

9:00 am - 9:45 am

GENERAL SESSION #2 - Hall 3

Moderators: Hannah Linden, MD

University of Washington

Seattle, WA

David Rimm, MD, PhD

Yale School of Medicine

New Haven, CT

9:00 am - 9:15 am

GS2-01: Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02

Krop I, Park YH, Kim S-B, Borges G, Aksoy S, Gregori JG, Roynance R, Lim E, Yerushalmi R, Zagouri F, Duhoux FP, Fehm T, Takano T, Egorov A, Wu I, Cathcart J, Chu C, Andre F.

9:15 am - 9:30 am

GS2-02: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning J-W, Curigliano G, Pérez-García JM, Egorov A, Liu Y, Cathcart J, Ashfaq S, Cortés J.

9:30 am - 9:45 am

GS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Hurvitz SA, Bardia A (Presenter), Press MF, Wang LS, McAndrew NP, Chan D, Phan V, Villa D, Tetef ML, Chamberlain E, Abdulla N, Iomis T, Spring LM, Applebaum S, Dakhil S, DiCarlo B, Kim DD, Kirimis E, Lawler WE, Master AK, McCann K, Hayashi E, Kivork C, Chauv J.

9:45 am - 11:00 am

HER2 Low: A Separate Entity Special Session - Hall 3

Chairs: Adam Brufsky, MD, PhD

University of Pittsburgh
Pittsburgh, PA

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Posters

HER2-01 Clinical and molecular characteristics of HER2-low/zero early stage triple-negative breast cancer

Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NK, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodward WA, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D

HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy

Zattarin E, Sposetti C, Leporati R, Mariani L, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Presti D, Provenzano L, Vingiani A, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Berton Giachetti PPM, Carnevale Schianca A, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali DG, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C

HER2-04 Prevalence of HER2-low among Metastatic Breast Cancer Patients and Their Outcomes Compared to HER2 IHC 0

Singareeka Raghavendra A, Liu D, Mouabbi J, Tripathy D

HER2-05 Comprehensive genomic characterization of HER2-low breast cancer

Tarantino P, Gupta HV, Hughes ME, Files JL, Strauss S, Kirkner G, Feeney A-M, Li YY, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky b, MacConaill L, Lindeman N, Johnson B, Meyerson M, Kabraji S, Jeselsohn R, Qiu X, Li R, Long HW, Winer EP, Dillon DA, Curigliano G, Cherniack A, Tolaney SM, Lin NU

HER2-06 Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR+) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping

Denkert C, Martín M, Untch M, Bonnefoi HR, Knudsen ES, Im S-A, DeMichele A, Witkiewicz A, Van 't Veer L, Kim S-B, Bear HD, McCarthy N, Gelmon K, Marmé F, García-Sáenz JÁ; Turner N, Rojo F, Filipits M, Martin L-A, Fasching PA, Schem C, Kelly CM, Reimer T, TOi M, Rugo HS, Gnant M, Makris A, Liu Y, Weber K, Rachakonda S, Loibl S

HER2-07 Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers

Marra A, Safonov A, Drago J, Ferraro E, Selenica P, Gazzo A, Curigliano G, Modi S, Razavi P, Reis-Filho J, Chandarlapaty S

HER2-08 Molecular characterization of HER-2 low patients identifies basal-enriched subset with poor clinical outcomes in real-world data

Ahmed T, Stover DG, Hockenberry A, Mackay M, Nimeiri H, Chen J, Ben-Schachar R, Cristofanilli M

HER2-09 Withdrawn

HER2-10 Dynamics of HER2-low expression in triple-negative breast cancer

Garrido-Castro AC, Ngo LD, Richardson ET, Frangieh A, Mohammed-Abreu A, Hughes ME, Gomez Tejada Zanudo J, Navarro J, Tarantino P, Mittendorf EA, Tolaney SM, King T, Winer EP, Lin NU, Wagle N

HER2-11 Epidemiology and Prognosis of HER2-Low Breast Cancer (BC) in the National Cancer Data Base (NCDB)

Peiffer D, Howard FM, Chen N, Hahn OM, Nanda R, Olopade OI, Huo D

HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer

Bansal R, McGrath J, Bustos MA, Rodriguez E, Sammons SL, Accordino MK, Meisel J, Gatti-Mays M, Hsu E, Lathrop KI, Kaklamani V, Korn WM, Oberley M, Walker P, Graff SL

HER2-13 Proficiency assessment of HER2-low breast cancer scoring with the Ventana PATHWAY 4B5 and Dako HercepTest HER2 assays and the impact of pathologist training

Rüschhoff J, Penner A, Ellis IO, Hammond MEH, Lebeau A, Osamura RY, Penault-Llorca F, Rojo F, Atkey N, Scheel AH, D' Arrigo C, Schildhaus H-U, Moh A, Desai C, Viale G

HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series

Rothschild HT, Clelland E, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Schwartz CJ, Mukhtar R

HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer

Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn JH, Teixeira de Sousa R, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V

HER2-16 Inter-lesion heterogeneity of HER2-status in metastatic breast cancer: possible implications for treatment with anti-HER2 antibody-drug conjugates

Geukens T, De Schepper M, Richard F, Maetens M, Van Baelen K, Mahdami A, Nguyen H-L, Isnaldi E, Leduc S, Pabba A, Bachir I, Mertens F, Vander Borgh S, Smeets A, Nevelsteen I, Punie K, Neven P, Wildiers H, Van Den Bogaert W, Floris G, Desmedt C

HER2-17 Novel Quantitative HER2 Assay for Determining Dynamic HER2 Expression in the HER2 IHC 0 “Ultra-Low” Setting: Implications for Precision Therapy in HER2- Breast Cancer

Corgiat BA, O’Shaughnessy J, LoRusso P, Weinberg K, Davis J, Gawryletz C, Petricoin EF

HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04

Prat A, Modi S, Tsurutani J, Cameron D, Harbeck N, Garrido C, Karnoub M, Hsu C, Feng W, Yung L, Wang Y, Gambhire D, Ford SK, Vitazka P, Ueno NT.

HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score

Spring LM, Barlow WE, Bardia A, Sharma P, Pusztai L, Hortobagyi GN, Kalinsky K.

10:00 am - 5:00 pm

EXHIBITS - Hall 2

11:00 am - 12:00 pm

MINI-SYMPOSIUM #1 - Hall 3

C. Kent Osborne HER2 and ER Crosstalk: Signaling Mechanisms and Clinical Implications Symposium

Moderators: Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Special Guest: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

HER2 signaling the ER cistrome

Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Oncogene signal transduction and antiestrogen resistance

Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Treatment of ER+/HER2+ breast cancer

Stephen Johnston, MBBS
The Royal Marsden Hospital
London, United Kingdom

12:00 pm - 12:30 pm
PLENARY LECTURE #1 - Hall 3
Lineage-defined Metabolism of Normal Mammary Cells and Origins of Cancer Metabolic Heterogeneity

Rama Khokha, PhD
University Health Network
Toronto, Canada

12:30 pm - 1:00 pm
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH - Hall 3
12:30 pm - 1:30 pm
CAREER DEVELOPMENT FORUM - Room 304

The Career Roundtables provide interactive informational interviews with experts on a variety of topics that are important for career development of early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2022 SABCS.

Limited to 120 participants; attendance to the in-person Career Roundtables will be on a first-come, first-served basis and with no pre-registration required. Badges are required and will be scanned at door for entry. Boxed lunches will be provided.

Participants will have the opportunity to rotate tables every 20 minutes. Some tables topics will have a more clinical focus, while others will have a more laboratory research focus. The subthemes are denoted in parenthesis after the table topic name. .

Schedule

12:30 p.m. – 12:35 p.m.	Introduction
12:30 p.m. – 12:50 p.m.	Topic Selection 1
12:50 p.m. – 1:10 p.m.	Topic Selection 2
1:10 p.m. – 1:30 p.m.	Topic Selection 3

Roundtable Topics & Mentors*
Balancing Research and Clinical Practice (Clinical)

Cynthia Ma, Washington University Siteman Cancer Center, St. Louis, MO
Melinda Telli, Stanford University, Stanford, CA
Jeri Francoeur, Alamo Breast Cancer Foundation, San Antonio, TX

Becoming a Successful Clinical Trialist (Clinical)

Carey Anders, Duke Comprehensive Cancer Center, Durham, NC
Cheryl L. Jernigan, Susan G. Komen, Kansas City, MO
Additional mentor to be announced

Careers in Industry

See Phan, Gilead Sciences Inc., Foster City, CA
Additional mentors to be announced

Careers in Basic Science

Xi Chen, Baylor College of Medicine, Houston, TX
Heide Ford, University of Colorado, Denver, CO
Lesley K. Glenn, Project Life, OR

Careers in Translational Research (Clinical)

Rita Nanda, University of Chicago, Chicago, IL
Ian Krop, Yale Cancer Center, New Haven, CT
Janice K. Cowden, METAvivor Research and Support, Inc., Annapolis, MD

Careers in Translational Research (Laboratory)

Justin M. Balko, Vanderbilt University, Nashville, TN
Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, PA
Abigail Johnston, Connect IV Legal Services, Inc.

Career Transitions

Minetta C. Liu, Natera, Inc., San Carlos, CA
Sean Khozin, CancerLinQ LLC/ASCO
Additional advocate mentor to be announced

Negotiating a Job Offer or Promotion

Norah Lynn Henry, University of Michigan, Ann Arbor, MI
Kevin Kalinsky, Emory Winship Cancer Center, Atlanta, GA
Jamie LaScala, Patient Advocate Board Member Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, PA

How to Get Involved In & Make Collaborative Research Work for You

Angela M. DeMichele, University of Pennsylvania, Philadelphia, PA
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Ginny Mason, Inflammatory Breast Cancer Research Foundation, West Lafayette, IN

Time Management to Optimize Productivity and Wellness

Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, TN
Mediget Teshome, UT MD Anderson Cancer Center, Houston, TX
Bárbara Segarra-Vázquez, University of Puerto Rico, San Juan, PR

Building a Support Network for Better Work Life Balance

Alexea M. Gaffney, Stony Brook Medicine, Stony Brook, NY
Geoffrey Wahl, Salk Institute, La Jolla, CA
Additional advocate mentor to be announced

Funding Your Own Research

Andrew Tutt, Institute of Cancer Research, London, United Kingdom
Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, AL
Sandy Finestone, Association of Cancer Patient Educators, CA

Professional Fulfillment and Burnout Mitigation

Oluwadamilola "Lola" Fayanju, University of Pennsylvania, Philadelphia, PA
Eric Winer, Yale Cancer Center, New Haven, CT
Deltra James, Project Life MBC, for the Breast of Us, Waterbury, Connecticut

Challenges and Opportunities for Women in Research

Alana Welm, University of Utah School of Medicine, Salt Lake City, UT
Lori Pierce, University of Michigan, Ann Arbor, MI
Additional advocate mentor to be announced

Promoting Equity and Inclusion in Your Career and Teams

Reshma Jagsi, University of Michigan, Ann Arbor, MI
Amelie G. Ramirez, UT Health San Antonio, San Antonio, TX
Sanford Jeames, Huston Tillotson University, Austin, TX

1:00 pm - 2:00 pm

CLINICAL CASE DISCUSSION SESSION - Stars at Night Ballroom 1&2

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:

Michael Gnant, MD, FACS, FEBShon
Medical University of Vienna
Vienna, Austria

George Sledge, Jr, MD
Stanford University
Stanford, CA

Celina Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

Jonathan Strauss, MD
Northwestern
Chicago, IL

Julia Maues
GRASP
Washington, DC

1:00 pm - 2:00 pm

FORUM #1 - Stars at Night Ballroom 3&4

Molecular Aspects of DCIS Progression

Moderator: E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Tumor stroma in DCIS progression

Robert West, MD, PhD
Stanford University Medical Center
Stanford, CA

Clonal evolution of DCIS to invasion

Jelle Wesseling, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Defining clinical risk: How do we tailor therapy

Kimberly J. Van Zee, MS, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

2:00 pm - 3:00 pm

CLINICAL CONTROVERSIES - Hall 3

Moderator: Lisa Carey, MD, ScM, FASCO
UNC-Lineberger Comprehensive Cancer Center
Chapel Hill, NC

To clip or not to clip

Abigail Caudle, MD
UT MD Anderson Cancer Center
Houston, TX

Viviana E. Galimberti, MD, MPH
European Institute of Oncology
Milan, Italy

Duration of endocrine therapy

Kathryn Ruddy, MD, PhD
Mayo Clinic
Rochester, MN

Eleftherios (Terry) Mamounas, MD, MSc
Orlando Health Cancer Institute
Orlando, FL

Post neoadjuvant therapy in TNBC

Heather McArthur, MD, MPH
UT Southwestern
Dallas, TX

Susan Domchek, MD
University of Pennsylvania School of Medicine
Philadelphia, PA

2:00 pm - 3:00 pm

MINI-SYMPOSIUM #2 - Stars at Night Ballroom 1&2

Late Recurrence and Tumor Dormancy

Moderator: Alana Welm, PhD
Masonic Cancer Center
University of Minnesota
Minneapolis, MN

NK cell induced dormancy

Ana Luisa Correia, PhD
Champalimaud Research
Lisboa, Portugal

Extra cellular matrix and dormancy

Javier Bravo-Cordero, PhD
Icahn School of Medicine
New York, NY

Implications for clinical care

Alexandra Thomas, MD, FACP
Wake Forest School of Medicine
Winston, Salem, NC

2:00 pm - 3:00 pm CT

FORUM #2 New Targets and Strategies for Immunotherapy - Stars at Night Ballroom 3&4

Moderator: Justin Balko, PhD
Vanderbilt University Medical Center
Nashville, TN

Activating a collaborative innate-adaptive immune response to control metastasis

Mikala Egeblad, PhD
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY

Neutrophil elastase and anti-tumor effects

Lev Becker, PhD
University of Chicago
Chicago, IL

Immunosuppressive macrophages and PARP inhibitor resistance

Jennifer Guerriero, PhD
Brigham and Women's Hospital
Boston, MA

3:00 pm - 5:00 pm

EDUCATIONAL SESSION BLOCK #2

EDUCATIONAL SESSION BLOCK #2A - Hemisfair Ballroom 1&2

Digital Health and PROs in Breast Cancer Research and Care

Moderator: Ann H. Partridge, MD, MPH
Dana Farber Institute
Boston, MA

What are PROs and evidence for benefit?

Shoshana Rosenberg, ScD, MPH
Weill Cornell Medicine
New York, NY

How to incorporate PROs into clinical care

Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Where are we going with digital interventions and PROs

Ines Vaz Luis, PhD
Gustave Roussy
Villejuif, France

Patient Advocate Perspective

Patty Spears, BS
UNC Patient Advocates for Research Council
Chapel Hill, NC

EDUCATIONAL SESSION BLOCK #2B - Stars at Night Ballroom 1&2

Antibody Drug Conjugates: Future Directions and Opportunities

Moderator: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT

Bioengineering and mechanism of action of ADC

Puja Sapra, PhD
AstraZeneca
New York, NY

ADCs in breast oncology: Present and future

Shanu Modi, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Mechanisms of resistance

Leif Ellison, MD, PhD
Massachusetts General Hospital
Boston, MA

EDUCATIONAL SESSION BLOCK #2C - Stars at Night Ballroom 3&4

Spatial and Single Cell Characterization of Breast Cancer Progression

Moderator: Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

Single cell profiling

Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia

Multiplex spatial proteomic profiling

David Rimm, MD, PhD
Yale University
New Haven, CT

Imaging mass cytometry of breast cancer

Raza Ali, MD, FRCPC, MSc
Cancer Research UK Cambridge Institute
Cambridge, United Kingdom

Beyond the lab: Clinical implications

Christina Curtis, PhD, MSc
Stanford University School of Medicine
Stanford, CA

EDUCATIONAL SESSION BLOCK #2D - Hemisfair Ballroom 3

Breast Cancer and Cardiovascular Toxicity: What an Oncologist Needs to Know

Moderators: Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO

Susan Dent, MD
Duke
Durham, NC

Beyond anthracyclines and trastuzumab: Cardiotoxicity of new novel agents

Susan Dent, MD
Duke
Durham, NC

Radiation therapy and cardiovascular disease in breast cancer

Carmen Bergom, MD, PhD
Washington University in St. Louis
St. Louis, MO

Cardiovascular toxicity and breast cancer: Detection and prevention strategies

Dinesh Thavendiranathan, MD, MSc
Peter Munk Cardiac Center, Toronto General Hospital, University of Toronto
Toronto, Canada

Cardiac problems secondary to chemotherapy

Alexea Gaffney, MD
Stony Brook Medicine
Stony Brook, NY

5:00 pm - 6:15 pm
POSTER SESSION #3 - Hall 1

5:00 pm - 6:15 pm
SPOTLIGHT POSTER DISCUSSION SESSION #7 - Stars at Night Ballroom 3&4

Brain Metastasis

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Treatment

Barbara O'Brien, MD
UT MD Anderson Cancer Center
Houston, TX

Prognosis

Carey K. Anders, MD
Duke
Durham, NC

5:00 pm - 6:15 pm
SPOTLIGHT POSTER DISCUSSION SESSION #8 - Stars at Night Ballroom 1&2

Symptom Management and Associate Toxicities

Chair: Dawn Hershman, MD
Columbia University Medical Center
New York, NY

Symptom management

Ines-Maria Vaz-Duarte, MD, MSc
Dana-Farber Cancer Institute
Boston, MA

Psychosocial needs

Michele Melisko, MD
University California San Francisco
San Francisco, CA

Patient Advocate

Barbara Segarra Vazquez, DSc
University of Puerto Rico
San Juan, Puerto Rico

5:00 pm - 6:15 pm
SPOTLIGHT POSTER DISCUSSION SESSION #9 - Hemisfair Ballroom 1&2

Immune Landscape and Microenvironments

Chair: W. Fraser Symmans, MB ChB
UT MD Anderson Cancer Center
Houston, TX

Michail Ignatiadis, MD, PhD
Institut Jules Bordet
Brussels, Belgium

Daniel G. Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

7:00 pm - 10:00 pm

OPEN SATELLITE EVENTS - Marriott Rivercenter

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research To Practice

Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy presented by Clinical Care Options, LLC

THURSDAY, DECEMBER 8, 2022

7:00 am - 8:15 am

POSTER SESSION 4 - Hall 1

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #10 - Stars at Night Ballroom 3&4

Endocrine Therapy and Resistance

Chair: Rachel Schiff
Baylor College of Medicine
Houston, TX

Mechanisms of resistance and new treatment strategies

Julie Ostrander, PhD
University of Minnesota
Minneapolis, MN

Biomarkers of response and resistance

Luca Malorni, MD, PhD
Zienda USL Toscana Centro
Prato, Italy

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #11 - Stars at Night Ballroom 1&2

Improving Outcome for TNBC: New Directions in Immunotherapy

Chair: Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA

Heather McArthur, MD
UT Southwestern
Dallas, TX

Rebecca Dent, MD
Duke
Durham, NC

Margaret Gatti-Mays
The Ohio State University
Columbus, OH

7:00 am - 8:15 am
SPOTLIGHT POSTER DISCUSSION SESSION #12 - Hemisfair Ballroom 1&2

Obesity and Breast Cancer

Chair: Tarah J. Ballinger, MD
Indiana University
Indianapolis, IN

Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA

Stephanie Walker, RN
Metastatic Breast Cancer Alliance
Tarboro, NC

8:30 am - 11:00 am
GENERAL SESSION #3 - Hall 3

Moderators: Carey K. Anders, MD
Duke
Durham, NC

William M. Sikov, MD
Women & Infants Hospital
Providence, RI

8:30 am - 8:45 am
GS3-01 EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting

Bardia A, Bidard FC, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon P, Babu S, Waters S, Deleu I, García-Sáenz J, Bria E, Cazzaniga M, Aftimos P, Cortés J, Scartoni S, Sahmoud T, Habboubi N, Grzegorzewski KJ, Kaklamani V.

8:45 am - 9:00 am
GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in postmenopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Semegen Y, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Bennett M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E.

9:00 am - 9:15 am

GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Hurvitz SA, Schott AF (Presenter), Ma C, Hamilton E, Nanda R, Zahrah G, Hunter N, Tan AR, Telli ML, Anampa Mesias J, Jeselsohn R, Munster P, Lu H, Gedrich R, Mather C, Parameswaran J, Han HS.

9:15 am - 9:30 am

GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial

Turner NC, Oliveira M, Howell S, Dalenc F, Cortés J, Gomez H, Hu X, Jhaveri K, Loibl S, Morales Murillo S, Nowecki Z, Okera M, Park YH, Toi M, Zhukova L, Yan C, Schiavon G, Foxley A, Rugo HS.

9:30 am - 9:45 am

GS3-05 Discussant for GS3-01, GS3-02, GS3-03 and GS3-04

Fabrice André, MD, PhD
Gustave Roussy
Villejuif, France

9:45 am - 10:00 am

GS3-06 Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of Fulvestrant, Palbociclib, and Avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer

Mayer EL, Ren Y, Wagle N, Mahtani R, Ma CX, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Jolly T, Riley E, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block C, Ko N, Partridge AH, Chen WY, DeMeo MK, Attaya V, Okpoebo A, Liu Y, Gauthier E, Burstein H, Regan MM, Tolaney SM.

10:00 am - 10:15 am

GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer

Guarducci C, Cristea S, Feit A, Naumenko S, Nardone A, Ma W, Russo D, Cohen Feit G, Feiglin A, Hermida-Prado F, Sherman S, Brown M, Michor F, Jeselsohn R.

10:15 am - 10:30 am

GS3-08 Discussant for GS3-06 and GS3-07

Shom Goel, MBBS, B Med Sci, FRACP, PhD
Peter MacCallum Cancer Centre
Melbourne, Australia

10:30 am - 10:45 am

GS3-09 Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2-metastatic breast cancer: overall survival analysis of the randomized STIC CTC trial

Bidard F-C, Kiavue N, Alix-Panabières C, Dureau S, Bachelot T, Bourgeois H, Gonçalves A, Brain E, Ladoire S, Dalenc F, Gligorov J, Teixeira L, Emile G, Ferrero J-M, Loiraat D, Cabel L, Diéras V, Berger F, Jacot W, Pierga J-Y.

10:45 am - 11:00 am

GS3-10 Discussant for GS3-08

Daniel Hayes, MD
University of Michigan
Ann Arbor, MI

10:00 am - 5:00 pm

EXHIBITS - Hall 2

11:00 am - 12:00 pm

DEBATE - Hall 3

Are All of CDK4/6 Inhibitors the Same or Different?

Moderator: Sung-Bae Kim, MD, PhD
University of Ulsan College of Medicine
Seoul, South Korea

PRO Debra Patt, MD, MBA
Texas Oncology
Austin, TX

CON Ruth O'Regan, MD
University of Rochester
Rochester, NY

12:00 pm - 12:30 pm

PLENARY LECTURE #2 - Hall 3

Premenopausal ER+ Breast Cancer: Past, Present, and Future

Prudence Francis, MD
Peter MacCallum Cancer Centre
Victoria, Australia

12:30 pm - 1:00 pm

BRINKER AWARD LECTURE #1

Geoffrey M. Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA

1:00 pm - 2:00 pm

MOLECULAR TUMOR BOARD - Stars at Night Ballroom 1&2

Moderator: Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milano, Italy

Panelists:

Philippe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada

Amy L. Delson
University of California San Francisco
Atherton, CA

Erika Hamilton, MD
Sarah Cannon Research Institute
Nashville, TN

Sara Hurvitz, MD, FACP
University of California San Francisco
Los Angeles, CA

Antonio Marra, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Alex Prat, MD, PhD
Hospital Clínic Barcelona
Barcelona, Spain

Daniel Stover, MD
Ohio State University Comprehensive
Cancer Center
Columbus, OH

1:00 pm - 2:00 pm

FORUM #3 Stars at Night Ballroom 3&4

Modifying Tumor Response: Microbiome, Diet, and Fasting

Moderator: Sangeetha Reddy, MD, MSc
UT Southwestern Medical Center
Dallas, TX

Fungal regulation of breast tumor radiation response

Stephen L. Shiao, MD, PhD
Cedars-Sinai
Los Angeles, CA

Microbiome and response to immunotherapy

Jennifer A. Wargo, MD
UT MD Anderson Cancer Center
Houston, TX

Fasting and Microbiotic

Guido Kroemer, MD, PhD, PU-PH
University of Paris Descartes
Paris, France

2:00 pm - 3:00 pm

TRANSLATIONAL CONTROVERSIES - Stars at Night Ballroom 1&2

Moderator: Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, NY

RIP MTD

Hope S. Rugo, MD, FASCO
University of California San Francisco
San Francisco, CA

Geoffrey Shapiro, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Randomized trials vs real world evidence

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Sean Khozin, MD, MPH
CancerLinQ, LLC
New York, NY

Ki 67

Nadia Harbeck, MD, PhD
LMU University Hospital
Munich, Germany

Torsten Nielsen, MD, PhD, FRCPC
University of British Columbia
Vancouver, Canada

2:00 pm - 3:00 pm

FORUM #4 - Stars at Night Ballroom 3&4

Demystifying CDKs in Breast Cancer: Beyond CDK4/6

Moderator: Rinath Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

CDK4/6 inhibitor resistance: Biological mechanisms and novel approaches

Ariella Hanker, PhD
UT Southwestern Medical Center
Dallas, TX

Current status of CDK2 inhibitors in (pre-)clinical development

Sarat Chandralapaty, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Inhibiting transcriptional CDKs in breast cancer

Charles Coombes, MD PhD
Imperial College
London, United Kingdom

3:00 pm - 5:00 pm

EDUCATIONAL SESSION BLOCK #3

EDUCATIONAL SESSION BLOCK #3A - Hemisfair Ballroom 1&2

Management of Hereditary Risk: Moderate-Risk Genes and New Approaches

Moderator: Seema A. Khan, MD
Northwestern University
Chicago, IL

Cancer risks in patients with moderate penetrance gene mutations

Payal D. Shah, MD
Penn Medicine
Philadelphia, PA

Screening for high-risk patients: Does everyone need annual MRI with mammogram?

Madeleine M.A. Tilanus-Linthorst, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Hormonal exposure and risk in BRCA1/2 carriers

Joanne Kotsopoulos, MSc, PhD
University of Toronto
Toronto, Canada

EDUCATIONAL SESSION BLOCK #3B - Stars at Night Ballroom 1&2
Challenging Types of Breast Cancer

Moderator: Bora Lim, MD
Baylor College of Medicine
Houston, TX

Pathologic aspects

Jorge S. Reis-Filho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Metaplastic

Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Inflammatory

Filipa Lynce, MD
Dana-Farber Cancer Institute
Boston, MA

Lobular/pleomorphic

Sibylle Loibl, MD, PhD
German Breast Group
Neu-isenburg, German

EDUCATIONAL SESSION BLOCK #3C - Stars at Night Ballroom 3&4

What ctDNA Can Tell Us

Moderator: Nicholas Turner, PhD, FRCP
The Royal Marsden Hospital
London, United Kingdom

Which is the best technique

Heather Parsons, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Can ctDNA substitute tissue testing

Ben O'Leary, MBBS, PhD
The Institute of Cancer Research
London, United Kingdom

Using ctDNA in detecting disease

Minetta C. Liu, MD
Natera
Austin, TX

5:00 pm - 6:15 pm

POSTER SESSION #5 - Hall 1

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #13 - Stars at Night Ballroom 1&2

Therapeutic Approaches for HR+/Her2- Breast Cancer

Chair: Kevin Kalinsky, MD

Winship Cancer Institute

Atlanta, GA

Phillipe Bedard, MD

Princess Margaret Cancer Centre

Toronto, Canada

Rinath M. Jeselsohn, MD

Dana-Farber Cancer Institute

Boston, MA

Neil Vasan, MD, PhD

Columbia University

New York, NY

Roberta Albany

Cancer in the Know

Mt Penn, PA

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #14 - Stars at Night Ballroom 3&4

Breast Cancer Risk Modeling

Chair: Judith Balmaña, MD, PhD

Vall d'Hebron University Hospital

Barcelona, Spain

Genetics

Jennifer Caswell-Jin, MD

Stanford

Stanford, CA

Imaging

Sarah Eskreis-Winkler, MD, PhD

Memorial Sloan Kettering Cancer Center

New York, NY

5:00 pm - 6:15 pm

SPOTLIGHT POSTER DISCUSSION SESSION #15 - Hemisfair Ballroom 1&2

Local Regional/Management of the Axilla

Chair: Andrea V. Barrio, MD, FACS

Memorial Sloan Kettering Cancer Center

New York, NY

Axillary management

Tracy-Ann Moo, MD

Memorial Sloan Kettering Cancer Center

New York, NY

Local recurrence invasive cancer and DCIS

Jennifer K. Plichta, MD
Duke University
Durham, NC

Reconstruction, Topical Tam, MRI

Rachel Greenup, MD, MPH
Yale School of Medicine
New Haven, CT

7:00 pm - 10:00 pm

OPEN SATELLITE EVENTS - Marriott Rivercenter

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of ER-Positive Breast Cancer — An Independent Satellite Symposium Held in Conjunction with the 45th Annual San Antonio Breast Cancer Symposium presented by Research to Practice

Molecular Imaging and Breast Cancer: Selecting and Evaluating Targeted Treatments presented by Society of Nuclear Medicine and Molecular Imaging

FRIDAY, DECEMBER 9, 2022

7:00 am - 8:15 am

POSTER SESSION #6 - Hall 1

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #16 - Hemisfair Ballroom Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How?

Chair: David A. Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA

Janie Lee, MD, MSc
University of Washington
Seattle, WA

Disparities in utilization

Janie Lee, MD, MSc
University of Washington
Seattle, WA

Imaging to guide treatment

Amy Fowler
University of Wisconsin

AI/Radiomics and novel metrics applied and breast cancer imaging

Aimilia Gastouniotti, MD
Washington University School of Medicine
St. Louis, MO

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #17 - Stars at Night Ballrooms 1&2

Endocrine Therapy New Insights

Chair: Lajos Pusztai, MD, DPhil
Yale School of Medicine
New Haven, CT

Pavani Chalasani, MD, MPH
University of Arizona Cancer Center
Tucson, AZ

Seth A. Wander, MD, PhD
Massachusetts General Hospital
Cambridge, MA

7:00 am - 8:15 am

SPOTLIGHT POSTER DISCUSSION SESSION #18 - Stars at Night Ballrooms 3&4

Updates and New Therapies for HER2 Positive Disease

Chair: Ian E. Krop, MD, PhD
Yale School of Medicine
New Haven, CT

Roisin M. Connolly, MD
University College Cork
Cork, Ireland

Sara A. Hurvitz, MD
University of California
Los Angeles, CA

Paula R. Pohlman, MD, MSc, PhD
UT MD Anderson Cancer Center
Houston, TX

8:30 am - 9:00 am

**AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH
- Hall 3**

9:00 am - 11:30 am

GENERAL SESSION #4 - Hall 3

Moderator: Wendy A. Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

9:00 am - 9:15 am

**GS4-01 Impact of breast conservation therapy on local recurrence in patients
with multiple ipsilateral breast cancer – Results from ACOSOG Z11102 (Alliance)**

Boghey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, Kubicky CD,
Le-Petross HTC, Van Zee K, Giuliano AE, Hahn OM, Hunt KK, Carey LA, Partridge AH.

9:15 am - 9:30 am

GS4-02 Oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy

Montagna G, Mrdutt M, Botty A, Barrio AV, Sevilimedu V, Boughey JC, Hoskin TL, Rosenberger LH, Hwang ES, Inhgam A, Papassotiropoulos B, Nguyen-Sträuli BD, Kurzeder C, Diaz Aybar D, Vorburger D, Matlac DM, Ostapenko E, Riedel F, Fitzal F, Meani F, Fick F, Sagasser J, Heil J, Dedes KJ, Romics L, Banyas-Paluchowski M, Cueva Perez MDR, Chavez Diaz M, Heidinger M, Fehr MK, Reinisch M, Maggi N, Rocco N, Ditsch N, Gentilini OD, Resende Paulinelli R, Zarhi SS, Küemmel S, Bruzas S, Di Lascio S, Parissenti T, Güth U, Ovalle V, Tausch C, Morrow M, Kühn T, Weber WP.

9:30 am - 9:45 am

GS4-03 Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy

Karlsson P, Fyles A, Chang SL, Arrick B, Baehner F, Malmström P, Fernö M, Holmberg E, Sjöström M, Liu F-F, Cameron DA, Williams LJ, Bartlett JMS, Dunlop J, Caldwell J, Loane JF, Mallon E, Piper T, Jack WJ, Kunkler I, Feng FY, Speers CW, Pierce LJ, Bennett J, Taylor KJ.

9:45 am - 10:00 am

GS4-04 Population-based estimates of contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2

Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Dunn C, Holtegaard S, Huang H, Teras LR, Patel AV, Lacey Jr JV, Neuhausen S, Bernstein L, Martinez E, Haiman C, Chen F, Ruddy KJ, Olson J, John E, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli GR, Goldgar DE, Nathanson KL, Domchek SM, Palmer JR, Weitzel J, Kraft P, Couch FJ.

10:00 am - 10:15 am

GS4-05 Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy

Mutter R, Giri S, Fruth B, Remmes N, Anand A, Ruddy KJ, Villarraga H, Santos Patarroyo S, Yan E, Merrell K, McGee L, Vern-Gross T, Stish B, Gao R, Boughey JC, Park S, Corbin K, Vargas C.

10:15 am - 10:30 am

GS4-06 Radiomic phenotypes of breast texture and association with breast cancer risk and masking

Winham S, McCarthy AM, Gastouniotti A, Scott C, Norman A, Mankowski WC, Pantalone L, Jensen M, Cohen EA, Horng H, Brandt K, Conant EF, Kerlikowski K, Kontos D, Vachon C.

10:30 am - 10:45 am

GS4-07 Discussant for GS4-06

TBD

10:45 am - 11:00 am

GS4-08 10-year results of a phase 3 trial of low-dose tamoxifen in non-invasive breast cancer

De Censi A, Lazzeroni M, Puntoni M, Boni L, Guerrieri Gonzaga A, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B.

11:00 am - 11:15 am

GS4-09 Pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer: Initial Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13)

Partridge A, Niman SM, Ruggeri M, Peccatori FAA, Azim Jr HA, Colleoni M, Saura C, Shimizu C, Saetersdal A, Kroep J, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe J, Ruiz Borrego M, Moore H, Saunders C, Bjelic-Radisci V, Susnjar S, Cardoso F, Smith KL, Ferreiro Vilarino T, Ribi K, Ruddy KJ, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O.

11:15 am - 11:30 am

GS4-10 Discussant for GS4-09

Jennifer K. Litton, MD
UT MD Anderson Cancer Center
Houston, TX

10:00 am - 5:00 pm

EXHIBITS - Hall 2

11:30 am - 12:00 pm

BRINKER AWARD LECTURE #2

Norman Wolmark, MD, FACS, FRCSC
University of Pittsburgh
Pittsburgh, PA

12:00 pm – 3:00 pm

GENERAL SESSION #5 - Hall 3

Moderator: Alexander JR Bishop, DPhil
UT Health San Antonio
San Antonio, TX

12:00 pm - 12:15 pm

GS5-01 Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial

Gupta S, Nair NS, Hawaldar R, Vanmali V, Parmar V, Gulia S, Ghosh J, Joshi S, Sarin R, Wadasadawala T, Panhale T, Desai S, Shet T, Patil A, Chitkara G, Rath S, Bajpai J, Thakkur M, Badwe R.

12:15 pm - 12:30 pm

GS5-02 Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study

Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Denkert C, Schmutzler RK, Hahnen E, Untch M, Nekljudova V, Blohmer J-U, Loibl S.

12:30 pm - 12:45 pm

GS5-03 Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Isaacs C, Nanda R, Chien J, Trivedi MS, Stringer-Reasor E, Vaklavas C, Boughey JC, Sanford A, Wallace A, Clark AS, Thomas A, Albain KS, Kennedy LC, Sanft TB, Kalinsky K, Han HS, Williams N, Arora M, Elias A, Falkson C, Asare S, Lu R, Pitsouni M, Wilson A, Perlmutter J, Rugo HS, Schwab R, Symmans WF, Hylton NL, Van 't Veer L, Yee D, DeMichele A, Berry D, Esserman LJ, I-SPY Investigators.

12:45 pm - 1:00 pm

GS5-04 Identification of symptoms that are associated with irAEs in the I-SPY clinical trial

Basu A, Umashankar S, Melisko M, Lu R, Yu H, Yau C, Asare S, Pitsouni M, Shatsky RA, Isaacs C, DeMichele A, Hershman DL, Nanda R, Kim M-O, Esserman LJ, Rugo HS.

1:00 pm - 1:15 pm

GS5-05 ZNF689 deficiency promotes intratumor heterogeneity and resistance to immune checkpoint blockade in triple-negative breast cancer

Ge L-P, Jin X, Di G-H, Jiang J-Z, Shao Z-M.

1:15 pm - 1:30 pm

GS5-06 InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas

Xu L, Saunders K, Knutsdottir H, Chen K, Maués J, Hodgdon C, Roussos Torres ET, Reddy SM, Xu L, Chan I.

1:30 pm - 1:45 pm

GS5-07 Estradiol represses anti-tumoral immune response to promote progression of triple-negative breast cancer brain metastases

Contreras-Zarate MJ, Alvarez-Eraso K, Tescic V, Tsuji N, Chafee L, Karam S, Ormond DR, Kabos P, Cittelly DM.

1:45 pm - 2:00 pm

GS5-08 Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer

Hu X, Xiong Y, Villodre ES, Song J, Manyam GC, Tacam MJ, Wang J, Bartholomeusz C, Tripathy D, Ueno NT, Woodward WA, Krishnamurthy S, Chen J, Debeb B.

2:00 pm - 2:15 pm

GS5-09 Discussant for GS5-07 and GS 5-08

TBD

2:15 pm - 2:30 pm

GS5-10 Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial

Liefers G-J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, J.H. van de Velde C, Kleijn M, Dreezen C, Menicucci A, van't Veer L, Audeh W.

2:30 pm - 2:45 pm

GS5-11 Second interim analysis of overall survival (OS) from the TROPiCS-02 phase 3 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients with HR+/HER2- advanced breast cancer

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri K, Delaney R Fu O, Wang H, Verret W, Tolaney SM.

2:45 pm – 3:00 pm

GS5-12 Hypofractionated Radiotherapy in patients with Breast Cancer (HRBC): Acute toxicity data of a phase III randomized study

Yadav BS, Dahiya D, Gupta M.

3:00 pm - 5:00 pm

EDUCATIONAL SESSION BLOCK #4

**EDUCATIONAL SESSION BLOCK #4A - Stars at Night Ballroom 1&2
Advances in Pregnancy Associated Breast Cancer (PABC)**

Moderator: Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Updates in the pathology of PABC

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Special treatment issues in this young patient population

Ann Partridge, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Oncofertility and other quality of life issues

Matteo Lambertini, MD, PhD
University of Genova - San Martino Hospital
Genova, Italy

EDUCATIONAL SESSION BLOCK #4B - Stars at Night Ballroom 3&4

State of the Art Radiotherapy: Reducing Toxicity and Increasing Options

Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

The role of advanced radiation technology in reducing toxicity

Rachel Jimenez, MD
Massachusetts General Hospital
Boston, MA

Overview of the current state of the art - what patients and oncologists need to know

Melissa Mitchell, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Evidence for ablative radiation in metastatic breast cancer

Chiaojung Jillian Tsai, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

**EDUCATIONAL SESSION BLOCK #4C - Hemisfair Ballroom 1&2
Targeting the Tumor Microenvironment for Clinical Impact**

Moderator: Diana Cittelly, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO

Influence of bone microenvironment on metastasis

Igor Bado, PhD
Baylor College of Medicine
Houston, TX

The contribution of the tumor microenvironment to cancer dormancy

J. Javier Bravo-Cordero, PhD
Icahn School of Medicine at Mount Sinai
New York, NY

Effects of age on the tumor microenvironment

Sandra S. McAllister, PhD
Harvard Institutes of Medicine
Boston, MA

Can inflammation be targeted?

Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

5:00 pm - 5:15 pm

REFRESHMENT BREAK

5:15 pm - 7:15 pm CT

**View from the Trenches: What will You do on Monday Morning? - Stars at Night
Ballroom 1&2**

Moderators: Andrea Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Panelists:

Vernal Branch
Patient Advocate
UNC Chapel Hill Lineberger Cancer
Institute
Mooresville, NC

Mariana Chavez-MacGregor, MD, MSC,
FASCO
UT MD Anderson Cancer Center
Houston, TX

Tanja N. Fehm, MD
University Hospital Düsseldorf
Düsseldorf, Germany

Kalliopi Siziopikou, MD, PhD
Northwestern University
Chicago, IL

Mediget Teshome, MD, MPH, FACS
UT MD Anderson Cancer Center
Houston, TX

Cynthia Villreal Garza, MD, DSc
Tecnológico de Monterrey
Monterrey, Mexico

Richard C. Zellars, MD
Indiana University
Indianapolis, IN

SATURDAY, DECEMBER 10, 2022

8:00 am - 10:00 am

THE YEAR IN REVIEW - Hall 3

Moderators:

Carlos Arteaga, MD
UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Basic science

Andrei Goga, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Translational research

Shom Goel, MBBS, B Med Sci (Hons)
Peter MacCallum Cancer Centre
Melbourne, Australia

Early breast cancer

Marleen Kok, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Advanced breast cancer

Melinda Telli, MD
Stanford University School of Medicine
San Francisco, CA

10:00 am

ADJOURNMENT

YOU ARE CORDIALLY INVITED TO THE FOLLOWING PROGRAM:

A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation

Henry B. Gonzalez Convention Center
900 E. Market Street
San Antonio, TX

Wednesday, December 7, 2022 | 2:00–3:00 PM CT

Lunch will be served.

HEAR FROM THE FOLLOWING SPEAKERS:



Adam M. Brufsky, MD, PhD
University of Pittsburgh
School of Medicine
Pittsburgh, PA



Neil Iyengar, MD
Memorial Sloan Kettering
Cancer Center
New York, NY



Nicole R.
Patient Ambassador

If you plan to attend, kindly make every effort to arrive by the designated start time and to remain through the duration of the program. Please be advised that late arrivals may be prohibited from participating in the event.

Notice: This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit their ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this or any Pfizer event. Your attendance will be considered confirmation to Pfizer that you have obtained any necessary approvals to attend this event.

State Laws and Pfizer Disclosures: The cost of meals and refreshments provided to US licensed Healthcare Professionals attending this Pfizer-sponsored program will be subject to public disclosure on www.pfizer.com as part of Pfizer's Healthcare Professional Disclosure policies, and may also be subject to disclosure by state governmental authorities pursuant to your state law and applicable federal law such as the National Physician Payment Transparency Program (otherwise known as "Sunshine"). Pfizer's disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. **If you are licensed to practice in Massachusetts, Minnesota or Vermont, we are prohibited from providing you any meals and/or refreshments due to your state limitation on meals, gifts or other items of value to HCPs and ask that you do not partake in the hospitality provided.**

NO CNE or CME contact hours will be awarded.

This Exhibitor Product Theatre is a promotional activity and is not approved for continuing education credit. The content of this Exhibitor Product Theatre and opinions expressed by presenters are those of the sponsor or presenter and are not of the San Antonio Breast Cancer Symposium® (SABCS®).

PRODUCT THEATRE

Product Theatres will promote product or service of select SABCS exhibitors.

WEDNESDAY, DECEMBER 7, 2022

10:00 am CT

Advancing the Standards of Breast Cancer Care with Comprehensive Somatic Next-Generation Sequencing, Germline Testing and AI-Driven Data

presented by Tempus

12:00 pm CT

Exploring Treatment Options in HER2+ Early Breast Cancer

presented by Genentech

2:00 pm CT

A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation

presented by Pfizer

4:00 pm CT

Learn More About an FDA-Approved Treatment for Metastatic Triple-Negative Breast Cancer

presented by Gilead Sciences, Inc.

THURSDAY, DECEMBER 8, 2022

10:00 am

MammaPrint & Blueprint: Gene Expression Profiling for Risk of Distant Metastasis in Early-Staged Breast Cancer Tumors and Molecular Subtyping Driving its Growth

presented by Agendia, Inc.

12:00 pm

The Predictive Power of the Breast Cancer Index H/I Biomarker: Extended Endocrine Therapy and Beyond

presented by Biotheranostics, A Hologic Company

2:00 pm

Clinical Trial Data update for a HER2+ MBC treatment option

presented by Seagen Inc.

4:00 pm

Laying the Groundwork: Current and Future Applications of Signatera™ in Breast Cancer

presented by Natera

FRIDAY, DECEMBER 9, 2022

10:00 am

Explore data for an FDA-approved treatment option in HR+, HER2- breast cancer in certain adjuvant or metastatic settings. PP-AL-US-2989 © Lilly USA, LLC 2021. All rights reserved.

presented by Lilly Oncology

12:00 pm

The Evolving Role of the Oncotype Dx Breast Recurrence Score® Test and the Future of the Breast Cancer Care Continuum

presented by Exact Sciences

2:00 pm

The Efficacy and Safety of ENHERTU

presented by Daiichi Sankyo, Inc.

4:00 pm

Reducing Recurrence in HER2+ eBC

presented by Puma Biotechnology

SPOTLIGHT POSTER DISCUSSION SESSION 1

TUESDAY, DECEMBER 6, 2022: 5:00 PM – 6:15 PM
HEMISFAIR BALLROOM 1&2

Racial Outcomes and Disparities

Chair: TBD

Disparities in screening and outcomes

David Haynes, PhD
University of Minnesota
Minneapolis, MN

Race and outcomes

TBD

Patient Perspective

Tammie Denyse
Carrie's Touch
Sacramento, CA

PD1-01 The impact of structural racism on breast cancer stage at presentation

Hernandez A, Cohen BL, Westrick A, Thompson C, Kesmodel S, Goel N

PD1-02 Evaluating racial and ethnic disparities in diagnostic breast imaging: A retrospective cohort study

Milton A, Woods R, Elezaby M, Neuner J, Hackett K, Narayan A, Strigel R

PD1-03 Neighborhood deprivation and breast cancer mortality among black and white women

Barber LE, Miller-Kleinhenz JM, Maliniak ML, Moubadder L, Switchenko J, McCullough LE

PD1-04 Neighborhood deprivation index and survival in breast cancer in the United States

Roy AM, George A, Attwood K, Gandhi S

PD1-05 Racial/ethnic segregation and inequities in metastatic breast cancer treatment initiation and overall survival

Guadamuz JS, Calip GS, Asfaw AA, Wang X, Pittell H, Kaur M, Pierre AE, Ryals CA

PD1-06 Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy

Stecklein SR, Yoder R, Salgado R, Staley JM, O'Dea A, Nye L, Elia M, Satelli D, Crane G, McKittrick R, Godwin AK, Khan Q, Sharma P

PD1-07 Racial disparities in neoadjuvant chemosensitivity and survival in early breast cancer: A national database study

Roy AM, Catalfamo K, Attwood K, Gandhi S

PD1-08 PAM50 and 21-gene recurrence scores in younger and Black women with breast cancer

Vohra S, Van Alsten S, Ivory JM, Hamilton A, Gao X, Kirk E, Nsonwu-Farley J, Butler E, Taffe B, Perous CM, Carey LA, Troester M

PD1-09 Associations between the 21-gene oncotype DX recurrence score (RS), Ki67, and race in early breast cancer (EBC) using the National Cancer Database (NCDB)

Patel R, Kwon D, Van Hyfte G, Sparano J, Tiersten A

PD1-10 Impact of race on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with metastatic breast cancer

Sood R, Ryan L, Niemierko A, Spring LM, Juric D, Isakoff SJ, Wander SA, Shin J, Ko N, Ellisen LW, Moy B, Bardia A, Vidula N

SPOTLIGHT POSTER DISCUSSION SESSION 2

TUESDAY, DECEMBER 6, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 1&2

Tumor Immunology and Novel Immune Therapy Strategies

Chair: Cesar A. Santa-Maria, MD
Johns Hopkins Medicine
Baltimore, MD

Sangeetha Reddy, MD
UT Southwestern
Dallas, TX

Justin M. Balko, MD, PhD
Vanderbilt University Medical Center
Nashville, TN

PD2-01 Local and lymphoid immune surveillance mechanisms in “exceptional survivors” of stage 4 cancers following standard of care chemo- and targeted therapies

Kakkassery H, Alaguthurai T, Graham R, Carpenter E, Hossain F, Keane S, Irshad S

PD2-02 Longitudinal local and peripheral immunologic changes associated with checkpoint inhibition response in murine models of breast cancer

Hanna A, Sun X, Sheng Q, Sanders M, Balko JM

PD2-03 Targeting TGF- β and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in Triple Negative Breast Cancer (TNBC)

Shin S, Filimon B, Yang Y, Hu Z, Seth P, Gadi VK, Xu W

PD2-04 Preclinical development of CodaLytic™, a codon-modified influenza virus, as a novel virotherapeutic agent for breast cancer immunotherapy

Stawowczyk M, Zhao Y, Pfeffer K, Tafrova J, Rodriguez J, Yang C, Jahan N, Tasker S, Mueller S, Coleman JR, Kaufmann JK

PD2-05 CSF-1R antibody targeting therapy with combined metronomic chemotherapy enhances a B and T cell response for the treatment of metastatic triple negative breast cancer

Pedroza D, Wu W, Porter P, Zhang X, Rosen J.

PD2-06 Implications of heterogeneity in breast tumor cell MHC-I expression on immunity and therapeutic resistance

Taylor BC, Sun X, Balko JM, Gonzalez-Ericsson P, Sanders M

PD2-07 Tumor CD73 regulates zoledronate induced TIL accumulation into triple negative breast cancer

Petruk N, Siddiqui A, Tadayon S, Jukkola A, Määttä J, Mattila P, Sandholm J, Selander KS

PD2-08 Targeting of eIF4A1 along with anti-PD-L1 therapy limits lung metastases efficaciously in triple-negative breast cancer

Dulal D, Boring A, Raman D

PD2-09 Characterization of the lymphovascular invasion microenvironment reveals immune response dichotomy

Rivero-Gutiérrez B, Mello D, Espín-Pérez A, Vennam S, Zhu C, Varma S, Scott G, Foley J, Hwang ES, Maley C, West R

PD2-10 MiR-150 expression in breast cancer cells attract infiltration of lymphocytes to tumor microenvironment and is associated with better survival of the patients

Oshi M, Maiti A, Vaghjiani RG, Wu R, Yan L, Yamada A, Hait N, Ishikawa T, Endo I, Takabe K, Tokumaru Y

PD2-11 Human cytomegalovirus reactivation in immunosuppressive Th2 tumor microenvironment facilitates brain metastatic outgrowth

Wang X, Puri A, Irfan A, Han K, Qian W, Guzman L, Rosato R, Zhao H, Chang J, Wong S.

SPOTLIGHT POSTER DISCUSSION SESSION 3

TUESDAY, DECEMBER 6, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 3&4

New Radiation Techniques

Chair: Richard Zellars, MD
Indiana University School of Medicine
Indianapolis, IN

Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Ryan M. Rhome, MD, PhD
Indiana University

Indianapolis, IN PD3-01 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

McArthur H, Cortés J, Dent R, O'Shaughnessy J, Pusztai L, Küemmel S, Foukakis T, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Denkert C, Zhu Y, Ding Y, Pan W, Schmid P

PD3-02 Withdrawn

PD3-03 Preoperative robotic radiosurgery for early breast cancer: results of the phase II ROCK trial (NCT03520894)

Meattini I, Francolini G, Di Cataldo V, Visani L, Becherini C, Scoccimarro E, Mangoni M, Salvestrini V, Masi L, Bellini C, Doró R, Di Naro F, Bernini M, Nori J, Orzalesi L, Bianchi S, Livi L

PD3-04 Locoregional stereotactic body radiotherapy in breast cancer patients unsuitable for surgical resection

Palhares D, Chen H, Khan B, McCann C, Bosnic S, Hahn E, Soliman H, Rakovitch E, Lee J, Vesprini D

PD3-05 Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage breast cancer

Belkacemi Y, Gabelle-Flandin I, Le Deley MC, Petit A, Guilbert P, Geffrelot J, Carrie C, Rivin del Campo E, Hanzen C, Charra-Brunaud C, Lecouillard I, Magne N, Tallet A, Leduc N, Belgadi B, Fournere P, Coutte A, Capelo E, darloy F, Garcia Ramirez M, Dudouet P, Clavere P, Suchaud J-P, Auzac G, Lacornerie T, Lemonnier J, Bourgier C, Lartigau E

PD3-06 Robotic stereotactic APBI for early-stage breast cancer: 2-year outcomes of a prospective multi-institutional trial

Cantalino JM, D'Ambrosio D, Hirsch A, Collins B, Danner M, Matsanka D, Rudra S, Suy S, Collins S, Pernia Marin M, Good M, Feng J, Lamond J, Markiewicz D, Lanciano R, Obayomi-Davies O

SPOTLIGHT POSTER DISCUSSION SESSION 4

WEDNESDAY, DECEMBER 7, 2022: 7:00 AM – 8:15 AM
HEMISFAIR BALLROOM 1&2

Single Cell Approaches for Translational Research and Biomarker Discovery

Chair: Charles Perou, PhD
University of North Carolina
Chapel Hill, NC

Christine Desmedt, PhD
Catholic University Of Leuven
Leuven, Belgium

Alex Swarbrick, PhD
Garvan Institute of Medical Research
Darlinghurst, Australia

PD4-01 Spatial transcriptomics reveals a substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications

Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, Gacquer D, Dupont F, Rouas G, Serra M, Lundeberg J, Rothé F, Sotiriou C

PD4-02 Spatial and temporal heterogeneity of predictive and prognostic signatures in triple-negative breast cancer treated with neoadjuvant combination immune-chemotherapy

Denkert C, Schneeweiss A, Rey J, Hattesoehl A, Karn T, Braun M, Jank P, Huober J, Sinn H-P, Zahm D-M, Hanusch C, Marmé F, Furlanetto J, Thomalla J, Blohmer J-U, van Mackelenbergh M, Stiewe T, Staib P, Jackisch C, Tepy-Szymanski J, Fasching PA, Sinn BV, Untch M, Weber k, Loibl S

PD4-03 Pelareorep primes the tumor for checkpoint inhibition therapy by activating the interferon-gamma signaling pathway and tumor inflammation signature in early breast cancer patients - results of the AWARE-1 trial

Loghmani H, Gavilá J, Manso L, Coffey M, Trauger R, Salvador F, Pascual T, Prat A, Heineman T

PD4-04 A quantitative spatial analysis of microenvironmental biomarkers for breast cancer outcome

Nizzero S, Pelaez Soni M, Xu Y, Zhang L, Zheng J, Menegaz BA, Jordan LB, Purdie CA, Quinlan PR, Nagi C, Sepulveda KA, Oertle P, Appenzeller TA, Loparic M, Wang Z, Chen S-H, Cristini V, Plodinec M, Thompson AM

PD4-05 Integrated multi-cohort profiling identifies CCL19+ dendritic cells to potentiate immunotherapy efficacy in triple-negative breast cancer

Wu S-Y, Zhang S-W, Ma D, Jin X, Jiang Y-Z, Shao Z-M

PD4-06 Obesity-associated changes in transcriptomic profile and immune landscape of primary breast cancer revealed by bulk and single-cell gene expression data

Nguyen H-L, Geukens T, Maetens M, Van Baelen K, De Schepper M, Poncet C, Delorenzi M, Schmid MK, Rutgers E, Van 't Veer L, Piccart M, Cardoso F, Viale G, Bassez A, Vos H, Neven P, Nevelsteen I, Punie K, Wildiers H, Floris G, Lambrechts D, Smeets A, Biganzoli E, Richard F, Desmedt C

PD4-07 Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling

Shah OS, Nasrazadani A, Atkinson JM, Kleer C, McAuliffe PF, Bhargava R, Reis-Filho J, Lucas PC, Lee AV, Oesterreich S

PD4-08 A novel single cell model of Tamoxifen response in primary human breast tumors

Kim H, Whitman A, Wisniewska K, Garcia-Recio S, Kakati R, Franco HL, Perou CM, Spanheimer P.

PD4-09 Single cell RNA-sequencing identifies intra-tumoral cellular heterogeneity and drug-induced subpopulation shifts in triple negative breast cancer mouse models

Glodowski CR, Mott KR, Okumu D, East MP, Elston TC, Johnson GL, Perou CM.

SPOTLIGHT POSTER DISCUSSION SESSION 5

WEDNESDAY, DECEMBER 7, 2022: 7:00 AM – 8:15 AM STARS AT NIGHT BALLROOM 3&4

Advances in TNBC Biology

Chair: Ratna K. Vadlamudi, PhD

UT Health San Antonio
San Antonio, TX

Celina Kleer, MD, PhD
University of Michigan
Ann Arbor, MI

PD5-01 Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in triple negative breast cancer and ovarian carcinoma

Menghi F, Banda K, Kumar P, Straub R, Dobrolecki LE, Rodriguez I, Yost SE, Chandok H, Radke M, Somlo G, Yuan Y, Lewis MT, Liu E

PD5-02 An organoid model system to study resistance mechanisms, predictive biomarkers, and new strategies to overcome therapeutic resistance in early-stage triple-negative breast cancer

Bui TBV, Wolf DM, Moore K, Harris IS, Phadataré P, Yau C, Brown Swigart LA, Esserman LJ, Coppe J-P, Wulfskuhle J, Petricoin EF, Campbell M, Selfors LM, Dillon DA, Overmoyer B, Lynce F, Van 't Veer L, Rosenbluth J

PD5-03 Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial

Coakley M, Sritharan P, Villacampa G, Swift C, Dunne K, Kilburn L, Goddard K, Rojas P, Joad A, Emmett W, Knape C, Howarth K, Hall PS, Harper-Wynne C, Hickish T, Macpherson I, Okines AF, Wardley AM, Wheatley D, Waters S, Cutts R, Garcia-Murillas I, Bliss J, Turner NC

PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents

Wolf DM, Yau C, Wulfskuhle J, Gallagher RI, Brown Swigart LA, Hirst GL, Coppe J-P, Magbanua MJM, Sayaman R, I-SPY2 Investigators, Sit L, Hylton NM, DeMichele A, Berry DA, Pusztai L, Yee D, Esserman LJ, Petricoin EF, Van 't Veer L

PD5-05 DAPK3 modulates migration and invasion of triple negative breast cancers

Wang J, Kim B-J, Anurag M, Yu X, Qo X, Wang J, Zhang B, Cheng C, Ellis M

PD5-06 CCN6 promotes spindle metaplastic breast carcinoma in part via antagonizing Wnt/ β -catenin signaling

Gonzalez ME, Fearon ER, Kleer CG

PD5-07 Hepatic Leukemia Factor (HLF), a potential therapeutic target in triple negative breast cancer

Bouakka I, Tran-Dien A, Sirerol M, Silvin A, Andre F, Rocca A

PD5-08 Drug target activation mapping of matched triple negative primary and axillary lymph node metastases identifies and links the ER-AR-GR steroid hormone receptor axis with downstream AKT activation

Wulfskuhle J, Blas P, Williams H, Mueller C, Gallagher RI, Pierobon M, O'Shaughnessy J, Petricoin EF

PD5-09 Oncogenic pathways of tumor cells signal to stem-ness in TNBC: Relationship between stem cell markers and PI3K-DDR pathway targeted drugs

Dey N, Aske J, Lin X, Dale A, Sun Y, De P

PD5-10 Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer

Ding Z, Ji H, Sharko AC, Loskutov J, Mack Z, Myers J, Chen M, Pugacheva E, Roninson I, Broude E

SPOTLIGHT POSTER DISCUSSION SESSION 6

WEDNESDAY, DECEMBER 7, 2022: 7:00 AM – 8:15 AM
STARS AT NIGHT BALLROOM 1&2

Special Populations: Male Breast Cancer/ Geriatrics

Chair: Anne Blaes

University of Minnesota
Minneapolis, MN

Jose P. Leone, MD
Dana-Farber Cancer Institute
Boston, MA

PD6-01 Association between the CARG-BC score and clinical decline after adjuvant chemotherapy in fit older adults with breast cancer: Results from the Hurria Older PatiEnts (HOPE) Prospective Study

Ji J, Sun C, Muss HB, Cohen HJ, Sedrak MS

PD6-02 Health-related quality of life trajectories and predictors among older breast cancer survivors: A SEER-MHOS analysis

Lee E, Rupesj S, Ferdowski K, Hines R, Loerzel V

PD6-03 Serum methylmalonic acid concentrations at breast cancer diagnosis strongly correlate with frailty: a retrospective cross-sectional study

Wu Q, Hatse S, Kenis C, Lambrechts Y, Punie K, Neven P, Smeets A, Laenen A, Gomes A, Fendt S-M

PD6-04 Baseline insurance and unplanned Emergency Room use and hospitalizations among elderly breast cancer patients participating in clinical trials

Hershman DL, Vaidya R, Till C, Barlow WE, LeBlanc M, Unger JM

PD6-05 Retrospective analysis of VES-13 questionnaires in the Senior Women's Breast Cancer Clinic at Sunnybrook Health Sciences, Toronto, Ontario, Canada

Szumacher EF, Zereshkian A, Benazir BMK, Cao X, Henry=Noel N, Menjak I, Mehta R, Bristow B, Trudeau M, Neve M, Norris M, Pasetka M, Rice K, McCulloch F, Wright F, Dawdy K

PD6-06 Racial and ethnic disparities with influenza vaccine use in long-term survivors of metastatic breast cancer

Doshi SD, DeStephano D, Accordino MK, Elkin EB, Wright JD, Hershman DL

PD6-07 CDK 4/6 Inhibitors in combination with endocrine therapy for the treatment of metastatic breast cancer in men

Yildirim HÇ, Mutlu E, Chalabiyev E, Özen M, Keskinlikç M, Ön S, Çelebi A, Dursun B, Acar Ö, Kahraman S, Aykan MB, Kaman Ö, Doğan A, Erdoğan AP, Celayir ÖM, Günenç D, Güven DC, Bayoğlu İV, Yavuzşen T, Hacıbekiroğlu İ, İnanç M, Kılıçkap S, Aksoy S

PD6-08 Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer

Leone J, Hassett MJ, Freedman R, Tolaney SM, Graham N, Tayob N, Vallejo CT, Winer EP, Lin NU, Leone JP

PD6-10 The impact of post mastectomy radiation therapy on clinical outcomes of male breast cancer: A meta-analysis of comparative studies

Haddad PA, Zaheer U

PD6-11 Evaluation of the sensitivity to endocrine therapy index (SET2,3) in early male breast cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program

Zakon DB, Poncet C, Cardoso F, Anouk N, Valero V, Aebi S, Benstead K, Bogler O, Dal Lago L, Fraser J, Caballero C, Hedenfalk IA, Korde LA, Linderholm B, Martens JWM, Middleton LP, Murray M, Kelly CM, Nilsson C, Nowaczyk M, Peeters S, Beauvois M, Porter P, Schroder CP, Rubio it, Ruddy KJ, van Asperen C, Van Den Weyngaert D, HM van Deurzen C, van Leeuwen-Stok E, Vermeij JM, MS Bartlett J, Wolff AC, Giordano SH, Symmans WF

SPOTLIGHT POSTER DISCUSSION SESSION 7

WEDNESDAY, DECEMBER 7, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 3&4

Brain Metastases

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Treatment

Barbara O'Brien, MD
UT MD Anderson Cancer Center
Houston, TX

Prognosis

Carey K. Anders, MD
Duke
Durham, NC

PD7-01 Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: A multicenter retrospective study (ROSET-BM study)

Yamanaka T, Niikura N, Nomura H, Kusama H, Yamamoto M, Matsuura K, Inoue K, Takahara S, Kita S, Yamaguchi M, Aruga T, Shibata N, Shimomura A, Ozaki Y, Shiraiishi K, Sakai S, Kiga Y, Izutani T, Shiosakai K, Tsurutani J

PD7-02 Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial

Pérez-García JM, Vaz Batista M, Cortez-Castedo P, Ruiz Borrego M, Cejalvo JM, de la Haba-Rodríguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gión M, Nave M, Fernández A, Martínez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S

PD7-03 Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ breast cancer brain metastases (BCBM)

Freedman R, Ren S, Tayob N, Gelman R, Smith KL, Davis R, Pereslete A, Attaya V, Cotter C, Chen WY, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko M, O'Sullivan CC, Ashai N, Rauf Y, Nangia J, Trapani D, Savoie J, Burns R, Wolff AC, Winer EP, Rimawi MF, Krop I, Lin NU

PD7-04 Capecitabine treatment for patients with central nervous system metastases from breast cancer

Gouveia M, Hidalgo Filho CM, Colombo Bonadio R, Testa L

PD7-05 Survival of patients with brain metastases at initial breast cancer diagnosis over the last decade

Avila J, Leone J, Vallejo CT, Lin NU, Leone JP

PD7-06 Characteristics of long-term survival in breast cancer brain metastasis after stereotactic radiation

Tang JD, Mills MN, Thawani C, Oliver DE, Soyano A, Etame A, Yu H-HM, Tran N, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA

PD7-07 Somatic alterations in primary tumors of patients (pts) with metastatic breast cancer (MBC) may predict likelihood of brain metastasis

Kabraji S, Yi YY, Hughes ME, Gupta HV, Buckley L, Files JL, Mohammed-Abreu A, Feeney A-M, Kirkner G, Patel A, Garrido-Castro AC, Barroso-Sousa R, Bychkovsky B, Meyerson M, Tolaney SM, Dillon DA, Johnson B, Winer EP, Cherniack A, Lin NU

PD7-08 Gene expression profiling of breast cancer brain metastasis shows enrichment for non-luminal subtypes with potential prognostic implications

Griguolo G, Dieci MV, Fineberg S, Pinato C, Bottosso M, Bauchet L, Miglietta F, Jacob J, Zarrilli G, Rigau V, Guarascio MC, Zanconato F, Schiavi F, Fassan M, Jacot W, Piccolo S, Darlix A, Guarneri V

SPOTLIGHT POSTER DISCUSSION SESSION 8

WEDNESDAY, DECEMBER 7, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 1&2

Symptom Management and Associated Toxicities

Chair: Dawn Hershman, MD
Columbia University Medical Center
New York, NY

Symptom management

Ines-Maria Vaz-Duarte, MD, MSc
Dana-Farber Cancer Institute
Boston, MA

Psychosocial needs

TBD

Patient Advocate

Barbara Segarra Vazquez, DSc
University of Puerto Rico
San Juan, Puerto Rico

PD8-01 PantoCIN: Pantoprazole's effectiveness as prophylaxis against delayed Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy

Wewala N, Sharples K, Kim Y, Bengé S, Cartwright R, Clement L, Huang Y, Isaacs R

PD8-02 Metformin (MET) for the prevention of Alpelisib (ALP)-related hyperglycemia (HG) in PIK3CA-mutated, hormone receptor-positive (HR[+]) HER2-negative (HER2[-]) advanced breast cancer (ABC): The METALLICA study.

Ruiz Borrego M, Tolosa P, Blanch S, Fernández A, Urriticoechea A, Blancas I, Saura C, Rojas B, Bermejo B, Ponce J, Gi6n M, Llabres E, Galve E, Cueva JF, L6pez A, Alonso-Romero JL, Gonz6lez-Santiago S, Mart6nez De Dueñas E, Gomez Peralta F, Ciruelos E, P6rez-García JM, Lombart-Cussac A, Cortés J

PD8-03 Beta blockers and/or ACE inhibitors as cardioprotective strategy for patients affected by nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy (SAFE - NCT02236806): final results of a randomized trial

Meattini I, Becherini C, Visani L, Saieva C, Salvestrini V, Martella F, Bacci C, Molinara E, Airolidi M, Del Bene MR, Amoroso D, Coltelli L, Desideri I, Scotti V, Bernini M, Orzalesi L, Nori J, Bianchi S, Barletta G, Livi L

PD8-04 The role of Yoga as a complementary therapy in women undergoing treatment for breast cancer: A randomized controlled trial

Nair NS, Goel NS, Parmar V, Dewade A, Siddique S, Pandey A, Hawaldar R, Badwe R

PD8-05 Effectiveness of electroacupuncture versus auricular acupuncture in reducing pain and improving quality of life in breast cancer survivors with chronic musculoskeletal pain

Bao T, Zhi W, Baser R, Li Q, Mao J

PD8-06 Incidence of acute and persistent clinically meaningful chemotherapy induced peripheral neuropathy in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714 (NCT# 03939481)

Trivedi MS, Unger JM, Hershman DL, Darke AK, Hertz DL, Brannagan TH, Smith SJ, Schneider BP, Irvin Jr WJ, Hathaway AR, Vander Woude AC, Gudena VK, Henry NL, Fisch MJ

PD8-07 The changing informational needs of young women affected by breast cancer: A national needs assessment

Hanson A, Guglielmino J, Ormerod C, Katze N, Teteh D, Ericson M

PD8-08 Employment status change in a cohort of young women with breast cancer in Mexico

Villarreal-Garza C, Ferrigno A, Salazar M, Enriquez LF, Fonseca A, Platas A, Labra L, Cruz-Ramos M, Miaja M, Vaca-Cartagena B, Becerril-Gaitan A, Mesa-Chavez F, Bargallo-Rocha E, Mohar A

PD8-09 Impact of neighborhood disadvantage on biological and clinical indicators of anxiety and breast cancer survival

Goel N, Ream M, Hernandez A, Clarke E, O'Neil DS, Antoni M

PD8-10 Identifying racial and ethnic disparities in psychosocial care among adults with metastatic breast cancer (mBC): A retrospective analysis across six New York health systems

Pinheiro L, An A, Walker D, Mercurio AM, Hershman DL, Rosenberg SM

SPOTLIGHT POSTER DISCUSSION SESSION 9

WEDNESDAY, DECEMBER 7, 2022: 5:00 PM – 6:15 PM
HEMISFAIR BALLROOM 1&2

Immune Landscape and Microenvironments

Chair: W. Fraser Symmans, MB ChB
UT MD Anderson Cancer Center
Houston, TX

Michail Ignatiadis, MD, PhD
Institut Jules Bordet
Brussels, Belgium

Daniel G. Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

P9-01 Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer

Chen J, Wu S, Ruan T, Slapetova I, Millar E, Lim E, Swarbrick A

PD9-02 MHC class I and PD-L1 expression in triple-negative breast cancer subtypes: impact on T-cell infiltration and clinical outcome

Lee JS, Kim NI, Park MH

PD9-03 Breast cancer microenvironment change after neoadjuvant endocrine treatment

Oner G, Broeckx G, Van Berckelaer C, Altintas S, Canturk Z, Tjalma W, Zwaenepoel K, Berneman Z, Peeters M, Pauwels P, van Dam PA

PD9-04 Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients

Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J-U, Zahn D-M, Jackisch C, van Mackelenbergh M, Thomalla J, Marmé F, Huober J, Müller V, Schem C, Müller A, Stickeler E, Biehl K, Fasching Peter A, Untch M, Loibl S, Denkert C, Seliger B

PD9-05 Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients

Leon-Ferre RA, Jonas SF, Salgado R, Loi S, De Jong V, Carter JM, Nielsen T, Leung S, Riaz N, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman V, Linderholm B, Martens JWM, HM van Deurzen C, Timmermans M, Shimoi T, Yazaki S, Yoshida M, Kim S-B, Lee HJ, Dieci MV, Bataillon G, Salomon A, Andre F, Kok M, Linn S, Goetz MP, Michiels S

PD9-06 Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort

Tovey H, Sipos O, Hoadley KA, Parker JS, Quist J, Kernaghan S, Kilburn L, Salgado R, Loi S, Kennedy RD, Roxanis I, Gazinska P, Pinder SE; Bliss J, Perou CM, Haider S, Tutt A, Grigoriadis A, Cheang MCU

PD9-07 Role of immunosuppressive JNK pathway in the tumor microenvironment among triple negative breast cancer subtypes in IBCSG Trial 22-00

Joaquin Garcia A, Semba T, Rediti M, McGrail DJ, Xie X, Wang X, Rampa DR, Venet D, Majjaj S, Kammler R, Colleoni M, Loi S, Viale G, Regan MM, Rothé F, Sotiriou C, Ueno NT

PD9-08 ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database

Brufsky AM, Kuilman M, Mukhtar R, Wolf DM, Yau C, O'Shaughnessy J, Graham C, Gadi VK, Whitworth P, Hindenburg A, Grady I, Srkalovic G, Hoskins K, Dhakal A, Ma CX, Hunter N, Crozier J, Mavromatis B, Mittempergher L, Finn C, Modh S, Yoder EB, Dauer P, Menicucci A, van der Baan B, Audeh W, Esserman LJ

PD9-09 Molecular differences between younger versus older estrogen receptor positive / human epidermal growth factor receptor-2 negative breast cancers

Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L

SPOTLIGHT POSTER DISCUSSION SESSION 10

THURSDAY, DECEMBER 8, 2022 7:00 AM – 8:15 AM
STARS AT NIGHT BALLROOM 3&4

Endocrine Therapy and Resistance

Chair: Rachel Schiff

Baylor College of Medicine
Houston, TX

Mechanisms of resistance and new treatment strategies

Julie Ostrander, PhD
University of Minnesota
Minneapolis, MN

Biomarkers of response and resistance

Luca Malorni, MD, PhD
Zienda USL Toscana Centro
Prato, Italy

PD10-01 Impact of ESR1 mutations on selective estrogen receptor degraders and modulators: An integrated liquid-biopsy and pharmacodynamics approach

Gerratana L, Roncato R, Sturlese M, Davis AA, Velimirovic M, Reduzzi C, Clifton KK, Hensing WL, Shah AN, Dai CS, D'Amico P, Medford AJ, Franzoni A, Cucciniello L, Wehbe F, Wander SA, Belletti B, Gradishar W, Behdad A, Damante G, Ma CX, Puglisi F, Bardia A, Cristofanilli M

PD10-02 Novel ER fusion detection method to gain insight in fusion prevalence and endocrine resistant mechanisms

Yates ME, Liu T, Hooda J, Yang S, Bao R, Atkinson JM, Lee AV, Oesterreich S

PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Liu CC, Qin L, Sathe S, Nanda S, Veeraraghavan J, Cohen O, Wagle N, Rimawi MF, Osborne CK, Fu X, Schiff R

PD10-04 Combination of the next generation oral SERD camizestran (AZD9833) with CDK4/6 and mTOR/AKT inhibitors delivers robust efficacy in a broad range of ER+ breast tumors

Carnevali L, Ros S, Urosevic J, Cureton N, Darcy S, Lawson M, Williamson S, Morentin Gutierrez P, Bashi A, Moss J, Morrow C, Simon B, Klinowska T

PD10-05 Neoadjuvant tamoxifen therapy reactivates tumor suppressor protein p53 in luminal breast cancer patients: Results from a window-of-opportunity clinical trial

Das GM, Kulkarni SA, Oturkar C, Rosario S, Edge SB, Wang J, Swetzig WM, Hutson AD, Kaiparettu B, Groman A, Adjei A, Goey AK, Morrison CD, Kumar S

PD10-06 Clinical outcomes and exploratory gene expression analysis of OPPORTUNE: a phase II window-of-opportunity study to evaluate pictilisib+anastrozole versus anastrozole alone in ER-positive breast cancer

Martinez Chibly A, Shia A, Johnson R, Hwang MS, Hafner M, Metcalfe C, Shah K, Slyper M, Bolen C, Pinder SE, Thompson AM, Gendreau S, Schmid P

PD10-07 Low plasma estradiol, low expression of estrogen responsive genes and TP53 mutations are associated with poor anti-proliferative response to aromatase inhibitors

Schuster EF, López-Knowles E, Alataki A, Zabaglo L, Folkerd E, Evans D, Sidhu K, Tovey H, Maxwell P, Turner NC, Johnston S, Salto-Tellez M, Cheang MCU, Robertson J, Smith I, Bliss J, Dowsett M

PD10-08 Immune cell infiltration associated with poor anti-proliferative response to aromatase inhibitors in postmenopausal women with primary ER-positive HER2-negative breast cancer

Alataki A, Schuster G, Zabaglo L, Maxwell P, López-Knowles E, Folkerd E, Evans D, Sidhu K, Tovey H, Turner NC, Johnston S, Cheang MCU, Robertson J, Salto-Tellez M, Smith I, Bliss J, Dowsett M

PD10-09 Multiomics analysis of matched ER+ primary and recurrent breast cancers on or after adjuvant endocrine therapy

Martinez-Perez C, Kay C, Meehan J, Dixon JM, Turnbull AK

PD10-10 Single cell characterization of longitudinal biopsies from breast cancer patients treated with the aromatase inhibitors letrozole and exemestane in sequence

Ghannoum S, Steen C, Fongård M, Bjørnstad M, reitsma L, Geisler S, Seyedzadeh M, Buvarp U-C, Loeng M, Lüders T, Lambrechts D, Lyngra M, Kristensen V, Geisler J, Tekpli X

SPOTLIGHT POSTER DISCUSSION SESSION 11

**THURSDAY, DECEMBER 8, 2022: 7:00 AM – 8:15 AM
STARS AT NIGHT BALLROOM 1&2**

Improving Outcome for TNBC: New Directions in Immunotherapy

Chair: Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA

Heather McArthur, MD
UT Southwestern
Dallas, TX

Rebecca Dent, MD
Duke
Durham, NC

Margaret Gatti-Mays
The Ohio State University
Columbus, OH

PD11-01 Evaluation of the PD-1 Inhibitor Cemiplimab in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Stringer-Reasor E, Shatsky RA, Chien J, Wallace A, Boughey JC, Albain KS, Han HS, Nanda R, Isaacs C, Kalinsky K, Mitri Z, Clark AS, Vaklavas C, Thomas A, Trivedi MS, Lu J, Asare S, Lu R, Pitsouni M, Wilson A, Perlmutter J, Rugo HS, Schwab R, Symmans WF, Hylton NM, Van't Veer L, Yee D, DeMichele A, Berry D, Esserman LJ, I-SPY Investigators

PD11-02 A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 in early stage breast cancer: The INVINCIBLE Trial

Arnaout A, Robertson S, Keyhanian K, Hopkins M, Liao L, Talebian V, Awan A, Bartlett JS, Pond GR, Radvanyi L, Bender LH, Walters IB, Lopez Ozuna V, Spears M

PD11-03 Comparison of a mono Atezolizumab window followed by Atezolizumab and chemotherapy with Atezolizumab and chemotherapy in triple negative breast cancer – an interim analysis of the adaptive randomized neoadjuvant trial NeoMono

Kolberg H-C, Schumacher J, Erber R, Braun M, Heinrich B, Hoffmann O, Fasching PA, Kunz G, Lux MP, Schem C, Grischke E-M, Deryal M, Lübke K, Hartmann A, Kasimir-Bauer S, Kolberg-Liedtke C

PD11-04 Primary results of SOLTI-1503 PROMETEO phase 2 trial of Combination of Talimogene Laherparepvec (T-VEC) with Atezolizumab in patients with residual breast cancer after standard neoadjuvant multi-agent chemotherapy

Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Ganau S, Julve A, Zamora E, Miranda I, Delgado A, Bermejo B, de la Cruz-Merino; Juan M, Galván P, Gonzalez-Farré X, Ferrero-Cafiero JM, Villagrasa P, Oliveira M, Prat A

PD11-05 Gut microbiome signatures correlate with overall survival among patients receiving eribulin with or without pembrolizumab for hormone receptor-positive metastatic breast cancer

Barroso-Sousa R, Li T, Damania AV, DiLullo MK, Keenan T, Wulf GM, Spring LM, Mittendorf EA, Ligibel J, Ajami NJ, Wargo J, Tayob N, Tolaney SM

PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030

Parsons HA, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky AM, Rhoades J, Force J, Liu R, Traina TA, Carey LA, Rimawi MF, Elkhanany A, Stearns V, Specht JM, Burstein H, Wolff AC, Winer EP, Tayob N, Krop I, Golub T, Mayer EL, Adalsteinsson V

PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeopACT and NeoSTOP trials

Sharma P, Stecklein SR, Yoder R, Staley JM, Salgado R, Paré; Conte B, Brasó-Maristany F, O'Dea A, Nye L, Elia M, Satelli D, Crane G, McKittrick R, Khan Q, Godwin AK, Prat A

PD11-08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR-), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study

Schmid P, Wysocki P, Park YH, Jassem J, Jung KH, Lord S, Huisden R, Stewart R, Vuković P, Nunes AT, Nowecki Z

PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study

Schmid P, Wysocki P, Ma CX, Park YH, Fernandes R, Lord S, Baird RD, Prady C, Jung KH, Asselah J, Huisden R, Stewart R, Vuković P, Nunes AT, Nowecki Z

PD11-10 Efficacy, safety, and tolerability of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC): Final results of the Phase II trial

Li Q, Zhang Q, Zhang Y, Ouyang Q, Liu Q, Sun T, Ye F, Zhang B, Xu T, Xia S, Zhang K, Zhang B, Xu B

PD11-11 Results from ALICE – Atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple negative breast cancer, a randomized Phase IIb Trial

Kyte JA, Røssveold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Borgen E, Jahr T, Garred Ø; Lømo J, Mathiesen RM, Naume B

PD11-12 DORA: A phase II, multicenter, international, non-comparator study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC)

Sammons SL, Tan TJ, Im YH, Traina TA, Anders C, Renzulli E, Kim S-B, Dent R

SPOTLIGHT POSTER DISCUSSION SESSION 12

THURSDAY, DECEMBER 8, 2022: 7:00 AM – 8:15 AM
HEMISFAIR BALLROOM 1&2

Obesity and Breast Cancer

Chair: Tarah J. Ballinger, MD

Indiana University
Indianapolis, IN

Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Jennifer A. Ligibel, MD
Dana-Farber Cancer Institute
Boston, MA

Stephanie Walker, RN
Metastatic Breast Cancer Alliance
Tarboro, NC

PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019

Puklin L, Li F, Cartmel B, Sanft TB, Lisevick A, Winer EP, Lustberg M, Sharifi M, Irwin ML, Ferrucci L

PD12-02 Obesity is associated with poor breast cancer prognosis, particularly among women with low socioeconomic position

Harborg S, Feldt M, Cronin-Fenton D, Dalton S, Rosendahl A, Borgquist S

PD12-03 Withdrawn

PD12-04 Impact of race and body mass index on breast cancer diagnoses

Chung V, Maini R, Cattie R, Olet S, Sheen M

PD12-05 Adipocyte directed vaccination to reduce the risk of breast cancer

Disis M, Corulli L, Rodmaker ER, Cecil D

PD12-06 Longitudinal analysis of breast density change assessed by digital mammogram is associated with breast cancer

Colditz GA, Jiang S

PD12-07 The effect of BMI on the pathological response after neoadjuvant systemic therapy in breast cancer patients: a nationwide retrospective study

Jansen B, Gielen A, Agteroff M, van Maaren M, Beijer S, Moosdorff M, Smidt M, Postma E

PD12-08 Randomized trial of exercise and nutrition on pathological complete response among women with breast cancer receiving neoadjuvant chemotherapy: the Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) Study

Ferrucci L, Sanft TB, Harrigan M, Cartmel B, Li F, Zupa M, McGowan C, Puklin L, Nguyen TH, Tanasijevic AM, Neuhaus ML, Hershman DL, Basen Engquist K, Jones B, Knobf T, Chagpar AB, Silber ALM, Ligibel J, Irwin ML

PD12-09 Serum advanced glycation end-products are associated with breast cancer prognosis

Peterson LL, Tao Y, Luo J, Colditz GA, Park Y, Ligibel J, Turner D.

SPOTLIGHT POSTER DISCUSSION SESSION 13

THURSDAY, DECEMBER 8, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 1&2

Therapeutic Approaches for HR+/Her2- Breast Cancer

Chair: Kevin Kalinsky, MD

Winship Cancer Institute
Atlanta, GA

Phillipe Bedard, MD
Princess Margaret Cancer Centre
Toronto, Canada

Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute
Boston, MA

Neil Vasan, MD, PhD
Columbia University
New York, NY

Roberta Albany
Cancer in the Know
Mt Penn, PA

PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial

Vidal M, Pascual T, Falato C, Sanchez-Bayona R, Muñoz M, Cerbrecos I, Gonzalez-Farré X, Cortadellas T, Margelí M, Luna MA, Siso c, Amillano K, Galván P, Salvador F, Espinosa A, Paré: Sanfeliu E, Prat A, Bellet EzQuerra M

PD13-02 Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC

Chibly AM, Fernando TM, Metcalfe C, Hafner M, Owusu-Manu G, Hurvitz SA, Bardia A, Fasching PA, Park YH, Quiroga V, Steinseifer J, Perez-Moreno P, Moore HM

PD13-03 Biomarker analyses from the Phase 2 AMEERA-3 study of amcenestrant, an oral selective estrogen receptor (ER) degrader (SERD), in patients with ER+/HER2- advanced breast cancer (aBC)

Tolaney SM, Chan A, Petrakova K, Delalogue S, Fein L, Bauchet A-L, Ternès N, Boitier E, Cohen P, De Kermadec E, Wang L, Im -S-A

PD13-04 Exploratory subgroup and biomarker analyses of acelERA Breast Cancer: Phase II study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy for previously treated, estrogen receptor+, HER2- advanced breast cancer

Lim E, Chavez-MacGregor M, Bardia A, Sohn JH, Moore HM, Shivhare M, Martinalbo J, Roncoroni L, Perez-Moreno PD, Martin M.

PD13-05 Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status

Wesolowski R, Rugo HS, Stringer-Reasor E, Han HS, Specht JM, Dees EC, Kabos P, Vaishampayan U, Wander SA, Lu J, Gogineni K, Spira AI, Schott AF, Abu-Khalaf M, Nayak P, Sullivan BF, Gorbachevsky I, Layman RM

PD13-06 Long-term and very-long-term disease control in patients From BYLieve Study Cohort A with PIK3CA-Mutant, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer

Rugo HS, Chia Sk, Cortés J, Curigliano G, Neven P, Dent R, Tolaney SM, Ciruelos E, Park YH, Roux E, Chatrar Y, Patino H, Akdere M, Juric D

PD13-07 Combination therapy with the AKT inhibitor, ipatasertib, endocrine therapy, and a CDK4/6 inhibitor for hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC): results from the phase I TAKTIC trial

Wander SA, Keenan JC, Niemierko A, Juric D, Spring LM, Supko J, Vidula N, Isakoff SJ, Ryan L, Padden S, Fisher E, Newton A, Moy B, Ellisen LW, Micalizzi DS, Bardia A

PD13-08 Phase 1 TROPION-PanTumor01 Study evaluating Datopotamab Deruxtecan (Dato-DXd) in unresectable or metastatic hormone receptor-positive/HER2-negative breast cancer (BC)

Meric-Bernstam F, Krop I, Juric D, Kogawa T, Hamilton EP, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Bardia A

PD13-09 Clinical outcomes of patients with HR+ HER2- advanced breast cancer with early progression on CDK4/6 inhibitors

Clifton KK, Thomas SN, Luo J, Xi J, Bagegni NA, Ademuyiwa FO, Suresh R, Frith A, Davis AA, Bose R, Weilbaecher K, Hensing WL, Pluard T, Cristofanilli M, Han HS, Brufsky AM, Kalinsky K, Goel S, Wander SA, Peterson LL, Ma CX

PD13-10 Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) outcomes in hormone receptor-positive, HER2-negative advanced breast cancer (HR+/HER2- ABC): Exploratory analysis of the PARSIFAL Trial

Di Cosimo S, Pérez-García JM, Bellet Ezquerria M, Dalenc F, Gil Gil M, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M, Aguirre E, Schmid P, Marmé, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martínez De Dueñas E, Carañana V, Amillano K, Malfettone A, Cortés J, Llombart-Cussac A

PD13-11 Final overall survival analysis of Monarch 2 : A phase 3 trial of Abemaciclib plus Fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer

Sledge Jr GW, Toi M, Neven P, Sohn JH, Inoue K, Pivot X, Okera M, Masuda N, Kaufman PA, Koh H, Grischke E-M, Conte P, Andre V, Bian Y, Shahir A, van Hal G, Llombart-Cussac A

PD13-12 Imlunestrant, an oral selective estrogen receptor degrader, in combination with abemaciclib with or without an aromatase inhibitor, in estrogen receptor-positive advanced breast cancer: Results from the phase 1a/b EMBER study

Jhaveri K, Wang HOC, Ma CX, Lim E, Tao JJ, Manso L, Pierga J-Y, Parajuli R, Jerez Gilarranz Y, Lu Y-S, Beeram M, Larson T, Dhakal A, Ismail-Khan R, Karacsonyi C, Cao S, Osborne C

SPOTLIGHT POSTER DISCUSSION SESSION 14

THURSDAY, DECEMBER 8, 2022: 5:00 PM – 6:15 PM
STARS AT NIGHT BALLROOM 3&4

Breast Cancer Risk Modeling

Chair: Judith Balmaña, MD, PhD
Vall d'Hebron University Hospital
Barcelona, Spain

Genetics

Jennifer Caswell-Jin, MD
Stanford
Stanford, CA

Imaging

Sarah Eskreis-Winkler, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

PD14-01 A model to assess the utility of risk-based screening algorithms

Atakpa E, Cuzick J, Duffy SW, Evans DG, Howell SJ, Brentnall AR

PD14-02 Ten-year follow-up of an image-based AI risk model for breast cancer

Eriksson M, Czene K, Conant EF, Hall P

PD14-03 Reappraising the Fanconi Anemia DNA repair pathway in breast cancer risk and precision intervention: Insights and opportunities from the City of Hope INSPIRE study

Kruper L, McDonnell k, Bonner J, Tsang KK, Jones V, Mortimer J, Lindsey SS, Solomon I, Hampel H, Park W, Idos GE, Gray S, Gruber S

PD14-04 Whole mammogram image-based Cox regression improves 5-year breast cancer prediction

Jiang S, Colditz GA

PD14-05 Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women

Mabey B, Hughes E, Probst B, Pederson HJ, Simmons T, Morris B, Hullinger B, Domchek SM, Eng C, Gary M, Klemp J, Mukherjee S, Joseph V, Offit K, Olopade OI, Pruthi S, Kurian AW, Robson ME, Whitworth P, Wagner S, Lanchbury J, Slavin T, Gutin A

PD14-06 Polygenic risk score added to risk calculator improves prediction of breast cancer in U.S. Black women

Zirpoli GR, Lunetta KL, Pfeiffer RM, Palmer JR

PD14-07 Associations of breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network

Leggat-Barr K, Lewis T, Sayaman R, Warner P, Malvin K, Sabacan L, Tsopurashvili E, WISDOM Study and Athena Breast Health Network Investigators and Advocate Partners: Stover Fiscalini A, Tice J, Kerlikowske K, Shieh Y, Esserman LJ, Van 't Veer L

PD14-08 Impact of time between last childbirth and diagnosis of early-onset breast cancer on survival in germline BRCA1/2 carriers

Zhang Z, Ye S, Gareth E, Schedin

PD14-09 The effect of timing of TP53 genetic testing on treatment and outcomes among women with Li-Fraumeni syndrome and breast cancer

Sandoval R, Bottosso M, Polidorio N, Bychkovsky B, Verret B, Gennari A, Hyman S, Achatz MI, Caron O, Andre F, Garber J

SPOTLIGHT POSTER DISCUSSION SESSION 15

THURSDAY, DECEMBER 8, 2022: 5:00 PM – 6:15 PM
HEMISFAIR BALLROOM 1&2

Local Regional/Management of the Axilla

Chair: Andrea V. Barrio, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY

Axillary management

Tracy-Ann Moo, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Local recurrence invasive cancer and DCIS

Jennifer K. Plichta, MD
Duke University
Durham, NC

Reconstruction, Topical Tam, MRI

Rachel Greenup, MD, MPH
Yale School of Medicine
New Haven, CT

PD15-01 Axillary nodal recurrence is rare in patients with node-positive breast cancer undergoing SLNB following neoadjuvant chemotherapy: Early results of the Neosentiturk-Trial/MF-18-03

Cabrioğlu N, Karanlık H, Ali Gulcelik M, İgci A, Muslumanoğlu M, Kocer HB, Uras C, Akgül GG, Tukenmez M, İlgun S, Trabulus DC, Karadeniz Cakmak G, Dağ A, Yıldırım N, Zengel B, Sen Oran E, Senol K, Kara H, Emiroğlu S, Ugurlu MU, Citgez B, Ersoy YE, Celik A, Dilege E, Bolukbaşı Y, Karaman N, Basaran G, Soyder A, Polat AK, Sakman G, Ozbas S, Altınok A, Zer L, Akcan A, Ozemir IO, Yeniay L, Utkan NZ, Dogan L, Dogan M, Velidedeoglu M, Ozcinar B, Erozgen F, Kebudi A, Atahan K, Valiyeva V, Yormaz S, Sevinc A, Arici C, Soran A, Ozmen V

PD15-02 Long term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy

Lim SZ, Yoo T-K, Lee SB, Kim J, Chung I-Y, Ko BS, Lee JW, Son by, Ahn SH, Kim HJ

PD15-03 Incorporation of repeated core needle biopsy and targeted fine needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: A Prospective Feasibility Study

Wu S, Li J, Zhang Y, Hu N, Liu G

PD15-04 Overall survival following breast conserving surgery and adjuvant radiotherapy compared with mastectomy for early stage breast cancer: a systematic review and meta-analysis

Rajan KK, Fairhurst K, Birkbeck B, Wilson R, Savovic J, Holcombe C, Potter S

PD15-05 Breast conserving therapy has improved survival without an increased risk of locoregional recurrence compared to mastectomy in both clinically node positive and node negative patients

Vasilyeva E, Isaac K, Bazzarelli A, Nichol A, Hamm J, Lohrisch C, Brown C, Mckevitt E

PD15-06 Pathologic complete response and breast-conserving surgery are associated with improved prognosis in patients with early-stage triple-negative breast cancer treated with neoadjuvant chemotherapy

Krug D, Vladimirova V, Untch M, Kühn T, Schneeweiss A, Denkert C, Ataseven B, Solbach C, Gerber B, Tesch H, Golatta M, Seiler S, Heil J, Nekljudova V, Loibl S

PD15-07 7-gene predictive biosignature improves risk stratification for breast ductal carcinoma in situ patients compared to clinicopathologic criteria, identifying a low risk group not clinically benefiting from adjuvant radiotherapy

Rabinovitch R, Vicini F, Shah C, Margenthaler JA, Czerniecki BJ, Whitworth P, Dabbs DJ, Mann GB, Wärnberg F, Weinmann S, Leo M, Savala J, Shivers SC, Mittal K, Bremer T

PD15-08 Brazilian Randomized Study - BREAST-MRI Trial - Impact of preoperative magnetic resonance in the evaluation for breast cancer conservative surgery: Local recurrence and surgical outcomes

Mota BS, Reis YN, Barros N, Cardoso N, Mota RS, Shimizu C, Tucunduva T, Gonçalves R, Doria MT, Ferreira V, Ricci M, Trinconi A, Riera R, Baracat EC, Soares Jr JM, Filassi JR

PD15-09 Impact of procedure type on the long-term patient-reported outcomes of immediate breast reconstruction: The UK Brighter Study

Johnson L, White P, Jeevan R, Browne J, Gulliver-Clarke C, O'Donoghue J, Mohiuddin S, Hollingworth W, Fairbrother P, MacKenzie M, Holcombe C, Potter S

PD15-10 Impact of procedure type on long-term revisional surgery and secondary reconstruction following immediate breast reconstruction: The UK Brighter national population-based cohort study

Johnson L, White P, Jeevan R, Browne J, Gulliver-Clarke C, O'Donoghue J, Mohiuddin S, Hollingworth W, Fairbrother P, MacKenzie M, Holcombe C, Potter S

PD15-11 Axillary dissection to determine nodal burden to inform systemic therapy recommendations in patients with clinically node-positive breast cancer: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Weber WP, Matrai Z, Hayoz S, Tausch C, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Ruhstaller T, Muenst S, Ackerknecht, Küemmel S, Bjelic-Radic V, Smánykó V, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz R, Sarlos D, Dedes KJ, Leo C, Berclaz G, fansa H, Hager C, Reisenberger K, Sávolt Á, Singer CF, Reitsamer R, Winkler J, Lam Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, ostapenko V, Fitzal F, Heidinger M, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M, Kurzeder C

PD15-12 A pre-surgical window trial of oral tamoxifen versus transdermal 4-hydroxytamoxifen gel in women with estrogen receptor positive duct carcinoma in situ (DCIS)

Lee O, Mi X, Xu Y, Blanco L, Akasha AM, Benante K, Zhang S, LaBoy C, Helland T, Pilewskie M, Degnim A, Al-Hilli Z, Amin AL, Hwang ES, Guenther JM, Hustad SS, Gursel DB, Kocherginsky M, Mellgren G, Dimond E, Perloff M, Heckman-Stoddard BM, Khan S

SPOTLIGHT POSTER DISCUSSION SESSION 16

FRIDAY, DECEMBER 9, 2022: 7:00 AM – 8:15 AM HEMISFAIR BALLROOM 1&2

Imaging to Diagnose Breast Cancer and Direct Its Treatment: Who, When, and How?

Chair: David A. Mankoff, MD, PhD
University of Pennsylvania
Philadelphia, PA

Janie Lee, MD, MSc
University of Washington
Seattle, WA

Disparities in utilization

Janie Lee, MD, MSc
University of Washington
Seattle, WA

Imaging to guide treatment

Amy Fowler

University of Wisconsin

AI/Radiomics and novel metrics applied and breast cancer imaging

TBD

PD16-01 Racial disparities in the use of preoperative breast MRI after breast cancer diagnosis

Ginzberg SP, Grady CB, Fayanju OM, Edmonds CE

PD16-02 Factors associated with receipt of digital breast tomosynthesis among racially/ethnically diverse women undergoing screening mammography

McGuinness JE, Patel G, Amenta JN, Kukafka R, Crew KD

PD16-03 Use of post-neoadjuvant chemotherapy image-guided breast vacuum assisted biopsy to predict residual cancer in exceptional responders: A prospective cohort study

Tasoulis MK, Pope R, Gagliardi T, Nerurkar A, Okines AF, Turner NC, MacNeill F

PD16-04 To monitor or not to monitor? MRI monitoring of neoadjuvant chemotherapy effect and its benefit on breast cancer patients' pathological complete response rate

Vanovcanova L, Waszulikova I, Vertakova Krakovska B

PD16-05 Systemic staging in breast cancer patients receiving neoadjuvant chemotherapy

Lattimore C, Gabriella S, Brenin C, Showalter S, Millard T

PD16-06 Early MRI and PET biomarkers for hormone receptor-positive/HER2-negative early-stage breast cancer in the setting of neoadjuvant endocrine therapy and neoadjuvant chemotherapy in the I-SPY 2 TRIAL

Onishi N, Jones EF, Carmona-Bozo J, Gibbs JE, Bareng TJ, Molina-Vega J, Ray KM, Lawhn Heath C, Joe BN, Li W, Liang J, Newitt DC, Heditsian D, Brain S, Wolf DM, Yau C, Giridhar KV, Olopade OI, Kalinsky K, Mukhtar R, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Esserman LJ, Chien J, Hylton NM

PD16-07 Association of MRI morphologic phenotype from unsupervised learning with breast cancer subtypes and treatment response

le NN, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Gennatas E, LeStage B, Esserman LJ, Hylton NM, Li W

PD16-08 Characterizing changes in tumor heterogeneity via radiomic phenotyping for predicting response to neoadjuvant chemotherapy for locally advanced breast cancer: Preliminary results from the ACRIN 6698/I-SPY 2 trial

Cohen EA, Chitalia RD, Thakran S, Mankowski WC, Nguyen AA-T, Horng H, McDonald ES, Feldman M, DeMichele A, Kontos D

SPOTLIGHT POSTER DISCUSSION SESSION 17

FRIDAY, DECEMBER 9, 2022: 7:00 AM – 8:15 AM
STARS AT NIGHT BALLROOM 1&2

Endocrine Therapy New Insights

Chair: Lajos Pusztai, MD, DPhil
Yale School of Medicine
New Haven, CT

Pavani Chalasani, MD, MPH
University of Arizona Cancer Center
Tucson, AZ

Seth A. Wander, MD, PhD
Massachusetts General Hospital
Cambridge, MA

PD17-01 Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)

Ma CX, Waisman J, Brufsky AM, Yang ES, Wildiers H, Crown JP, Piha-Paul SA, Suga JM, García-Sáenz JÁ, Gambardella V, Guerrero A, Stemmer S, Bose R, Novara-Demgen T, DiPrimeo D, Eli LD, Jhaveri K

PD17-02 ctDNA molecular response based on breast cancer driver mutations predicts progression in aromatase inhibitor-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer

Bailleux C, Bachelot T, Bidard F-C, Hardy-Bessard A-C, Bièche I, Pradines A, Clatot F, de la Motte Rouge T, Canon J-L, Pistilli B, Chang K, Quinn KJ, Gustafson H, Dalenc F, Foa C, Ammarguella H, Bernard-Marty C, Lucas B, Barthier S, Lorchel F, Gisserot O, Arnould L, Mauduit M, Lemonnier J, Berger F, Delalogue S, Andre F

PD17-03 Cell-free DNA monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized HR+/HER2- breast cancer (LEADER)

Medford AJ, Scarpetti L, Niemierko A, Isakoff SJ, Moy B, Wander SA, Deluca E, Abraham E, Shin J, Schnipper L, Comander AE, Mulvey T, Spickard E, Kalashnikova E, Rodriguez A, Ellisen LW, Bardia A, Spring LM

PD17-04 Withdrawn

PD17-05 Development and validation of a composite biomarker predictive of Palbociclib + endocrine treatment benefit in early breast cancer: PENELOPE-B and PALLAS Trials

Loibl S, Denkert C, Liu Y, Knudsen ES, DeMichele A, Zhang Z, Teplý-Szymanski J, Filipits M, Fasching PA, Gnant M, Deng S, Balic M, Rojo F, Watson M, Deshpande C, Turner NC, Metzger O, Theall KP, Witkiewicz A, Valota O, Symmans WF, Mayer EL

PD17-06 Immunohistochemical markers and determinants of clinical response in the Penelope-B trial

Knudsen ES, Rachakonda S, Marmé F, Martín M, Untch M, Bonnefoi HR, Schmitt WD, Kim S-B, Bear HD, Witkiewicz A, Im S-A, DeMichele A, Van 't Veer I, McCarthy N, Sinn BV, Gelmon K, García-Sáenz JÁ; Kelly CM, Reimer T, Turner N, Rojo F, Filipits M, Fasching PA, Schem C, Martin L-A, Liu Y, Toi M, Rugo HS, Gnant M, Makris A, Furlanetto J, Weber K, Denkert C, Loibl S

PD17-07 Cell-cycle inhibition and immune microenvironment in HR+/HER2- breast cancer during and after preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial

Pascual T, Chic N, Fernandez-Martinez A, González-Farré B, Paré L, Saura C, Hernando C, Muñoz M, Arumí M, Galván P, Gonzalez-Farré X, Oliveira M, Gil Gil M, Ciruelos E, Villagrasa P, Gavila Gregori J, Prat A, Perou CM

PD17-08 Pooled gene expression analysis and association with treatment response in patients with HR+/HER2- advanced breast cancer in the MONALEESA-2, -3, and -7 trials

Bardia A, Su F, Solovieff N, Andre F, Arteaga CL, Neven P, Yap Y-S, Lu Y-S, Chia SK, Slamon D, Im S-A, Chakravartty A, Lteif A, Taran T, Tripathy D

PD17-09 Utility of the 70-gene MammaPrint assay for prediction of extended letrozole therapy benefit in early-stage breast cancer patients in the IDEAL Trial

Liefers G-J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde CJH, Kleijn M, Dreezen C, Menicucci A, van't Veer L, Audeh W

PD17-10 Genomic characterization of hormone receptor-positive, HER2-negative breast cancer arising in young women: a secondary analysis of the SOFT trial

Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperis A, Brown LC, Láng I, Tondini C, Bellet Ezquerra M

PD17-11 Circulating tumor DNA (ctDNA) reveals complex biological features with clinical relevance in metastatic breast cancer

Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet Ezquerra M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, Margelí M, Oliveira M, Ballana E, Felip E, Matito J, Sánchez-Bayona R, Suñol-Camas A, Saura C, Ciruelos E, Tolosa P, Muñoz M, González-Farré B, Villagrasa P, Parker JS, Perou CM, Vivancos A

PD17-12 Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2- advanced breast cancer

Cardoso F, Jacot W, Küemmel S, Gupta S, Balaraman R, Lebedeva L, Ji Y, Lakshmanan A, Amin K, Li Z, Sparano J

SPOTLIGHT POSTER DISCUSSION SESSION 18

FRIDAY, DECEMBER 9, 2022: 7:00 AM – 8:15 AM
STARS AT NIGHT BALLROOM 3&4

Updates and New Therapies for HER2 Positive Disease

Chair: Ian E. Krop, MD, PhD

Yale School of Medicine
New Haven, CT

Roisin M. Connolly, MD
University College Cork
Cork, Ireland

Sara A. Hurvitz, MD
University of California
Los Angeles, CA

Paula R. Pohlman, MD, MSc, PhD
UT MD Anderson Cancer Center
Houston, TX

PD18-01 Adjuvant Trastuzumab Emtansine versus Paclitaxel plus Trastuzumab for Stage I HER2+ breast cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)

Tarantino P, Tayob N, Dang CT, Yardley D, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain KS, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi MF, Abramson V, Pohlmann P, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Zheng Ym Barroso-Sousa R, Waks A, DeMeo MK, DiLullo MK, Curigliano G, Burstein H, Partridge AH, Winer EP, Viale G, Hui W, Mittendorf EA, Schneider BP, Prat A, Krop I, Tolane SM

PD18-02 Adjuvant Paclitaxel and Trastuzumab Trial (APT) for node-negative, human epidermal growth factor receptor 2–positive (HER2+) breast cancer: final 10-year analysis

Tolane SM, Tarantino P, Graham N, Tayob N, Dang CT, Yardley D, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Barroso-Sousa R, DeMeo MK, DiLullo MK, Partridge AH, Waks A, Hudis C, Krop I, Burstein H, Prat A, Winer EP

PD18-03 Final analysis of the Phase III PEONY trial: long-term efficacy and safety of neoadjuvant–adjuvant pertuzumab or placebo, plus trastuzumab and docetaxel, in patients with HER2-positive early or locally advanced breast cancer

Shao Z-M, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y-s, Wang C, Chang Y-C, Wang H-C, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Huang L, Wang H, Lamour F, Song G, Restuccia E

PD18-04 Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601

Zagami P, Fernandez-Martinez A, Rashid NU, Hoadley KA, Spears PA, Perou CM, Carey LA

PD18-05 MEN1611, a PI3K inhibitor, combined with trastuzumab fl fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)

Piccart M, Hennequin A, Ruiz Borrego M, Escrivá-de-Romani S, Williams A, Jiménez Rodríguez B, Del Conte G, Howell S, Palleschi M, Simonelli M, Duhoux FP, Tosi D, Doger de Speville Uribe B, Jerez Gilarranz Y, Tassone P, Curigliano G, Waters S, Aftimos P, Wildiers H, Scartoni S, Piza Vallespir B, Shankaraiah RC, Grzegorzewski K, Habboubi N

PD18-06 Image-guided optimization of neoadjuvant chemotherapy duration in stage II and III HER2-positive breast cancer: radiologic and pathologic complete response (pCR) rates in the multicenter phase 2 TRAIN-3 study (BOOG 2018-01)

van der Voort A, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters M-JTFD, Mann RM, Sonke GS

PD18-07 Omission of chemotherapy in the treatment of HER2-positive and hormone-receptor positive metastatic breast cancer – interim results from the randomized phase 3 DETECT V trial

Janni W, Fehm T, Müller V, Schochter F, De Gregorio A, Decker T, Hartkopf A, Just M, Sagasser J, Schmidt M, Wimberger P, Banys-Paluchowski M, Fasching PA, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Hoffmann O, Blohmer J-U, Niederacher D, Neubauer H, Pantel K, Friedl TW, Huober J

PD18-08 Efficacy and safety results of KNO26, a HER2-targeted bispecific antibody combined with docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer

Zhang Q, Wang J, Ouyang Q, Wang X, Wang J, Gan L, Lin D, Ouyang Z, Xu T, Liu Y, Xia S

PD18-09 ACE-Breast-03: Efficacy and safety of ARX788 in patients with HER2+ metastatic breast cancer previously treated with T-DM1

Hurvitz SA, Kalinsky K, Ganju V, Ali K, Agrawal L, Gradishar W, Sledge Jr GW, Thummala A, Chan A, Frentzas S, Sohn JH, Park K-H, Park KU, Shannon C, Drago J, Tolaney SM, Rugo HS, Press MF, Aliko A, Xu D, Lu J, Tripathy D

PD18-10 Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant

Escrivá-de-Romani S, Alba E, Rodríguez Lescure Á; Hurvitz SA, Cejalvo JM, Gión M, Ferrario C; Ruiz Borrego M, Pezo RC, Hamilton EP, Webster M, Pluard T, Beeram M, Jiménez Rodríguez B, Linden H, Saura C, Omidpanah A, Harvey P, Savard M-F

PD18-11 Dose-expansion study of Trastuzumab Deruxtecan as monotherapy or combined with Pertuzumab in patients With metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in DESTINY-Breast07 (DB-07)

Hamilton EP, Jhaveri K, Loi S, Anders C, Schmid P, Penkov K, Artamonova E, Zhukova L, Stroyakovsky DL, Doval DC, Villanueva R, Michelini F, Chandarlapaty S, Wilson M, Boston SR, Konpa A, Mondal S, Andre F

IT'S ABOUT

THEM



Real KISQALI patients.



How can KISQALI help meet your patients' goals?
Find out at [KISQALI-hcp.com](https://www.kisqali-hcp.com)



POSTER SESSION 1

TUESDAY, DECEMBER 6, 2022 5:00 PM – 6:15 PM
HALL 1

Treatment - Adjuvant Therapy: Adjuvant Chemotherapy

P1-01-01 The role of adjuvant chemotherapy for elderly women with triple-negative breast cancer

Lan T, Guo Q, Lu Y, Gu J, Shao X, Xu H, Hu Z

P1-01-02 The impact of adjuvant chemotherapy on overall survival in hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis

Ashok Kumar P, Huang D, Sivapiragasam A, Wang D

P1-01-03 The impact of comorbid HIV infection on neoadjuvant and adjuvant chemotherapy relative dose intensity in South African breast cancer patients

O'Neil DS, Ayeni OA, Farrow Woolridge HA, Chen WC, Demetriou G, Buccimazza I, Cacala S, Joffe M, Pumpalova Y, Mapanga W, Jacobson JS, Crew KD, Neugut AI, Ruff P, Cubasch H

P1-01-04 Comparing the effects of TC and Anthracycline-based chemotherapy in women with breast cancer HER2 negative treated in the adjuvant setting – An individual patient meta-analysis

Giffoni M. M. Mata D, Smowton M

P1-01-05 Adjuvant S-1 plus endocrine therapy for estrogen receptor-positive, HER2-negative, primary breast cancer: updated overall survival analysis from the POTENT trial

Takada M, Saji S, Ueno T, Masuda N, Ishiguro H, Ishida T, Saeki T, Imoto S, Ohno S, Iwata H, Sugie T, Aogi K, Mukai H, Takayama S, Sato N, Kai Y, Kitada M, Nakamura R, Matsuyama Y, Toi M

P1-01-06 Differences in breast tumor response to neoadjuvant chemotherapy by race- Is obesity the key?

Rumano R, Grimm M, Palettas M, Stephens J, Williams N, Sardesai S, Quiroga D, Ramaswamy B, Paskett E, Oppong B

P1-01-07 Adjuvant and neoadjuvant chemotherapy for treatment of early and locally advanced breast cancer in the elderly population at a UK tertiary cancer centre

Chung A, Sheri A, King J, Newby J, Chopra N

Treatment - Adjuvant Therapy: Adjuvant Endocrine Therapy

P1-02-01 Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis

Janni W, Untch M, Harbeck N, Gilgorov J, Jacot W, Chia SK, Boileau J-F, Jager A, Haftchenary S, Gupta R, Mishra N, Pathak P, Curigliano G

P1-02-02 Withdrawn

P1-02-03 Real world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer

Sukumar JS, Sardesai S, Ni A, Williams N, Ramaswamy B, Wesolowski R, Cherian MA, Stover DG, Gatti-Mays M, Pariser AC, Sudheendra PK, George MA, Lustberg M.

P1-02-04 Real world adjuvant endocrine treatment in premenopausal breast cancer patients compared with the proposed algorithm using the Regan Composite Risk Score

Berteloot C, Neven P, Vangoitsenhoven M, Laenen A, Wildiers H, Punie K, Smeets A, Nevelsteen I, Han S, Baert T, Janssen H, Oldenburger E, Baten A, Berteloot P, Vanhoudt R, Deblander A, Remmerie C, Desmedt C

P1-02-05 Endocrine-targeted therapies modify the gut microbiome affecting responsiveness in ER+ breast cancer

Arnone A, Wilson AS, Chiba A, Kerr B, Soto-Pantoja DR, Thomas A, Cook KL

P1-02-06 Improved survival with ovarian function suppression in premenopausal hormone receptor-positive breast cancer: a propensity score matching of ASTRRA-trial participants with single-center postmenopausal patients

Lee Y-j, Yoo T-K, Lee SB, Kim J, Chung I-Y, Ko BS, Lee JW, Son BH, Ahn SH, Kim S, Kim HJ

P1-02-07 EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET

Jhaveri KL, O'Shaughnessy J, Andre F, Goetz MP, Harbeck N, Martín M, Bidard F-C, Thomas ZM, Young S, Ismail-Khan R, Smyth LM, Gnant M

P1-02-08 CBD-oil: a potential solution in case of severe tamoxifen-related side effects

Buijs S, Braal L, Buck S, van Maanen NF, van der Meijden-Erkelen L, Kuijper-Tissot van Patot H, Oomen-de Hoop E, Saes L, van den Boogerd S, Struik L, van Rossum-Schornagel Q, Mathijssen R, Koolen S, Jager A

P1-02-09 Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial

Haddad TC, Suman V, Giridhar KV, Moreno-Aspitia A, Northfelt D, Ernst B, Sideras K, O'Sullivan CC, Singh R, Desta Z, Taraba J, Goodnature B, Goetz MP, Wang L, Ingle JN

Treatment - Advanced Disease Treatment: Advanced Chemotherapy

P1-03-01 Eribulin versus S-1 as first- or second- line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomized controlled trial

Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe K-i, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, Mukai H, Takahashi M

P1-03-02 Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies

Twelves C, Kaufman PA, Awada A, Im S-A, Lalayan B, Xie R, Vahdat LT, Cortés J

P1-03-03 Real-world treatment patterns and clinical outcomes in patients treated with Eribulin after prior PI3K inhibitor therapy for metastatic breast cancer

Goyal RK, Zhang J, Davis KL, Kaufman PA

P1-03-04 Visceral fat area as a predictive factor in metastatic HER2 negative breast cancer patients treated by first line chemotherapy with weekly paclitaxel and bevacizumab

Guiu S, Guiu B, Chevrier M, Billa O, Levy C, Trédan O, Desmoulins I, Debled M, Ferrero J-M, Jouannaud C, Gonçalves A, Rios M, Mouret-Reynier M-A, Berger F, Toumi F-Z, Lemonnier J, Pierga J-Y, Dabakuyo S, Gourgou S

P1-03-05 Overview of the management and factors associated with outcomes of metastatic breast cancer among elderly patients

Vidaurre Mendes S, Zanin Orsi B, Monteiro Vasconcellos J, Araujo Neto A, Andrade Rocha E, Messias AP, Noschang Moreira O, Galvão Freire PJ, Vecchi Leis L, Baptista Pereira M, Petry V, Colombo Bonadio R, Testa L

Prognostic and Predictive Factors: Predictive Biomarkers for Combined Modality Therapies

P1-04-01 High HER2/CEP17 ratio is associated with better treatment outcomes in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 2+ or 3+ results

Seo J, Koh J, Lee D-W, Ryu HS, Lee H-H, Kim T-Y, Im S-A

P1-04-02 Gut microbiome diversity correlates with tumor PD-L1 status in metastatic triple negative breast cancer (mTNBC): correlative analysis of gut microbiome and tumoral biomarkers

Chun B, Goodyear S, Rice-Stitt T, Karstens L, Dahl E, Li A, Hobbs E, Zahi M

P1-04-03 Withdrawn

P1-04-04 A multiomic approach to the identification of immune signatures of anti-PD1/PDL1 therapy responders in metastatic triple negative breast cancer: new implications in the role of helper T-cell and B-cell interplay

Wilkerson AD, Rayman PA, Pavicic Jr PG, Husic H, Makarov V, Juric I, Chan T, Montero AJ, Diaz-Montero M

P1-04-05 Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial

Waks A, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galvan P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Tarantino P, Desai N, Guerriero JL, Metzger O, Tung N, Krop I, Parker JS, Perou CM, Prat A, Winer EP, Tolaney SM, Mittendorf EA

P1-04-06 Characterization of recurrence risk after lumpectomy and radiotherapy in HER2-positive ductal carcinoma in situ of the breast, using 7-gene predictive biosignature: Implications for the NSABP-B43 trial results

Vicini F, Shah C, Rabinovitch R, Whitworth P, Margenthaler JA, Czerniecki BJ, Dabbs DJ, Weinmann S, Leo M, Mann GB, Wärnberg F, Savala J, Shivers SC, Mittal K, Bremer T

P1-04-07 pCR Score: a novel prognostic method to estimate the predictive probability of pCR in early-stage breast cancer patients

Peterson J, Cole Jr JA, Berry DA, Cook D, Howard FM, Nanda R, Wolf C, Gabani PS, Takiar V, Kuzmiak C, Carey LA, Fox D, Chalasani P, Antony AK

P1-04-08 Independent validation of a novel, non-invasive approach to predict pathologic complete response (pCR) in a blinded, prospectively-run single center trial

Kuzmiak C, Hartman TS, Benefield T, Peterson J, Antony AK, Pandey T, Cole Jr JA, Calhoun BC, Carey LA

P1-04-09 Correlating predicted adjuvant therapy benefit and risk of recurrence between Breast Cancer Index (BCI) and 21-gene oncotype DX Recurrence Score (RS)

Patel R, Casasanta N, Li Z, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Fink M, Zhou X, Zimmerman B, Cascetta K, Chen R, Oh W, Tiersten A

P1-04-10 Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52

Pogue-Geile KL, Maley SK, Kim RS, Wang Y, Salgado R, Lipchik C, Feng H, Cecchini RS, Jacobs SA, Srinivasan A, Mamounas EP, Geyer Jr CE, Rastogi P, Osborne CK, Paik S, Wolmark N, Lucas PC, Rimawi MF

P1-04-11 Tumor infiltrating lymphocytes in initial HER2-low breast cancer

Fernandes I, Damasceno E, Kaliks R, Corpa M, Schwartsman G

P1-04-12 Systemic immune response to a Phase I/II trial of Durvalumab concomitant with neoadjuvant chemotherapy in early stage TNBC

Blenman K, Marczyk M, Foldi J, Gunasekharan V, Silber ALM, Pusztai L

P1-04-13 ER + / HER2- metastatic breast cancer (MBC): analysis of the lipidomic profile in patients treated with CDK 4/6 inhibitors and endocrine therapy

Manfredi M, Martini V, Branni C, Ayed RB, Gobbato S, Tassone A, Gioffi E, Ciocca M, D'Avanzo F, Buffoni M, Gennari A

P1-04-14 Predicting the likelihood of response in PDL-1 positive metastatic triple negative breast cancer treated with an immune checkpoint inhibitor

Aldrich J, Hu T, Switchenko J, Coskun A, Gokmen-Polar Y, Badve S, Bhawe M

P1-04-15 Clinical application of 21-gene breast-cancer assay (Oncotype DX) in early hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer with lymph-node-positive disease

Gasol Cudós A, Morales Murillo S, Tuset Der-Abraín N, Velasco Sánchez A, Vilardell Villellas F, Sánchez Guzmán D, Canosa Morales C, Melé Olivé J, Arbones Cid L

P1-04-16 A nomogram based on clinicopathologic factors and pretreatment systemic inflammation response index to predict pathological complete response of neoadjuvant systemic therapy in HER2-positive breast cancer: A dual-center study

Wu HY, Tzeng Y-D, Yang JR, Hung CC

P1-04-17 Clinical and pathological differences between HER2 Low and other cancer subtypes in breast cancer patients

Mattar A, Amorim A, Diogenes M, Shida J, Gebrim LH

P1-04-18 Identification of UGT2B family genes as potential biomarkers of response to neoadjuvant therapy in HER2+ breast cancer

Gil-Torralvo A, Benavent M, Dominguez-Cejudo MA, Falcon A, Cejuela M, Vieites B, Molina-Pinelo S, Ruiz Borrego M, de la Haba-Rodríguez J, Queipo MI, Salvador Bofill FJ

Detection/Diagnosis: Detection/Diagnosis - Other

P1-05-01 Withdrawn

P1-05-02 Reducing delays of breast cancer care using an innovative digital health platform

Holmes DR, Pulicharam R

P1-05-03 Prevalence of BRCA1/2 mutations in an underrepresented population of women with breast cancer: Observations from the City of Hope INSPIRE study

Mortimer J, Lindsey SS, Solomon I, Park W, Sturgeon D, Blazer K, Gray S, Bonner J, Xia X, Gruber S

P1-05-04 Physician practice patterns of breast imaging after treatment: Survey of real-world practice

Whittaker M, Farr K, Potluri P, Foster N, Erdrich J, Segar J, Ehsani S, Jiralerspong S, Roe D, Chalasani P

P1-05-06 Establishment of the breast ultrasound support system using deep-learning system

Odani E, Hayashida T, Kikuchi M, Nagayama A, Seki T, Takahashi M, Matsumoto A, Murata T, Watanuki R, Yokoe T, Nakashoji A, Maeda H, Onishi T, Asaga S, Hojo T, Jinno H, Sotome K, Matsui A, Suto A, Imoto S, Kitagawa Y

P1-05-07 Detection of progression or regression of breast cancer by circulating tumor DNA (ctDNA)

Karki J, Ghimire B, Herrman E, Yadav S, Muhsin Chisti M

P1-05-08 Assessment and diagnosis of breast pathology in young women: What can we learn?

Ramirez SA, Menegaz BA, Roark A, Bonefas E, Sepulveda KA, Thompson AM, Carter S

P1-05-09 Targeting treatment to tumor response: demonstration of response monitoring with subsequent impact on treatment choices in real time utilizing a novel technology

Tannenbaum S, Hsu E, Hundal J, Wilkes A, Fergusson A, Mamuya F, Tafas T

P1-05-10 Referral pathways for breast cancer diagnosis and treatment in Mexico: a physicians' survey

Vazquez-Juarez D, Andrade-Moreno R, Villarreal-Garza C

P1-05-11 Improving the performance of early breast cancer diagnosis by a model combining breast ultrasound with methylation markers in non-invasive circulating tumor DNA

Zhang X, Ye Z, Yin Y, Zeng L, Wang J, Lei S, Bibikova M, Chen Z, Fan J-B, Pang D

P1-05-12 Evaluation of the benefit of the tumor marker cancer antigen 15-3 (CA 15-3) in different subtypes of metastatic breast cancer

Lindman H, Cederqvist Molin E, Jernling M, Schiza A

P1-05-13 Clinical impact of whole-body magnetic resonance imaging on subsequent management in luminal/HER2-negative breast cancer patients

Merloni F, Palleschi M, Rossi A, Prochowski Iamurri A, Gianni C, Sarti S, Mannozi F, Fiori F, Di Menna G, Cecconetto L, Sirico M, Casadei C, Bleva S, Gasperoni L, Casadei R, Tontini L, Romeo A, Barone D, De Giorgi U

P1-05-14 ctDNA in breast milk for early detection of pregnancy associated breast cancer

Saura C, Ortiz C, Arenas EJ, Matito J, Suñol-Camas A, Cordoba O, Martinez-Sabadell A, Garcia-Ruiz I, Miranda I, Morales-Comas C, Carrasco Lopez E, Viaplana C, Peg V, Nuciforo P, Bayo N, Miquel JM, Gomez-Rey M, Villacampa G, Arevalo S, Carmona J, Espinosa-Bravo M, Balmaña J, Dienstmann R, Arribas J, Tabernero J, Sanso M, Vivancos A

P1-05-15 DCE-MRI for early prediction of excellent response versus chemoresistance in triple negative breast cancer

Guirguis MS, Adrada B, Patel M, Perez F, Candelaria R, Yang W, Sun J, Mohamed RM, Boge M, Le-Petross HTC, Leung J, Whitman GJ, Lane DL, Scoggins ME, Moseley T, White J, Wei P, Son JB, Hwang K-P, Panthi B, Pagel M, Hunt KK, Thompson AM, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G

P1-05-16 Bioimpedance spectroscopy monitoring reduces long-term clinical lymphedema risk

Boyages J, Vicini F, Shah C

P1-05-17 Radiomic models based on dynamic contrast-enhanced magnetic resonance imaging predict the immunophenotype reflecting spatial distribution of CD8+ tumor-infiltrating lymphocytes in breast cancer

Jeon SH, Kim S-W, Seo M, Lim YJ

P1-05-18 Orphan non-coding RNAs for early detection of breast cancer with liquid biopsy

Cavazos TB, Wang J, Afolabi OI, Huang A, Lam DN, Kiliinc S, Wang J, Fish L, Zhao X, Pohl A, Li H, Chau KH, Arensdorf PA, Hormozdiari F, Goodarzi H, Alipanahi B

P1-05-19 Impact of the COVID-19 pandemic on the diagnostic pathway of breast cancer in the Netherlands: a population-based study

Wolffkamp W, Meijer J, Van Hove J, Veltman J, Siesling S

P1-05-20 COVID-19 lockdown resulting in advanced cancer and worse histology at presentation in Hispanics

Hussain J, Roman Souza G, Aldawoodi T, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M

P1-05-21 Change in breast cancer detection method, stage at diagnosis and treatment during the COVID-19 Pandemic: 2019-2021

Malmgren JA, Atwood M, Kaplan H

P1-05-22 The impact of the COVID-19 pandemic on breast cancer diagnoses in San Antonio, TX

Roman Souza G, Aldawoodi T, Hussain J, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M

P1-05-23 Optimizing the diagnosis of leptomeningeal metastases in breast cancer patients by circulating tumor cells and circulating tumor DNA

Jongbloed EM, Angus L, van den Bent MJ, Jongen JLM, Martens JWM, Van NM, de Weerd V, HM van Deurzen C, Kraan J, Wilting SM, Jager A

P1-05-24 Delays in diagnosis of adolescent and young adult breast cancer and lack of breast health education, community based research

Peters M, Tubman S

P1-05-25 Clinical and biological features of 158 consecutive and unselected oligometastatic breast cancers

Lacaze JL, Brac de la Perrière C, Ung M, Dalenc F, Nicolai V, De Maio E, Montastruc M, Cabarrou B, Monselet N, Chira C, Glemarec G, Cassou-Mounat T

P1-05-26 A blood-based lipid panel for personalized risk assessment of breast cancer

Fahrman J, Irajizad E, Vykoukal J, Gutierrez Barrera A, Dennison J, Wu R, Arun BK, Brewster A, Hanash S

P1-05-27 Liquid biopsy for HER2 status assessment in breast cancer using surrogate DNA methylation markers

Zhang X, Lu S, Li H, Liu X, Wang J, Zeng L, Lu Z, Liu S, Yin Y, Bibikova M, Chen Z, Fan J-B, Pang D

P1-05-28 Decreases in circulating tumor associated cells predicts PFS and OS in a pooled analysis of phase I clinical trials using SV-BR-1-GM therapy with or without immune check-point inhibitors in metastatic breast cancer patients

Adams D, Chang M, Lopez-Lago M, Tang C-M, Williams W, Del Priore G

P1-05-29 Breast cancer laterality: Is age a factor?

Elleson K, Sokol GH, Sun W, Whiting J, Lee MC, Czerniecki BJ, Loftus L

P1-05-30 Concordance of preoperative breast MRI finding with definitive postoperative pathology report, after neoadjuvant systemic treatment in patients with breast cancer

Tecic Vuger A, Peric Balja M, Jaksic P, Linaric P, Pavlovic Mavic M, Vazdar L, Separovic R

P1-05-31 A single center retrospective analysis of 259 cases of metaplastic breast cancer

Liu D, Chen J, Hao S, Xiu B, Zhang Q, Zhang L, Liu G, Shao Z, Wu J

P1-05-32 Outcomes of diagnostic breast imaging in young women (less than 50 years old)

Dehar N, Samuel JN, Jabs D, Hopman W, Mates M

P1-05-33 RNA in extracellular vesicles used for the prediction of distant metastasis of breast cancer and the function of TGM2 in promoting breast cancer development

Wu J, Chi Y

P1-05-34 MicroRNAs as prognostic markers in breast cancer

Nguyen AQ, Cunningham C, Okpechi S, Yousefi H, McKinney S, Boulmay B, Garcia A, Alahari S

P1-05-35 Identification of circulating tumor cells captured by the FDA cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

Ciccioli M, Moore R, Kwang Kim K, Khazan N, Miller MC, Pailhes-Jimenez A-S

P1-05-36 AI-based smartphone app using a single-lead ECG for automated QTc diagnostics in oncology

Schinköthe T, Tonk CH, Harbeck N, Carmelo V, Gomes Feliciano J, Wuerstlein R, Kümmel S, Schmidt A

Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects

P1-06-01 Associations of historic and contemporary “redlining” with breast cancer stage at diagnosis

Wiese D, Stroup AM, Jemal A, Henry KA, Islami F

P1-06-02 The effect of race on pathologic complete response rates and overall survival in patients with triple negative breast cancer

Worixax HE, Thomas SM, Plichta JK, Rosenberger LH, Botty van de bruele A, Chiba A, DiLalla G, Menendez C, Hwang ES, DiNome ML

P1-06-03 Differences in breast cancers among American-Indians and Whites in the United States

Gaba A, Cao L, Renfrew R, Wernisch J, Sahmoun A, Goel S, Crosby R

P1-06-04 Impacts of treatment delay on breast cancer mortality and benefit of timely care in black and non-black women

Jackson B, Wheeler S, Yanguela J, LeBlanc M, Kuo T-M, Baggett C, Reeder-Hayes K

P1-06-05 Trends of distant stage breast cancer incidence among young women in the United States 2001-2018

Morgan T, Panton J, Chan J

P1-06-06 Access to medical coverage in newly diagnosed Breast cancer patients a minority population during the COVID 19 pandemic

Aldawoodi T, Roman Souza G, Hussain J, Jameson LC, Rahman L, Agim NC, Gelfond J, Mazo-Canola M

P1-06-07 Interrogating the molecular profile of breast cancer tumors in Hispanics living in Puerto Rico (PRH)

Martinez-Viota N, Bittman-Soto X, Montes-Rodriguez IM, Carrasquillo K, Centeno-Girona H, Cruz-Correa M

Prognostic & Predictive Factors: Prognosis-Biomarkers of Natural History Prog Factors-Clin Testing&Val

P1-07-01 Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with HR+/HER2- early breast cancer: a systematic review and meta-analysis

Martins-Branco D, Molinelli C, Nader Marta G, Ameye L, Paesmans M, Salgado R, Aftimos P, de Azambuja E

P1-07-02 Using clinical characteristics and molecular markers to predict the risk of subsequent ipsilateral breast events after excision of DCIS

Liu Y, Strand SH, King L, Harmon B, Couch FJ, Gallagher K, Kilgore M, Wei S, DeMichele A, King T, McAuliffe PF, Marks J, Maley C, West R, Hwang ES, Colditz GA

P1-07-03 Unmet needs and future applications of breast cancer multigene signatures in routine clinical practice: results from the European PROCURE Project

Gnant M, Lænkholm A-V, Prat A, King J, Curigliano G, Harbeck N, Penault-Llorca F, Cardoso F

P1-07-04 Claims-derived comorbidities associations with real-world overall survival (rwOS) among patients with metastatic breast cancer in an electronic health record-claims linked dataset

Ascha MS, Asfaw AA, Yerram P, Reiss SN, Brake SD, Wadé NB

P1-07-05 Clinical utility of twenty-five gene-expression profiling using LAMP method in early stage breast cancer

Tsuchida Y, Ueda T, Nagatake Y, Michiyuki S, Hattori M, Sato M, Tomita N, Kanomata N, Yamauchi H

P1-07-06 Withdrawn

P1-07-07 Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer

Wang X, Xiong M, Xiu B, Wu J, Chi Y

P1-07-08 Prediction of breast cancer late recurrence according to Clinical Treatment Score post-five years (CTS5) and progesterone receptor in a wider patient population

Carvalho GS, Bretas GO, Musse D, Gondim V, Bines J

P1-07-09 Clinical and pathologic characteristics in early breast cancer Her2-low and high risk Oncotype DX RS

Galve E, Pikabea-Diaz F, Lopez-de-San-Vicente-Hernandez B, Figaredo-Berjano C, Legaspi-Folgueira J, Sala-Gonzalez MA, Arango-Arteaga JF, Fernandez-Ferrer S, Loaiza-Jaramillo PL, Casado-Cuesta P, Temino-Frances M, Bilbao-Penas A, Martinez-del-Prado P

Psychosocial, Quality of Life and Educational Aspects-Social and Education Issues: Education

P1-08-01 Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration

Mortensen L, Keenan JC, Abraham E, Padden S, Ma A, Denault E, Ryan L, Medford AJ, Ellisen LW, Schwartz JH, Bardia A, Spring LM

P1-08-02 Implementation of integrative medicine program for breast medical oncology professionals in an academic cancer center

Zhi WI, Wanq R, Bao T

P1-08-03 Exploratory analysis of a mobile app that addresses radiotherapy informational needs for breast cancer patients

Muñoz Lozano JF, Pérez Ibave DC, Abundis Marquez E, Alcorta Nuñez F, Gonzalez Alcorta CB, Salazar Mejia C, Noriega MF, Zayas Villanueva O, Oyervides Juarez V, Renteria Garcia LM, Alcorta Garza A, Gonzalez Guerrero JF, Luna V, Hernandez D, Piñeiro Retif R, Vidal Gutiérrez O

P1-08-04 Therapeutic advances in metastatic triple-negative breast cancer: Identifying and reducing clinician knowledge gaps

Heller EJ, Smith K, Williams SL

P1-08-05 Educating pathologists in quantitating stromal tumor-infiltrating lymphocytes in breast cancer for artificial intelligence applications

Garcia V, Ly A, Salgado R, Gallas BD

P1-08-06 Oncology nursing in India: are we up to speed?

Chitkara G, Murali-Nanavati S, Bardeskar N, Gupte A, Behal S, Lad M, Dongarkar P, Shaikh M, Talapatra K

P1-08-07 Educational opportunities to improve HER2 testing and use of newer therapies for HER2-positive MBC among community healthcare professionals

Topping RP, Andrie RM, Rosenthal K, Quill TA

P1-08-08 Approach to prevention and management of chemotherapy toxicities in a interprofessional education program

Duffy A, Vasaiwala D, Bernhardt C, Lawson J, Rosenblatt P

P1-08-09 DIVAS - DC Pink Divas Intervening Virtually to Advance Saving Lives: Assessing the impact of digital behavioral health breast cancer education program for Black women

Zuend F, Thompson S, Wilson L

P1-08-10 A web-based patient decision aid toolkit for unaffected BRCA mutation carriers

McGarrigle SA, Spillane C, Byrne N, Polus M, Prizeman G, Drury A, Connolly E, Brady A-M, Hanhauser Y

P1-08-11 Using co-design to develop culturally and linguistically appropriate breast cancer education materials

Rakoff M, Serrano M, Neuhausen S

Treatment - Surgery and Radiotherapy: Breast Conservation

P1-09-01 The impact of the extent of the type of primary breast cancer surgery on outcome: final evidence on disease dynamics from the analysis of historical Italian trials

Biganzoli E, Bianchi F, Boracchi P, Marano G, Tagliabue E, Desmedt C, Romano D

P1-09-02 Oncological, cosmetic and quality of life outcomes following breast conservation surgery in patients presenting after non-oncological excision of breast primary: A prospective follow up study

Irrinki RNNS, Khare S, Singh G, Laroija I, Mishra A

P1-09-03 Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery

Kondo S, Kida K, Suzuki M, Fukano C, Yoshida A, Hayashi N, Takei J, Yamanaka M, Yamauchi H

P1-09-04 Comparison of length and quality of life (QoL) and the side effects of therapy between breast conserving surgery with intraoperative radiotherapy (TARGIT-IORT) versus mastectomy for in-breast-recurrence of breast cancer

Kolberg H-C, Niesing H, Vaidya JS, Akpolat-Basci L, Maguz A, Hoffmann O, Lövey G, Stephanou M, Kolberg-Liedtke C

P1-09-05 Effect of wire vs magnetic seed localization on lumpectomy cavity size

Dykstra M, Thompson J, Aldous J, Jiang S, Hughes T, Hayman J, Dragovic A, Shah J, Chang A, Speers CW, Sabel M, Dossett L, Schipper M, Jagsi R

P1-09-06 Save the breast after neoadjuvant therapy – identifying radiological and tumor related factors of importance for breast conserving surgery after neoadjuvant chemotherapy

Gulis K, Ellbrant J, Bendahl P-O, Svensjö T, Vallon-Christersson J, Dalene Skarping I, Loman N, Rydén L

P1-09-07 Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?

Qu F, Lin C, Li J-J, Shao Z-M

P1-09-08 Comparisons of aesthetic outcomes and prognosis of conventional breast conserving surgery, oncoplastic breast conserving surgery and breast conserving surgery plus immediate lipofilling in early breast cancer

Ren JH, Wang Y, Zhang X, Wang K, Tang R, Yang L, Gong J, Xu J, Li Q, Zhu WM, Cheng Q, Ren G, Li H

P1-09-09 Salvage mastectomy is not always necessary for aggressive subtypes of ipsilateral breast cancer recurrence: A single-institution retrospective study

Gentile D, Sagona A, Barbieri E, Di Maria Grimaldi S, Spoto R, Franceschini D, Vaccari S, Vinci V, Biondi E, Scardina L, Tinterri C

P1-09-10 Factors associate with borderline or invaded margins in breast cancer surgery at the Val d'Aurelle Montpellier CRLC

Mboua Batoum VM, Dina Bell ED

P1-09-11 Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: mastectomy versus conservative treatment

Jankowski C, Mahiou K, Laura V, Costaz H, Padeano M-M, Causeret S, Mamguem A, Dabakuyo S, Coutant C

P1-09-12 Intraoperative Pegulicianine fluorescence guidance for intraoperative tumor detection during lumpectomy surgery for Stage 0-III breast cancer

Smith BL, Hunt KK, Carr D, Blumencranz P, Hwang ES, Gadd M, Stone K, Dyess DL, Dodge D, Valente S, Dekhne N, Clark P, Lee MC, Samiiian L, Lesnikoski B-A, Clark L, Smith K, Chang M, Schlossberg B, Ferrer J, Wapnir IL

Treatment - Surgery and Radiotherapy: Radiotherapy

P1-10-01 Postmastectomy electron beams radiation therapy (PMERT) : long term results

Sami S, Loap P, Fourquet A, Kirova YM

P1-10-02 FLASH-RT, ultra-high dose rate radiotherapy, is as effective as conventional dose rate radiotherapy in eradicating tumor in a preclinical model of breast cancer

Dirbas F, Melemenidis S, Loo Jr BL, Horst K, Graves EE, Dutt S, Viswanathan V, Lau B, Yu A

P1-10-03 Ultra-hypofractionated radiotherapy for breast cancer: A Brazilian single-institutional series

Hernandes de Brito L, Cicci Farinha Restini F, Mansur Starling MT, Silva Moreira de Siqueira G, Nader Marta G, de Andrade Carvalho H, Abdallah Hanna S

P1-10-04 Withdrawn

P1-10-05 Safety of stereotactic body radiation therapy, stereotactic radiosurgery, and other radiation therapy with use of CDK 4/6 inhibitors for hormone receptor positive (HR+), HER2- metastatic breast cancer: a retrospective cohort study

Chauhan K, Kowalchuk RO, Garda AE, Shumway DA, Waddle MR, Mutter R, Corbin K

P1-10-06 Carcinoma en Cuirasse Secondary to Locally Advanced Breast Carcinoma: a case report

Liu C-T, Lanier K, Brinkley W

P1-10-07 Role of postmastectomy radiation therapy in breast cancer patients according to pathologic nodal status after neoadjuvant chemotherapy

Kim D, Kim JH, Kim IA, Chang JH, Shin KH

P1-10-08 Incidence of rib fracture following treatment with proton therapy for breast cancer

Bradley J, Liang X, Mailhot Vega R, Liu C, Brooks E, Burchianti T, Viviers E, Dagan R, Oladeru O, Morris C, Mendenhall N

P1-10-09 AQP4 inhibition prevents cytotoxic edema of AQP4+ astrocytes but promotes tumor growth of AQP4+ breast cancer brain metastasis

Contreras-Zarate MJ, Alvarez-Eraso K, Tsuji N, Kabos P, Ormond DR, Karam S, Cittelly DM

P1-10-10 Radiation treatment patterns for elderly women with breast cancer brain metastases

Upadhyay R, Perlow HK, Williams N, Klamer B, White J, Bazan JG, Jhawar SR, Blakaj DM, Grecula J, Arnett A, Thomas E, Chakravarti A, Raval RR, Lustberg M, Palmer J, Beyer S

P1-10-11 Optical stimulated luminescence dosimeters for skin dose measurements during accelerated partial breast brachytherapy: In vivo dosimetric validation and clinical outcomes

Gutschenritter T, Yorke A, Polissar N, Miljacic N, Kim J, Young L

P1-10-12 AI-based cardiac sub-structures segmentation for safer radiotherapy planning

Loap P, Botticella A, De Marzi L, Levy A, Bolle S, Colame S, Cannard A, Martineau-Huyh C, Oumani A, Roque TS, Paragios N, Deutsch E, Luo C, Kirova YM, Rivera S

P1-10-13 Economic comparison of standard external beam whole breast (WBI) versus accelerated partial breast irradiation (ABPI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial

Le Bras A, Belkacemi Y, Bourcier C, Gabelle-Flandin I, Petit A, Guilbert P, Geffrelot J, Carrie C, Rivin del Campo E, Hanzen C, Charra-Brunaud C, Auzac G, Lacornerie T, Lemonnier J, Lartigau E, Durand-Zaleski I

P1-10-14 Higher radiation dose to the heart in left sided breast cancer; anatomy versus dosimetry

Alm El-Din M, Niemierko An, Taghian A

P1-10-15 Conscious sparing of contralateral thyroid lobe in Ca Breast patients receiving post mastectomy radiotherapy by IMRT technique – A single institution dosimetric study

Chomal M, Iyer M, Kalimurthy A, Sahay J, Banik S

P1-10-16 Cardiac conduction system exposure with modern radiotherapy techniques for breast cancer irradiation

Loap P, Goudjil F, De Marzi L, Servois V, Kirov K, Fourquet A, Kirova YM

P1-10-17 Axillary radiotherapy in selected patients with a preoperative diagnosis of lymph node involvement is a safe alternative to axillary lymph node dissection

Arabiyat HA, Brown I, Drew P, English R, Sulieman M, Abbas I, Wheatley D, Potiszil K, Thomson A, King P

P1-10-18 Impact of adjuvant chemoradiation on cardiopulmonary function and quality of life in breast cancer

Anup Sr A, Wadasawala T, Johnny C, Sarin R, Pathak R, Krishnamurthy R, Gupta S, Parmar V, Ghosh J, Bajpai J, Gulia S

Treatment - Therapeutic Strategies: HER2-Targeted Therapy

P1-11-01 Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04

Harbeck N, Modi S, Jacot W, Yamashita T, Sohn JH, Vidal M, Tsurutani J, Ueno NT, Prat A, Niiikura N, Xu B, Rugo HS, Papazisis K, Cortés J, Krop I, Gambhire D, Yung L, Wang Y, Singh J, Cameron D

P1-11-02 Moved to HER2 Session

P1-11-03 Withdrawn

P1-11-04 Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort

Cucciniello L, Blondeaux E, Bighin C, Gasparro S, Russo S, Dri A, Pugliese P, Fontana A, Naso G, Ferzi A, Riccardi F, Sini V, Boni L, Fabi A, Montemurro F, De Laurentiis M, Arpino G, Del Mastro L, Gerratana L, Puglisi F

P1-11-05 Provider perceptions of DESTINY-Breast04, HER2-low directed treatment, and interstitial lung disease

Leon B, Bone R, Jeune-Smith Y, Feinberg B

P1-11-06 Multi-omics profiling of HER2-low breast cancer reveals clinically relevant subgroups and therapeutic pathways

Chen L, Liu C-C, Ge J-Y, Shao Z-M, Yu K-d.

P1-11-08 Moved to HER2 Session

P1-11-09 Five year follow up of a randomized phase II comparison of neo-adjuvant docetaxel, carboplatin, trastuzumab with or without lapatinib in HER-2 positive breast cancer

Crown J, Collins DM, Eustace AJ, Keane M, Coate L, Kennedy J, O'Reilly S, Kelly C, O'Connor M, Martin MJ, Murphy C, Duffy K, Walshe J, Mahgoub T, Gullo G, Moulton B, Alvarez-Iglesias A, Parker I, Hennessy B

P1-11-10 Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

Ashfield N, Mahdi AF, Conlon NT, Crown J, Collins DM

P1-11-11 HER2-directed therapy in early breast cancer – improvement over 20 years

Engel J, Reinhardt K, Strauß H-G, Große R, Barrot S, Bauer M, van Uden L, Kaufhold S, Schüler K, Wieder V, Kantelhardt EJ, Vetter M, Thomssen C

P1-11-12 Soluble TNF α blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer

Bruni S, Mauro FL, Proietti C, Cordo Russo R, Mercogliano MF, Schillaci R

P1-11-13 DE-REAL: Italian multicenter experience of Trastuzumab Deruxtecan in a real world setting

Botticelli A, Scagnoli S, Pisegna S, Santini D, Palazzo A, Scafetta R, Rossi L, de Laurentiis M, Caputo R, Verrazzo A, Berardi R, Barberi V, Bilancia D, D'auria G, Alesini D, Palleschi M, Fabbri A, Strigari L, Preissner R, Marchetti P, Fabi A

P1-11-14 Withdrawn

P1-11-15 Withdrawn

P1-11-16 Treatment with tyrosine kinase inhibitors (TKIs) in HER2-positive metastatic breast cancer after trastuzumab emtansine (T-DM1) failure: A real-world study

Yin Y, Li W, Huang X, Sun C, Hua Y, Jin N, Wu X

P1-11-17 The real-world outcome of human epidermal growth factor type-2 positive breast cancer patients receiving neoadjuvant therapy with or without pertuzumab

Acevedo F, Walbaum B, Medina L, Merino T, Bauerle C, Camus M, Leon A, Manzor M, Veglia P, Martinez R, Guerra C, Navarro M, Dominguez F, Sanchez C

P1-11-18 The efficacy and safety of trastuzumab and pertuzumab in combination with different chemotherapy regimens for neoadjuvant treatment of HER2-positive breast cancer: a multi-center real-world study in China

Qi X, Hu H, Wenlin C, Yan X, Shu L, Yanman F, Li T, Jia M, Sihai Z, Fan C, Yueyang L, Yuanming F, Zhang Y, Tang P, Jun J, Jianyun N, Chen L, Wang S

P1-11-19 A real-world evidence study of treatment patterns in patients with HER2-positive metastatic breast cancer who have received at least 2-lines of therapy

Varghese D, Cruz GI, Johanson C, Toland L, Miranda M, Faherty EC, Harland D, Kaplan HG

P1-11-20 Trastuzumab (HLX02) plus Pertuzumab as dual-target neoadjuvant therapy for HER2-positive breast cancer: A real-world study

Liu Y, Zuo W-J, Wang R-X, Wang Z-H, Shao Z-M

P1-11-21 A retrospective, single center study comparing two neoadjuvant protocols for HER2 positive breast cancer patients

Itay A, Levanon K, Bernstein R, Shapira T, Globus O, Oedegaard C, Meckel-Modiano T, Gold R, Gal-Yam E

Treatment - Therapeutic Strategies: Toxicities - Management

P1-12-01 Impact of anti-estrogen therapy on early vascular referrals, tests and medications in premenopausal women with operable breast cancer

Ansari A, Levine B, Douglas E, Ansley K, Melin S, Park C, Richardson K, D'Agostino R, Jordan J, Thomas A

P1-12-02 Unusual hepatotoxicity with the use of Ribociclib in a premenopausal patient

Carlos G, Zucchetti B, Donatelli V, Carlos A, Ferrari A, Cruz M, Dagostim C

P1-12-03 Antidiarrheal prophylaxis with loperamide for patients with lymph node-negative (N0) or micrometastatic (N1mi), HER2-positive breast cancer who received adjuvant pyrotinib plus nab-paclitaxel: a randomized sub-study of PHAEDRA

Wang C, Lin Y, Zhou Y, Mao F, Guan J, Shen S, Wang X, Zhang X, Zhang Y, Pan B, Zhong Y, Peng L, Li Y, Huang X, Xu Y, Sun Q

P1-12-04 Side effects of the mRNA COVID-19 vaccines in women treated for breast cancer

Juhel B, Brunelle CL, Bernstein MC, Smith LH, Jung AW, Hausman EK, Bucci LK, Naoum GE, Taghian AG

P1-12-05 The impact of adjuvant chemotherapy, including taxanes, on breast cancer-related lymphedema risk

Jung AW, Juhel B, Smith LH, Brunelle CL, Hausman EK, Bucci LK, Naoum GE, Taghian AG

P1-12-06 Prevalence and spectrum of manifestations of Tamoxifen retinopathy as assessed by multimodal and ultra-widefield retinal imaging

Zhao E, Kovacs K

P1-12-07 Management of genitourinary symptoms in breast cancer patients: An updated systematic review of available evidence from randomized trials

Fallah P, Wolfe DM, Hutton B, Clemons M, Shorr R, Vandermeer L, Rushton-Marovac M

P1-12-08 Biomarker analysis of hepatotoxicity in a Phase II study of nivolumab, abemaciclib and endocrine therapy in patients with HR-positive, HER2-negative breast cancer: WJOG11418BTR NEWFLAME_TR

Tsurutani J, Masuda J, Masuda N, Tanabe Y, Iwasa T, Takahashi M, Futamura M, Matsumoto K, Aogi K, Iwata H, Hosonaga M, Mukohara T, Yoshimura K, Imamura CK, Miura S, Yamochi T, Yoshimura K, Takano T, Kawabata H

P1-12-09 Withdrawn

P1-12-10 Superior effectiveness of Plinabulin (Plin) versus no-treatment for Docetaxel (Doc)-induced neutropenia (N) and other hematologic complication in breast cancer (BC) patients

Blayney D, Wells J, Duprez S, Legaspi G, Huang L, Mohanlal R

P1-12-11 Real-world incidence and management of diarrhea secondary to pyrotinib in patients with HER-2 positive breast cancer

Liu H, Ma L, Wang X, Chang X, Yu Q, Huang Q, Hao C, Liu J, Zhao J, Li S, Tong Z, Shi Y, Lu N, Zhao W, Wang T, Cao X, Wang C, Liu J, Zhao Y, Zhang L, Guo B, Wang X, Di X, Gao C, Liu Z, Sun S, Li L

P1-12-12 Adverse events associated with breast cancer vaccines

Dowding R, Liu Y, Childs JS, Disis M

Tumor Cell and Molecular Biology: Drug Resistance

P1-13-01 Targeting RRM2 for the treatment of palbociclib resistant breast cancer

Sultana N, Elford HL, Faridi JS

P1-13-02 The aberrant activity of retrotransposon elements mediates the chemo-tolerant persister cells relapse in TNBC

Zhang Z, Wang Y, Luo X, Li X, Zhan X, Zheng Y, Ding J, Wu T

P1-13-03 Establishment and characterization of two T-DM1-resistant, ER+/HER2+ breast XPDX models developed sequentially from the same patient with differential in vivo sensitivity to trastuzumab deruxtecan (DS-8201a)

Plasko G, Flores J, Simonson A, Forofontov P, Varma A, Lang A, Rodriguez G, Papadopoulos KP, Rasco D, Patnaik A, Conway B, Johnston J, Wick M

P1-13-04 Potentiating alpelisib in PI3K pathway overactive triple negative breast cancers

Boyd D, Harrell C

P1-13-05 Extracellular vesicles-transported lncRNA BCDR1 promotes tumor cell proliferation and therapy resistance via upregulating G1/S-phase transition in breast cancer

Zhang Q, Xiu B, Chi Y, Wu J

P1-13-06 Loss of emerging tumor and metastasis suppressor RasGAPs mediates therapeutic resistance in HER2+ breast cancer

Perurena N, Pilla N, Schade A, Watanabe M, Loi P, Rodriguez CL, Gardner AM, Cichowski K

P1-13-07 Investigating NF1 mutations in circulating tumor DNA of patients with hormone-receptor positive (HR+) breast tumors resistant to CDK4/6 inhibition (CDK4/6i): A retrospective clinical analysis

Lloyd MR, Ryan L, Medford AJ, Keenan JC, Spring LM, Vidula N, Moy B, Juric D, Ellisen LW, Bardia A, Wander SA

P1-13-08 Inhibition of RNA binding protein HuR function sensitizes the TNBC to chemotherapy

Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L

P1-13-09 Withdrawn

P1-13-10 Deconvoluting dynamics of acquired chemoresistance in triple negative breast cancer tumors

Kumar P, Menghi F, Straub R, Mukashyaka P, Lloyd MW, Chandok H, George J, Chuang J, Liu E

P1-13-11 YES1 is a targetable vulnerability for improving taxane response in triple-negative breast cancer

Ingles N, Piemonte K, Singh S, Weber-Bonk K, Keri R

P1-13-12 Targeting Dynamin-related protein 1 for the management of taxane-resistant triple-negative breast cancer

Terrero D, Tiwari A, Raman D

P1-13-13 Nuclear envelope expression of the oncogene adipocyte-associated methionine domain containing conveys inferior prognosis but increased sensitivity to statins and fluorouracil-based therapy

Redfern AD, Weerasena I, Spalding L, Ong M, Golden E, Woodward E, Blancafort P

P1-13-14 Increased androgen receptor expression as a mechanism of acquired anti-androgen resistance in androgen receptor-positive triple negative breast cancer

Krause H, Sharifi MN, Wolfe SK, Sperger JM, Wisinski KB, O'Regan R, Lang J

P1-13-15 Elevated TCEAL9 expression is correlated with trastuzumab-based neoadjuvant chemotherapy resistance in HER2-positive breast cancer

Goh CW, Chi W-R, Zhang L, Zhang Q, Chen M, Xiong M, Liu D, Ren H, Xiu B, Xue J, Chi Y, Wu J

P1-13-16 Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Adamo B, Vidal M, Muñoz M, Perou CM, Gavilá J, Pascual T, Prat A, Brasó-Maristany F

P1-13-17 Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Liao F-T, Gordon T, Liu CC, Selenica P, Zhu Y, Patel J, Nanda S, Qin L, Fu X, Gazzo A, Marra A, Blanco-Heredia J, Weigelt B, Reis-Filho J, Osborne CK, Rimawi MF, Schiff R, Veeraraghavan J

P1-13-18 EGFR signaling contributes to acquired resistance to CDK4/6 inhibitors in ER+ breast cancer cells in vitro and in vivo

Lypova N, Lanceta L, Daugherty S, Chesney J, Imbert-Fernandez Y

P1-13-19 ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer

Wu J, Zhou X, Chi Y, Xue J

P1-13-20 Reprogramming of oncogenic signal pathways and metabolism during trastuzumab resistance formation of HER2 positive breast cancer

Duan N, Hua Y, Hu S, Yin Y

P1-13-21 Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in luminal breast cancer cells

Cordani N, Mogni L, Piazza R, Cogliati V, Pepe F, Capici S, Di Bella C, Jaconi M, Cerrito MG, Villa M, Tettamanti P, Cavaletti G, Lavitrano M, Cazzaniga ME

P1-13-22 Establishment and characterization of two ER+/HER2- XPDX models developed sequentially before and after acquired resistance to the CDK4/6 inhibitor palbociclib from a patient with metastatic breast cancer

Varma A, Flores J, Simonson A, Stackpole A, Papadopoulos KP, Patnaik A, Rasco D, Beeram M, Sandera M, Wick M

P1-13-23 Carboplatin resistance-associated changes in the 3D chromatin landscape of a triple-negative breast cancer patient-derived xenograft

Dozmorov M, Marshall M, Rashid N, Grible J, Valentine AD, Olex A, Murthy K, Chakraborty A, Reyna J, Salgado Figueroa D, Lee D-I, Baur B, Roy S, Ay F, Harrell C

Treatment - Types and Sites of Breast Cancer: Other

P1-14-01 Incidence, clinicopathological features and treatment outcomes of young breast cancer patients: A cohort analysis from a high-volume tertiary cancer center in the United Arab Emirates

Al-Awadhi A, Hourani M, Hussein M, Alkindi F, Wahba L, AlAgha A, Shoqeir A, Yousif A, AlShebli M, Trad D, Masih A, Azribi F, Luiten E, Al-Shamsi H, Toffaha K

P1-14-02 Breast cancer in pregnancy: A retrospective clinical study in a single large tertiary cancer center in the United Arab Emirates

Hourani M, Bdair R, Hussein M, Yousif A, Wahba L, AlAgha A, Shoqeir A, Alkindi F, Alawadhi A

Treatment - Types and Sites of Breast Cancer: Brain Metastases

P1-14-03 Efficacy and safety of pyrotinib-based therapy in the treatment of HER2-positive breast cancer patients with brain metastases: a multi-center real-world study

Li H, Huang J, Tan Q, Man X, Yin S, Sun S, Hu Y, Li W, Zhou D, Song L, Zhang B, Xu L, Wang X, Xie X

P1-14-04 A phase 0 clinical trial of Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma

Ghamasae P, Balinda H, Brenner A, Floyd J

Treatment - Types and Sites of Breast Cancer: Inflammatory Breast Cancer

P1-14-05 Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients with Chest Wall Breast Cancer (PERICLES): an immune-biomarker analysis of tumor infiltrating lymphocytes (TILs) and programmed cell death ligand protein 1 (PD-L1)

Valenza C, Berton Giachetti PPM, Zagami P, Nicolò E, Trapani D, Boldrini L, Taurelli Salimbeni B, Ascione L, Antonarelli G, Corti C, Esposito A, Criscitiello C, Fusco N, Curigliano G.

ONGOING CLINICAL TRIALS 1 POSTER SESSION

**TUESDAY, DECEMBER 6, 2022: 5:00 PM – 6:15 PM
HALL 1**

Ongoing Clinical Trials: Adjuvant Endocrine Therapy

OT1-01-01 A randomised phase II trial of palbociclib and fulvestrant vs standard endocrine therapy in patients with ER positive HER2 negative breast cancer and ctDNA detected molecular relapse during adjuvant endocrine therapy (TRAK-ER)

Turner NC, Phillips ER, Bunce C, Robert M, Bailleux C, Garcia-Murillas I, Khabra K, Macpherson I, O'Brien CS, Okines AF, Palmieri C, Schmid P, Swift C, Yara S, Connolly S, Lemonnier J, Lee D, Andre F

Ongoing Clinical Trials: Androgen Receptor Antagonists

OT1-02-01 4CAST: A Phase 1b dose exploration and dose expansion, open-label study evaluating the safety and efficacy of INO-464 in combination with Chemotherapy in patients with metASTatic breast cancer

Dear RF, Batty K, Perez B, Chaffer C

OT1-02-02 A phase 1/2 study to evaluate the safety and efficacy of EP0062, an oral Selective Androgen Receptor Modulator (SARM), for the treatment of AR+/HER2-/ER+ advanced breast cancer

Lim E, Hamilton EP, Palmieri C, Arkenau H-T, Brook S, Fisher G, Mazur A

Ongoing Clinical Trials: Antibody-Drug Conjugates

OT1-03-01 XMT-1660: A Phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers

Hamilton EP, Chaudhry A, Spira AI, Adams S, Abuhadra N, Giordano A, Parajuli R, Han HS, Weise A, Marchesani A, Josephs K, Shin CR, Kalinsky K

OT1-03-02 Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study

Yin Y, Wu X, Ouyang Q, Yan M, Song L, Liu Y, Tong Z, Geng C, Yu G, Wang X, Cheng Y, Zhao W, Li Q, Diao Y, Liu G, Ge J, Li J

OT1-03-03 Phase 1 open-label study of Idiratuzumab vedotin in patients with first-line unresectable locally advanced or metastatic triple-negative breast cancer (SGNLVA-001, part F, trial in progress)

Han HS, Montero AJ, Tkaczuk K, Assad H, Hurvitz SA, Pusztai L, Wilks S, Nanda R, Specht JM, O'Shaughnessy J, Medgyesy D, Abraham J, Beckwith H, Chen LC, Wu S, Li H, Croft B, Burris HA

OT1-03-04 Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2- breast cancer: TROPION-Breast01

Bardia A, Kalinsky K, Tsurutani J, Hamilton EP, Sohn JH, Park KH, Park YH, Im S-A, Lee KS, Dastur D, Haddad V, Khan S, Xu B, Pistilli B, Rugo HS

OT1-03-05 TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who are not candidates for anti-PD-(L)1 therapy

Dent R, Cescon DW, Bachelot T, Jung KH, Shao Z-M, Saji S, Traina TA, Vuković P, Mapiye D, Maxwell M, Schmid P, Cortés J

OT1-03-06 Phase 1b/2 study of ladiratumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress)

Dillon P, Basho R, Han HS, Kolberg H-C, Tkaczuk K, Zahrah G, Gion M, Voss H, Meisel J, Pluard T, Fox J, Oliveira M, Brown-Glaberman U, Stringer-Reasor E, Manso L, Küemmel S, Chen LC, Wu S, Croft B, Boni V

Ongoing Clinical Trials: Aromatase Inhibitors

OT1-04-01 AMEERA-6: Phase 3 study of adjuvant Amcenestrant versus Tamoxifen for patients with hormone receptor-positive early breast cancer, who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity

Metzger O, Herold C, Poncet C, De Swert H, Casas-Martin J, Partridge AH, Guita S, Carey LA, Schumacher-Wulf E, Goulioti T, Meyskens T, Gannon J, Benlhassan K, Rossi G, Xenophontos E, Arahmani A, Dueck AC, Paux G, Brain E, Cameron DA

Ongoing Clinical Trials: Advanced TNBC

OT1-05-02 Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial

Li H, Tan Q, Sun S, Zhou D, Yu B, Su M, Li B, Fang S, Qiang L, Ren G, Bu B, Yin S, Man X, Qiu P, Wang X, Li C, Cao F, Shao Q, Han D, Song L, Fan B, Zhang B, Xu L, Zhao X, Liao Y, Xie X, Liu L

Ongoing Clinical Trials: Axillary Nodes

OT1-06-01 Preservation of axillary lymph nodes in breast cancer patients undergoing mastectomy with 1-2 metastatic sentinel lymph nodes: The current status and future perspectives of the multicenter randomized clinical trial SINODAR-ONE

Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A, Errico V, Bottini A, Di Maria Grimaldi S, Caraceni G, Boni L, Bruzzi P, Fernandes B, Franceschini D, Spoto R, Torrisi R, Scorsetti M, Santoro A, Canavese G, Tinterri C

Ongoing Clinical Trials: Axillary Nodes - Omitting Sentinel Node Biopsy

OT1-07-01 Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104)

Reimer T, Kuehn T, Stachs A, Kleine-Tebbe A, Bangemann N, Stefek A, Hammerle C, Heil J, Nixdorf A, Bonatz G, Nolte A, Rubio IT, Peintinger F, Mehta K, Loibl S, Botteri E, Gentilini OD

Ongoing Clinical Trials: Axillary Staging after Neoadjuvant Chemotherapy

OT1-08-01 AXSANA – EUBREAST3: An international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy

Kühn T

Ongoing Clinical Trials: Axillary Surgery

OT1-09-01 Axillary surgery de-escalation after neoadjuvant chemotherapy in breast cancer patients with initially involved node: the GANEA 3 trial

Renaudeau C, Gimbergues P, Guillot E, Chauvet M-P, Gutowski M, Jouve E, Rauch P, Cohen M, Faure C, Padeano M-M, Ceccato V, Uzan C, Bats A-S, Charitansky H, Dupré P-F, Reynard A, Alran S, Bendavid-Athias C, Campion L, Doutriaux I, Classe J-M

OT1-09-02 ATNEC: A multicentre, randomized trial investigating whether axillary treatment can be avoided in T1-3N1M0 breast cancer patients with no residual cancer in the axillary lymph nodes after neoadjuvant chemotherapy

Goyal A, Nicholls S, Marshall A, Hammonds N, Wheatley D, Elsberger B, Rose J, Edwards H-T, Butt R, Shaaban A, Puri S, Ahmed S, Homer T, Vale L, Bruce J, Gasson SJ, Higgins H, Dunn JA

Ongoing Clinical Trials: Brain Metastases

OT1-10-01 Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer (HER2+ MBC) after local therapy of isolated brain progression: InTTercept, a UCBG/GINECO study

Bachelot T, Jouannaud C, Verret B, CHabaud S, Petrau C, Stefani L, Ung M, Desmoulins I, Jacot W, Bailleux C, Marques S, Lemonnier J, Hardy-Bessard A-C

OT1-10-02 Trial of Neratinib plus Capecitabine in subjects with HER2-negative metastatic breast cancer with brain metastases and abnormally active HER2 signaling

Dhakal A, O'Regan R, Falkson C, Hicks D, Hawkins D, Turner B, Mohile N

Ongoing Clinical Trials: BRCA 1/2 Mutants

OT1-11-01 Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping

Vidula N, Damodaran S, Blouch EL, Horick N, Ruffle-Deignan NR, Bhave M, Shah AN, Varella L, Abramson V, Sparano J, Ellisen LW, Alim I, Ostrer H, Rugo HS, Bardia A

Ongoing Clinical Trials: Breast Conserving Surgery

OT1-12-01 A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer: NRG-BR007

White J, Cecchini RS, Harris EE, Mamounas EP, Stover DG, Ganz PA, Jagsi R, Bergom C, Théberge V, El-Tamer MB, Zellars RC, Shumway DA, Chen G-P, Anderson SJ, Julian TB, Wolmark N, Rea W

OT1-12-02 Preliminary report of the PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer

Braunstein LZ, Wong J, Dillon DA, Chen Y-H, Catalano P, Cahlon O, El-Tamer MB, Jimenez R, Khan A, Perez C, Punglia R, Shiloh R, Warren L, Wazer D, Wright J, Buckley E, King T, Powell S, Winer EP, Bellon J

OT1-12-03 Precision breast conserving surgery with the guidance of localization combined with multidetector CT 3-dimensional image reconstruction: a single center, prospective, cohort study

Xia Y, Cao D, Yang L, Zheng M, Weng M, Bachelor KS, Wang R, Zhao M, Xie H, Wang S

OT1-12-04 MRO PMS study - intraoperative specimen Magnetic resonance imaging system for intraoperative margin assessment for invasive breast cancer using the ClearCoast™ system in breast conserving surgery

Thill M, Kelling K, van Haasteren V, Schnitzbauer T, Kiene P, Levin A, Kolka E, Peles Z, Aulmann S

Ongoing Clinical Trials: Breast Reconstruction

OT1-13-01 BIOSYM - A feasibility randomised controlled trial comparing biological matrices with synthetic meshes in women undergoing one stage implant based breast reconstruction. ClinicalTrials.gov identifier: NCT05449691

Goyal A, Garreffa E, Newcombe R, Harder H, Rose J, Jenkins V

Ongoing Clinical Trials: CDK4/6 Inhibitors

OT1-14-01 Efficiency and safety of palbociclib in patients with locally advanced or metastatic breast cancer: a multi-center real world study

Yin Y, Huang X, Li W, Wu X, Hua Y, Sung C

Ongoing Clinical Trials: Chemoprevention Decision Support

OT1-15-01 SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)

Crew KD, Anderson G, Arnold K, Stieb A, Amenta JN, Law C, Sandoval-Leon A, Colonna S, King T, Mangino D, Pruthi S, Grosse Perdekamp M, Braun-Inglis C, Krisher S, Yee L, Bertoni D, Seaward S, Wisinski KB, Floyd J, Zarwan C, Ballinger T, VanderWalde L, Ross MM, Steen P, Lo S, Conlin A, Yost K, Ellerton J, Lin E, Pederson HJ, Sardesai S, Jernigan C, Hershman DL, Neuhouser ML, Arun BK, Kufafka R

Ongoing Clinical Trials: Chemotherapy

OT1-16-01 Trial in progress: An evaluation of FACIT-fatigue in patients with locally advanced or metastatic breast cancer receiving treatment with Taxane-based chemotherapy

Fabi A, Hager S, Lourdes L, Pedersini R, Malaguti P, Gavioli EM, Wakade R, Ruffini PA, Sergio F, Leone M, Mantelli F, Allegretti M, Blaes A

Ongoing Clinical Trials: Chemotherapy Induced Peripheral Neuropathy

OT1-17-01 Protocol description of genetics and inflammatory markers to predict chemotherapy-induced peripheral neuropathy among early stage breast cancer patients receiving Taxane therapy – GENIE Study

Wei M, Sharma A, Johnson K, Bie B, Hershberger C, Sen A, Rhoades EE, Hocking C-F, Budd G, Henry NL, Eng C, Foss J, Rotroff D

Ongoing Clinical Trials: Chemotherapy Side Effects

OT1-18-01 Comparative analysis between acupuncture and exercise in improving dermal sensitivity during Paclitaxel-containing chemotherapy: A randomized clinical trial

Costa Luz RP, Alliz CS, Lopes de Almeida Rizzi SK, Haddad C, Bittencourt Machado C, Nazário A, Facina G

Ongoing Clinical Trials: Cryoablation

OT1-19-01A single arm phase 2 study of peri-operative checkpoint-mediated immune therapy and cryoablation in women with hormone receptor-negative, HER2-negative early stage/resectable breast cancer

McArthur H, Comen E, Bryce Y, Solomon S, Santos Leal JH, DiLauro Abaya C, Martinez C, Basho R, Park D, McAndrew P, Larkin B, Mills W, Page DB, Mellinger S, Fredrich N, Moxon N, Reddy SM, Carter M, Patil S, Norton L

Ongoing Clinical Trials: DCIS

OT1-20-01 SentiNot 2.0: Avoid unnecessary sentinel lymph node biopsies in women with DCIS

Pantiora E, Eriksson S, Pistiolis L, Olofsson Bagge R, Nagy G, Thompson AM, Man V, Kwong A, Karakatsanis A, Wärnberg F

OT1-20-02 Intralesional injection of anti-PD-1 (pembrolizumab) and OX40L/IL-23/IL-36γ mRNAs (mRNA-2752) results in regression of DCIS characterized by lymphocytic infiltrates

Esserman LJ, Glencer A, Ramalingam K, Schwartz CJ, Borowsky A, Hirst GL, Woody R, Schindler N, Hylton NM, Campbell M

Ongoing Clinical Trials: De Novo Metastatic Breast Cancer

OT1-21-01 Preoperative radiotherapy and systemic therapy following surgery in 'de novo' metastatic breast cancer (Protocol MF22-01; Intervention Systemic Treatment METastasis-ISTMET)

Soran A, Ozbas S, Dogan L, İbis K, Dogan M, Selam M, Senol K, Aksoy SA, Ozsen M, Cetintas S, Evrensel T, Sezgin E

Ongoing Clinical Trials: Drug Resistance

OT1-22-01 Liquid biopsy and Ado-trastuzumab emtansine (T-DM1): drug-resistance traits in the blood of HER2-positive metastatic breast cancer patients

Fabi A, Allegretti M, Giordani E, Ferretti G, Arpino G, Zambelli A, Omarini C, Paris I, Botticelli A, Bria E, Palazzo A, Gori S, Cognetti F, Giacomini P

Ongoing Clinical Trials: Early Diagnosis

OT1-23-01 Development of a hoRizontal data intEgration classifier for NOn-invasiVe early diAgnosis of breasT canceR: the RENOVATE trial

Ravera F, Dameri M, Lombardo I, Stabile M, Tagliafico A, Calabrese M, Ballestrero A, Ferrando L, Zoppoli G.

POSTER SESSION 2

**WEDNESDAY, DECEMBER 7, 2022: 7:00 AM – 8:15 AM
HALL 1**

Treatment - Adjuvant Therapy: Adjuvant Therapy - Targeted

P2-01-01 Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Bartsch R, Harbeck N, Wrobel D, Zaiss M, Terhaag J, Guth D, Distelrath A, Wuerstlein R, Zahn M-O, Lüftner D, Schwitter M, Balic M, Jackisch C, Müller V, Rinnerthaler G, Schmidt M, Zaman K, Schinköthe T, Resch A, Breitenstein U

P2-01-02 Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant Olaparib

Morganti S, Jin Q, Vinciuilla J, Buehler R, Ryan S, Stokes S, Parker T, Mittendorf EA, King T, Weiss A, Partridge AH, Bychkovsky B, Curigliano G, Tayob N, Lin NU, Garber J, Tolaney SM, Lynce F

P2-01-03 Withdrawn

P2-01-04 Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumab

Debien V, Agostinetti E, Sirico M, Jacobs F, Molinelli C, Moreau M, Paesmans M, De Giorgi U, Santoro A, Taylor D, Duhoux FP, Botticelli A, Barchiesi G, Lambertini M, de Azambuja E, Piccart M

P2-01-05 MBQ-167 chemosensitizes triple-negative breast cancer cells to current chemotherapies and reduces paclitaxel-induced metastasis

Grafals-Ruiz N, Cruz-Collazo AM, Torres-Sánchez A, Dharmawardhane S

P2-01-06 Real-world outcome and cost analysis of the addition of pertuzumab to neoadjuvant therapy in localized HER2 positive breast cancer: a single center experience

Panet F, Young M, Wong S, Dragomir A, Rose AAN, Panasci L

P2-01-07 Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial

Zhou H, Wang L, Wang L, Guo Z

P2-01-08 The efficacy of Anlotinib combined with TEC in neo-adjuvant treatment for triple-negative breast cancer and the value of multi-point core needle biopsy in prediction of pathologic complete remission: A retrospective analysis

Ren K, Hong S, Zhu Z, Wang S, Liu J, Gao H, Wang S

Treatment - Adjuvant: Adjuvant Therapy - Other

P2-02-01 Benefit of adjuvant bisphosphonates in early breast cancer treated with contemporary systemic therapy: A meta-analysis of randomized control trials

Mittal A, Tamimi F, Molto Valiente C, Di Iorio M, Amir E

P2-02-02 Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer

Stanton SE, Wisinski KB, Gwin III WR, Coveler A, Liao JB, Burkard M, Bailey H, Kim K, Havinghurst T, DeShong K, Childs JS, Dimond E, Wojtowicz M, Heckman-Stoddard BM, Cecil D, Disis M

P2-02-03 Efficacy and safety of the addition of internal mammary irradiation to standard adjuvant radiation in early-stage breast cancer: A systematic review and meta-analysis

Korzets Y, Levitas D, Grubstein A, Corn BW, Amir E, Goldvaser H

P2-02-04 De-escalation of bone-targeted treatment: Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12

Beltran-Bless A-A, Clemons M, Fesl C, Hlauschek D, Soelkner L, Pond GR, Vandermeer L, Greil R, Balic M, Bjelic-Radusic V, Singer CF, Steger G, Helfgott R, Egle D, Gampenrieder SP, Kaceroosky-Strobl S, Suppan C, Ritter M, Rinnerthaler G, Pfeiler G, Fohler H, Hilton J, Gnant M

P2-02-05 Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States

Odzer N, Jaber Chehayeb R, Lustberg M, Gross CP, Foldi J

P2-02-06 Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials

Mastrantonio L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Chiara Cannizzaro M, Di Bello A, Fabi A, Palazzo A, Bria E, Tortora G, Orlandi A

P2-02-07 Patients' selection of daily timing of oral intake of adjuvant hormone therapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial

Giacchetti S, Hamy A-S, Bachelot T, Lemonnier J, Andre F, Cameron DA, Bliss J, Chabaud S, Hardy-Bessard A-C, Lacroix-Triki M, Canon J-L, Bonnefoi HR, Campone M, Dalenc F, Ballesta A, Lévi F, Laas E

Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive for Endocrine Tx

P2-03-01 Sarcopenia on baseline imaging is associated with toxicity-related discontinuation of endocrine therapy in women with early-stage hormone-positive breast cancer

Saraf A, Tahir I, Hu B, Dietrich A-S, Tonnesen PE, Sharp G, Tillman G, Fintelmann F, Jimenez R

P2-03-02 Prospective assessment of the decision-making impact of the Breast Cancer Index in the BCI Registry Study

Sanft TB, Wong J, O'Neal B, Siuliukina N, Jankowitz RC, Pegram M, Fox J, Zhang Y, Treuner K, O'Shaughnessy J

P2-03-03 Neutrophil-to-Lymphocyte Ratio (NLR) as a potential prognostic marker in patients with hormone receptor-positive/HER2-negative advanced-stage breast cancer treated with CDK4/6 inhibitors: A focus on ribociclib

Sharaf B, Qaddoumi A, Tamimi F, Abu-Fares H, Daoud R, Abdel-Razeq H

P2-03-04 Long-term benefit from adjuvant Tamoxifen in luminal A and luminal B breast cancer patients

Dar H, Johansson A, Nordenskjöld A, Perez-Tenorio G, Yau C, Benz CC, Esserman LJ, Nordenskjöld B, Stål O, Fornander T, Lindström LS

P2-03-05 HOXB13/IL17RB-low breast cancers are predicted to respond to PIK3CA inhibitors independent of PIK3CA mutational status

Boyraz B, Kirkpatrick G, Kaluziak ST, Morris R, Kreuzer J, Haas W, Iafrate AJ, Sgroi D

P2-03-06 Real world treatment of node negative low and intermediate recurrence score breast cancer

Globus O, Levanon K, Nili-Gal Yam E

P2-03-07 Multi-parametric algorithm integrating on-treatment Ki67 value and standard clinicopathological variables to predict risk of recurrences for women > 70 years old with early ER+HER2- tumours in POETIC trial

Cheang MCU, Dewan M, Kilburn L, Morani G, Zabaglo L, Sidhu K, Tovey H, Zhu X, Holcombe C, Skene A, Smith I, Robertson J, Ring A, Turner N, Bliss J, Dowsett M

P2-03-08 Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles

Zhu X, Xiao H, López-Knowles E, Bergamino Sirvén MA, Alataki A, Maxwell P, Tovey H, Kilburn L, Holcombe C, Skene A, Smith I, Robertson J, Hoadley KA, Salgado R, Bliss J, Turner N, Salto-Tellez M, Schuster G, Dowsett M, Cheang MCU

P2-03-09 Withdrawn

P2-03-10 DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Nanda S, Shea MJ, Schiff R, Osborne CK, Rimawi MF, Fu X

P2-03-11 Differential long-term benefit from adjuvant Tamoxifen therapy in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative premenopausal and postmenopausal breast cancer patients

Johansson A, Dar H, Nordenskjöld A, Perez-Tenorio G, Yau C, Benz CC, Esserman LJ, Van 't Veer L, Nordenskjöld B, Stål O, Fornander T, Lindström LS

P2-03-12 Impact of adjuvant endocrine therapy (ET) omission in ER+ breast cancer (BC) treated with neoadjuvant chemotherapy (NAC)

Choong GM, Boughey JC, Hoskin TL, Day CN, Goetz MP

P2-03-13 Breast Cancer Index (BCI) identifies fewer patients with high risk of late recurrence and high likelihood of benefit from extended endocrine therapy with invasive lobular compared to invasive ductal carcinoma

Metzger O, Parimi N, Siuliukina N, Zhang Y, Treuner K, Liefers G-J

P2-03-14 Tumor-agnostic measurement of ctDNA levels in first line ER+, HER2- metastatic breast cancer patients as a ; for survival

Verschoor N, Kraan J, de Weerd V, Van NM, Jager A, Sleijfer S, Martens JWM, Wilting SM

P2-03-15 Retrospective study using database for the effectiveness of medroxyprogesterone acetate in patients with ER-positive/HER2-negative postmenopausal advanced breast cancer: An additional analysis of the JBCRG-C06 Safari study

Utsunomiya K, Kawaguchi H, Yamamoto Y, Saji S, Masuda N, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S

P2-03-16 Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series

Clelland E, Rothschild HT, Patterson A, Molina-Vega J, Kaur M, Abel MK, Symmans WF, Chien J, Schwartz CJ, Mukhtar R

P2-03-17 Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2+ or HER2- metastatic breast cancer

Hunter N, Peterson LM, Mankoff D, Muzi M, Chen D, Gwin III WR, Vinayak S, Davidson NE, Specht JM, Linden H

P2-03-18 Clinical use of Breast Cancer Index for prediction of late breast cancer recurrence and prediction of benefit in extended endocrine therapy: A single institution experience

Chacko R, Godbole MM, Springer K, Ali H, Dabak V

P2-03-19 The efficacy of neoadjuvant endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor positive breast cancer

Maeda Y, Naruse S, Isono Y, Sato A, Yamada M, Matsumoto A, Ikeda T, Jinno H

P2-03-20 Clinical profiling and comprehensive analysis of candidate genes related to breast cancer estrogen receptor intratumour heterogeneity

Wang X, Yin Y, Fu Z

P2-03-21 Chemotherapy is not mandatory in premenopausal, node-positive, HR+HER2- breast cancer patients

Yoo T-K, Lee SB, Lee Y, Hwang Y, Shin E, Lee J, Kim HJ, Chung I-Y, Ko BS, Lee JW, Son BY

P2-03-22 Assessment of the relationship between duration of treatment with hormonal therapy and the detection of ESR1 mutations in hormone-receptor positive, HER2 negative, breast cancer

Ayettey-Anie H, Ahmed KA, Washington I, Yamoah K, Knepper T

P2-03-23 Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict: Results from the Charité registry

Schmitt WD, Jank P, Hoffmann I, Pfitzner BM, Lenz L, Clegg W, Keil E, Ratzel S, Cogan ES, Blohmer J-U, Wimberger P, Kronenwett R, Horst D, Denkert C

P2-03-24 Predictors of incomplete ovarian function suppression (OFS) in adolescent and young adult (AYA) women with hormone receptor positive (HR+) breast cancer

Anandan A, Ghosh T, Zhao J, Wisinski KB

P2-03-25 Pilot study to evaluate circulating tumor DNA (ctDNA) to PET/CT imaging using 18F-Fluorodeoxyglucose (FDG) and 18F-Fluoroestradiol (FES) PET/CT imaging as biomarkers in patients with metastatic breast cancer

Hunter N, Peterson LM, Muzi M, Konnick EQ, Reichel J, Kinahan P, Specht JM, Yung R, Gwin III WR, Linden H, Tran C

Prognostic and Predictive Factors: Response Predictive Factors - Clinical Testing and Validation

P2-04-01 Immunoexpression of markers related to the HER2 pathway in cases of pure positive her2 breast carcinoma treated with trastuzumab

Franco AFV, Waitzberg AFL, Araujo Neto JT, Pasini FS

Epidemiology, Risk, and Prevention: Prevention - Behavioral Interventions

P2-05-01 Addressing barriers to adherence and quality of life among women recommended to receive chemoprevention for breast cancer prevention

Jones JT, Whisenant M, Brassil KJ, Warlick HG, Solis E, Kamat S, Maliackal A, Walters A, Ponce D, Gonzalez A, Rios D, Emily R

P2-05-02 Potential empowerment and risk of genetic counseling with genetic breast cancer risk assessment in personalized Health care : prospective cohort study using genetic counseling outcome scale (GCOS-24)

Kawaguchi-Sakita N, Senda N, Inagaki-Kawata Y, Murakami H, Honda S, Yamada T, Kataoka Y, Takahara S, Tsuyuki S, Yamagami K, Moriguchi Y, Torii M, Kato T, Suwa H, Tsuji W, Suzuki E, Yamauchi A, Okamura R, Kosugi S, Toi M

P2-05-03 Perceived Guideline Clarity & Deferral to Patient Preferences impact guideline concordant care for breast cancer screening in women age 40-49

Nadler M, Corrado AM, Wilson BE, Desnoyers A, Amir E, Ivers N, Desveaux L

P2-05-04 Safety of breast MRI under general anesthesia

Le-Petross HTC, Bhavsar S, Scoggins ME, Sun J, Bui T, Shin K, Stafford J, Carlson III R, Adrada B

Epidemiology, Risk, and Prevention: Prevention - Nutritional Studies

P2-06-01 Improving the health of women on aromatase inhibitors: A pilot controlled dietary and exercise intervention trial

Carpenter CL, Master AK, Julian O, Ben-Nissan D, Rakoff M, Thames G, Li Z.

P2-06-02 A randomized controlled trial of soy isoflavone intake on mammographic density among Malaysian women

Rajaram N, Yap B, Eriksson M, Mariapun S, Tan LM, Saat H, Ho E, Mohd Taib NA, Khor GL, Yip CH, Ho Wk, Hall P, Teo SH

P2-06-03 Dietary exposure to acrylamide and breast cancer risk: results from the NutriNet-Santé cohort

Bellicha A, Wendeu-Foyet G, Coumoul X, Koual M, Pierre F, Guéraud F, Zelek L, Debras C, Srouf B, Sellem L, Kesse-Guyot E, Julia C, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M

P2-06-04 Effects of BMI velocity on outcomes in patients with metastatic breast cancer in the Dallas Metastatic Breast Cancer Study

Lim M, Pathak M, Cao M, Moscovitz A, Ladner J, Reddy SM, Chan I

Epidemiology, Risk, and Prevention: Prevention - Clinical Studies

P2-07-01 Hydroxytyrosol, a component of olive oil for breast cancer prevention in women at high risk

Puri A, Yin Z, Granados-Principal S, Ensor J, Guzman L, Rosato R, Zhao H, Wong S, Patel T, Chang J

P2-07-02 Effects of different duration of prophylactic antibiotic use on unplanned reoperation in breast cancer patients undergoing implant-based breast reconstruction: A retrospective study with overlap weighting analysis

Li Z, Chen J, Hao S, Cao A-Y, Huang X, Shao Z, Wu J

Epidemiology, Risk, and Prevention: Prevention - Preclinical Studies and Model Systems

P2-08-01 Licochalcone A from licorice reprograms metabolic and antioxidant pathways in the breast leading to a tumor preventive environment

Hajirahimkhan A, Bartom ET, Chandrasekaran S, Clare S, Khan S

Detection/Diagnosis - Imaging and Screening: Molecular, Functional, and Novel Imaging

P2-09-01 An emerging technology for breast cancer detection - Preliminary data of breast cancer detection using novel low dose positron emission mammography

Freitas V, Waterston ML, Olsen KO, Bubon O, Parker S, Baldassi B, Komarov B, Taeb S, Reznik A

P2-09-02 Noninvasive detection of lymph node involvement in subjects with human epidermal growth factor receptor 2 positive (HER2+) breast cancer using the MagSense® HER2 test reagent – A first-in-human phase 1 study

Jayalakshmi Y, Fox J, Yang N, Zhang M, Proulx R, Reich S

Detection/Diagnosis - Imaging and Screening: Radiology - Tumor Monitoring

P2-10-01 Correction of gradient non-linearity in multi-site multi-vendor Breast DWI: initial characterization and evaluation of effects on quantitative tumor ADC measures

Liang J, Wilmes LJ, Malyarenko D, Newitt DC, Li W, Gibbs JE, Zimmermann J, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Chenevert T, Hylton NM

P2-10-02 Impact of neoadjuvant treatment on the accuracy of breast MRI and calliper in premenopausal ER-positive, HER2-negative, and node-positive breast cancer patients: Prospective phase III clinical trial

Gwark S, Ahn SH, Lee JW, Son BH, Ko BS, Kim J, Chung I-Y, Lee SB, Ahn J-H, Jung KH, Kim S-B, Lee HJ, Gong G, Kim HJ

Prognostic and Predictive Factors: Prognosis-Biomarkers of Natural History-Prog Factors- Clinical Testing and Validation

P2-11-01 Secondary endocrine resistance and high Ki-67 labeling index (#20%) in patients with low genomic risk identified by 21-gene recurrence score

Lee J, Kim H, Bae SJ, Lee JW, Son BH, Ahn SH, Jeong J, Lee SB, Ahn SG

P2-11-02 Biomarkers related to survival benefit in the treatment of metastatic luminal breast cancer (mBC) with cyclin 4/6 inhibitors (CDK 4/6i) plus endocrine therapy (ET)

Morales Murillo S, Gasol Cudós A, Tuset Der-Abbrain N, Urdanibia I, Rodriguez Galindo A, Velasco Sánchez A, Vilardell Villellas F, Sánchez Guzmán D, Canosa Morales C, Melé Oliv J, Arbones Cid L

P2-11-03 How to make decisions in ductal carcinoma in situ? The first study of clinical applicability of the MSKCC ductal carcinoma in situ nomogram in the prediction of local recurrence risk after breast conserving surgery in a Brazilian cohort

Marques L, Carvalho H, Carvalho F, Rodrigues L, Aguiar F, Barros A

P2-11-04 Moved to HER2 Session

P2-11-05 Effects of intrinsic subtypes and 21-gene assay on the early and late recurrence risks in patients with early stage HER2+ breast cancer: An analysis of the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) Trial

Chumsri S, Li Z, Norton N, Moreno-Aspitia A, Colon-Otero G, Knutson KL, Wolff AC, Perez EA, Thompson EA

P2-11-06 Plasma assay of methylated DNA markers (MDM) detects patients with metastatic breast cancer (MBC) compared to healthy controls and treated breast cancer patients with no evidence of disease

Giridhar KV, Couch FJ, Sinnwell JP, Slettedahl SW, Taylor WR, Mahoney DW, Foote PH, O'Connell MC, Robran MJ, Devens ME, Gonser AM, Larson NL, Doering KA, Burger KN, Kaiser M, Allawi H, Ruddy KJ, Olson JE, Kisiel JB

P2-11-07 Association of PIK3CA mutations with efficacy in HER2-positive first-line metastatic breast cancer: a meta-analysis

Swain S, Cortés J, Xu B, Lambertini C, Essioux L, Knott A, Restuccia E, Madjar K, De Haas SL

P2-11-08 Multimodal prediction of breast cancer recurrence assays and risk of recurrence

Howard FM, Dolezal JM, Kochanny S, Hhramtsova G, Vickery J, Srisuwananukorn A, Woodard A, Chen N, Nanda R, Perou C, Olopade OI, Huo D, Pearson A

P2-11-09 Association of 21-gene recurrence score with overall survival in phase 3 TAILORx trial

Yang SX, Yu J, Wang M

P2-11-10 Validation of the Breast Cancer Index (BCI) prognostic models optimized for late distant recurrence in postmenopausal women with early-stage HR+ breast cancer in the TEAM trial

Bartlett JMS, Xu K, Wong J, Pond GR, Zhang Y, Spears M, Salunga R, Mallon E, Taylor KJ, Hasenburger A, Dirix L, Seynaeve C, J.H. van de Velde C, Rea D, Schnabel CA, Treuner K, Bayani J

P2-11-11 Computer analysis of nuclear morphology with multiple instance learning predicts overall survival for node positive breast cancer patients from SWOG S8814: A blinded validation study

Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes DF, Godwin AK, Thonpson AM, Madabhushi A, Pusztai L

P2-11-12 Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts

Dieci MV, Bisagni G, Bartolini S, Frassoldati A, Giulio Generali D, Piacentini F, griguolo G, Tagliafico E, Brasó-Maristany F, Chic N, Porra F, Vicini R, D'Amico R, Balduzzi S, Prat A, Conte P, Guarneri V

P2-11-13 High PD-L2 protein expression in cancer cells is an independent marker of unfavorable prognosis in luminal breast tumors

Chaudhary LN, Chervoneva I, Peck AR, Sun Y, Yi M, Langenheimer JF, Jorns JM, Kamaraju S, Cheng YC, Burfeind J, Chitambar CR, Hooke JA, Kovatich AJ, Shriver C, Hu H, Palazzo JP, Bibbo M, Hyslop T, Pestell R, Mitchell EP, Rui H

P2-11-14 Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?

Wimmer K, Hlauschek D, Balic M, Pfeiler G, Strobl-Kacerovsky S, Greil R, Singer CF, Halper S, Steger G, Suppan C, Gampenrieder SP, Helfgott R, Egle D, Filipits M, Jakesz R, Sölkner L, Fesl C, Gnant M, Fitzal F

P2-11-15 Focal ESR1 gene amplification is an independent prognostic marker in postmenopausal patients with endocrine-responsive early breast cancer

Singer CF, Holst F, Steurer S, Burandt E, Lax S, Jakesz R, Rudas M, Stöger H, Greil R, Sauter G, Filipits M, Simon R, Gnant M

P2-11-16 Computerized measurements of nuclear morphology features, mitosis rate, and tubule formation from H&E images predicts disease-free survival in patients with HR+ & LN+ invasive breast cancer from SWOG S8814

Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KS, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A

P2-11-17 Prognostic value of TroP2 expression levels in non-metastatic triple-negative breast cancer and correlation with other biomarkers

Jacot W, Chateau M-C, Thezenas S, Guiu S, Firmin N, Boissière-Michot F

P2-11-18 Serum methylmalonic acid concentrations at breast cancer diagnosis are not associated with distant metastases

Wu Q, Hatse S, García JF, Altea-Manzano P, Billen J, Planque M, Vandekerke A, Lambrechts Y, Richard F, Laenen A, Punie K, Neven P, Nevelsteen I, Floris G, Desmedt C, Gomes A, Fendt S-M, Wildiers H

P2-11-19 Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients

Gianni C, Palleschi M, Scarpi E, Merloni F, Blondeaux E, Puglisi F, Collovà E, Pugliese P, Cognetti F, Giannubilo I, Ruelle T, Bighin C, Del Mastro L, De Giorgi U

P2-11-20 Challenging the current 1-10% cut-off for defining estrogen receptor low positive grade 2-3 estrogen receptor positive, human epidermal growth factor receptor 2 negative early breast cancer

Roobroeck B, Vanderstichele A, Floris G, Desmedt C, Punie K, Han S, Smeets A, Janssen H, Baten A, Weltens C, Nevelsteen I, Baert T, Wildiers H, Neven P

P2-11-21 Outcomes and treatment pattern in women with 1 cm or smaller, node-negative hormone receptor-negative breast cancer in Fudan University Shanghai cancer center

Liu X, He M

P2-11-22 Expression of milk whey protein genes in human breast carcinoma cells isolated by LCM impacts prediction of clinical outcomes

Wittliff JL, Daniels MW

P2-11-23 Evaluation of T-cell infiltrating lymphocytes vs. Th2 in triple negative breast cancers (TNBC)

Brousse S, Godey F, Laffont E, Tas P, Campillo-Gimenez B, Lavoué V, Le Gallo M

P2-11-24 A novel, rapid and economical prognostic tool for adjuvant therapy decisions in hormone positive breast cancer

Amrania H

P2-11-25 A 10-gene signature to predict the prognosis of early-stage triple-negative breast cancer

Kim CM, Park KH, Yu YS, Kim JW, Park JY, Lee JE, Sim SH, Seo BK, Kim JK, Lee ES, Park YH, Kong S-Y

P2-11-26 The prognostic role of circulating tumor DNA after neoadjuvant chemotherapy in triple negative breast cancer with residual tumor

Roseshter T, Klemantovich A, Cavallone L, Aguilar-Mahecha A, Lafleur J, Lan C, Elebute OO, Jenna S, Boileau J-F, Pelmus M, Basik M

P2-11-27 Peritumoral desmoplasia in breast cancer – does it matter?

Weydandt L, Wolf B, Horn L-C, Aktas B

P2-11-28 Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients

Nagahashi M, Toshikawa C, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Kuwayama T, Nakamura S, Yamauchi H, Yamauchi T, Kaneko K, Kanbayashi C, Sato N, Tsuchida J, Moro K, Nakajima M, Shimada Y, Ichikawa H, Lyle S, Miyoshi Y, Takabe K, Okuda S, Wakai T

P2-11-29 The expression of Claudin-10 in relationship with Her family members in patients with breast cancer

Zhuang X, Jiang WG, Ruge F, Davies E, Xu B, Martin TA

P2-11-30 Performance of tumor vascularity as a biomarker is correlated with the change of tumor vascularity after preoperative systemic treatment in patients with breast cancer

Choi HS, Son EJ, Hany Noh H, In-Jeong Cho I, Lim ST, Lee J-I, Han A

P2-11-31 Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: A single institutional study with 10-year follow-up

Uras C, Cabioğlu N, Tokat F, Kara H, Er O, Korkmaz T, Bese N, Ince U

P2-11-32 Withdrawn

P2-11-33 Striatin and its interactive proteins Protein Phosphatase-2 (PP2) and PP2 regulatory elements in breast cancer

Li AX, Sanders AJ, Martin TA, Ye L, Ruge F, Dou Q, Davies E, Jiang WG

P2-11-34 Mitotic spindle hotspot counting using deep learning networks is highly associated with clinical outcomes in patients with early-stage triple-negative breast cancer who did not receive systemic therapy

Leon-Ferre RA, Carter JM, Zahrieh D, Sinnwell JP, Salgado R, Suman V, Hillman D, Boughey JC, Kalari KR, Couch FJ, Ingle JN, Balkenkohl M, Ciompi F, van der Laak J, Goetz MP

P2-11-35 A tight junctional scaffold protein MUPP1/MPDZ and its docking proteins, angiomotins in breast cancer

Gao H, Ruge F, Ye L, Lane J, Davies E, Jiang WG, Martin TA

P2-11-36 Osteopontin splice variants indicate prognosis in premalignant breast lesions

Weber GF, Ziolkowski P

Treatment: Research Resources - Tissue and Data Banks

P2-12-01 A comprehensive assessment of researcher needs to increase biospecimen donations for breast cancer research: A Patients and Researchers Together (PART) Program

Morris H, Van Lokeren M, Spears PA, Potter JA, Branch V, Patient And Researchers Together Team†, Perou CM, Carey LA

P2-12-02 ClinicalomicsDB - Bridging the gap between clinical omics data and machine learning

Moon CI, Jia B, Zhang B

Treatment: Research Resources - Clinical Trials Design and Management

P2-13-01 Enrollment trends among patients with breast central nervous system metastasis in active clinical trials

Elghawy O, Banfield W, Wang J, Horton B, Kaur V

P2-13-02 COBRA: Characteristics and Outcomes of patients with BReast cancer in phase I trials at Gustave Roussy Cancer center

Seknazi L, Geraud A, Goldschmidt V, Baldini C, Champiat S, Massard C, Postel-Vinay S, Marabelle A, Bahleda R, Hollebecque A, Smolenski C, Gazzah A, Michot J-M, Martin-Romano P, Vozy A, Vuagnat P, Danlos F-X, Bayle A, Mahjoubi L, Pistilli B, Loriot Y, Ponce-Aix S, Ouali K

P2-13-03 Feasibility of generating an external control comparator using RWD by matching with previously conducted RCTs: CDK4/6 Inhibitors for the treatment of metastatic breast cancer

Osgood C, Fan J, Gao X, Keane C, Bryan J, Roose JP, Bloomquist E, Torres A, Baxi S, Nussbaum N, Rivi F, Tang S, Nunes I, Beaver J, Rivera DR, Howie L, Paliwal P, Amiri-Kordestani L

P2-13-04 Inclusion of patients with leptomeningeal disease in phase III randomized clinical trials of patients with advanced breast cancer, lung cancer, and melanoma: A systematic review

Sharma A, Corbett K, Qazi M, Soliman H, Sahgal A, Das S, Lim-Fat MJ, Pond GR, Jerzak K, Michael G

Treatment - Surgery and Radiotherapy: Surgery

P2-14-01 Molecular fluorescence-guided surgery using BEVA800 for the assessment of tumor margins during breast conserving surgery of patients with primary breast cancer (MARGIN-II)

Kolberg H-C, Röhm C, Stachs A, Schütz F, Blohmer J-U, Wetzig S, Hartmann S, Heil J, Hahn M

P2-14-02 Surgical options of the breast and clinical outcomes in breast cancer patients after neoadjuvant chemotherapy: a single-center retrospective study

Sang Y, Chen J, Yang B, Hao S, Huang X, Liu G, Shao Z, Su J

P2-14-03 Learning curve for Robotic assisted nipple sparing mastectomy: a single institution experience

Kim YJ, Chung SY, Chae BJ, Yu J, Lee JE, Ryu JM

P2-14-04 Withdrawn

P2-14-05 Patient rather than tumor factors predict contralateral prophylactic mastectomy for inflammatory breast cancer

Drapalik LM, Amin AL, Simpson A, Rock L, Freyvogel M, Shenk R, Miller ME

P2-14-06 Prospective, multicenter, clinical validation study of the repeatability and accuracy of internal mammary sentinel lymph node biopsy with modified injection technique (CBCSG026/CBCSG027)

Wang Y-S, Lu Q, Zhu S-G, Zhao W-H, Yang G-L, Huang Y-X, Zhong H, Sun X, Qiu P

P2-14-07 Omission of sentinel lymph node biopsy in patients with early stage breast cancer: Looking beyond the choosing wisely guidelines for age < 70

Carleton N, Saadawi G, Oesterreich S, Lee AV, Diego E

P2-14-08 Trends in neoadjuvant systemic therapy rates in Europe: Pre-planned substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Weber WP, Matrai Z, Hayoz S, Henke G, Zwahlen DR, Gruber G, Zimmermann F, Ruhstaller T, Muenst S, Ackerknecht M, Kurzeder C, Küemmel S, Bjelic-Radicic V, Smanyakó V, Vrieling C, Satler R, Meyer I, Becciolini C, Bucher S, Simonson C, Fehr PM, Gabriel N, Maráz r, Sarlos D, Dedes KJ, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Sávolt Á; Singer CF, Reitsamer R, Winkler J, Lam Lam GT, Fehr MK, Naydina T, Kohlik M, Clerc K, Ostapenko V, Fitzal F, Heidinger M, Maggi N, Schulz A, Markellou P, Lelièvre L, Egle D, Heil J, Knauer M, Tausch C

P2-14-09 Sensory evaluation of nipple-areolar complex after nipple-sparing mastectomy: A comparison of incision approaches

Kook Y, Jang JS, Baek SH, Bae SJ, Ahn SG, Jeong J

P2-14-10 Axillary reverse mapping aids in reducing the rates of BCRL in underserved ethnically diverse population

Bhimani F, McEvoy M, Johnson K, Feldman S

P2-14-11 Oncological outcomes in patients undergoing targeted axillary dissection with carbon marker

Budel LR, Spautz CC, Louveira MH, Cavalcanti TCS, Fornazari AC, Gasperin Jr, P, Nissen LP, Budel VM

P2-14-12 Endoscopic nipple-sparing mastectomy : A single institutional experience of 50 consecutive cases

Lee H, Cho K, Chang Y, Son G

P2-14-13 Propensity score matching for survival outcomes in breast cancer patients with nipple sparing mastectomy versus total mastectomy and breast-conserving surgery: a single-center retrospective study

Xiong M, Hao S, Chen J, Huang X, Liu G, Shao Z, Wu J

P2-14-14 Effect Of intra-operative and post-operative topical tranexamic acid on early post-operative complications in patients undergoing axillary lymph node dissection for breast cancer- A randomized controlled study

Pachimatla AG, Irrinki RNNS, Laroia I, Khare S

P2-14-15 Comparison of recurrence-free survival according to axillary surgery extent for clinical NO, sentinel node(s) positive, primary breast cancer patients who underwent total mastectomy

Chun JW, Kim H-K, Lee H-B, Moon H-G, Lee JW, Han W

P2-14-16 Breast surgery for metastatic breast cancer: a Cochrane systematic review

Tosello G, Riera R, Christofaro D, Oliveira C, Cruz M, Paulo TR, Mota BS

P2-14-17 Withdrawn

P2-14-18 Oncological outcomes of nipple-sparing mastectomy after neoadjuvant chemotherapy

Rabinovich I, Nissen LP, Soares IC, Fornazari AC, Spautz CC, Sebastião APM, Urban CA, Anselmi KF, Schunemann E, Kuroda F, Doria MT, Andrade ACS, Lima RS

P2-14-19 Targeted axillary lymph node dissections using radar reflector localization can reduce unnecessary axillary lymph node

Lunt L, Coogan A, Madrigano A, O'Donoghue C

P2-14-20 Comparison of robot-assisted nipple sparing mastectomy with conventional nipple sparing mastectomy: a single-center experience

Young You J, Lee H, Lee E-S, Jung SP

P2-14-21 NiToNo Study. Evaluation in terms of quality of life and upper extremity functionality after targeted axillary dissection versus lymphadenectomy

Vila Homs L, Carrillo-Guivernau ML, Sampol C, Matheu Capo G, Camarasa P, Serra C, Mariño M, Tarongí A, Córdoba O, Perelló A

P2-14-22 Evaluation of male breast cancer and the application of sentinel lymph node biopsy: A multi-center retrospective study

Shang Q, Wei Y, Qiao G, Li J, Wang X

Treatment - Surgery and Radiotherapy: Reconstruction

P2-15-01 Withdrawn

P2-15-02 Omentum-lipoaspirate free-flap breast reconstruction in women with BMI < 25

Wapnir IL, Dua MM, Zak Y, Nguyen D

P2-15-03 Impact of radiotherapy on the long-term patient-reported outcomes of immediate breast reconstruction: The UK Brighter

Johnson L, White P, Jeevan R, Browne J, Gulliver-Clarke C, O'Donoghue J, Mohiuddin S, Hollingworth W, Fairbrother P, MacKenzie M, Holcombe C, Potter S

P2-15-04 Surgical outcomes of ambulatory mastectomy with immediate alloplastic reconstruction for breast cancer or risk reduction

Sandhu S, Cil TD, Escallon JM, Brown M, Semple J, Lim D

P2-15-05 Prepectoral versus subpectoral implant-based breast reconstruction: A systemic review and meta-analysis

Ostapenko E, Nixdorf L, Devyatko Y, Wimmer K, Exner R, Fitzal F

P2-15-06 Light-based bioprinting of vascularized fatty tissue for the development of biological breast implants

Hedemann N, Thomas A, Tribian N, Kloke L, Bauerschlag D, van Mackelenbergh M

P2-15-07 Current status of latissimus dorsi flaps with or without implants for breast reconstruction in patients with breast tumor: A single-center retrospective study

Zheng S, Chen J, Hao S, Yang B, Huang X, Liu G, Wu J

P2-15-08 Aesthetic incisions and early complications for nipple-sparing mastectomy followed by immediate breast reconstruction

Pimentel Cavalcante F, Novita G, Oliveira Lima T, Alcantara R, Cardoso A, Ulisses F, Zerwes F, Millen E

P2-15-09 Impact of neoadjuvant chemotherapy on the short- and long-term outcomes in patients who underwent immediate breast reconstruction after mastectomy

Nogi H, Ogiya A, Kondo N, Ishitobi M, Yamauchi C, Mori H, Shimo A, Narui K, Nagura N, Seki H, Sasada S, Sakurai T, Shien T

P2-15-10 Impact of the withdrawal of textured breast implants from the market on breast reconstruction practices

Jankowski C, Martinez M, Laura V, Burnier P, Coutant C

Tumor Cell and Molecular Biology: Cellular Mechanisms

P2-16-01 The Kinesin-like protein Kif11 is essential for the Survival of TP53-mutant triple negative breast cancer cells

Lanier A, Mazumdar A, Tahaney W, Brown P

P2-16-02 TXNIP-dependent tumor suppressive pathways in breast cancer growth and progression

Singh J, Sah B, Liu L

P2-16-03 The Speckle-type POZ protein (SPOP) inhibits breast cancer malignancy by destabilizing oncogene TWIST1

Wei C, Liu Y, Liu X, Cheng J, Fu J, Xiao X, Moses RE, Li X, Fu J

P2-16-04 MNX1 promotes tumor sensitivity to HER2-targeted therapy in HER2-positive breast cancer

Chi W-R, Xiu B, Xiong M, Li p, Zhang Q, Li L, Hou J, Zhou X, Sang Y, Chen M, Zhang L, Xue J, Chi Y, Wu J

P2-16-05 Targeting EZH2 to overcome chemoresistance in triple negative breast cancers employing combinatorial approach

Shankar E, SNC S, Rima XY, Kushwaha P, Verma S, Sarathy GK, Kulkarni A, Allimuthu D, Reátegui E, Gupta S, Ramaswamy B

P2-16-06 Protein expression and subcellular localization of a clathrin adaptor AP-1 associate with tumor growth activity in breast cancer

Hoshi N, Tachibana K, Uemura T, Nishimagi Y, Noda M, Okano M, Abe S, Otake T, Waguri S

P2-16-07 Overexpression of the alpha subunit of the epithelial sodium channel in MDAMB231 breast cancer cells reduces cell migration and proliferation

McQueen S, Ware A, Cunliffe H, McDonald F

P2-16-08 Mechanistic understanding of PARP inhibitor trapping clarifies BRCAness

Dubach M

P2-16-09 Dual Specific Phosphatase-7 (DUSP7/PYST2) and its role in regulating vascular endothelial functions

Ji W, Jiang WG, Ye L, Martin TA

Tumor Cell and Molecular Biology: DNA Damage and Repair

P2-17-01 Targeted CRISPR screen to identify synthetic lethal combinations between APOBEC3B and DNA repair

Stefanovska B, Lin K, Troness B, Myers C, Harris R

P2-17-02 SMC6 down-regulation: marker of genetic instability and poor outcome in breast cancer

Rotea Mangone FR, Krepischi ACV, Carraro DM, Nagai MA

P2-17-03 Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low/Hormone receptor negative breast cancer patient-derived xenograft models

Gonzalez-Gonzalez A, Guo Z, Meroni A, Cybulla E, Hoog J, Vindigni A, Ma CX

P2-17-04 Pharmacological inhibition of LY6K induced cell cycle arrest and DNA damage by disrupting the LY6K-Histone-Aurora B signaling axis

Selvanesan B, Varghese S, Andrys J, Arriaza R, Prakash R, Tiwari P, Olsen C, Huplo D, Gusev Y, Patel M, Contente S, Sanda M, Wilkerson M, Dalgard C, Shimizu LS, Chruszcz M, Borowski T, Upadhyay G

Tumor Cell and Molecular Biology: Epigenetics

P2-18-01 Matched single-cell RNA-seq and single-cell ATAC-seq of male breast cancers nominate salient cancer-specific enhancers

Wisniewska K, Kim H, Regner MJ, Spanheimer P, Franco HL

P2-18-02 Promoter hypomethylation associated upregulation of MEN1 mRNA expression and its correlation with pathological parameters in Indian breast cancer patients

Massey S, Khan A, Khan A, Deo SVS, Akhtar S

Tumor Cell and Molecular Biology: Hormonal Factors and Receptors

P2-19-01 Characterization of fully human internalizing anti-HER2 monoclonal antibodies that compete with Trastuzumab for binding to HER2

Serrero G, Dong J, Yue B, Yerramalla U, Hayashi J

P2-19-02 Androgen mediated signaling induces epithelial to mesenchymal transition phenotype in MDA-MB-453 breast cancer cells and human breast tumors

Rajarajan S, Snijesh VP, Nair MG, Apoorva D, Chandrakala M, Nimbalkar VP, Pillai M, Jolly MK, Prabhu JS

Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy

P2-20-01 Patient-derived triple-negative breast cancer organoids as a platform for glucocorticoid receptor-mediated mechanisms of immunotherapy response and resistance

Shiang C, Frerich C, Durdana I, Lewis C, Bennett LB, Arteaga CL, Conzen SD



Passion for Innovation. Compassion for Patients.®

Explore **Booth #100**, to see how we create **new standards of care** and better futures through medicine.



Scan the QR code to view our
oncology pipeline.



P2-20-02 Enrichment of atypical memory double negative (CD27— IgD—) tumour infiltrating B cells following neoadjuvant chemotherapy for early-stage breast cancer

Carpenter E, Alaguthurai T, Hossain F, Graham r, Kakkassery H, Keane S, Irshad S

P2-20-03 Combination Therapy with an Anti-GD2 Antibody, Transforming Growth Factor Beta Imprinted Natural Killer Cells and Gemcitabine Improve Tumor Control and Survival in a Triple Negative Breast Cancer Model

Pereira M, Trikha P, Vasu S, Li Z, Stober DG, Lee D, Gatti-Mays M

P2-20-04 Vaccination against HIF1 α /c-MET peptides overcome lapatinib resistance and inhibits tumor growth by immunomodulating in HER2 positive breast cancer

Lee JM, Hong JH, Lim SY, Kim JW, Lim AR, Hyun MH, Park KH

P2-20-05 Personalized tumor vaccine can suppress tumor growth and metastasis in the syngeneic mouse breast cancer model

Moon H-G, Son HY, Heo WH, Quan M, Li S, Valentina H, Jeong H, Han W, Lee H-B, Her Y, Kim JH

P2-20-06 Anti-B7-H3 antibody (T-1A5) blocks immunomodulatory function of B7-H3 and enhances NK and T cell-mediated cytotoxicity against breast cancer cells

Anand V, Tyagi A, Battula VL

P2-20-07 Immunotherapy becomes a treatment option in cryoablated Luminal A breast cancers

Aukers Z, Klein J, Ciocca V, Zemba-Palko V, Sabol J, Ciocca R, Mandik-Nayak L, Carp N, Wallon M

P2-20-08 Expression of ACVRL1 in a subset of recruited tumor-associated macrophages drives resistance to PD-1 therapy in human breast cancer

Safaei Talkhonchek M, Sjölund J, Bolivar Balbas P, Kurzejamska E, Larsson S, Cordero E, Oudenaarden CR, Pantaleo J, Jonsson G, Rolny C, Bocci M, Pietras K

P2-20-09 Enhancement of anti-tumor immunity in ER+ breast cancer through dual inhibition of MCL1 and caspases

Yi JK, Spektor A

P2-20-10 Prognostic impact of lymphocyte-Activation Gene-3 (LAG-3) expression in triple negative breast cancer

Kim J-Y, Kim J, Jung HH, Cho EY, Park YH, Ahn JS, Kim K-M, Im Y-H

P2-20-11 Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors

Werner LR, Helm DE, Tinoco J, Chowanec EI, Holloran SM, Hastings RC, Wei J, Lei G, Yang X-Y, Markiewicz MA, Chalise P, Balko JM, Hartman ZC, Hagan CR

P2-20-12 Abundance of tumor-infiltrating lymphocytes is associated with pathologic complete response to neoadjuvant chemotherapy but not with survival in ER-positive/HER2-negative breast cancer

Wu R, Nagahashi M, Oshi M, Miyoshi Y, Ishikawa T, Takabe K

P2-20-13 Withdrawn

P2-20-14 Relationship of HIF-1 α and tumor infiltrating lymphocytes in patients with HER2-negative early-stage breast cancer treated with neoadjuvant chemotherapy

Grabinski V, Augusto Santa-Maria C, Oza H, Gilkes D, Shah M, Cimino-Matthews A, Gabrielson E, Pipa Z, Lehman J, Ke S, Tsai H-L, Stearns V, Ibanez H, Zhi WI

P2-20-15 Proteolytic regulation of CD73 by TRIM2 orchestrates tumor immunogenicity

Fu Z, Zhu Y, Kalinsky K, Wan Y

P2-20-16 Hormone receptor expression is associated with specific immunological profiles in the breast cancer microenvironment

Hanamura T, Kitano S, Kagamu H, Yamashita M, Terao M, Okamura T, Kumaki N, Hozumi K, Iwamoto T, Honda C, Kurozumi S, Niikura N

P2-20-17 Eribulin is an immune potentiator in breast cancer by up-regulation of human leukocyte antigen class I

Wada A, Kutomi G, Hirohashi y, Kyuno D, Shima H, Kuga Y, Torigoe T, Takemasa I

Tumor Cell and Molecular Biology: Microenvironment - Stromal-Epithelial Interactions

P2-21-01 Decoding inter- and intra-tumor heterogeneity in lobular breast cancer using spatial transcriptomics and clustering analysis

Serra M, Rediti M, Lifrange F, Venet D, Occelli N, Collet L, Vincent D, Rouas G, Craciun L, Larsimont D, vikkula M, Duhoux FP, Rothé F, Sotiriou C

P2-21-02 Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial

Zerdes I, Salgkamis D, Matikas A, Selander L, Wang K, Tzoras E, Sifakis E, Agartz S, Chen X, Hellström M, Hartman J, Bergh J, Foukakis T, Hatschek T

P2-21-03 Unique collagen peptide signatures between ductal carcinoma in situ and invasive breast cancer by mass spectrometry tissue imaging

Hulahan TS, Wallace EN, Strand SH, Colditz GA, Hwang ES, West R, Spruill L, Marks J, Drake RR, Angel PM

P2-21-04 The tumor immune microenvironment composition and prognostic value in breast cancer during pregnancy is dynamic during the gestation period

Sajjadi E, Venetis K, Ivanova M, Noale M, Blundo C, Scarfone G, Di Loreto E, Ferrero S, Maggi S, Veronesi P, Galimbreti VE, Viale G, Peccatori FAA, Guerini-Rocco E, Fusco N

P2-21-05 Vascular effects of Platelet-derived growth factor-B (PDGFB) in breast cancer metastasis to the brain

Shah S, Packard R, Steck S, Mossing A, Ramamoorthy Y, Thies K, Didier A, Spehar J, Richardson D, Arsiwala T, Godbout J, Sizemore S, Lockman P, Sizemore G

P2-21-06 The relationship between the gene expression difference of fibroblasts in the tumor microenvironment and metastasis of triple-negative breast cancer

Heo WH, Lee W, Li S, Kim J-I, Moon H-G

P2-21-07 Exploring spatial correlations in Breast invasive Lobular Carcinoma subtypes using a novel CAF multiplex immunofluorescence panel

Batra H, Pandurengan RK, Ibarguen HP, McAllen SA, Ding Q, Sahin A, Wistuba I, Parra ER, Raso MG

P2-21-08 Digital spatial profiling of RNA and protein in the invasive lobular breast cancer microenvironment

Bennett LB, Frerich C, Sahoo S, Lewis C, Raman I, Xu M, Chen G, Conzen SD

P2-21-09 Detailed analyses of pro-metastatic and anti-metastatic microenvironments of murine breast tumors in syngeneic mice

Alkan F, Wilson JD, Shekastehband N, Hedrick C, Arnold A, Bollag R, Shi H, Korkaya H

P2-21-10 Tumour associated macrophages in Breast Cancer - Are they critical players in response to Neo Adjuvant Chemotherapy?

Krishna L, Korlimarla A, Srinath BS, Ranjolkar A, Nascar S, Hari PS, Devi D, Nidhi I, Kumar RV

P2-21-11 A high content imaging and analysis approach to screen compounds for novel drug targets in 3D breast cancer co-culture model

Ali R, Huwaizi S, Alsubait A, Boudjelal M

P2-21-12 Targeting ADAM8 dependent maintenance of the myCAF phenotype in the breast cancer tumor microenvironment

Mi Z, Kuo PC

Tumor Cell and Molecular Biology: MicroRNAs and Other Non-coding RNAs

P2-22-01 Nuclear long non-coding RNA LINC00355 expression and treatment using antisense oligonucleotides in Estrogen Receptor positive late-stage relapse breast cancer

Wells D, Gelev K, Thunugungla P, Jayasinghe R, Ding L, Shao J, Ma CX, Silva-Fisher J

P2-22-02 The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance

Wang X, Emch M, Hawse J

P2-22-03 Effect of miR-660-5p in breast cancer progression

Villarreal-Garcia V, Estupiñan Jimenez JR, Noriega R, Bayraktar R, Reséndez-Pérez D, Rodríguez-Padilla C, Vázquez-Guillén JM, Lopez-Berestein G, Vivas-Mejía P, Gonzalez-Villasana V

P2-22-04 Functional effect of miR-1307-3p on breast cancer progression

Estupiñan Jimenez JR, Villarreal-García V, Noriega R, Bayraktar R, Reséndez-Pérez D, Rodríguez-Padilla C, Vázquez-Guillén JM, Mar-Aguilar F, Lopez-Berestein G, Vivas-Mejía PE, Gonzalez-Villasana V

Tumor Cell and Molecular Biology: Molecular Profiles

P2-23-01 Patient-derived xenografts allow deconvolution of single agent and combination chemotherapy responses in triple-negative breast cancer

Lei JT, Huang C, Srinivasan RR, vasaikar S, Dobrolecki LE, Lewis AN, Zhao N, Cao J, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan v, Saltzman AB, Malovannaya A, Landua JD, Wen B, Jain A, Wulf GM, Li S, Kraushaar DC, Wang T, Chen X, Echeverria GV, Anurag M, Zhang B, Lewis MT

P2-23-02 Withdrawn

P2-23-03 Genomic evaluation of malignant phyllodes tumors reveals multiple targetable opportunities

Rosenberger LH, Riedel RF, Danziger NA, Sokol E, Ross JS, Sammons SL

P2-23-04 Moved to HER2 Session

P2-23-05 Trastuzumab-induced tumor microenvironment changes in early HER2+ breast cancer

Kennedy LC, Alvarez R, Dintzis S, Gadi VK

P2-23-06 Estrogen receptor-negative progesterone receptor-positive breast cancer is a molecularly distinct group characterized by the down-regulation of genes controlled by ESR1 and SUZ12

Kunc M, Popęda M, Bieńkowski M, Braun M, Łacko A, Radecka B, Pikiel J, Litwiniuk M, Pogoda K, Niemira M, Szałkowska A, Iżycka-Świeszewska E, Cserni G, Biernat W, Senkus E

P2-23-07 DNA methylation analysis of triple negative breast cancers

Lin LH, Tran I, Yang Y, Cotzia P, Roses D, Schnabel F, Darvishian F, Snuderl M

P2-23-08 Concordance of targeted sequencing from circulating tumor DNA and paired tumor tissue

Huang C-C, Tseng L-M

P2-23-09 Ultra-high tumor mutation burden in metastatic/clinically advanced breast cancer (MBC)

Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger NA, Sokol E, Sivakumar S, Pavlick D, Ross JS, Pusztai L

P2-23-10 Gene expression and mutation profiles in HER2-mutated metastatic breast cancer

Hensin WL, Thomas SN, El-Refai S, Mauer E, Ma CX, Bose R

P2-23-11 Quantitative gene expression by RT-PCR in histologic subtypes of invasive breast carcinoma: an update in nearly one million cases

Can NT, Flannery CA, Hoag J, Akkunuri A, Bailey H, Baehner F

P2-23-12 The mutational landscape of 1172 patients with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors

Shah AN, Lim B, Mita MM, Mauer E, Layng KV, Chao C, Brufsky AM

P2-23-13 Highly proliferative estrogen receptor-positive breast cancer is associated with better response to neoadjuvant chemotherapy but worse clinical outcome

Wu R, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K

P2-23-14 Molecular characterization of HER2-low invasive breast carcinoma by quantitative RT-PCR using Oncotype DX®

Rozenblit M, Lin H-K, Can NT, Flannery CA, Hoag J, Akkunuri A, Bailey H, Baehner F, Puszta L

P2-23-15 Histologic, immunohistochemical and genomic comparison between classic Invasive lobular carcinomas and lobular-like invasive ductal carcinomas

da Silva EM, Basili T, Yu J, Blanco-Heredia J, Selenica P, Ye Q, da Cruz Paula A, Dopeso H, Marra A, Oesterreich S, Reis-Filho J, Bhargava R

P2-23-16 Clinico-pathological and molecular characterization of HER2-enriched breast tumors independently of HER2 status

Muñoz-Carrillo FJ, Paré L, Conte B, Rodríguez A, Galván P, Sanfeliu E, González-Farré B, Falato C, Garcia-Fructuoso I, Adamo B, Chic N, Martínez-Sáez O, Pascual T, Moreno R, Muñoz M, Brasó-Maristany F, Prat A, Schettini F, Vidal M

P2-23-17 Programmed death ligand-1 expression in triple-negative breast cancer from Nigeria

Olasehinde O, Wuraola F, Kajetanowicz A, Bethune G, Edelweiss M, Ntiamoah P, Odujoko O, Sharma A, Mango V, Kingham P, Alatise O, Knapp G

P2-23-18 Analysis of serum galectin profiles by breast cancer subtypes and patient characteristics

Shealy J, Kesic A, Funkhouser A, Martin J, Gluck WL, Edenfield WJ, Blenda A

P2-23-19 Interrogating multicellular signaling in breast cancer using a bio-orthogonal chemistry-based proteomics platform

Krajina BA, Yamamoto A, Cheung KJ, Madasu S

Tumor Cell and Molecular Biology: New Drugs and Mechanisms

P2-24-01 The development of covalent microtubule stabilizers for drug-resistant cancers

Essif JN, Risinger A

P2-24-02 Analyzing susceptibility to macrophage-activating immunotherapy bexmarlimab in breast cancer by using patient-derived tumor explants

Rannikko JH, Virtakoivu R, Takeda A, Boström P, Koskivuo I, Bono P, Hollmén M

P2-24-03 Z-endoxifen allosterically inhibits PKC β I and its paradoxical membrane translocation

Sarkar Bhattacharya S, Witter TL, Cong AT, Bruinsma ES, Jayaraman S, Goetz MP, Hawse J, Schellenberg M

P2-24-04 The ER antagonist giredestrant induces profound chromatin remodeling including activation of cis-regulatory elements bound by FOXA1 and GATA3 in HR+ breast cancer models

Ahmed M, Guan J, Zhou W, Yao X, Metcalfe C, Hafner M

P2-24-05 TAVO412 - A novel trispecific cMet x EGFR x VEGF antibody for triple negative breast cancer

Chiu M

P2-24-06 α EGFR-E-P125A antibody-endostatin fusion protein reduces vasculogenic mimicry and tumor cell motility by inhibition of EGFR, integrin and FAK signaling

Sankar AP, Gil Henn H, Cho HM, Nassar D, Ramakrishnan S, Das R, Zhang Y, Elledge C, Shin S-U, Rosenblatt J

P2-24-07 Combination of complete estrogen receptor antagonist, OP-1250, and CDK4/6 inhibitors enhances tumor suppression and inhibition of cell cycle-related gene expression

Parisian AD, Palanisamy GS, Ortega F, Sapugay JL, Bodell WJ, Kulp D, Kushner P, Harmon C

P2-24-08 Altersolanol B, a fungal metabolite, induces proteasome-dependent degradation of estrogen receptor α (ER α) and inhibits downstream signaling targets in ER+ breast adenocarcinoma cells

Siraj MA, Rahman MS, Jacobs AT, Tan GT

Tumor Cell and Molecular Biology: Oncogenes/Tumor Suppressor Genes

P2-25-01 TRPS1 regulates angiogenesis via JAG1 and TYMP in triple-negative breast cancer

Guzman L, Ayerbe C, Rangel R, Chang J, Rosato R

P2-25-02 Examining MDMX and MDM2 signaling pathways in breast cancers expressing mutant p53

Lee R, Forbes D, Ellison V, Xiao G, Leybengrub P, Kern A, Bargonetti J

P2-25-03 β -arrestin1, a potential tumour suppressor in breast cancer is downregulated in PERK/ATF4-dependent manner

Sultana A, Gupta A, Gupta S

P2-25-04 Granzyme B expression in tumor microenvironment as a biomarker for prognosis of triple-negative breast cancer

Mizoguchi K, Nakamura M

Tumor Cell and Molecular Biology: Other

P2-26-01 Prospective breast biopsy collection at an urban safety-net hospital serving a diverse patient population

Ilinski A, Mahdavian K, Fishman M, Cassidy M, Ko N

P2-26-02 Valproic acid induces apoptosis and mitochondrial perturbations in breast cancer cells

Paoli A, Forestiero M, Naimo GD, Mauro L, Panno ML, Giordano F

P2-26-03 TRAF3 as a regulator of breast cancer aggressiveness

Papanastasiou A, Sirinian C, Theakou M, Peroukidis S, Chaniotis D, Kalofonos H, Koutras A

P2-26-04 Human papillomavirus protein E6 regulates Toll like receptor-9 expression in breast cancer cells

Parviainen E, Nurmenniemi S, Bravaccini S, Pirini F, Ravaioli S, Jukkola A, Selander KS

P2-26-05 Olaparib in advanced breast cancer (ABC) patients with methylation of BRCA1/2 promoter. GEICAM/2015-06 study ("COMETA-Breast")

de la Haba-Rodríguez J, Antón A, Quiroga V, Guerrero-Zotano A, Andrés R, Melé M, González-Santiago S, Pérez-fidalgo JA, Ramón Y Cajal T, Escudero MJ, Bezares S, Caballero R, Rojo F

P2-26-06 Association between CK+/CD45+ circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) alterations in advanced breast cancer patients

Reduzzi C, Gerratana L, Zhang Y, Manai M, D'Amico P, Davis AA, Donahue J, Shah AN, Cristofanilli M

P2-26-07 Alteration of gut microbiota signatures and its association with diarrhea during abemaciclib treatment: A multicenter prospective cohort study (KBCRN-A002 study)

Kawaguchi K, Maeshima Y, Ishiguro H, Yamagami K, Takahara S, Suwa H, Torii M, Nagai S, Sagara Y, Tsuji W, Yamashiro H, Kotake T, Fukuda S, Saito K, Yamamoto Y, Kataoka M, Himoto Y, Yonezawa A, Fukui Y, Nakamura Y, Li W, Tanaka S, Morita S, Toi M

P2-26-08 Influence of genetic ancestry on breast stromal cells provides biologic basis for increased incidence of metaplastic breast cancer in women of African descent

Kumar B, Batic K, Bhat-Nakshatri P, Granatir M, Addison R, Szymanski M, Baldrige LA, Temm C, Sandusky G, Althouse S, Storniolo AM, Nakshatri H

P2-26-09 Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway

Moon YW, Gosh M, Park N, Pandey K, Katwal NB, Hong SD

P2-26-10 Statins exhibit an anti-tumor effect by attenuating PD-L1 in breast cancer cells and macrophages and reducing breast tumor progression in xenograft mouse model

Lee S, Kim HS, Yoon S-H, Ryu S, Baek M, Park AY, Lee H-B, Han W

P2-26-11 Protein phosphatase 1 catalytic units, PPP1CA, PPP1CB and PPP1CC in breast cancer

Dong X, Martin TA, Dou Q, Jiang WG, Davies E

P2-26-12 Interaction between CTCs and platelets complicate their detection by masking surface epitopes

Schott D, Pizon M, Pachmann K

P2-26-13 Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing

Zhang X, Monteiro M, Yee D

P2-26-14 CDK4/6 inhibitors modulate the ubiquitin–proteasome pathway in ER+ breast cancer by downregulation of UBE2C/S/T

Lin C-Y, Yu C-J, Liu C-Y, Chao T-C, Huang C-C, Tseng L-M, Lai J-I

P2-26-15 CCR7 expression in Inflammatory breast cancer

Balema W, Krishnamurthy S, Lawrence A, Rodriguez M, Larson R, Fowlkes n, Ueno NT, Woodward WA

P2-26-16 MELK is a downstream target of Del-1 and promotes breast cancer progression

Lee IH, Lee SJ, Lee J, Jung JH, Park HY, Park NJ-Y, Park J-Y, Kang J, Kim EA, Chae YS, Kang B

P2-26-17 Establishment of an in vitro preclinical platform: A living biobank of patient-derived organoids with ER+ breast cancer

Dominguez-Cejudo MA, Chapresto R, Gil-Torralvo A, Salvador Bofill FJ, Molina-Pinelo S

P2-26-18 Adiponectin regulates stem cell activity in tamoxifen-resistant breast cancer cells

Naimo GD, Forestiero M, Paoli A, Giordano F, Panno ML, Mauro L, Andò S

P2-26-19 Slc26a9 cooperates with HER2 to regulate the progression and development of HER2-positive breast cancer

Zhou Z, Ma Z, Liu X, Zhang C, Wang H, Mu R, Cheng X, Tuo B, Li T

P2-26-20 Marvel D3 and its associated junctional proteins in breast cancer

Ji W, Jiang WG, Martin TA

P2-26-21 The principal factors associated with engraftment success of patient-derived xenograft of breast cancer

Lee J, Lee U, Lee HJ, Gong G

P2-26-22 Elevated expression of high mannose glycans in tissue and serum samples of breast cancer patients

Kesic A, Funkhouser A, Shealy J, Martin J, Gluck WL, Edenfield WJ, Blenda A

P2-26-23 Transcriptomic modification induced by the first cycle of neoadjuvant chemotherapy impacts response to treatment in triple negative breast cancer (TNBC)

Desmoulins I, Chardin D, Richard C, Arnould L, Cochet A, Humbert O, Boidot R

POSTER SESSION 3

**WEDNESDAY, DECEMBER 7, 2022: 5:00 PM – 6:15 PM
HALL 1**

Treatment - Advanced Disease Treatment: Advanced Endocrine Therapy

P3-01-01 Unicentric experience with icdk4/6 in metastatic breast cancer

Henaó F, Nogales Fernández E, Sevilla Ortega L, De Toro Salas R, Palazón Carrión N, Álamo de la Gala MdC, Sanchez-Camacho Mejías A, Sanchez Leon ML, de la Cruz-Merino L

P3-01-02 Withdrawn

P3-01-03 Characterization of neutropenia in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer on palbociclib in a real-world setting: Results from POLARIS

Tripathy D, Blum JL, Sleckman B, Patel K, Nakhoul I, Gauthier E, Montelongo MZ, Zhang Z, Wang Y, Rocque GB

P3-01-04 A real-world evidence study of everolimus plus endocrine therapy beyond CDK4/6 inhibitors for HR+/HER2- advanced breast cancer

Sánchez-Bayona R, Alva M, López de sa A, Jerez Gilarranz Y, Sánchez de torre A, Tolosa P, de luna A, López-Tarruella S, Lema L, Moreno F, Echavarría I, Madariaga A, Benítez J, Herrero B, Rey M, Ortega J, Gámez S, Modrego A, Martín Lozano R, Figuero-Pérez L, Jiménez R, González Sevilla M, González I, Bringas Beranek M, de toro M, Massarrah T, del Monte-Millán M, Pinardo M, Manso L, Bueno-Muiño C, García-Sáenz JÁ; Martín M, Ciruelos E

P3-01-05 Laboratory monitoring in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer treated with palbociclib in a real-world setting: Results from POLARIS

Rocque GB, Blum JL, Specht JM, Dul C, Corso S, Cuevas D, Gauthier E, Montelongo MZ, Zhang Z, Wang Y, Tripathy D

P3-01-06 Withdrawn

P3-01-07 Phase II trial of palbociclib with fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor

Tao JJ, Blackford AL, Nunes CI, Mahosky J, Jones MK, Leasure NC, Cescon T, Christou A, Werner JL, Couzi R, Smith KL, Augusto Santa-Maria C, Wolff AC, Stearns V

P3-01-08 Metronomic chemo-endocrine treatment (FuVEEC) for patients with advanced hormone-refractory ER+ breast cancer

Buda-Nowak A, Kwinta L, Potocki P, Streb J, Wysocki P

P3-01-09 Maintenance therapy with ET and Ribociclib after 1st line chemotherapy (CT) in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (BC): a phase II trial (AMICA)

Decker T, Lüdtke-Heckenkamp K, Melnichuk L, Furlanetto J, Lübke K, Zahn M-O, Schmidt M, Denkert C, Lorenz R, Müller V, Zahm D-M, Mundhenke C, Bauer S, Thill M, Seropian P, Filmann N, Loibl S

P3-01-10 Going beyond the median: Estimating survival times for patients with hormone receptor positive, metastatic breast cancer commencing endocrine therapy

Parsonson AO, Sarkar S, Brown L, Kiely B, Vasista A

P3-01-11 Withdrawn

P3-01-12 Chidamide combined with fulvestrant in the treatment of HR-positive and HER2-negative advanced breast cancer after failure of previous endocrine therapy: A single-arm, single-center, phase 2 study

Li W, Zou L, Zeng X

P3-01-13 Palbociclib, ribociclib and abemaciclib in real-world data: risk of disease progression on first-line treatment of metastatic breast cancer

Cejuela M, Castilla Má, Benavent M, Molina-Pinelo S, Dominguez-Cejudo MA, Gil A, Falcon A, Salvador Bofill FJ

P3-01-14 Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database

Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky AM

P3-01-15 Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in African American (AA) patients with metastatic breast cancer (MBC)

Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky AM

Treatment - Advanced Disease Treatment: Advanced Therapy - Other

P3-02-01 Chemotherapy plus immunotherapy in stage IV triple-negative breast cancer patient during pregnancy: a case report

Lima C, Apolinario TL

P3-02-02 Real-world time-to-treatment discontinuation in hormone-receptor-positive metastatic breast cancer patients following CDK4/6 inhibitor treatment, based on observational data collected through patient-partnered research

Carmeli AB, Wander SA, McGillicuddy M, Block C, Wagle N

P3-02-03 A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)

Damodaran S, Liu D, Schwartz J, Valero V, Ramirez D, Saleem S, Ueno NT, Ibrahim NK, Karuturi MS, Murthy RK, Moulder S, Litton JK

P3-02-04 Phase II study of Pembrolizumab maintenance treatment in patients with HER2-negative inflammatory breast cancer (IBC) and triple-negative breast cancer (TNBC) after response to chemotherapy

Iwase T, Alexander A, Chiv V, Kai M, Kida K, Parker C, Marx AN, Cohen E, Gao H, Reuben J, Wang X, Krishnamurthy S, Liu D, Shen Y, Ramirez D, Tripathy D, Booser D, Yam C, Valero V, Lim B, Ueno NT, Willey JS

P3-02-05 Interim analysis results from a European disease registry study aimed to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer

Balic M, Costa L, Ojaimi J, Oprean CM, Passos Coelho JL, Pazos I, Puglisi F, Sanglier T, Scandurra G, Schenker M, Wahyudi LA, Zhbantov G, Timcheva C

P3-02-06 Demographic and clinical features of patients with metastatic HER2 positive breast cancer: a retrospective multicenter registry study of the Turkish Oncology Group

Eralp Y, Doğan I, Aksoy S, Çakar B, Başaran G, Ercelep Ö; Molinas Mandel N, Korkmaz T, Gökmen E, Aydinler A, Saip P

P3-02-07 Combined chemo-endocrine therapy maybe a new option for HR+/HER2- advanced breast cancer: A prospective, single-center clinical study of Fulvestrant plus oral Vinorelbine

Wang X, Yue J, Wang J, Zhang P, Ma F, Xu B, Yuan P.

Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention – Other

P3-03-01 The impact of the COVID19 pandemic on treatment practices for patients diagnosed with early breast cancer: a cross-sectional study from a large comprehensive cancer centre in Italy

Girardi F, Marini S, Porra F, Mietto I, Carpentieri S, Marchet A, Saibene T, Lo Mele M, Giarratano T, Giorgi CA, Mioranza E, Falci C, Faggioni G, Caumo F, Griguolo G, Dieci MV, Guarneri V

P3-03-02 Can artificial intelligence derived ultrasound breast density provide comparable breast cancer risk estimates to density derived from mammograms

Valdez D, Bunnell A, Wolfgruber T, Altamirano A, Quon B, Maskarinec G, Sadowski P, Shepherd J

P3-03-03 Risk factors associated with chemotherapy-induced nausea and vomiting among breast cancer patients receiving highly emetogenic chemotherapy

Yeo W, Ngai N, Yip C, Yeo V, Ko J, Yip C, Mo F

P3-03-04 Cyclin-dependent kinase 4/6 inhibitor in advanced breast cancer during the COVID pandemic period: efficacy in relation to vaccination for SARS-COV 19

Giovanardi F, Carretto E, Bisagni G, Degli Esposti C, Gasparini E, Bologna A, Di Cicilia R, Moretti G, Pinto C

P3-03-05 A randomized study assessing interventions to improve comfort during screening mammography

Mazo-Canola M, Ko HC, Kist K, Michalek J, Franco L, Otto P, Kaklamani V

P3-03-06 A pilot study of personal care product use and exposure to environmental chemicals among Black and Hispanic breast cancer survivors

Bethea TN, Hicks J, Speiser E, Llanos A, Starr GE, Dash C, Adams-Campbell LL

P3-03-07 The breast cancer prevention clinic: A single institution's experience

Stephenson J, Perkins L, Crowe E, Franco R, Hancock C, Cloys P, Smith M

P3-03-08 Depression and breast cancer recurrence among female veterans in the United States: a retrospective cohort study

Aboumrad M, Shiner B, Connor A, Watts BV, Visvanathan K

P3-03-09 Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system

Kantor ED, O'Connell K, Ergas IJ, Valice E, Roh JM, Bhimani J, Heon N, Griggs JJ, Lee J, Bowles EJ, Rivera DR, Kolevska T, Bandera E, Kushi LH

P3-03-10 The impact of type 2 diabetes on complications after primary breast cancer surgery: a Danish population-based cohort study

Kjærgaard K, Wheler J, Dihge L, Christiansen P, Borgquist S, Cronin-Fenton D

P3-03-11 Racial and ethnic disparities in screening mammography during COVID-19

Milton A, Woods R, Elezaby M, Hackett K, Neuner J, Narayan A, Strigel R

P3-03-12 Risk of recurrence with adjuvant endocrine therapy in real world patients with hormone receptor positive/human epidermal growth factor receptor-negative early breast cancer: a US database analysis

O'Shaughnessy J, Yardley D, Hart L, Razavi P, Graff SL, Wogen J, McDermott C, Dionne P-A, Haftchenary S, Pathak P, Tolaney SM

P3-03-13 Long-term heart failure risk of trastuzumab with or without anthracyclines in early stage breast cancer: A SEER-Medicare Database Analysis

McAndrew NP, Britten K, Wang X, Yang E, Hurvitz SA, Slamon D

P3-03-14 Comparing risk of breast cancer and cardiovascular disease and uptake of chemoprevention and statins among racially/ethnically diverse women with atypical hyperplasia or lobular carcinoma in situ

Nilan L, Amenta JN, McGuinness JE, Kukafka R, Crew KD, Lawal K

P3-03-15 Physical activity and risk of death in breast cancer survivors: A prospective study

Chen LH, Irwin MR, Olmstead R, Haque R

P3-03-16 A methodology for using real-world data from electronic health records to assess chemotherapy administration in women with breast cancer

Bhimani J, O'Connell K, Burganowski RP, Ergas IJ, Foley MJ, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bowles EJ, Bandera EV, Kushi LH, Kantor ED

P3-03-17 The impact of cardiovascular disease risk on cancer progression among female breast cancer survivors: A longitudinal study within the Boss Cohort

Feng X, Deng Z, McCollough M, May B, Selznick E, Connor A, Armstrong DK, Visvanathan K

P3-03-18 M1 registration: Signaling patients who develop metachronous metastases after primary breast cancer

de Munck L, Knors D, Buisman H, Scholman K, Verloop J, Siesling S

P3-03-19 Real-world data of clinical characteristics, risk factors and outcomes of Chilean triple-negative breast cancer patients

Walbaum B, Acevedo F, Bauerle C, Camus M, Manzor M, Martinez R, Veglia P, Navarro M, Guerra C, Dominguez F, Merino T, Medina L, Sánchez C

P3-03-20 Breast cancer stage, molecular subtype and survival in patients with obesity: a Brazilian cohort study

Mattar A, Chrispim L, Cavagna F, Gebrim LH

P3-03-21 Biological and cultural drivers of early-onset breast cancer: a mixed-method study

Houghton L, Ulanday KT, Topaz M, Walker D, Lewis S, Terry MB

P3-03-22 Overweight and obesity trends over 5 years in early stage and metastatic breast cancer patients

Tsou T, Blackford AL, Stearns V, Sheng JY

P3-03-23 Breast cancer and subsequent risk of type 2 diabetes mellitus: A systematic review and meta-analysis

Jordt N, Kjærgaard K, Borgquist S, Thomsen RW, Cronin-Fenton D

P3-03-24 The WISDOM Study: Early ascertainment of breast cancer diagnoses by utilizing self-reported questionnaires and data warehouse electronic health records

Leggat-Barr K, Ryu RH, Stover Fiscalini A, Lewis T, Bulusu RS, Raouf SA, Park HL, Rocha AN, Johansen L, Van 't Veer L, Esserman LJ, Hogarth MA

P3-03-25 An automated risk stratification system for breast cancer screening using Thermalytix

Kakileti ST, Madhu H, Bansal R, Singh A, Sampangi S, Aggarwal B, Manjunath G

P3-03-26 Osteopenia and osteoporosis in women with breast cancer in Taiwan: Single center retrospective data

Liu C-H, Hung C-C, Tsai I-C

P3-03-27 Assessment of the proliferative activity of breast tissue after the administration of combined oral hormonal contraceptive, associated or not with estriol

Pellegrini Jr O, Nazário A, Waitzberg AFL

P3-03-28 Clinicopathological risk factors of brain metastasis in breast cancer patients: A systematic review and meta-analysis

Garcia KBC, Lubay AAA

P3-03-29 SMARTphone-based cardiovascular risk reduction in breast cancer patients [SMART-BREAST]: A randomized controlled trial

Murphy AC, Farouque O, Koshy AN, Yeo B, Dick R, Nadurata V, Roccisano L, Reid C, Yudi M

Detection/Diagnosis - Imaging and Screening: Breast Imaging - Mammography etc.

P3-04-01 The role of routine post-operative mammogram after breast conserving surgery

Globus O, Grinin K, Keidar-Person O, Nili-Gal Yam E, Levanon K, Herman N

P3-04-02 Population level access to diagnostic mammography and ultrasound guided breast biopsy in Nigeria: a geospatial analysis

Omisore A, Sutton EJ, Tansley G, Akinola RA, Knapp G

P3-04-03 Safety, tolerability, and efficacy of the novel intravenous manganese-based contrast agent SN132D in patients with breast cancer: initial results of a Phase I, First-In-Human clinical trial SPAGOPIX-01

Wärnberg F, Karakatsanis A, Shcherbina L, Sjöberg F, Hargreaves P, Curiac I-D, Johansson E, Axelsson O, Hansen M

P3-04-04 Correlation of mammographic microcalcifications with final surgical pathology after neoadjuvant chemotherapy for breast cancer

Azam RM, Look Hong N, Lim D

P3-04-05 Artificial intelligence detects, classifies, and describes lesions in clinical breast ultrasound images

Bunnell A, Valdez D, Wolfgruber T, Altamirano A, Hernandez B, Sadowski P, Shepherd J

P3-04-06 Artificial intelligence-based triaging of breast cancer screening mammograms and radiologist workload reduction: a systematic review and meta-analysis

Xavier D, Miyawaki IA, Campello Jorge CA, Barbosa Moreira MJ, Carvalho BM, Batalini F

P3-04-07 Safety and artifact testing of a nitinol breast biopsy clip in an ultra-high resolution magnetic resonance imaging (MRI) environment

Dong W, Ramchandran K, Galloy A, Nino MA, Kleingartner M, Raghavan ML, Phadke S, Magnotta VA

P3-04-08 Comparison of cone beam breast CT and breast MRI in preoperative assessment of primary breast cancer tumor size

Ji Y, Liao G, Luo N, Jiang Y, Liao X, Tang W, Yang H

P3-04-09 3-dimensional intraoperative analysis of screen-detected breast cancers reduce re-excision rates

Mondani J, Arabiyat H, Kastora S, Sulieman M, Abbas I, King P, English R, Brown I, Barta M, Jackson N, Drew P

P3-04-10 The TILs-US score adding vascularity assessment based on ultrasonography for predicting tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive and triple-negative breast cancer

Kimura Y, Masumoto N, Akashi-Tanaka S, Fukui K, Noma M, Nagata A, Nakamura T, Shima H, Okuno T, Murakami A, Kamei Y, Nakano S, Arihiro K

P3-04-11 Longitudinal changes of contralateral breast mammographic artificial intelligence algorithms score in ductal carcinoma in situ patient with Tamoxifen

Lim C, Park EK, Kim H-K, Kang E, Jung J-J, Yeoh H, Kim J-i, Chun JW, Lee H-B, Moon H-G, Han W

P3-04-12 Intraoperative valuation of the resection margin with the usage of digital two-point sectorography (Faxitron BioVision)

Krivorotko P, Bondarchuk Y, Zhiltsova E, Pesotsky R, Emelyanov A, Tabagua T, Gigolaeva L, Yerechshenko S, Komyakhov A, Nikolaev K, Zernov K, Paltuev R, Mortada V, Semiglazova T, Enaldieva D, Amirov N, Channov V, Chernaya A, Ulyanova R, Artemyeva A, Semiglazov V, Semiglazov V

P3-04-13 Patient experience with automated SoftVue 3D whole breast tomographic ultrasound

Yamashita M, Brem RF, Baker L, Mahoney TF, Walker P, Treat RM, Hovanesian Larsen L

Prognostic and Predictive Factors - Prognostic Factors: Other

P3-05-01 Withdrawn

P3-05-02 Trends in clinical treatment of early stage ER+PR- breast cancer in the National Cancer Database

Saha P, Yu A, Thakkar P, Kuchta K, Yao K

P3-05-03 Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer

Danielsson O, Dar H, Perez-Tenorio G, Nordenskjöld A, Yau C, Benz CC, Esserman LJ, Nordenskjöld B, Stål O, Fornander T, Johansson A, Lindström LS

P3-05-04 Absence of lobular carcinoma in situ, a poor prognostic marker in invasive lobular carcinoma

Mouabbi J, Singareeka Raghavendra A, Christgen M, Hassan A, Hortobagyi GN, Tripathy D, Layman RM

P3-05-05 Racial disparities among patients with breast cancer receiving neoadjuvant chemotherapy therapy and impact on pathologic response: An urban, single-institution experience

Chacko R, Abdel-Razeq NH, Shango K, Li P, Dabak V, Ali H

P3-05-06 Prognostic impact of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis-related liver fibrosis on postoperative long-term outcomes of breast cancer

Yeoh H, Jang S, Cheun J-H, Kwon JA, Lee MS, Oh B, Choi IS, Oh S, Kim J, Park JH, Kim W, Hwang K-T

P3-05-07 Primary neuroendocrine carcinoma of the breast: A case series by WHO classification in 2019

Jeon YK, Kim J-Y, Ahn JS, Im YH, Choi K-H, Jeong SY, Jung Y, Jang JY, Choi D, Hong J, Kim HJ, Cho SY, Park YH

P3-05-08 Prevalence and prognosis of ER-loss in advanced invasive lobular carcinoma

Hensing WL, Xiu J, Korn WM, Graff SL, Kang i, Roussos Torres ET, Heeke AL, Davis AA, Bagegni NA, Clifton KK, Bose R, Ma CX, Ademuyiwa FO

P3-05-09 LAG3+ tumor infiltrating lymphocytes predict outcome in treatment naïve triple negative breast carcinoma

Bose S, Wang Y, Ramanujan VK, Walts AE

P3-05-10 Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients

Wang J, Liu Y, Shao B, Dong H, Zheng T, Du P, Jia S, King B, Wang J, Liu X, Li H

P3-05-11 Breast cancer characteristics in premenopausal women by contraception method

De Maeyer I, Borowski E, Van baelen K, Laenen A, Nevelsteen I, Wildiers H, Han S, Smeets A, Baert T, Punie K, Neven P

P3-05-12 A matched cohort study of the prognosis of early breast cancer in patients with Li-Fraumeni syndrome

Petry V, Colombo Bonadio R, Jafet D, Campos R, Senna L, Cagnacci A, Testa L, Villares Fragoso MC, Estevez Diz MdP

P3-05-13 Influence of metabolic syndrome on overall survival (OS), disease free survival (DFS) and invasive free survival (IFV) in a cohort of patients treated for breast cancer in Brazil

Antonini M, Guimaraes AL, Bauk Richter Sr FG, Ferraro o, Coelho Lopes RG, Real JM

P3-05-14 Clinicopathological features of early breast cancer in Japanese premenopausal women

Tajiri W, Koh S, Nakamura Y, Kawasaki J, Koi Y, Koga C, Ijichi H, Tokunaga E

P3-05-15 Clinical significance of breast cancer resistance protein (BCRP) quantified by fluorescence nanoparticle in breast cancer patients undergoing neoadjuvant chemotherapy

Tada H, Gonda K, Kitamura N, Miyashita M, Harada-Shoji N, Hamanaka Y, Ebata A, Ishida T

P3-05-16 Moved to HER2 Session

P3-05-17 Withdrawn

P3-05-18 Unravelling the clinicopathological and functional significance of Replication Protein A (RPA) heterotrimeric complex in sporadic breast cancers

Algethami MA, Toss M, Brownlie J, Woodcock CL, Jaipal C, Shoqafi A, Mesquita K, Alblihy A, Mongan N, Rakha E, Jeyapalan JN, Madhusudan S, Green AR

P3-05-19 Moved to HER2 Session

P3-05-20 Low 21-gene recurrence score is not associated with a high axillary nodal burden in post-menopausal women presenting with a clinically negative axilla

Botty van den Bruele A, Paul M, THomas SM, Sammons SL, DiNome ML, Plichta JK, Chiba A, Rosenberger LH, Hwang ES

P3-05-21 A novel AI-digital test with an automated approach for grading and phenotyping breast cancer enriches recurrence score risk prediction in an oncoType evaluated cohort

Fernandez G, Prastawa M, Scott R, Marami B, Shpalensky N, Madduri A, Cascetta K, Sawyer M, Chan MS, Koll G, DeAngel RE, Shtabsky A, Feliz A, Hansen T, Veremis B, Cordon-Cardo C, Zeineh J, Donovan M

P3-05-22 Serum S100A8/S100A9 levels are associated with increased risk of brain metastasis in patients with aggressive breast cancer

Villodre ES, Hu X, Song J, Gomez K, Su X, Reuben J, Ueno NT, Tripathy D, Krishnamurthy S, Debeb B

P3-05-23 Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers

de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, Gonçalves A, Bertucci F

P3-05-24 Correlation between the expression of JCAD in plasma exosomes and breast cancer

Liu D, Chi Y, Xiu B, Zhang Q, Chi W-R, Zhang L, Xiong M, Wu J

P3-05-25 Clinical factors associated with survival outcomes in patients with metaplastic breast cancer

Chinniah S, Zarrar R, Li Z, Sideras K, Moreno-Aspitia A, Chumsri S, Rao R, McLaughlin S, Jakub J, Gabriel E, Bagaria S, Vallow L, Maimone S, Advani P

P3-05-26 Association of muscle mass and density with outcomes in patients with ER positive metastatic breast cancer: correlative analysis of ECOG-ACRIN 2112

Ballinger T, Xue G, Marques HS, Gatsonis C, Hoffman R, Miller KD, Zhao F, Sparano J, Connolly R

P3-05-27 The impact of co-existing ductal carcinoma in situ in invasive early hormone receptor positive breast cancer on the genomic and clinical risk of recurrence

Bar Y, Bar K, Ben-Dror J, Feldman D, Shahoha M, Weiss-Meilik A, Dershowitz N, Ido W, Sonnenblick A

P3-05-28 Impact of increased adiposity on extended aromatase inhibitor treatment in postmenopausal patients with estrogen receptor positive (ER+) breast cancer: a retrospective analysis of the SOLE trial

Isnaldi E, Richard F, Marano G, Boracchi P, Maetens M, Floris G, Jerusalem G, Gombos A, Thompson AM, Hitre E, Aebi S, Colleoni M, Dell'Orto P, Kammler R, Neven P, Viale G, Regan MM, Biganzoli E, Desmedt C

P3-05-29 Use of bioimpedance spectroscopy as a surrogate for bone mineral content in oncology patients: Practical application of the SOZO device

Vicini F, Shah C

P3-05-30 Survival after development of contralateral breast cancer

Kim H, Kim HJ, Tae In Y

P3-05-31 PVT1, CASC16, TNFRSF13B and NAMPT may be the key genes correlated with recurrence and metastasis of breast cancer

Li H, Yin S, Sun S, Tan Q, Man X, Huang J, Xie X

P3-05-32 Positive sentinel lymph node does not affect prognosis in T1 breast cancer patients who undergo breast conserving surgery with sentinel lymph node biopsy

Koh HW, Shin H-C, Kim E-K, Kang E

P3-05-33 High expression of MiR-99b in breast cancer is associated with cell proliferation signaling and worse patient survivals in breast cancer

Oshi M, Tokumaru Y, Sugito N, Sasamoto M, Wu R, Yan L Yamada A, Ishikawa T, Endo I, Takabe K

P3-05-34 CANTO-RT: Skin toxicities evaluation of a multicenter prospective cohort of irradiated patients for early-stage breast cancer

Allali S, Carton M, Sarrade T, Everhard S, Peigneux K, Guibert P, Chara-brunaud C, Blanchecotte J, Pasquier D, Racadot S, Bourcier C, Kirova YM

P3-05-35 The impact of parity and age of first full term pregnancy on the prevalence of invasive lobular carcinoma in patients with breast cancer

Van Baelen K, Nguyen H-L, Richard F, Vangoitsenhoven M, Floris G, Wildiers H, Punie K, Smeets A, Nevelsteen I, Amant F, Han S, Baert T, Neven P, Desmedt C

P3-05-36 Prognostic factors in non-metastatic hormone receptor-positive HER2-negative mucinous breast cancer: an international multicentre cohort study

Tan R, Ong WS, Lee K-H, Park S, Iqbal J, Park YH, Lee J-E, Yu JH, Lin C-H, Lu Y-S, Ono M, Ueno T, Naito Y, Onishi T, Lim Gh, Tan S-M, Lee H-B, Koh J, Ryu HS, Han W, Tan VKM, Wong F-Y, Im S-A, Tan PH, Yap Y-S

P3-05-37 Influence of clinical heterogeneity on pregnancy associated breast cancer survival: Systematic review with metanalysis

Antonini M, Tais BT, Real JM, Coelho Lopes RG, Ferraro O, Mattar A, Okumura L

P3-05-38 Biology and clinical course of lobular cancer in breast cancer (BC)

Singareeka Raghavendra A, Bassett R, Mouabbi J, Layman RM, Tripathy D

P3-05-39 Expert consensus on the definition of high risk of recurrence in HER2-negative early breast cancer: a modified Delphi panel

Copson ER, Abraham JE, Braybrooke JP, McIntosh ST, Michie CO, Palmieri C, Roylance R, Spensley S

P3-05-40 Association of body mass index with clinicopathological features and survival in patients with primary ER+/HER2- invasive lobular breast cancer

Van Baelen K, Nguyen H-L, Richard F, Hamy A-S, Toussaint A, Reyal F, Salomon A, Dirix L, Vermeulen P, Wuyts H, Karsten M, Dordevic AD, Nader Marta G, de Azambuja E, Sotiriou C, Larsimont D, Amato O, Maetens M, De Schepper M, Geukens T, Han S, Baert T, Punie K, Wildiers H, Remmerie C, Smeets A, Nevelsteen I, Floris G, Biganzoli e, Neven P, Desmedt C

P3-05-41 Pre-treatment endocrine symptoms and risk of recurrence among premenopausal young breast cancer patients: a prospective cohort study

Kang D, Cho J, Park S, Park YH

P3-05-42 Identification of subpopulation of breast cancer patients with poor clinical outcome using CUB domain containing protein-1 (CDCP1)/CD318 and its interactive proteins SRC and the HGF axis

Yang Y, Dong X, Martin TA, Ye L, Lane J, Sanders AJ, Dou Q, Davies E, Jiang WG

P3-05-43 Germline testing results in patients with genomic tumor profiling

Beitsch P, Wernecke C, Patel R, Rosen B, Brown E, Compagnoni G, Grady I, Gold I, Whitworth P, Smith LA, Wirga M, Reitherman R, Cai S, Nguyen T, Traina V, Holmes D, Baron P, Krautheim B, Peled A, Taylor W, Bontempo K, Bentley B, Ortega K, Ahmadi P

P3-05-44 Genomic testing and Ki-67 Percentage: Two puzzle pieces being undervalued in breast cancer treatment

Wernecke C, Ortega K, Bontempo K, Bentley B, Hoyer-Kimura C, Beitsch P, Patel R, Rosen B, Compagnoni G, Grady I, Brown E, Gold L, Whitworth P, Smith LA, Reitherman R, Wirga M, Cai S, Nguyen T, Traina V, Holmes D, Baron P, Krautheim B, Peled A, Taylor W

P3-05-45 Circulating tumor cells, immunohistochemical subtypes, and genes mutation as prognostic markers in HER2 negative metastatic breast cancer patients candidates to chemotherapy

Risi E, Pestrin M, Biagioni C, Romagnoli D, Migliaccio I, Galardi F, De Luca F, Benelli M, Moretti E, Sanna G, Livraghi L, Cappadona S, Di Marsico R, Amoroso D, Martignetti A, Ribocco AS, Rota Caremoli E, Coltelli L, Puglisi F, Malorni L, Biganzoli L

P3-05-46 scRNA-seq profiling reveals different tumor immune-microenvironment in triple negative breast cancer and decodes pivotal role of THBS1- SDC1 axis in tumor metastasis

Zhang L, Zhang Q, Li P, Xiong M, Zhou Y, Xue J, Chen M, Chi W-R, Ren H, Goh CW, Liu D, Wangxu L, Chi Y, Xiu B Wu J

P3-05-47 Regional lymph node percutaneous analysis in patients with breast cancer

Diogenes M, Mattar A, Amorim A, Caldas Sawada MI, Gebrim LH, Shida J

P3-05-48 Prediction of disease recurrence in low risk Oncotype Dx breast cancers from digital H&E-stained whole slide images of pre-treatment resections alone

Mukhopadhyay S, Dasgupta T, Walsh E, Millican-Slater R, Hanby A, Stephenson J, Bunnell CA, Orsi NM

P3-05-49 Number of involved organs at baseline is prognostic for overall survival in patients with metastatic breast cancer: Results from the AGMT_MBC-Registry

Rinnerthaler G, Gampenrieder SP, Tinchon C, Petzer A, Balic M, Heibl S, Sandholzer M, Zabernigg AF, Egle D, Hager C, Pichler P, Roitner F, Andel J, Strasser-Weippl K, Knauer M, Hubalek M, Singer CF, Greil R

P3-05-50 Comprehensive analysis of pyroptotic gene prognostic signatures associated with tumor immune microenvironment and genomic mutation in breast cancer

Rinnerthaler G, Gampenrieder SP, Tinchon C, Petzer A, Balic M, Heibl S, Sandholzer M, Zabernigg AF, Egle D, Hager C, Pichler P, Roitner F, Andel J, Strasser-Weippl K, Knauer M, Hubalek M, Singer CF, Greil R

P3-05-51 Patients with low expression of BCL 2 experience more late recurrence than patients who do not, which neutralized the protective effect of low BCL2 expression in patients with estrogen receptor positive breast cancer

Choi HS, Hany Noh H, Cho I-J, Lim ST, Lee J-I, Han A

P3-05-52 Sarcopenia and post-mastectomy breast reconstruction outcomes after radiation therapy

Sharifzadeh Y, Gao R, Harmsen WS, Klug J, Korfiatis P, Gergelis K, Shumway DA, Mutter R, Corbin K

P3-05-53 Impact of the body mass index (BMI) on the survival of breast cancer women who achieved a complete pathological response (pCR) after neoadjuvant chemotherapy (NACT) in Brazil

Bauk Richter Sr FG, Mattar A, Antonini M, Coelho Lopes RG, Shida JY, Gebrim LH, Monte Real J

P3-05-54 Clinical presentations of young women aged < 40 years old with ductal carcinoma in situ (DCIS) and their outcomes

Lim Gh, Yan Z

P3-05-55 The effects of comorbidities on the effectiveness of neoadjuvant chemotherapy in breast cancer

Friend K, Breese R, Pu T, Wood J, Arif F

P3-05-56 The clinical impact of preoperatively needle-aspiration biopsy for axillary lymph nodes in T1-T2 breast cancer patients with axillary lymph node metastasis

Ahn JH, Lee SJ, Go J, Park HS, Kim JY, Kim SI, Park BW, Park S

P3-05-57 Lymphatico-venous communications and rhythmic, respiratory pressure changes influence the incidence of metastatic disease at presentation in solid tumours

Badwe R, Joshi S, Hawaldar R, Chaubal R, Bhattacharjee A, Vanmali V, Nair NS, Gupta S

P3-05-58 Frequency and prognosis of HER2-low status in Mexican patients with metastatic breast cancer

Martinez-Cannon BA, Verduzco-Aguirre, HC

P3-05-59 ER+ HER2-negative mBRCA1/2 carriers breast cancer patients (n=81): Clinical outcomes and molecular characterization via the 21-gene Breast Recurrence Score (RS) test vs the general RS-tested population (799,986 samples)

Yerushalmi R, Pomerantz A, Lewin R, Paluch-Shimon S, Soussan-Gutman L, Baehner F, Voet H, Baretet-Samish A, Kedar I, Goldberg Y, Peretz-Yablonski T, Kadouri L

P3-05-60 Understanding ethnorracial differences in oncotype DX recurrence scores in patients with early-stage breast cancer: An analysis based on Hispanic ethnicity

Bazan JG, Jhawar SR, Stover DG, Beyer S, White J, Obeng-Gyasi S

Treatment: Therapeutic Strategies - Immunotherapy (Clinical)

P3-06-01 Unleashing NK- and CD8 T cells by combining monalizumab (anti-NKG2A) and trastuzumab for metastatic HER2+ breast cancer: first results MIMOSA trial

Geurts V, Voorwerk L, Sikorska K, Salgado R, van de Vijver K, van Dongen M, Kemper I, Mandjes IA, Heuver-mes M, Haanen J, Sonke GS, Horlings H, Kok M

P3-06-02 TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis

Prat A, Pascual T, Muñoz M, Hernando C, Vazquez S, Blanch S, Alva M, Oliveira M, Sanfeliu E, Villanueva L, Brasó-Maristany F, Chic N, Ciruelos E

P3-06-03 Trilaciclib induces immune changes within the tumor microenvironment in early-stage triple-negative breast cancer

Danso M, O'Shaughnessy J, Wang LS, Mosalpuria K, Hurvitz SA, Goel S, Ahn S, Cao S, Yi JS, Oyekunle T, Jacobson A, Beelen A, Force J

P3-06-04 Treatment of metastatic breast cancer with multipotent oncolytic/helper adenovirus CADVEC

Chen N, Wang D, Porter CE, Rosewell Shaw A, Robertson CR, Woods ML, Xu Y, Biegert G, Kuriakose A, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki M, Lim B

P3-06-05 Effects of isoflavone genistein, combined with anti-estrogen fulvestrant, on anti-PD1 therapy response against E0771 mammary tumors in mice

de Oliveira Andrade F, Verma V, Molina Hoyo E, Andrade de Oliveira k, Koak P, Jin L, Hilakivi-Clarke L

P3-06-06 Real-world analysis of adverse events of patients with triple negative breast cancer receiving therapy per KEYNOTE-522

Hofherr M, Hedgecorth J, Ademuyiwa FO, Peterson LL, Bagegni NA, Suresh R, Frith A, Bose R, Weilbaecher K, Ma CX, Davis AA, Clifton KK

P3-06-07 Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer

Davis AA, Hernandez-Aya L, Luo J, Opyrchal M, Ademuyiwa FO, Bagegni NA, Clifton KK, Anderson J, Hammerschmidt T, Nehring L, DeNardo D, Watson M, Aft R, Ma CX, Weilbaecher K

P3-06-08 Turning tumor cells into antigen-presenting cells for cancer immunotherapy

Lopez-Lago M, Williams W, Wiseman C

P3-06-09 Real-world toxicity of pembrolizumab-based neoadjuvant regimen in patients with early triple negative breast cancer

Arnaud E, Alaoui K, Vaflard P, Korbi S, Meziani D, Thibault L, Desmaris R-P, Feron J-G, Pierga J-Y, Bidard F-C, Cottu P, Loirat D

P3-06-10 Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)

Marhold M, Udovica S, Wimmer K, Bago-Horvath Z, Robinson T, Fitzal F, Strasser-Weippl K, Bartsch R

Treatment: Therapeutic Strategies - New Drugs and Treatment Strategies

P3-07-01 Mebendazole displays selective anti-breast cancer cytotoxicity via the induction of mitotic catastrophe

Yan Y, Baranowska-Kortylewicz J, Graff B

P3-07-02 Anti-tumor efficacy of GMF-1A3, an MMAE-based antibody drug conjugate targeting cell surface cleaved Amphiregulin in breast cancer

Lofgren K, Sreekumar S, Reker N, Ernzen K, Kenny PA

P3-07-03 Anti-tumor activity of a liposomal formulation of Eribulin compared with the same dose of Eribulin in patient-derived breast cancer xenografts

Tanioka M, Semba T, Shimoi T, Niwa Y, Yonemori K

P3-07-04 A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)

Li W, Yin Y, Cui J, Wang W, Liang Y, Liang H, Xu B

P3-07-05 Withdrawn

P3-07-06 Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer surviVAL INtErAction) study (n=235,368)

Dumas E, Grandal B, Gougis P, Houzard S, Latouche A, Toussaint A, Alsafadi S, Abecassis J, Delrieu L, Dubois T, Sella N, Espie M, Asselain B, Ballesta A, Marande B, Daoud E, Laas E, Kassara A, Jochum F, Del Nery E, Anthony E, Le Bihan-Benjamin C, Bousquet P-J, Azencott C-A, Reyat F, Hamy A-S

P3-07-07 The use of ribociclib/letrozole combination as an alternative for neoadjuvant chemotherapy in selected patients with early luminal breast cancer

de Groot AF, Cohen D, Heijns JB, Mandigers C, Keizer DM, Putter H, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Dijkstra K, van Leeuwen-Stok E, Liefers G-J, Linn S, Kroep J

P3-07-08 Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in HR+/HER2- metastatic breast cancer (MBC)

Tolaney SM, Schmid P, Bardia A, Marmé F, Loirat D, Sharma P, Wang H, Fu O, Verret W, Rugo HS

P3-07-09 Pan-NOS inhibitor L-NMMA in combination with Docetaxel enhances antitumor effect in obesity-associated triple negative breast cancer

Sun K, Anselme AC, Qian W, Zhou J, Cheng R, Rosato R, Chang J

P3-07-10 CCTG IND.236: A Phase 1b trial of combined CFI-402257 and weekly paclitaxel in patients with HER2-negative (HER2-) advanced breast cancer (aBC)

Bedard P, Mates M, Hilton J, Levasseur N, Awan A, Srikanthan A, Cescon DW, Gelmon K, Robinson A, Drummond-Ivars N, Li I, Rastgou L, Edwards J, Hagerman L, Zhang S, Seymour L, Rushton M, Gaudreau P-O

P3-07-11 Leveraging the immunomodulatory activity of entolimod, our clinical stage TLR5 agonist, to improve chemo-immunotherapy mediated control of locally advanced tumors in pre-clinical TNBC

Brackett C, Aldrich A, Greene K, Kandar B, Veith J, Burdelya L, Gudkov A, Abrams S

P3-07-12 Allogeneic, antigen-presenting, GM-CSF-secreting, SV-BR-1-GM whole cell therapeutic vaccine in advanced metastatic breast cancer

Chumsri S, Williams W, Chang M, Del Priore G, Lopez-Lago M, Wiseman C, Holmes J, Nangia C, Mohammed K, Barve M, Dakhil S, Guerin B, Calfa C

P3-07-13 The next generation oral selective estrogen receptor degrader (SERD) camizestrant (AZD9833) is active against wild type and mutant estrogen receptor α

Morrow C, Carnevalli L, Baird RD, Brier T, Ciardullo C, Cureton N, Lawson M, McEwen R, Nikolaou M, Armstrong A, Bermejo B, Calvo E, Ciruelos E, Garcia-Corbacho J, Hamilton EP, Incorvati J, Kabos P, Oliveira M, Patel MR, Ruiz-Borregó M, Turner N, Twelves C, Vaklavas C, Carroll D, Ching S, Cveticic N, DuPont M, Gibbons L, Mathewson A, Maudsley R, Morentin Gutierrez P, Reddy A, Rodriguez-Canales J, Ros S, Sudhan D, Sykes A, Whitson D, Klinowska T, Lindemann J

P3-07-14 A phase II study of CFI-400945 in patients with advanced/metastatic cancer: Canadian Cancer Trials Group (CCTG) IND.237

Cescon DW, Hilton J, Bedard P, Blanchette P, Pezo RC, Bashir A, Kumar V, Ng TL, Awan A, Lott A, Raphael JA, Hagerman L, Bray M, Muyot L, Fuentes Antras J, Seymour L, Tu D, Gaudreau P-O, Rushton M

P3-07-15 Preliminary data from a Phase 1b dose escalation study of OP-1250, an oral CERAN, in combination with palbociclib in patients with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer

Chan A, Day D, Hui R, McCarthy N, Wilson R, Faltaos D, Shaw M, Murphy C

P3-07-16 Pre-clinical study of amcenestrant and HER2-targeted therapies in HER2+/ER+ breast cancer cell line models

Ashfield N, Mahdi AF, Conlon NT, Crown J, Collins DM

P3-07-17 Nanosecond electric pulses modify breast tumor microenvironment to promote antitumor immunity

Yang L, Nanajian A, Beebe S, Guo S.

P3-07-18 CCTG IND.239: A phase 2 study of combined CFI-400945 and durvalumab in patients with advanced triple negative breast cancer (aTNBC)

Hilton J, Cescon DW, Robinson A, Dhesy-Thind S, Taylor S, Awan A, Ng TL, Rushton M, Savard M-F, Muyot L, Reeves MC, Hagerman L, Lui H, Bray M, Tu D, Seymour L, Gaudreau P-O

P3-07-19 Anti-depressant Amitriptyline augments the efficacy of Tamoxifen in ER positive breast cancer

Pitta Venkata P, Rao AD, Timilsina S, Singh d, Vadlamudi RK, Kaklamani V, Rao MK

P3-07-20 Treatment of 4T1 breast cancer with liposome-encapsulated AdAPT-001, a TGF-beta trap encoded oncolytic adenovirus currently in a phase 1/2 anticancer trial

Reid T, Kummel A, Caroen S, Shah J, Oronsky B, Larson C

P3-07-21 Therapeutic efficacy of NGY-091 against triple negative breast cancer is mediated by direct cell killing and activation of antitumor immunity

Sharma S, Wijerathna S, Wu K, Tyagi A, Wu S-Y, Watabe K, Kuklin N, Escobedo J, Sandanayaka V

P3-07-22 Presurgical trial of Metformin plus Atorvastatin in women with operable breast cancer

McGuinness JE, Crew KD, Trivedi MS, Accordino MK, Lee SM, Guo H, Hibshoosh H, Hershman DL, Kalinsky K

P3-07-23 Defendor Special: Primary empegfilgrastim prophylaxis (prolonged G-CSF) for optimal treatment outcomes in high risk early breast cancer cohort. The interim analysis

Sorokina I, Ganshina I, Ibragimova T, Bondareva I, Zhukova L

P3-07-24 Role of tumor cell-derived lactic acid in the PD-1/PD-L1 blockade resistant tumor

Oh W, Lim S-O

P3-07-25 Efficacy and safety of neoadjuvant pertuzumab biosimilar TQB2440, trastuzumab and docetaxel in HR negative, HER2 positive breast cancer: a single-arm trial

Wu J, Yu J, Yang Y, Wen X, Yang J, Wei H, Xu X, Li Y, Yang L, Xu D, Wang L, Wang Y, Ma W, Li N

P3-07-26 Anti-cancer activity of naturally formulated Trigonella foenum graecum (Fenugreek) PLGA hyaluronic acid-coated nanoparticles for treatment of breast cancer cell lines

Yahiya I, Saeed R, Sultan A

P3-07-27 In vitro antitumoral activity of endophytic fungi isolated from *Lophocereus marginatus* against the human breast cancer cell line MCF-7

Ramírez Villalobos JM, Romo Sáenz CI, Morán Santibañez KS, Tamez Guerra P, Pérez González O, Tamez Guerra R, Rodríguez-Padilla C, Gomez Flores RA

Tumor Cell and Molecular Biology: Animal Models

P3-08-01 Loss of NF1 drives hormone dependent mammary carcinogenesis in a rat model with intact immune system

Wallis D, Fay C, Bradley K, Westin E, Bradley W, Liu H, Lambert L, Crossman D, Foote J, Kesterson R

P3-08-02 Prospective use of feline mammary carcinomas to study MiR-10b and metastasis
Halim A, Savan NA, Saavedra PV, Yuzbasiyan-Gurkan V, Kiupel M, Sempere L, Moore A

P3-08-03 Establishment of patient-derived xenograft tumor models from breast cancer patients for quantitative elemental profiles and testing candidate therapies

Qiang W, Chen H, Yang Y, Crawford A, Gursel DB, Wei J-J, O'Halloran T, Cristofanilli M

P3-08-04 Discovery of cancer genes and pathways operative in PI3K-activated mammary cancer reveals clinically relevant genotype-phenotype correlations

Kurata M, Pope E, Shu J, Yuan W, Hudson W, Sokolowski M, Bagherzadeh S, Modrusan Z, Stawiski E, Durinck S, Seshigiri S, Sarver A, Temiz N, Largaespada D

P3-08-05 Correlation of TroP2 expression with in vivo sensitivity to sacituzumab govitecan in a panel of breast XPDX models

Simonson A, Flores J, Anderson E, Moreno C, Plasko G, Papadopoulos KP, Patnaik A, Rasco D, Rodriguez G, Lang A, Beeram M, Rodriguez L, Drengler R, Abbate S, Salih H, Smith L, Elmi M, DeBerry B, Rosenthal A, Hernandez T, Lakhani N, Sharma M, Wick M

P3-08-06 Monitoring lymphovascular invasion and tumor growth of inflammatory breast cancer in a murine lymphatic reporter window chamber model

Devi GR, Sannareddy D, Bennion A, Rickard A, Rouse DC, Dewhirst MW, Palmer GM

P3-08-07 Self-renewal signatures of peripheral blood T cells are associated with successful engraftment to establish a humanized mouse model of breast cancer

Fukui Y, Kawaguchi K, Murakami R, Li W, Nakamura Y, Maeshima Y, Tanaka S, Kawaoka S, Suzuki E, Toi M

P3-08-08 Establishment of a breast cancer rat model of chemotherapy-induced cardiotoxicity

Wallis K, Boerma M, Allen A, Su J, Markhoul S, Hsu P-C

P3-08-09 Development and molecular characterization of hard-to-treat breast cancer pre-clinical models to enhance precision medicine

Kuasne H, Fortier A-M, Busque S, Mathien S, Savage P, Martinez Ramirez C, Monast A, Soleinova M, Omeroglu A, Asselah J, Bouganim N, Meterissian S, Basik M, Park M

P3-08-10 Combining multiomics and histological assessment to identify patient derived xenograft models of invasive lobular carcinoma

Atkinson JM, Yates M, Brown DD, Hooda J, Bhargava R, Schiavini P, Zipeto M, Oesterreich S, Lee AV

P3-08-11 Establishing breast cancer patient-derived xenografts from circulating cancer stem cells in the chorioallantoic membrane (CAM) Model

Pizon M, Schott D, Pachmann K

Tumor Cell and Molecular Biology: Ex vivo Models

P3-09-01 Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP)

Rosenbluth J, Schwartz CJ, Binh Bui T, Warhadpande S, Phadatare P, Eini S, Bruck M, Molina-Vega J, Pullakhandam K, Schindler N, Brown Swigart LA, Yau C, Hirst G, Mukhtar R, Giridhar KV, Olopade OI, Kalinsky K, Ewing CA, Wong JM, Alvarado MD, Van 't Veer L, Esserman LJ, Chien J

P3-09-02 Patient derived breast cancer organoids as a model for testing personalized therapies

Wajih N, Erali R, Forsythe S, Soker S, Votanopoulos K

Tumor Cell and Molecular Biology: Cell Cycle Regulation

P3-10-01 Deciphering the heterogeneity of cell cycle in breast cancer and relevance to clinical application of CDK inhibitors

Knudsen ES, M V, Wang J, Witkiewicz A

P3-10-02

Cell cycle dysregulation in breast cancer: why the details matter

Seker S, Oropeza E, Carrel S, Mazumder A, Punturi N, Lei J, Anurag M, Lim B, Bainbridge M, Haricharan S

Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance

P3-11-01 Increasing DAXX expression in ER+ breast cancer cells to overcome endocrine therapy resistance

Osipo C, Albain KS, Peiffer D, Wyatt D

P3-11-02 CST1 interaction with RAB1B modulates tamoxifen resistance of breast cancer by regulating autophagy

Liu L

P3-11-03 Novel targeting of semaphorin 7a-mediated survival signaling in ER+ breast cancer

Steinmetz R, Wyatt G, Lyons T, Porter W, Crump L

P3-11-04 Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 in ER+/HER2- breast cancer

Jayaraman S, Wu X, Kalari KR, Tang X, Kuffel M, Bruinsma ES, Renuse S, Ingle JN, Reid J, Schellenberg M, Hawse J, Pandey A, Goetz MP

P3-11-05 Efficacy of gonadal steroids on aromatase inhibitor-resistant ER+ breast cancer: Insights from single-cell trajectory analysis of a patient-derived xenograft model

Mori H, Saeki K, Chang G, Wang J, Wu X, Kanaya N, Somlo G, Chen S

P3-11-06 Chromatin landscape analysis based on ATAC-seq and RNA-seq reveals that GRHL2 is a novel key transcription factor for endocrine therapy resistance

Fujiwara S, Baek S, Wagh K, Stavreva D, Varticovski L, Hager G

P3-11-07 Inhibition of FASN as a potential treatment of advanced endocrine therapy-resistant breast cancer

Balinda H

P3-11-08 Inhibition of sirtuin 3 sensitizes breast cancer cells to fulvestrant

Andrade de Oliveira K, Sengupta S, Jin L, de Oliveira Andrade F, Ozgu-Onal M, Yadav A, Clarke R

P3-11-09 Extracellular vesicle-based biomarker assay for the monitoring of the efficacy of frontline endocrine therapy + CDK4-6 inhibitors in metastatic breast cancer

Richard M, Sebastien J, Mathiot L, Campone M, Colombie M, Robert M, Patsouris A, Bigot F, Gavard J, André-Grégoire G, Guevel L

P3-11-10 Estrogen receptor reprogramming by HOXB13 and GATA3 in ER-positive breast cancer cells

Treuner K, De Arruda Saldanha C, Heinz S

ONGOING CLINICAL TRIALS POSTER SESSION 2

**WEDNESDAY, DECEMBER 7, 2022: 5:00 PM – 6:15 PM
HALL 1**

Ongoing Clinical Trials: Endocrine Therapy

OT2-01-01 Trial in progress: Clinical utility of Fluoroestradiol F18 PET/CT in metastatic breast cancer patients with ER-positive and HER2-negative primary lesions after progression on first line hormonal therapy

van de Ven S, Luo F, DiGregorio N, Fuentes-Albuero A, Tranquart F

OT2-01-02 The SMILE Study: A phase II trial of onapristone in combination with fulvestrant for patients with ER-positive and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 inhibitors

Kamaraju S, Fowler AA, Chaudhary LN, Burkard M, Giever T, Hegeman RN, Pipp-Dahm M, Cheng YC, Lange C, Jorns JM, Stella A, Siddiqui N, Zurbriggen L, Rajguru S, Tarima S, Sriram D, Retseck J, Rui H, Sahmoud T, Wisinski KB

OT2-01-03 ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with metastatic breast cancer (mBC)

Rugo HS, Bardia A, Cortés J, Curigliano G, Hamilton E, Hurvitz SA, Loibl S, Scartoni S, Sahmoud T, Grzegorzewski K, Habboubi N, O'Shaughnessy J

OT2-01-04 ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer

Hamilton E, Pusztai L, Soliman HH, Hurvitz SA, Grzegorzewski K, Habboubi N, Marreddy P, Sahmoud T, Ibrahim N

OT2-01-05 The CROWN Study (CaRdiac Outcomes With Near complete estrogen deprivation): A multicenter, prospective cohort study of cardiovascular outcomes in premenopausal women treated with ovarian suppression and an aromatase inhibitor

Douglas E, O'Connell N, Hackney M, Bottinor W, Grizzard J, Klem I, Park C, Vasu S, Richardson K, Dent S, D'Agostino R, Hundley G, Jordan J, Thomas A

OT2-01-06 Phase II trial of palbociclib plus endocrine therapy followed by combination of pembrolizumab, palbociclib and endocrine therapy in patients with hormone receptor positive metastatic breast cancer

Yuan Y, Egelston CA, Guo W, Yost SE, Frankel PA, Ruel C, Murga M, Tang A, Martinez N, Schmolze D, Stewart D, Waisman J, Yap K, Mortimer J, Tank N

OT2-01-07 evERA breast cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2- locally advanced or metastatic breast cancer

Mayer EL, Tolaney SM, Brufsky AM, Gradishar W, Jhaveri K, Martin M, Moscetti L, Vidal G, Cortazar P, Feldman M, Day B-m, Rugo HS

OT2-01-08 SEQUEnce of endocrine therapy in advanced luminal breast cancer (SEQUEL-Breast): A phase 2 study on fulvestrant beyond progression in combination with alpelisib for PIK3CA-mutated, HR+ HER2- advanced breast cancer

Almekinders CAM, Konings IRHM, van der Noort V, van den Berg SM, Bos MEMM, Dezentjé VO

OT2-01-09 ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden – A prospective multicenter observational study

Ettl J, Sophia R, Kotzur F, Müller L, Seitz S, Fasching PA, Jilg S, Fischer D, Egert-Schwender S, Victora K, Reuning U, Rösch R, Rief L, Bronger H, Winter C, Kiechle M

OT2-01-10 WinPro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early-stage hormone receptor-positive breast cancer

Downton T, Segara D, Ong A, Bingham j, Carson E-K, Chen J, Middleton K, Lindeman G, Parker A, Lim E

OT2-01-11 ctDNA-guided adaptive therapy escalation in ER+ MBC: A phase 1b study with Letrozole, Palbociclib and Onapristone ER

Drago J, Walsh E, Gonen M, Berger M, Robson ME, Chandarlapaty S, Razavi P, Jhaveri K

Ongoing Clinical Trials: Estrogen Receptor Degradar

OT2-02-01 SERENA-1: Updated analyses from a Phase I study of the next generation oral selective estrogen receptor degrader camizestran (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer

Turner NC, Vaklavas C, Calvo E, Garcia-Corbacho J, Incorvati J, Ruiz Borrego M, Twelves C, Armstrong A, Bermejo B, Hamilton E, Oliveira M, Ciruelos E, Kabos P, Patel MR, Borrell M, Burris H, de Paula B, Falcon A, Hernando C, Moreno I, O'Brien CS, Shagisultanova E, Victoria Ruiz I, Wang JS, Wei M, Brier T, Carroll D, Ciardullo C, Gibbons L, Irurzun-Arana I, Jack T, Kirova B, Klinowska T, Lindemann JPO, Maidment J, Mathewson A, Maudsley R, McEwen R, Morrow CJ, Sykes A, Baird RD

Ongoing Clinical Trials: Estrogen Receptor Antagonists

OT2-03-01 heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection fl giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer

Kümmel S, Harper-Wynne C, Park YH, Franke F, De Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Shivhare M, Restuccia E, O'Shaughnessy J

OT2-03-02 lidERA breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician's choice of endocrine therapy in patients with estrogen receptor+, HER2-early breast cancer

Schmid P, Geyer Jr CE, Harbeck N, Rimawi MF, Survitz SA, Martín M, Loi S, Saji S, Jung KH, Werutsky G, Stroykovsky DL, López-Valverde V, Davis M, Badovinac Crnjevic T, Perez-Moreno PD, Bardia A

Ongoing Clinical Trials: Genomic Testing

OT2-04-01 A video intervention to improve patient understanding of tumor genomic testing in patients With metastatic cancer

Stover DG, Veney D, Hampel H, Toland AE, Presley C, Padamsee T, Lee C, Hovick S, Senter L

Ongoing Clinical Trials: Genomics

OT2-05-01 FLEX: 30K full transcriptome, real-world evidence database for early-stage breast cancer, and investigator-initiated protocols

Perez A, Linden H, Johnson N, Diab S, Jani C, Gawryletz CD, Fine R, Lawson L, Baker M, Poillucci V, Blumencranz LE, Audeh W

Ongoing Clinical Trials: Health Coaching After Cancer

OT2-06-01 Breast cancer cohort of the comprehensive outcomes for after cancer health (COACH) study: Study protocol

Lally RM, Schmidt RL, Tlusty G, Arthur EK, Flora LK, Krok-Schoen JL, Jones JT, Whisenant M, Kaler AJ, Tripathy D, Saligan L, Hammer M, Barr A, Jackson L, Loftis J, Brassil KJ

Ongoing Clinical Trials: Imaging

OT2-07-01 Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy

Wapnir IL, Hunt KK, Hwang ES, Smith K, Blumencranz P, Carr D, Ferrer J, Santa Cruz H, Webster A, Shanno J, Pogrebinsky A, Chang M, Smith BL

Ongoing Clinical Trials: Immune Checkpoint Inhibitors

OT2-08-01 A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC)

Sun T, Zhang L

OT2-08-02 SOLTI-1907 ATREZZO: Targeting hormonal receptor negative (HR-) or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive metastatic breast cancer (MBC)

Ciruelos E, Perelló A, González-Santiago S, López A, Salvador Bofill FJ, Albacar C, Cejalvo JM, Escrivá-de-Romani S, Blancas I, Pernas S, Martínez-Sáez O, Cruz J, Ponce J, Servitja S, Perez-Lopez M-E, Guerra JA, Sanfeliu E, Rodriguez CA, Villacampa G, Villanueva L, Tolosa P, Pascual T, Prat A

OT2-08-03 Immunogenicity of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple negative breast cancer

Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee P, Waisman J, Yuan Y

Ongoing Clinical Trials: Immune Stimulation

OT2-09-01 TBCRC-055: A phase II study of Niraparib, Dostarlimab, and radiotherapy in metastatic, PD-L1 negative or immunotherapy-refractory triple-negative breast cancer (NADiR) – NCT04837209

Scott E, Isakoff SJ, Taghian AG, Wright J, Augusto Santa-Maria C, Shah PD, Taunk N, Anders C, Blitzblau R, Gupta G, Ho A

Ongoing Clinical Trials: Immunotherapy

OT2-10-01 A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer

Rainey N, Joshi R, Chiu JWY, Chen A, Wang H, Odegard J, Howland M, Adams S

OT2-10-02 Phase I trial of an alpha-lactalbumin vaccine in patients with operable triple-negative breast cancer (TNBC)

Budd G, Johnson JM, Rhoades E, Moore H, Kruse ML, Roesch E, Abraham J, Elliott B, Haury E, Tuohy VK

OT2-10-03 HCRN BRE 19-433: A multi-institutional phase II study to evaluate efficacy and safety of Talazoparib, radiotherapy and Atezolizumab in gBRCA 1/2 negative patients with PD-L1+ metastatic triple negative breast cancer (TARA)

Torres MA, Kalinsky K, Stringer-Reasor, Elkhanany A, Iin J, Schuster DM, Friend S, Switchenko J, Bhav M

OT2-10-04 Treatment of advanced or metastatic triple-negative breast cancer with adoptive therapy of PD1+ tumor-infiltrating lymphocytes (TILS001 trial)

Chic N, Ciruelos E, Saura C, Gonzalez E-A, Álvarez-Vallina L, Lasarte JJ, Gros A, Villanueva L, Canes J, Angelats L, Prat A, Pascual T, Santisteban M, Juan M

OT2-10-05 HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer

Downton T, Karlsen E, Cuff K, Walpole E, Simpson F, Lim E

OT2-10-06 Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01

Patel S, Thompson J, Patel M, Daugherty FJ, Osborne CK, Rimawi MF

Ongoing Clinical Trials: Immunotoxins

OT2-11-01 A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results

Okerla M, Van Tine BA, Hubbard JM, Barve M, Hamilton E, Mita MM, Valdes-Albini F, Ahn D, Mamuye A, Pelham J, Yuet A, Yurewicz D, Liu Y, Machado Sandri A, Edenfield WJ, Morikawa A, Gradishar W, Kumar R, Wainberg ZA

Ongoing Clinical Trials: Li-Fraumeni Risk Assessment

OT2-12-01 Clinical application of LFSPRO: A prospective study

Woodman-Ross J, Dodd-Eaton E, Corredor J, Green SO, Nguyen NH, Hernandez N, Di-Nardo CD, Wang W, Arun BK

Ongoing Clinical Trials: Li-Fraumeni Syndrome - Genetic Counseling

OT2-13-01 Willingness to participate in a trial comparing standard genetic counseling versus genetic counseling with personalized cancer risks estimates in patients with Li-Fraumeni Syndrome

Woodman-Ross J, Green SO, Corredor J, Dodd-Eaton E, Hernandez N, Peterson SK, Wang W, Arun BK

Ongoing Clinical Trials: Long-term Adjuvant Pan-HER TKI

OT2-14-01 Pyrotinib after trastuzumab-based adjuvant therapy in high-risk early human epidermal growth factor receptor 2-positive breast cancer: a multicenter phase 2 trial

Cao F, Ma Z, Hu G, Zhu X, Li S, Chen S, Chen B, Li Z, Wu W, Ji X, Shu J, Tao D, Hu X, Zheng M, Wang O, Feng Q, Hao J, Li X

Ongoing Clinical Trials: Metastatic Breast Cancer Management

OT2-15-01 Continue the SaMe systemic therapy after local ablative therapy for Oligoprogression in metastatic breast cancer - the COSMO study

Almekinders CAM, Steenbruggen TG, Mandjes IA, Lopez-Yurda M, Bos MEMM, Wiersma TG, Sonke GS

Ongoing Clinical Trials: Monoclonal Antibodies

OT2-16-01 ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)

Zelnak AB, Lenz H-J, Culm K, Makris L, Chamberlain Santos V, Youssoufian H, Mockbee C, Miller KD

OT2-16-02 Open-label, phase 3b/4 study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with advanced/metastatic human epidermal growth factor receptor 2-positive breast cancer: DESTINY-Breast12

Lin NU, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Oscruff E, Anand S, Prahlanan Mm Harbeck N

OT2-16-03 Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Hamilton E, Tsurutani J, Curigliano G, Martín M, O'Sullivan CC, Sohn JH, Tryfonidis K, Santarpia L, Yang S, Diéras V

OT2-16-04 KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer: A single arm, multicenter, phase 2 study
Wu J, Yang B, Ma L, Zhang M, Wang K, Chen Y, Fan Z, Zhang J, Xia S

OT2-16-05 Safety analyses of NRG BR004: A randomized, double-blind, phase III trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or placebo in first-line HER2-positive metastatic breast cancer (MBC)

Geyer Jr CE, Tang G, Rastogi P, Valero V, Chia SK, Cobain EF, Obeid E, Page DB, Poklepovic AS, Irvin Jr WJ, Brufsky AM, Wapnir IL, Suga JM, Mamounas EP, Wolmark N

Ongoing Clinical Trials: Metastatic TNBC Chemotherapy

OT2-17-01 Phase 1 trial of anthracycline chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer

Reddy SM, Carter M, Chan I, Unni N, Peswani N, Klemow D, Syed S, Shakeel S, Fattah F, Ahn C, Fang Y, McArthur H, Sinclair N, Yellin M, Yardley D, Chen N, O'Shaughnessy J, Nanda R, Conzen SD, Arteaga CL

OT2-17-02 The ARETHA Study: A phase 2 randomized control trial of Eribulin with Evexomostat (SDX-7320) or placebo for patients with metastatic triple-negative breast cancer and metabolic dysfunction

Shen S, Whalen A, Robson ME, Norton L, Traina TA, Iyengar NM

Ongoing Clinical Trials: Neoadjuvant Chemotherapy

OT2-18-01 Nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: an open-label, single-arm phase II study

Liu Y, Fan L, Shao Z-M, Wang Z-H

OT2-18-02 OlympiA^N: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancer

Balmaña J, Dymond M, Lowe ES, Lukashchuk N, Winter M, Tung N

OT2-18-03 Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study

Fan J, Wang T, Meng H, Li S, Kong J, Wang Y

Ongoing Clinical Trials: Neoadjuvant Chemo - Immune Cell Recruitment

OT2-19-01 Single cell characterization of longitudinal biopsies from breast cancer patients treated neoadjuvantly with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib in concert

Fongård M, Steen C, Ghannoum S, Bjørnstad M, Holm B, Bosnjak T, Reitsma L, Geisler S, Fjernerros K, Bruteig J, Seyedzadeh M, Buvarp U-C, Loeng M, Vuoriluoto A, Lüders T, Lambrechts D, Lyngra M, Kristensen V, Geisler J, Tekpli X

Ongoing Clinical Trials: Neoadjuvant Endocrine Therapy

OT2-20-01 Neoadjuvant survivin immunotherapy maveuropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer

Stanton SE, MacDonald LD, Fiset S, Mellinger S, Moxon N, Hirsch H, Kelly TL, Young KH, Page DB

Ongoing Clinical Trials: Neoadjuvant Taxotere + Trastuzumab

OT2-21-01

Assessing Response to neoadjuvant Taxotere and Trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA)

Ntekim A, Adeniji-Sofoluwe A, Ibraheem A, Sowunmi A, Folasire A, Olajide T, Olasehinde O, Komolafe A, Lawal A, Omodele F, Sanni A, Ajani M, Kotila O, Folorunsho S, Aniagwu T, Alabi A, Popoola A, Asuzu C, Daramola A, Babalola C, Karrison T, Abdulkareem F, Olopade OI

Ongoing Clinical Trials: Neoadjuvant Therapy

OT2-22-01 Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

Shi Q, Qi X, Tang P, Fan L, Chen L, Wang S, Zhang G, Wang M, Che H, Lv P, Chen D, Hu J, Li Q, Zhang Y, Yu Q, Yang K, Zhong Y, Chen C, Zhou Z, Qian L, Zhang J, Ma M, Sun Y, Liu J, Zhang Y, Jiang J

Ongoing Clinical Trials: Neoadjuvant Therapy

OT2-22-02 A single-arm confirmatory study to evaluate the efficacy of non-surgical therapy for HER2 positive early breast cancer with clinical complete response after primary systemic therapy: (JCOG1806)

Reinert T, Souza CP, Liedke P, Werutsky G, Test L, Antunes V, Barrios C, Vasconcelos V, Resende H, Silva Queiroz G, Guilgen G, Nerón Y, Arruda Bastos L, Aleixo S, Cubero D, Magalhães MCF, Coradazzi A, de Oliveira DGB, Nunes JS, Jesus RG, Gössling G, Bines J

POSTER SESSION 4

**THURSDAY, DECEMBER 8, 2022: 7:00 AM – 8:15 AM
HALL 1**

Treatment - Advanced Disease Treatment: Advanced Therapy - Targeted

P4-01-01 RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib + endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2- ABC

Jackisch C, Brucker C, Decker T, Engel A, Fasching PA, Göhler T, Janssen J, Köhler A, Lütke-Heckenkamp K, Lüftner D, van Mackelenbergh M, Marmé F, Nusch A, Rautenberg B, Reimer T, Schmidt M, Weide R, Wimberger P, Roos C, Wöckel A

P4-01-02 Results from a dose escalation phase 1b study of palbociclib and avelumab in advanced breast cancer in the PAveMenT Trial

Okines AF, Moghadam H, Sparks L, Mohammed K, Dunne K, Nerurkar A, Osin P, Swift C, Sardinha R, Turner N

P4-01-03 Progression-free survival and patient-reported outcomes in HR+, HER2- ABC patients treated with first-line ribociclib + endocrine therapy (ET) or ET monotherapy or chemotherapy in real world setting: 5th interim analysis of RIBANNA

Fasching PA, Brucker C, Decker T, Engel A, Göhler T, Jackisch C, Janssen J, Köhler A, Lütke-Heckenkamp K, Lüftner D, van Mackelenbergh M, Marmé F, Nusch A, Rautenberg B, Reimer T, Schmidt M, Weide R, Wimberger P, Roos C, Wöckel A

P4-01-04 Phase IV multicenter study evaluating RWE and the safety of talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a BRCA1/2 mutation (ViTAL) - Cohort 2: patients treated according to the EMA

Loirat D, Dubois de la barre M, Villanueva C, Mailliez A, Isambert N, Moreau L, Jacquet E, Spaëth D, Creisson A, Jouannaud C, Legouffe E, Delbado M, Deiana L, Soibinet P, Hrab I, Grellety T, Dohollou N, Longo R, Thery J-C, Fumet J-d, Zineb S, Pujol P, de la Motte Rouge T

P4-01-05 Machine learning to predict treatment response and tolerability in HR+, HER2- advanced breast cancer: German study AI4ANNA

Fasching PA, Wöckel A, Tesch H, Volz B, Pritzsche U, Bachmann M, Vodencarevic A, Kreuzeder J, Lüftner D

P4-01-06 LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in HR deficient and PARP inhibitor resistant triple negative breast cancer

Kulkarni A, Biyani N, Brullé-Soumaré L, Cairo S, Sharma P, Bhatia K

P4-01-07 FS-1502, an anti-HER2 ADC, in patients with HER2 expressing advanced solid tumors: A phase 1a dose-escalation study

Li Q, Wang X, Cheng Y, Liu Y, Chang J, Wang Z, Wu C, Wang M, Hui A-M, Wu Z, Jin Y, Huang X, Zhong L, Diao L, Zhao H, Xu B

P4-01-08 Efficacy of PARP inhibitors in patients With BRCA1/2-related breast cancer with prior platinum exposure: A systematic review and meta-analysis

Marinho AD, Mella S Pessoa B, Brandao GR, Da Silva CH, Reis PA, Comini ACM, Batalini F

P4-01-09 Characterization of breast cancer brain metastases overall and progression-free survival and timing of cyclin-dependent kinase 4/6 inhibitor use: Retrospective single institution experience

Chew Minmin S, Chen Y, Kelly D, Robson ME, Seidman AD

P4-01-10 Evaluating the safety of tucatinib in combination with trastuzumab and capecitabine for human epidermal growth factor 2 (HER2)-positive metastatic breast cancer in a real-world setting

Moore H, Anders C, Sammons SL, Erkanli A, Parish A, DiCola C

P4-01-11 Withdrawn

P4-01-12 BAT8006, a novel FR α ADC with strong bystander effect, for the treatment of advanced solid tumor

Mai S, Mei X, Tang W, Zhou X, Qi X, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Li S, Yu J-C

P4-01-13 A retrospective study of anlotinib in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatment

Sun J, Tang Y, Liu X, Li J, Xia J, Xu L, Guo J, Wang J, Guo S, Sheng Z, Zhang Y, Yuan Y

P4-01-14 Changes in the genomic spectrum of actionable alterations in HER2 negative metastatic breast cancer in serial cell free DNA (cfDNA) analysis

Bar Y, Keenan JC, Ryan L, Juric D, Shin J, Wander SA, Spring LM, Moy B, Ellisen LW, Isakoff SJ, Bardia A, Vidula N

P4-01-15 Preliminary results from a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Miller K, Tolaney SM, Emens LA, Kim S-B, Hamilton EP, Saura C, Sanz L, Boni V, Lynce F, Cejalvo JM, Crozier J, Wang S, Uppal H, Hannah AL, Hurvitz SA

P4-01-16 High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor

Wang JS, Beeram M, Chalasani P, Mina L, Shatsky RA, Hurvitz SA, Trivedi MS, Wesolowski R, Han HS, Patnaik A, Bahadur S, Huynh M-m, Jayanthan A, Los G, Dunn SE, Dorr A

P4-01-17 Phase I/II study of pembrolizumab in combination with oral binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer

Shumsri S, Larson JJ, Tenner KS, He J, Polley M-Y, Weidner MT, Arnold AN, Haley D, Advani P, Sideras K, Moreno-Aspitia A, Perez EA, Knutson KL

P4-01-18 Real-world second-line treatment patterns and associated clinical outcomes for 2795 patients with advanced HR+ HER2- breast cancer treated with first-line CDK4/6 inhibitors

Clifton KK, Wander SA, Ma CX, Davis AA, Weipert C, Zhang N, Bucheit L

P4-01-19 Real world statistics on CDK4/6 inhibitor use in metastatic hormone receptor positive and HER2-negative breast cancer with a focus on age

Monahan K, Kamaraju S, Cheng YC, Retseck J, Sriram D, Burfeind J, Chitambar C, Chaudhary LN

P4-01-20 Phase IV study evaluating talazoparib in patients with locally advanced or metastatic negative HER2 breast cancer and a somatic or germline BRCA1/2 mutation (ViTAL) – Analysis of cohort 1 according to hormonal receptor status

Loirat D, Duboys de la barre M, Thery J-C, Hrab I, Jouannaud C, Mouysset J-L, Salabert L, Soibinet P, Mailliez A, Valery R, Creisson A, Villanueva C, Dohollou N, Fumet J-d, Grellety T, Perez-staub N, Lachaier E, Iltis-roux A, Delbado M, Najem A, Le Scodan R, Curtit E, Aldabbagh K, Pujol P, de la Motte Rouge T

P4-01-21 Phase 2 study of the CDK4/6 inhibitor FCN-437c in combination with Fulvestrant or Letrozole and Goserelin in patients with HR+, HER2– advanced breast cancer

Shi J, Li W, Tong Z, Zang A, Zeng X, Wang S, Huang T, Wang Y, Song Y, Kang L, Lv Z, Shi Y, Yang H, Wu J, Yin Y, Liang Y, Tan J, Ming J, Yang Y, Luo S, Gui X, Hui A-M, Wu Z, Tian L, Yang Y, Diao L, Zhang W, Zhang Y, Liu Y

P4-01-22 Clinical outcomes of metastatic breast cancer patients treated with poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi): the Mayo Clinic experience

Jahan N, Taraba J, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O'Sullivan CC, Peethambaram P, Hobday TJ, Ruddy KJ, Mina LA, Advani P, Batalibi F, Goetz MP, Haddad TC, Couch FJ, Yadav S

P4-01-23 Updated data from the phase 1 trial of DZD1516, a BBB-penetrant selective HER2 inhibitor, in patients with HER2 positive metastatic breast cancer

McAndrew NP, Hu X, Zhang J, Wang X, Yu W, Pan X

P4-01-24 Targeting receptor tyrosine kinases in overcoming tamoxifen resistance and dormancy in invasive lobular cancer

Ramaswamy B, Pramod N, Kulkarni A, Rima XY, Reátegui E, Shankar E, Majumder S

P4-01-25 Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer

Rabaglio M, Dietrich D, Scheibe B, Ruhstaller T, Nole F, Eppenberger S, Oehlschlegel C, Hess D, Mamot C, Munzone E, Pestalozzi B, Aebi S, Vetter M, Thuerlimann B, von Moos R, Zaman K, Pagani O

P4-01-26 Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan

Sawaki M, Muramatsu Y, Togo K, Iwata H

P4-01-27 Prognosis and treatment landscape of HER2-positive metastatic breast cancer (MBC) before the availability of tucatinib and trastuzumab-deruxtecan: Results from the Austrian AGMT_MBC-Registry

Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, Sandholzer M, Zabernigg AF, Egle D, Hager C, Pichler P, Roitner F, Andel J, Strasser-Weippl K, Knauer M, Hubalek M, Singer CF, Greil R

P4-01-28 Palbospain: Observational analysis of first-line therapy with Palbociclib in patients with HR+/HER2- metastatic breast cancer (MBC) in real-life conditions

Martínez-Jáñez N, Bellet Ezquerro M, Henao F, Manso L, Antón A, Zamora P, Morales Murillo S, Tolosa P, Andrés R, Calvo L, Galve E, Lopez R, Ayala de la Peña F, López-Tarruella S, Boronat L, Martos T, Chacón JI, Álvarez I, de la Haba-Rodríguez J, Moreno Antón F

P4-01-29 Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2- metastatic breast cancer

Lambrechts Y, Hatse S, Kenis C, Decoster L, de Azambuja E, Jerusalem G, Neven P, Dal Lago L, Denys H, Vuylsteke P, Cornelis F, Punie K, Floris G, Desmedt C, Laenen A, Pondé N, Wildiers H

P4-01-30 Real-world treatment patterns and survival among adults with metastatic breast cancer with BRCA1/2 mutations

Bobbili P, Ivanova J, Solit DB, Mettu N, McCall S, Dhawan M, DerSarkissian M, Arondekar B, Chang J, Niyazov A, Lee J, Huq RJ, Green M, Turski M, Muthukumar A, Guo M, Duh MS, Oh W

P4-01-31 High incidence of Palbociclib related neutropenia in Asian patients associated with genetic polymorphisms

Huang K-J, Kuo T-H, Chao T-C, Liu C-Y, Tsai Y-F, Huang C-C, Tseng L-M, Hsu C-CR, Lai J-I

P4-01-32 BAT8008, a novel Trop-2 ADC with strong bystander effect, for the treatment of Trop-2 positive cancer

Mei X, Tang W, Zhou X, Qi X, Mai S, Zhong Z, Li S, Fan J, Gan J, Tan B, Qi Y, Guo Y, Yu J-C, Li S

P4-01-33 Withdrawn

P4-01-34 Benefits provided by antibody drug conjugates in overall survival outweighs those in progression-free survival for metastatic breast cancer: A class effect

Chen I-C, Lin C-H, Lu Y-S

P4-01-35 A phase 1 study of the oral CDK7 inhibitor XL102 as a single agent and in combination therapy in patients With advanced solid tumors (QUARTZ-101): Initial results from the dose-escalation stage

Patnaik A, Barve M, Bhave M, Subbiah V, Rasco D, Bhatt A, Li J, Andrianova S, Shapiro G

P4-01-36 Real world data for Trastuzumab Deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases

Toler A, Bobolts LR, Mangurian M, Pozotrigo M, Wise C, Solomon H, Hartung N, Makielski R, Marur S, Ravindranathan M, Marur S

P4-01-37 Discontinuation of HER2+ targeted therapy among cancer survivors with metastatic HER2+ breast cancer: A case report

Hui LF, Shah NN, Hui RL

P4-01-38 A single arm phase II trial of Palbociclib in combination with Tamoxifen as first line therapy for metastatic hormone receptor positive breast cancer

Danciu OC, Hoskins K, Weiss J, Truica CI, Blaes A, Tamkus D, Rana J, Pavankumar T, Green L, Gao Y, Yu M, Zhao Q, Toppmeyer D, O'Regan R, Wisinski KB

P4-01-39 Real-world efficacy of dual antiHER2 therapy in first line metastatic HER2-positive breast cancer and the possibility of prediction of long-term response

Križić M, Silovski T, Popović, M, Dedić Plavetić N

P4-01-40 Real world data with off-label insurance approval of Trastuzumab Deruxtecan in metastatic breast cancer

Bobolts LR, Mangurian M, Marur S, Wise C, Pozotrigo M, Solomon H, Hartung N, Ravindranathan M, Makielski R, Marur S, Toler A

P4-01-41 Clinical outcome and toxicity profile of Cyclin-dependent kinase 4/6 inhibitors in combination with hormonal treatment in management of metastatic breast cancer patients: A Middle-East Real World Experience

Mostafa Gad A, AISayed A, AlShibani A, Twegieri T, Suleman K, Ajarim D

P4-01-42 Pooled analysis of post-progression treatments after first-line ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer in the MONALEESA-2, -3, and -7 studies

Hamilton E, Spring LM, Fasching PA, Franco S, DeBoer RH, Cortés J, Kalinsky K, Juric D, Bardia A, Haftchenary S, Lteif A, Zarate JP, Cen L, Neven P

P4-01-43 Pyrotinib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Hu X, Cao J, Teng Y, Li H-P, Zhang L, Ouyang Q, Xie W, Pan Y, Song Z, Ling X, Wu X, Xu J, Li L, Ren L, Wang H, Zhou D, Luo J

Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: Predictive Biomarkers-Other

P4-02-01 Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer

Ferraro E, Safonov A, Chen Y, White C, Marra A, Ahmed M, Acevedo B, Dang CT, Modi S, Solit DB, Norton I, Robson ME, Reis-Filho J, Chandarlapaty S, Razavi P




LEARN WHAT TUKYSA CAN OFFER


VISIT US AT BOOTH #102

[TUKYSAhcp.com](https://www.tukysahcp.com)



TUKYSA[®]
tucatinib
50 mg | 150 mg tablets



TUKYSA and its logo, and Seagen and  are US registered trademarks of Seagen Inc.
© 2022 Seagen Inc., Bothell, WA 98021. All rights reserved. Printed in USA. US-TUP-22-410-MT

P4-02-02 Changes in treatment recommendation for patients with ductal carcinoma in situ using a 7-gene predictive biosignature: Analysis of the PREDICT study

Whitworth P, Shivers SC, Shah C, Patel R, Mittal K, Bremer T, Cox C

P4-02-03 Transcriptomic signature score of Epithelial-Mesenchymal Transition (EMT) of a bulk tumor may not reflect that of cancer cells

Tokumar Y, Wu R, Ukai J, Oshi M, Niwa Y, Mori R, Takabe K, Futamura M

P4-02-04 Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance

Cani A, Dolce E, Turnbull A, Hu K, Liu C-J, Darga E, Robinson D, Wu Y-M, Thomas DG, Paoletti C, Tomlins S, Rae J, Udager A, Chinnaiyan A, Cobain EF, Hayes DF

P4-02-05 Predictors of long-term durable response in de novo HER2 positive metastatic breast cancer and the real world treatment experience at two institutions

Smith CE, Marcom PK, Zahi M, Ko N

P4-02-06 Clinical and biological predictors of lymph node involvement in patients with early breast cancer for adjuvant treatment personalization

Pivetta T, Pastò B, Urbani M, Benozzi E, De Pascalis N, Perin T, Mileto M, Pasquotti B, Piccoli E, Vinante L, Bampo C, Bolzonello S, Garutti M, Nicoloso M, Corsetti S, Scalone S, da Ros L, di Nardo P, Lisanti C, Spazzapan S, Belletti B, Bartoletti M, Gerratana L, Massarut S, Puglisi F

P4-02-07 A large real-world study of circulating tumor DNA in early breast cancer patients

Liu Q, Wu M, Li S, Li Y, Jin L, Shi Q, Zhang Y, Gong C

P4-02-08 Towards precision radiation oncology: Endocrine therapy resistance as a biomarker for radiation resistance in ER-positive breast cancer

Udden SMN; Rahimi A, Kim DWN, Alluri P

P4-02-09 Evaluation of the automated liquid biopsy-breast cancer methylation (LBx-BCM) cartridge assay for predicting early disease progression and survival: TBCRC-005 Prospective Trial

Visvanathan K, Cope L, Fackler MJ, Considine M, Carey LA, Forero-Torres A, Ingle JN, Lin NU, Nanda R, Storniolo AM, Tulac S, Wu NC, Marla S, Venkatesan NR, Wolff AC, Sukumar S

P4-02-10 MRI models by response predictive subtype for predicting pathologic complete response

Li W, Onishi N, Wolf DM, Newitt DC, Yau C, Wilmes LJ, Gibbs JE, Price ER, Joe BN, Kornak J, LeStage B, the I-SPY 2 Imaging Working Group and the I-SPY 2 Consortium, Esserman LJ, Van 't Veer L, Hylton NM

P4-02-11 Moved to HER2 Session

P4-02-12 Validation of profile for the omission of local adjuvant radiotherapy (POLAR) in early-stage invasive breast cancer patients of the Scottish Conservation Trial

Taylor KJ, Bartlett JMS, Bennett J, Chang SL, Arrick B, Baehner F, Loane JF, Piper T, Mallon E, Dunlop J, Jack WJ, Caldwell J, Kunkler I, Williams LJ, Speers CW, Feng FY, Pierce LJ, Cameron DA

P4-02-13 Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials

Griguolo G, Miglietta F, Paré L, Generali DG, Frassoldati A, Musolino A, Spazzapan S, Vernaci G, Giarratano T, Lo Mele M, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Schiavi F, Pinato C, Prat A, Guarneri V, Dieci MV

P4-02-14 Gain of HER2 amplification in patients with HR+/HER2- and triple negative early breast cancer treated with neoadjuvant chemotherapy

Ferraro E, Chew Minmin S, Safonov A, Barrio AV, Modi S, Seidman AD, Wen HY, Brogi E, Robson ME, Dang CT

P4-02-15 Withdrawn

P4-02-16 Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional radiotherapy trial

Riaz N, Chen B, Bane A, Gao D, Stovgaard E, Kos Z, Leung S, Shenasa E, Parulekar W, Chambers S, Nielsen T, Whelan TJ

P4-02-17 Impact of low hormone receptor expression on neoadjuvant chemotherapy response and patterns of care in early-stage HER2-negative breast cancer: a US National Cancer Database analysis

Quiroga D, Grimm M, Stephens J, Johnson K, Williams N, Sudheendra PK, Cherian MA, Stover DG, Pariser AC, Gatti-Mays M, Wesolowski R, Bazan JG, Beyer S, Park KU, Oppong B, Ramaswamy B, White J, Jhawar SR, Sardesai S

P4-02-18 Impact of clonal hematopoiesis on disease progression following CDK4/6 inhibitor therapy

Tao J, Sanchez Vela P, Safonov A, Ferraro E, Franch Exposito S, Menghrajani K, Ptashkin R, Comen E, Braunstein LZ, Robson ME, Chandralapaty S, Reis-Filho J, Berger M, Zehir A, Levine R, Razavi P

P4-02-19 Development of a novel imaging biomarker to ascertain responsiveness to immunotherapy

Norris G, Pfeiffer J, Peterson J, Liadis N, Biancalana M, Lopez-Ramos D, Antony AK, Cook D

P4-02-20 Utility of the 70-gene signature and 10 year follow up in patients with early-stage breast cancer in a single institution study

Nasrazadani A, Gomez Marti JL, Rosenzweig MQ, McGuire M, Quinn K, Haan J, Houzelle A, Bhargava R, Audeh W, Brufsky AM

P4-02-21 Withdrawn

P4-02-22 Breast microcalcification chemistry predicts DCIS prognosis

Nallala J, Calabrese D, Gosling S, Lips E, Factor R, Hall A, Pinder SE, Bouybayoune I, King L, Marks J, Lynch T, Pinto D, Wesseling J, Hwang ES, Rogers K, Stone N

P4-02-23 Integrating tumor-intrinsic and immunological factors to improve locoregional treatment individualization of high-risk breast tumors

Stenmark Tullberg A, Sjöström M, Niméus E, Killander F, Lundstedt D, Kovács A, Holmberg E, Karlsson P

P4-02-24 A 3D visualization and prediction device for breast cancer surgeons and their patients

Parker A, Peterson J, Cole Jr JA, Whitman J, Hobbs N, Cook D, Antony AK

P4-02-25 Analysis of prognosis in different subtypes of invasive lobular carcinoma using a National Cancer Database Breast Cancer Registry of Japan

Adachi Y, Asaga S, Kumamaru H, Yamamoto Y, Imoto S, Jinno H

P4-02-26 Quantitative estrogen receptor expression affects pathologic complete response to neoadjuvant chemotherapy in patients with early-stage breast cancer with low expression of HER2

Iwase T, Fujii T, Yam C, Dong W, Shen Y, Tripathy D, Ueno NT

P4-02-27 Preliminary attainability assessment of real-world data for answering clinical questions about breast cancer brain metastases

Kim M-j, Kim HJ, Kang D, Ahn HK, Shin S-Y, Park S, Cho J, Park YH

P4-02-28 EMP1 low expressing tumor is associated with cell proliferation and poor overall survival of ER-positive breast cancer patients

Ukai J, Tokumaru Y, Oshi M, Niwa Y, Mori R, Takabe K, Futamura M

P4-02-29 A 3D visualization method for breast cancer surgeons and patients

Parker A, Earnest TM, Pekis A, Kannan V, Peterson j, Cole Jr JA, Antony AK, Cook D

P4-02-30 Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer

Sanfeliu E, Brasó-Maristany F, Dieci MV, Marín-Aguilera M, González-Farré B, Griguolo G, Pascual T, Galván P, Angelats L, Castillo O, Blasco P, Sirenko V, Jares P, Puig-Butillé JA, Paré L, Martínez A, Llombart-Cussac A, Cortés J, Vivancos A, Villagrasa P, Parker JS, Perou CM, Prat A, Conte P, Guarneri V

Epidemiology, Risk, and Prevention: Epidemiology - Population Studies

P4-03-01 Persistence with adjuvant endocrine therapy in patients with early breast cancer at high risk of recurrence: a US-based real-world study

Sheffield KM, Vitko AS, Brown J

P4-03-02 Low-dose aspirin prescriptions and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up

Solmunde E, Pedersen RN, Nørgaard M, Mellemejkær L, Friis S, Ejlersen B, Ahern TP, Cronin-Fenton D

P4-03-03 Elevated risk of breast cancer diagnosis in women with dense breasts reflects a similarly elevated risk of breast cancer onset that is robust to the effect of density on mammography sensitivity

Lange JM, Gard C, O'meara E, Etzioni R

P4-03-04 The first population level description of all women diagnosed with breast cancer in Costa Rica from 2008 to 2012 using data from the National Tumor Registry

Guzman PG, Ramirez-Pena E

P4-03-05 HER2 + breast cancer in Afro-Caribbean women in New York City

Cimpeanu E, Frangopoulos E, Ventura AM, Chiu E, Lin B, Taiwo E

P4-03-06 Clinical and socioeconomic disparities in treatment and survival between Hispanic and non-Hispanic Black women with non-metastatic triple-negative breast cancer

Alvarez Soto A, Bernal AM, Anampa Mesias J

P4-03-08 Breast cancer incidence rates in Japan turned into bimodal age distribution in this decade

Uchida K, Ohashi H, Nogi H, Kinoshita S, Nosaka R, Kamio M

P4-03-09 Risk of breast cancer after false-positive mammography recalls: a matched cohort study

Mao X, He W, Humphreys K, Yang H, Czene K

P4-03-10 Breast density and risk of breast cancer

Lynge E, Vejborg I, Lillholm M, Nielsen M, Napolitano G, von Euler-Chelpin M

P4-03-11 Population-based survival outcomes of pure vs mixed invasive lobular breast carcinoma in Ontario, Canada

Lim D, Giannakeas V, Narod S, Metcalfe K

P4-03-12 Withdrawn

P4-03-13 An evaluation of breast cancer recurrence data reported to the NCI SEER Program

Ramirez-Pena E, Negoita S

P4-03-14 Proinflammatory dietary patterns and risk of total and subtypes of breast cancer among US women

Romanos-Nanclares A, Willett WC, Rosner BA, Stover DG, Asad S, Sardesai S, Holmes MD, Chen WY, Tamimi RM, Tabung FK, Eliassen AH

P4-03-15 Does age affect outcome? Data from a large cohort from British Columbia, 2005-2014

Jackson EB, Gondara L, Speers CH, Gelmon K

P4-03-16 Association between tamoxifen and the incidence of cataract in ductal carcinoma in situ patients

Kim D, Park W-C, Jeon S, Lee HS, Yoon CI

P4-03-17 Parity, use of statins and low-dose aspirin, and breast cancer risk – data from two large cohort studies

Schmidt JA, Fournier A, Cairat M, Mailhac A, Sørensen H, Gunter M, Cronin-Fenton D

P4-03-18 Group-based trajectories of endocrine therapy adherence and risk of recurrence in a Danish premenopausal breast cancer cohort

Woolpert KM, Schmidt JA, Ahern TP, Lash TL, Collin LJ, Ejlersen B, Cronin-Fenton D

P4-03-19 Expected real-world impact of escalation and de-escalation of Her2-directed therapy in breast cancer patients receiving neoadjuvant therapy

Mollenthel A, Morris A, Lauren C, Simmons C

P4-03-20 Association between reproductive factors (parity and age first full term birth) and the frequency of estrogen receptor negative breast cancer according to age at diagnosis

Vangoitsenhoven M, Theys E, Van Baelen K, Laenen A, Desmedt C, Floris G, Wildiers H, Punie K, Han S, Baert T, Amant F, Smeets A, Nevelsteen I, Vanhoudt R, Neven P

P4-03-21 Racial disparities in survival trends in patients with metastatic Hormone receptor positive/Her 2 negative breast cancer: a SEER population-based study

Alvarez Soto A, Bernal AM, Anampa Mesias J

P4-03-22 Linking internal medicine care to metastatic breast cancer patients for success: LIMBS

Kaler AJ, Singareeka Raghavendra A, Kirklin GT, Cunningham D, Manzullo E, Tripathy D, Razouki Z

P4-03-23 Comparison of breast cancer vs cardiovascular disease risk and uptake of chemoprevention vs statins in a cohort of predominantly Hispanic women undergoing screening mammography

Nilan L, McDermid MM, Amenta JN, McGuinness JE, Crew KD, Kukafka R

P4-03-24 State variation in racial and ethnic disparities in triple-negative breast cancer rates: NPCR-SEER incidence data, 2015-2019

Sung H, Wiese D, Jatoi I, Jemal A

P4-03-25 Patient-level predictors of skipping screening mammograms during the COVID-19 pandemic at a large tertiary care center in Texas

Nemati Shafae M, Rosales O, Kirby RP, Ortiz-Perez T, Gilman L, Hardeman A, Bhavsar Bhakta P, Amos C, Oluyomi A

P4-03-26 Blood DNA methylation and breast cancer: A prospective case-control analysis in the breast cancer prospective family study cohort

Wu H, Castano A, Liao Y, Santella R, Brenner D, Terry MB, Tycko B

P4-03-27 The impact of sociodemographic disparities on overall survival of adolescent and young adults (AYA) with invasive breast cancer

Lopetegui-Lia N, Thayyil Jayakrishnan T, Barot S, Wei W, Kruse M

P4-03-28 Patient reported symptom burden amongst immigrant and Canadian long-term resident women undergoing breast cancer surgery

Parvez E, Chu MM, Kirkwood D, Doumouras A, Bogach J

P4-03-29 Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway

Eijkelboom A, de Munck L, Larsen M, Nygård J, Hofvind S, Siesling S

P4-03-30 Patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer

Kaufman PA, Neuberger E, Hsu L-I, Schwartz N, Bartley K, Wang S, Liu Y, Blahna MT, Pittner BT, Wong G, Anders C

P4-03-31 Lifestyle factors are associated with breast cancer risk in women biopsied for benign breast diseases in China: 10-year results of a multi-center, hospital-based, case-control study

Zheng C, Ma D, Zhao L, Guo M, Cui S, Tian F, Fan Z, Geng C, Cao X, Yang Z, Wang X, Liang H, Wang S, Jiang H, Duan X, Wang H, Li G, Wang Q, Zhang J, Jin F, Tang J, Li L, Zhu S-G, Zuo W, Wang F, Yu L, Zhou F, Xiang Y, Guo M, Wang Y, Zhou W, Huang S, Li Z, Zhou Y, Hou L, Yang X, Zhang X, Liu L, Yu Z

P4-03-32 Association between androgen receptor expression and recurrence free survival among locally advanced triple negative breast. Real world data from a single Institution in Mexico City

Araiza Alvarado E, Arce Salinas CH

P4-03-33 A population-based analysis of prophylactic G-CSF biosimilar and originator administration over time among patients diagnosed with breast cancer

Pawloski PA, McDermott CL, Vazquez Benitez G, DeFor T, Mendelsohn AB, Marshall J, Moynour E, Lockhart C

P4-03-34 Treatment patterns and associated outcomes among patients with HER2+ metastatic breast cancer in the United States

Lam C, Varghese D, Nordstrom BL, Murphy B, Collins J, Mehta S

P4-03-35 Withdrawn

P4-03-36 Determinants of severe COVID-19 infection in patients with breast cancer from a community oncology practice in Brazil

Cascelli F, Costa e Silva M, Dienstmann R, Ferrari BL, Ferreira CG, S.Mano M, Canedo J, Cunha D, Gimenes DL, Goncalves A

P4-03-37 The characteristics of male breast cancer by molecular subtypes: a population-based study

Wang M, Liu D, Zhu L

P4-03-38 Rare breast cancer histologic subtypes: 30-year experience in a Mexican cancer center

Valdez-Sandoval P, Martinez-Cannon BA, Perez Alvarez SI, Leon-Rodriguez E

P4-03-39 Breast density and body mass index association with breast cancer molecular subtypes in early breast cancer Spanish population

Calvo I, González M, Neria F, Gallegos I, García-Sánchez L, Pérez S, Estévez LG

P4-03-40 Patient and treatment characteristics in HR+/HER2- metastatic breast cancer in a real-life setting

Karadurmus N, Sendur MAN, Cil T, Cakmak Oksuzoglu OB, Arslan C, Harputluoglu H, Sezgin Goksu S, Ozturk B, İnanç M, Cubukcu E, Demirci U, Erdem D, Cihan S, Tural D, Dumludag A, Aykan MB, Yılmaz F, Avsar E, Dinc Sonusen S, Ozturk OF, Aver B, Kaplan MA

P4-03-41 Prospective observational study of breast cancer patients during the cycle of chemotherapy with taxanes: evaluation of the incidence and prevalence of peripheral neuropathy

Costa Luz RP, Alliz CS, Lopes de Almeida Rizzi SK, Haddad C, Bittencourt Machado C, Nazário A, Facina G

P4-03-42 Evaluating the impact of race and body mass index on the diagnosis and prognosis of early onset breast cancer

Kordic A, Reyes A, Ashai N

P4-03-43 Disease characteristics and outcomes of people with metastatic breast cancer in a single center cohort study: The Dallas Metastatic Breast Cancer Study

Cao M, Lim M, Moscovitz A, Ladner J, Hodgdon C, Maués J, Reddy SM, Chan I

P4-03-44 A case series of male breast cancer patients at Methodist Dallas Medical Center

Nong H, Moparty V, Manhas A

Psychosocial, Quality of Life, and Educational Aspects: Palliation and Pain Management

P4-04-01 Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy in breast cancer patients

Costa RB, Nogueira-Rodrigues A, Oliveira Bessa CP, Adalberto Menezes RC, Coelho de Miranda Jorge Oliveira F, Costa e Silva M, Rocha Paes F, Ferrari BL

P4-04-02 Evaluation of Dronabinol to decrease opioid use for cancer- induced bone pain
Segar J, Farr K, Junak M, Roe D, Ehsani S, Jiralerspong S, Mohab I, Vanderah T, Chalasani P

Psychosocial, QOL, and Educational Aspects - QOL Issues: Psychosocial Aspects

P4-05-01 Cancer-related distress and unmet needs among triple negative breast cancer patients: Findings from the Cancer Experience Registry

Lawrence C, Fortune EE, Badt H, Doughtie K, Popalis ML, Miller MF

P4-05-02 Oncoplastic breast surgery and involvement of plastic surgery improve quality of life by Breast-Q score in breast conserving surgery

Stuntz ME, Rychkov TA, Garcia J

P4-05-03 Investigating financial toxicity among breast cancer patients diagnosed during the pandemic: The role of cancer care disruptions and social isolation

Acquati C, Chen T, Martinez Leal I, Connors S, Rogova A, Banegas M, Smith G, Reitzel LR, McNeill L

P4-05-04 Health-related quality of life and work impairment among individuals living with HER2+ breast cancer with brain metastases

Morris VG, Zaleta AK, Badt H

P4-05-05 The psycho-social factors impacting black women breast cancer survivors

Leach V

P4-05-06 Surgical outcomes for reconstruction after delayed contralateral prophylactic mastectomy

Soh CL, Muktar S, Malata CM, Benson JR

P4-05-07 Making Choices with Scarce Resources While Battling Breast Cancer In Nigeria

Okwu GC, Nwosu-Zita TO, Haruna AE

Treatment - Therapeutic Strategies: Neoadjuvant Chemotherapy

P4-06-01 Platinum-based chemotherapy for early triple-negative breast cancer: A Cochrane systematic review and meta-analysis

Mason S, Willson M, Goodwin A, Beith J, Egger SJ, Dear RF

P4-06-02 Complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis

Ploumen R, Claassens E, Kooreman L, Keymeulen K, van Kats M, Gommers S, Siesling S, van Nijnatten T, Smidt M

P4-06-03 Pathological complete response (ypCR) in early and locally advanced breast cancer (LABC) patients treated with neoadjuvant chemotherapy in a middle-income country. Results from a real-world historical cohort

Mantilla W, Gonzalez M-F, Rojas S, Borrás-Osorio M, Molano-Gonzalez N, Guerra J, Munevar I, Moran D

P4-06-04 Clinical outcomes of loco-regional HER2-positive invasive lobular carcinoma of the breast

Gaire S, Budhathoki P, Joshi U, Shah A, Choong GM, Yadav S

P4-06-05 Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status

Budhathoki P, Shah A, Gaire S, Joshi U, Yadav S

P4-06-06 Neoadjuvant B27 protocol in triple-negative breast cancer: Evaluation response rate, pathological complete response rates, toxicity, and the prognosis of adolescent and young adult (AYA) age group compared to older population

Tamimi F, Sharaf B, Khater S, Al-Sawajneh S, Horani M, Elrabii KM, Zayed A, Abdel-Razeq H

P4-06-07 Preliminary indications of safety and efficacy of neoadjuvant chemotherapy plus chemokine-modulating regimen (rintatolimod, IFN- α 2b, celecoxib) in triple negative breast cancer

Gandhi S, Opyrchal M, Ford C, Slomba R, Attwood K, O'Connor T, Levine E, Kalinski P

P4-06-08 HER2-protein expression is a predictive marker for treatment response in patients with HER2-positive breast cancer who received neoadjuvant chemotherapy with dual HER2-blockade

Bae SJ, Jang JS, Kook Y, Baik SH, Kim JH, Ahn SG, Jeong J

P4-06-09 A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+ /HER2- IBC

Marx AN, Kai M, Fu M, Murphy HE, Willey JS, Sun H, Alexander A, Bassett Jr RL, Whitman GJ, Le-Petross HTC, Patel M, Arun BK, Abouharb S, Thomas PS, Barcenás CH, Ibrahim NK, Valero V, Ueno NT, Layman RM, Lim B, Woodward WA, Lucci A

P4-06-10 Is Anthracycline chemotherapy essential in the treatment of women with breast cancer? – A real world comparison in the neoadjuvant setting

Giffoni D, Castelo M, Sutradhar R, Nguyen L, Faught N, Rodin D, Hahn E, Fatiregun o, Fong C, Trebinjac S, Eisen A, Paszat L, Jerzak K, Rakovitch E

P4-06-11 Pathologic complete response in triple negative breast cancer of black vs white patients in the post-keynote 522 era

Sheen M, Chung V, Maini R, Duggan M, Levy J

P4-06-12 Decision of neoadjuvant therapy in younger vs. older breast cancer patients: A real-world data analysis

Alanya E, Falcon-Lizaraso S, Aldecoa-Falcon S, Aldecoa-Bedoya F

P4-06-13 Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of GeparOLA study

Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, Link T, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Denkert C, Schmutzler RK, Hahnen E, Untch M, Nekljudova V, Blohmer J-U, Loibl S

Treatment - Treatment: Other

P4-07-01 Overall survival with locoregional surgery in de novo metastatic breast cancer

Chongxi R, Jianna S, Lingjun K

P4-07-02 Toxicity profile of single agent trastuzumab deruxtecan in solid tumors: A meta-analysis

Tamimi F, Mittal A, Molto Valiente C, Di Iorio M, Al-Showbaki L, Nadler M, Amir E

P4-07-03 The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa

Ayeni OA, Chiwambutsa S, CHen WC, Kapungu NN, Kanji C, Thelingwani R, Murugan N, Mathiba R, Phakathi B, Nietz S, Ramiah D, O'Neil DS, Jacobson JS, Ruff P, Cubasch H, Chirwa T, Joffe M, Masimirembwa C, Neugut AI

P4-07-04 STX-478, a mutant-selective PI3K α H1047X inhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Buckbinder L, St. Jean Jr DJ, Ladd B, Tieu T, Jonsson P, Alltucker J, Manimala S, Wang W, Guzman-Perez A, Stuart DD, Dowdell G

P4-07-05 Real world data of adjuvant endocrine therapy for breast cancer in very young women. A Chilean 20-year experience

Heredia A, Walbaum B, Acevedo F, Sánchez C

P4-07-06 Implementation of a bone modifying agent pathway at UChicago Medicine for metastatic breast cancer patients

Lin k, Baur J, Parsad S, Yang H

P4-07-07 Impact on overall survival according to sites of metastasis: Real-world data

Yagual Bohorquez L, Valencia-Espinoza E, Pulla-Cadmilema E, Velez Avila LP, Sanchez Salazar MdM, Tamayo Aguilar P, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Campoverde Merchan F, Engracia Vivanco R, Santacruz Maridueña M, Escala Cornejo R, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Rodriguez-Melendez EA

P4-07-08 Impact on overall survival according to breast cancer immunophenotypes: Real-world data in metastatic breast cancer in Ecuador

Valencia-Espinoza E, Pulla-Cadmilema E, Velez Avila LP, Yagual Bohorquez L, Sanchez Salazar MdM, Tamayo Aguilar P, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Escala Cornejo R, Campoverde Merchan F, Engracia Vivanco R, Santacruz Maridueña M, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Rodriguez-Melendez EA

P4-07-09 Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices

Brufsky AM, Maculaitis MC, Kopenhafer L, Olsen P, Cha AS, Arruda LS, Heck W, Kurosky SK

P4-07-10 Effect of acupuncture and exercise therapy on muscular strength, lymphedema and quality of life in breast cancer survivors: randomized clinical trial

Santolia P, Facina G, Haddad C, Lopes de Almeida Rizzi SK, Nazário A, Elias S

P4-07-11 Disparities in the uptake of telemedicine and implications for clinical trial enrollment in breast cancer patients

Hardy Abeloos C, Xiao J, Oh C, Maisonet O, Gerber N

P4-07-12 Development of triple-negative breast cancer (TNBC) syngeneic models and TROP2-directed antibody-drug conjugate (ADC) surrogate to model therapeutic combinations

Chou C-C, Kardos J, Yang B, Orf J, Dave R, Lai Y, Lee CV, Papalia GA, Boyd K, Diehl L, Scholler N

P4-07-13 Satisfaction of patients after implant-based subpectoral reconstruction with a titanized polypropylene mesh (TiLOOP® Bra) compared to prepectoral reconstruction with a titanized polypropylene pocket (TiLOOP® Bra Pocket)

Paepke S, Andrulat A, Ankel C, Bauer L, Baumann K, Blohmer J-U, Faridi A, Fink V, Gerber-Schaefer C, Gschwantler-Kaulich D, Heil J, Kuemmel S, Kossmann-Meiré A, Ohlinger R, Thill M

P4-07-14 Long-term outcomes after 1 or 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancer

Nakhlis F, Niman S, Ueno NT, Troll E, Ryan S, Yeh E, Warren L, Bellon J, Harrison B, Iwase T, Le-Petros HTC, Saleem S, Teshome M, Whitman GJ, Woodward WA, Overmoyer B, Tolaney SM, Regan MM, Lynce F, Layman RM

P4-07-15 Incidence and timeline of primary and central adrenal insufficiency due to immunotherapy in the I-SPY2 TRIAL

Nanda R, Cohen R, Liu MC, Robinson P, Chien J, Soliman HH, Pusztai L, Han HS, Stringer-Reasor E, Sit L, Lu R, Yau C, Asare S, Pitsouni M, Wilson A, Perlmutter J, Symmans WF, Hylton NM, Van 't Veer L, Berry D, I-SPY Investigators, Schwab R, DeMichele A, Shatsky RA, Isaacs C, Yee D, Esserman LJ, Rugo HS

P4-07-16 B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers

Devaux A, Beniuga G, Quaghebeur C, Henry S, Van Bockstal M, Galant C, Delrée P, Canon J-L, Honhon B, Korman D, Verschaeve V, Lonchay C, Lefevre S, D'Hondt L, Berlière M, Delmarcelle S, Mine J-M, Willems T, Müller G, Myant N, Bar I, Haussy S, Coulie PG, Duhoux FP, Carrasco J

P4-07-17 Follow-up in breast cancer care: guidelines and individual risks

Van Dongen L, Meijer J, Van Hoeve J, van den Bongard D, Hendriks M, Honkoop A, Strobbe L, Guerrero Paez C, Siesling S

P4-07-18 FerOX, an anthracyclines nanoformulation to lead toward immuno-mediated cancer remission, preserving T-cell immune competence

Mazzucchelli S, Mainini F, Andreato F, Truffi M, Bonizzi A, Piccotti F, Sevieri M, Corsi F

P4-07-19 Eribulin enhances STING-dependent induction of type I interferons in immune and triple-negative breast cancer cells

Takahashi-Ruiz L, Fermaintt C, Wilkinson N, Mooberry S, Risinger A

P4-07-20 Effect of prior treatments on post-CDK 4/6 inhibitor overall survival in hormone receptor positive breast cancer

Franks J, Caston NE, Elkhanany A, Gerke T, Azuero A, Rocque GB

P4-07-21 Neo-adjuvant chemotherapy in various breast cancer subtypes in the 21st century

Ananthula A, Thomas K, Chen L, Carey VK, Sullivan CM, Martin KM, Baas E, Plasko KC, Sun B, Lanza M, Nguyen C, Chapple A, Loch MM

P4-07-22 Clinical decision support systems for multidisciplinary team decision-making in patients with solid cancer: an implementation model based on a scoping review

Hendriks MP, Ebben KC, Van Til JA, Jager A, Siesling S

P4-07-23 Results of a phase 2 trial of combination immunotherapy with concurrent Nelipecimut-S + GM-CSF and Trastuzumab in high-risk HER2+ breast cancer patients

Tiwari A, Clifton G, Calfa C, Alatrash G, Holmes J, Bedrosian I, Peoples G, Mittendorf EA

P4-07-24 Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

Pierga J-Y, Billa O, Dabakuyo S, Lemonnier J, Berger F, Trédan O, Jacot W, Gonçalves A, Debled M, Levy C, Jouannaud C, Mouret-Reynier M-A, Ferrero J-M, Dalenc F, Toumi F-Z, Bonnetain F, Bidard F-C, Renault S

P4-07-25 Performance of sentinel lymph node biopsy after neoadjuvant chemotherapy in clinically node positive breast cancer patients: Systematic review and meta-analysis

Zahwe M, Ghzaiel A, Ghezzawi M, El Iskandarani S, Diab M, Soueid L, El Jibbawi M, Najia A, El Asmar K, Sbaity E

P4-07-26 Development of CDCP1-targeting antibody-drug conjugate for triple negative and metastatic breast cancer

Gough M, Khan T, Kwah K, He Y, Ratnayake G, Pyke C, Snell C, Hooper J, Kryza T

P4-07-27 Clipped lymph nodes for cN+ patients decrease false negative rate and lead to potential changes in surgical and oncological management after clinical complete response following neoadjuvant chemotherapy

Arienzo F, Campagna D, Scavina P, Broglia L, Ascarelli A, Colavito H, Montanari M, Manna E, Mastropietro T, Zarba Meli E, La Pinta M, Musio D, Minelli M, Scavina P, Amato MMC, Costarelli L

P4-07-28 Prognostic impact of delaying multimodality treatment in HER2 positive breast cancer

Chang H, Gornbein J, Lim SY

P4-07-29 Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advanced Breast Cancer Patients: The OPHELIA Study

Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Salvador Bofill FJ, García-Sáenz JÁ, Pimentel I, Morales Murillo S, Fernández A, Lahuerta Martínez A, Ferrer N, Zamora P, Bermejo B, Díaz-Redondo T, Lopez-Ceballos MH, Galán M, Malfettone A, Calabuig L, Sampayo-Cordero M, Pérez-García JM, Cortés J, Llombart-Cussac A

P4-07-30 Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

Álvarez I, Guerrero-Zotano A, Tibau A, Falo C, Hernández M, Miguel A, Andrés R, Rodríguez-Lescure Á, Corbellas M, López-Tarruella S, Martínez P, Rodríguez CA, Malón D, Marin M, Echarrí AJ, Antón A, Cruz J, Moreno D, Chacón JI, Campo R, Blasco A, Bezares S, Rojo F, Antolin S

P4-07-31 A whole food, plant-based (WFPB) dietary intervention to improve cardiometabolic and cancer-related outcomes in women with breast cancer

Campbell E, Campbell T, Culakova E, Wixom N, Guido J, Blanchard L, Fettes J, Janelins M, Mustian K, Peppone L

P4-07-32 Prognostic factors among elderly patients with operable non-metastatic breast cancer treated with primary endocrine therapy

Andrade Rocha E, Monteiro Vasconcellos J, Vidaurre Mendes S, Galvão Freire PJ, Messias AP, Vecchi Leis L, Noschang Moreira O, Baptista Pereira M, Zanin Orsi B, Araujo Neto A, Petry V, Colombo Bonadio R, Testa L

P4-07-33 Differences in treatment outcomes between patients with HER2-low versus HER2-zero, hormone receptor-positive advanced-stage breast cancer treated with CDK4/6 inhibitors

Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh AA, Al-lababidi S, Abdel-Razeq H

P4-07-34 CO₂ laser, radiofrequency, and promestriene in treatment of genitourinary syndrome of menopause in breast cancer survivors. Clinical and histological aspects of a randomized control trial

Waltzberg AFL, Franco AFV, Bianchi-Ferraro AM, Marcela R, Cantarelli G, Dedonato C, Patriarca M, Dardes R, Speck N, Jarmy-di Bella Z, Sartotti M, Almeida J

P4-07-35 Changes in left ventricular global longitudinal strain in breast cancer patients receiving anti-HER2 and/or Adriamycin therapy and outcomes with early implementation of cardio-protective measures

Abunafeesa HE, Mckay C, Li P, Reddy M, Dabak V

P4-07-36 Chest-wall and nodal irradiation in non-metastatic, node positive breast cancer patients with pathologic complete response after neoadjuvant chemotherapy and surgery, in a retrospective cohort of women aged 45 years and younger

Cerbon D, Sanchez-Covarrubias A, Conte B, Takita C, Freedman L, Meshman J, Samuels S, Shermoen C, Goel N, Carmona R, Wang L

P4-07-37 A UK study exploring the attitudes and experience of patients living with metastatic breast cancer with regard to clinical research: A patient advocate-academic collaborative study

Stephen L, Dunn JA, Balmer C, Gasson SJ, Elbeltagi NI, Copson ER, Palmieri C

P4-07-38 Real-world data of advanced breast cancer (ABC) patients with HER2-positivity before the second-line therapy: data from the observational study GEICAM/2014-03 (RegistEM)

López-Tarruella S, Guerrero-Sotano A, Cruz J, Antolin Novoa S, Martínez P, Hernández M, Rodríguez CA, Chacón JI, Tibau A, Falo C, Rodríguez-Lescure Á; Margelí M, Servitja S, Andrés R, Galán-Gramaje M, Adrover E, Miguel A, Villanueva R, Varela S, Campo R, Escudero MJ, Bezares S, Rojo F, Álvarez I

P4-07-39 Neoadjuvant treatment in the COVID era

Alonso de Castro B, Gomez-Randulfe Rodriguez I, Silva Diaz S, Reboredo C, Antolin Novoa S, Perez Lopez E, Cordeiro P, Lesta R, Parajo Vazquez I, Calvo L

P4-07-40 Magnetic resonance imaging (MRI) and clinicopathological analysis of triple-negative breast cancer (TNBC) patients (pts) treated with primary anthracyclines(A)/taxanes(TX)-based chemotherapy

Sierra Boada M, Fernandez LA, Dalmau E, Llort G, Marin M, Andreu P, Lopez N, Climent C, Rodriguez M, Soriano S, Sequi MA

P4-07-41 Is axillary evaluation still necessary in DCIS?

Ramos M, Mattar A, Amorim A, Cavagna F, Passos M, Fernandes R, Shida J, Gebrim LH

P4-07-42 Intervention to distant metastatic lesions in patients with breast cancer

Abidi H, Ozbas S, Ozcinar B, Dogan L, Isik A, Diego E, McAuliffe PF, Johnson R, Steiman J, Sezgin E, Soran A

P4-07-43 Effect of acupuncture and exercise therapy in rehabilitation of physical disfunctions in breast cancer survivors: randomized clinical trial

Santolia P, Facina G, Haddad C, Nazário A, Lopes de Almeida Rizzi SK, Elias S

P4-07-44 Association between tissue mobilization with physical exercise and physical exercise alone in patients with axillary web syndrome who underwent breast cancer surgery

Figueira PV, Haddad C, Lopes de Almeida Rizzi SK, Estevao A, Elias S, Facina G, Nazário A

P4-07-45 Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)

Antolin Novoa S, Rodríguez CA, Cruz J, López-Tarruella S, Tibau A, Adrover E, Miguel A, Margelí M, Martínez P, Hernández M, Antón A, Rodríguez-Lescure Á, Falo C, Álvarez I, Malón D, Andrés R, Alonso-Romero JL, Gómez C, Illaramendi JJ, Campo R, Miralles, JJ, Bezares S, Rojo F, Guerrero-Zotano A

P4-07-46 The out-of-pocket cost of breast cancer care in Nigeria: A prospective analysis

Wuraola F, Blackman C, Owoade IA, Adeleye AO, Kingham P, Alatise O, Knapp G

P4-07-47 Real-world practice patterns in the management of metastatic breast cancer in Washington State

Manohar P, Linden H, Shankaran V, Fedorenko C, Voutsinas J, Sun Q, Wu V

P4-07-48 Preliminary results of the FIRST (Freezing bReaST cancer in Brazil) trial: a before-after study

Sanvido VM, Bromberg SE, Junior AR, Tachibana BMT, Nazário A

P4-07-49 Neoadjuvant therapy in Asian breast cancer patients with early & locally advanced breast cancers – A contemporary experience from a large tertiary hospital in Singapore

Zhang Z, Ma J, Ting Tan JY, Ong WS, Kamis S, Yang G, Tee Tan BK, Tan VKM, Tan TJ

P4-07-50 mRNA expression and delivery efficacy of lipid nanoparticles in the cells breast tumor microenvironment: in vitro and in vivo evaluation

Court KA, Tiwari A, Chau E, Cooke J, Godin B

P4-07-51 Impact of the Theralink CLIA protein/phosphoprotein assay on treatment selection in routine clinical practice: a prospective observational study in advanced breast cancer

Weinberg K, Pierobon M, Blais E, Davis J, O'Shaughnessy J, Petricoin EF

P4-07-52 Caloric restriction for oncology research (CaReFOR): Assessing dietary adherence and outcomes in African American patients during breast cancer treatment

Harding S, Adekeye A, Mitchell EP, Simone N

P4-07-53 Adverse events (AEs) in phase III clinical trials of patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC): a meta-analysis

Henderson M, Yalamanchili P, Wang E, Salas M

P4-07-54 Health related quality of life of patients treated with bevacizumab and paclitaxel as first-line treatment for HER2 negative metastatic breast cancer: impact of clinical factors

Billa O, Dabakuyo S, Chevrier M, Bonnetain F, Desmoulin I, Jacot W, Trédan O, Debled M, Levy C, Gonçalves A, Ferrero J-M, Dalenc F, Jouannaud C, Mouret-Reynier M-A, Mousseau M, Grenier J, Jacquin J-P, Toumi F-Z, Berger F, Lemonnier J, Pierga J-Y

P4-07-55 Neoadjuvant trastuzumab and pertuzumab in combination with anthracyclines in HER2-positive early breast cancer: real-world data on effect of body mass index in cardiac safety

Simão D, Sardinha M, Gil L, Montenegro A, Mendes J, Fernandes L, Winckler P, Luz R, Oliveira S

P4-07-56 Mayo Clinic Enterprise patterns of growth-factor utilization for sacituzumab govitecan (SG)-induced neutropenia among patients with metastatic triple negative breast cancer

Clark K, Carroll JL, Moreno-Aspitia A, Ernst B, Raheem F, Heil A, Boyer B, Mara K, Goetz MP, Leon-Ferre RA, Giridhar KV, Taraba J

P4-07-57 Outcomes of triple-negative breast cancer in older versus younger women

Munir A, Khawaja S, Khan S, Sharaiha Y, Huws AM

P4-07-58 Adjuvant endocrine therapy adherence in breast cancer patients and the Brazilian National Health System

Herrera AC, Kasai CC, Gonçalves ET, Homa LA, de Oliveira CEE

P4-07-59 Management of isolated contralateral axillary lymph node metastasis in breast cancer: A single institution experience

Patel R, Berwick S, Jin C, Klein P

P4-07-60 Identification of optimal carboplatin containing regimen for triple negative breast cancer

Rempel GJ, Rim CS, Hussein A, Bocicariu A, Kulkarni S, Gupta R, Matthews J, Kay A, Porter L, Hamm C

P4-07-61 Lymphedema, shoulder range of motion, pain, and presence of cords in patients undergoing breast cancer treatment with axillary web syndrome: Late follow-up

Figueira PV, Haddad C, Lopes de Almeida Rizzi SK, Esteveao A, Elias S, Facina G, Nazário A

P4-07-62 Real-world, single-center experience on the outcomes of neoadjuvant chemotherapy and Trastuzumab alone or in combination with Pertuzumab in human epidermal growth factor receptor 2 breast cancer patients

Vaid AK, Sharma D, Wadhwa J, Agarwal R, Kaur K, Goyal S, Gautam D, Arora J, Gupta S, Sen A, Goel RK, Mahajan S

P4-07-63 Local delivery of immunotherapeutics as an in situ vaccine in triple negative breast cancer

Mantooth s, Zaharoff D

P4-07-64 Impact of baseline ECOG, comorbidities, and surgery treatment election on overall survival

Rodriguez-Melendez EA, Pulla-Cadmilema E, Velez Avila LP, Sanchez Salazar MDM, Tamayo Aguilar P, Yagual Bohorquez L, Martin-Delgado J, Ramos Martinez G, Garcia Matamoros K, Santacruz Maridueña M, Engracia Vivanco R, Escala Cornejo R, Campoverde Merchan F, Delgado Guerrero I, Torres Floril V, Garcia Gamboa D, Pendola Gomez L, Gamarra Cabezas E, Garces Santos JC, Valencia-Espinoza E

P4-07-65 Effect of sacituzumab govitecan vs chemotherapy in HR+/HER2- metastatic breast cancer: patient-reported outcomes from the TROPiCS-02 trial

Marmé F, Bardia A, Rugo HS, Schmid P, Tolaney SM, Oliveira M, Schneeweiss A, Shi L, Verret W, Gharaibeh M, Shah A, Cortés J

Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets

P4-08-01 Targeting CDK7 enhances the antitumor efficacy of enzalutamide in androgen receptor-positive triple-negative breast cancer

Xie X, Manai M, Fuson JA, Pearson T, Rampa DR, Tripathy D, Lee J, Ueno NT

P4-08-02 LOXO-783: A potent, highly mutant selective and brain-penetrant allosteric PI3K α H1047R inhibitor in combination with standard of care (SOC) treatments in preclinical PI3K α H1047R-mutant breast cancer models

Puca L, Dowless MS, Perez-Ferreiro CM, Ortiz-Ruiz MJ, Donoho GP, Capen A, Huber L, bogner SM, Fei D, Manro JR, Yu CP, Xu WG, Wang R, Chen S, Hicks II MA, Zolfaghari P, Faber A, Gilmour R, Ramstetter MD, Chang MT, Lallena MJ, Gong X, Hyman DM, Smyth LM, Brandhuber BJ, Taylor BS, Klippel A

P4-08-03 Operation of eIF4A1-PD-L1 axis in therapy-naïve and drug-resistant TNBC

Boring A, Dulal D, Raman D

P4-08-04

Withdrawn

P4-08-05

NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer

Reddy T, Puri A, Guzman L, Qian W, Zhou J, Rosato R, Zhao H, Thomas C, Li X, Mahboubi B, Oo A, Cho Y-J, Kim B, Thaiparambil J, Ayerbe C, Giese N, Moulder S, Piwnica-Worms H, Meric-Bernstam F, Chang J

P4-08-06 Clock genes in breast cancer

Jayachandran P, Baca Y, Xiu J, Pan Y, Walker P, Battagliin F, Arai H, Khushman M, Le J, Spicer D, Mumenthaler S, Goldberg R, Weinberg B, Lou E, Hall M, Heeke AL, Korn WM, Kay SA, Lenz H-J, Roussos Torres ET

P4-08-07 Inhibition of the NUDT5 phosphatase suppresses the growth of triple-negative breast cancers

Qian J, Brown P

P4-08-08 Moved to HER2 Session

P4-08-09 Deoxycytidine kinase (dCK) inhibition is synthetic lethal with BRCA2-deficiency

Guantay ML, Garro CA, Siri S, Pansa M, Ghidelli-Disse S, Paviolo N, Racca A, Nicotra V, Radu C, Bocco JL, Felice R, Gloger I, Muelbaier M, Drewes G, Madauss K, García M, Gottifredi V, Soria G

P4-08-10 Azeliragon (TTP488), an orally- available small molecule RAGE inhibitor, reduces metastasis in preclinical mouse models of breast cancer

Magna M, Hwang GH, McIntosh A, Drews-Elger K, Takabatake M, Mera B, Kwak T, Miller P, Lippman M, Hudson BI

P4-08-11 AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

Schade A, Perurena N, Watanabe M, Rodriguez CL, Loi P, Pilla N, Davis RA, Mattioli K, Xiang D, Zoeller JJ, Li Zhe, Garrido-Castro AC, Tolaney SM, Cichowski K

P4-08-12 Clinical and genomic landscape of breast cancers carrying CCNE1 amplification

Marra A, Selenica P, Zhu Y, Razavi P, Safonov A, Ferraro E, Chandarlapaty S, Reis-Filho J

P4-08-13 Withdrawn

P4-08-14 Overcoming drug transport barriers in breast cancer liver metastasis by using macrophages as carriers: valuation in 2D and 3D models

Tiwari A, Chau E, Court KA, Carr J, Goodin D, Frieboes H, Godin B

P4-08-15 Identification of target kinases whose inhibition enhances antitumor efficacy of sacituzumab-govitecan in metastatic HER2-negative breast cancer

Oh N, Fuson JA, Liu H, Tripathy D, Ueno NT, Lee J

P4-08-16 Selective Androgen Receptor Modulators in combination with CDK4/6 inhibitors demonstrate anti-cancer activity in preclinical treatment resistant ER+AR+ breast cancer models

Freelander A, Iaven-Law G, Eshraghi L, Geetha N, Somerville P, Pickering M, Alexandrou S, Caldon CE, Tilley WD, Hickey TE, Lim E

P4-08-17 Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer

Larsson P, Pettersson D, Olsson M, Forssell-Aronsson E, Kovács A, Karlsson P, Helou K, Parris TZ

P4-08-18 Engineered toxin bodies specific for TROP2 positive cancers

Cornelison GL, Pedraza I, Garrison K, Kapeel EM, Pletka C, Khan A, Momb J, Martin R, Bartos A, Dekker JD, Zhao J, Majercak J, Robinson GL

P4-08-19 Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer

Lim B, Alexander A, Willey JS, Sun H, Liu S, Patel AB, Parra ER, Haymaker C, Solis Soto L, Serrano A, Sun B, Pinto Lima CF, Tamegnon A, Pandurengan RK, Douse D, Lan J, Raja L, Chu R, Knafel M, Woodman SE, Zhu H, Shulze K, Fedenko K, Darbonne W, Ueno NT, Valero V

P4-08-20 Inhibition of TACC3 blocks the growth of highly aggressive breast cancers with centrosome amplification

Saatci O, Akbulut O, Cetin M, Sikirzhyski V, Sahin O

P4-08-21 Development of novel inhibitors of the serum/glucocorticoid induced kinase (SGK) family to address limitations of AKT/PI3K/mTOR inhibitors in breast cancer

Labit D, Pradhananga S, Khalifa M, Blackburn E, Sajid N, Vidal M, Odink D, Campeau E

P4-08-22 Expression of dual specific phosphatase-7 (DUSP7/PYST2) and its connection with salt inducible kinases (SIKs) and downstream MKKs in breast cancer

Ji W, Lin L, Davies E, Jiang WG, Ye L

P4-08-23 ZHX2 promotes HIF1 α oncogenic signaling in triple-negative breast cancer

Liao C, Fang W, Shi R, Simon J, Ptacek T, Zurlo G, Ye Y, Han L, Fan C, Bao L, Ortiz CL, Lin H-R, Manocha U, Luo W, Peng Y, Kim WY, Yang L-W, Zhang Q

P4-08-24 Palmitoylation of Flotillin-1 contributes to breast cancer metastasis

McClellan B

Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification

P4-09-01 Moved to HER2 Session

P4-09-02 A molecular classification system for basal-like breast cancer based on the tumor microenvironment is prognostic for survival

Khorkova S, Shamsutdinova D, Kushnarev V, Popyvanov L, Dymov D, Zotova A, Valiev I, Antysheva Z, Love A, Brown JH, Bagaev A, Kotlov N, Fowler N

P4-09-03 Survival differences between HER2-zero and HER2-low-expressing breast cancer—A meta-analysis of early breast cancer patient data from 12 studies including 39831 patients

Zhang X, Yang C, Wang K

P4-09-04 Correlation between histology and molecular subtypes in triple negative breast cancer

Domingos TA, Pimenta Peixoto RB, Patel A, Taneja K, Chen WY, Mittendorf EA, Zimbalist A, Cespedes Feliciano EM, Dillon DA

P4-09-05 Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials

Rediti M, Venet D, Joaquin Garcia A, Agbor-Tarh D, Maetens M, Vincent D, Majaj S, El-Abed S, Ueno T, Di Cosimo S, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C

P4-09-06 Moved to HER2 Session

P4-09-07 Characterization of immune contexture in HR+/HER2- and triple negative breast cancer in a real-world cohort

Chhibber A, Dillon LM, Wojcik JB, Dostal V, Lee G, Seifuddin F, Ely S, Stern MD, Benson-Garnett C, Roberts M, Wu J

P4-09-08 AI-based quantitation of cancer cell and fibroblast nuclear morphology reflects transcriptomic heterogeneity and predicts survival in breast cancer

Abel J, Kirkup C, Kos F, Gerardin Y, Srinivasan S, Brosnan-Cashman J, Leidal K, Vasudevan S, Rajan D, Jain S, Prakash A, Padigela H, Conway J, Patel N, Trotter B, Yu L, Taylor-Weiner A, Krause EL, Bronnimann M, Chambre L, Glass B, Parmar C, Hennek S, Khosla A, Resnick M, Beck AH, Montalto M, Najdawi F, Drage MG, Wapinski I

P4-09-09 Withdrawn

P4-09-10 Spatial protein and RNA expression in tumor, immune and stromal cells in BRCA1/2 mutated metastatic breast cancer

Collier KA, Miller K, Li Z, Westfall J, Tallman D, Vater M, Tinoco G, Mardis E, Stover DG

P4-09-11 Development of personalized medicine for breast cancer based on elucidation of resistance mechanisms to CDK4/6 inhibitors

Kobayashi Y, Motoi Y, Fujimoto M, Shigematsu H

P4-09-12 Baseline and end-of-treatment biomarkers in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor Receptor 2-negative advanced breast cancer From BYLieve study cohorts A and B

Juric D, Turner NC, Loi S, Andre F, Chia SK, Jhaveri K, Neven P, Dent R, Ciruelos E, Joshi M, Roux E, Patino H, Akdere M, Rugo HS

POSTER SESSION 5

THURSDAY, DECEMBER 8, 5:00 PM – 6:15 PM, HALL 1

Detection/Diagnosis - Axillary Nodes: Axillary Staging and Sentinel Nodes

P5-01-01 Multiscale deep learning framework to capture systemic immune features in lymph nodes predictive of triple negative breast cancer outcome

Vergheze G, Li M, Liu F, Lohan A, Cherian n, Gazinska P, Shah A, Oozeer A, Gillett C, Alberts E, Hardiman T, Salgado R, Jones S, Jones L, Thavaraj S, Pinder SE, Rane S, Sethi A, Grigoriadis A

P5-01-02 Diagnostic accuracy of 18F-FDG PET/CT plus contrast-enhanced MRI for axillary lymph node metastasis involved in invasive ductal carcinoma

Kawaguchi S, Tamura N, Tanaka K, Kobayashi Y, Sato J, Kinowaki K, Shiiba M, Ishihara M, Kawabata H

P5-01-03 Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined with an automatic reader for detecting metastases in sentinel lymph nodes of patients with breast cancer: a multi-center prospective study

Matsumoto M, Baba M, Tanaka A, Kuba S, Morita M, Kaseida F, Hayashi H, Maeda S, Yano H, Inamasu E, Ogiya A, Sekiya K, Nakashima M, Ikari H, Ohno S, Takei H, Yanagilhana K, Eguchi S, Nagayasu T, Otsubo R

P5-01-04 Contralateral Axillary Lymph Node Metastasis after Ipsilateral Breast Tumor Recurrence: Is it distant metastasis or locoregional progression?

Jung J-J, Moon H-G, Han W, Lee H-B, Kim H-K, Chun JW, Kang E, Lim C, Kim J-i, Yeoh H

P5-01-05 A predictive model for axillary pathologic response after neoadjuvant chemotherapy for clinically node-positive breast cancer

Matsumoto A, Naruse S, Isono Y, Maeda Y, Sato A, Yamada M, Ikeda T, Jinno H

P5-01-06 Single cell profile of tumor and immune cells in primary triple-negative breast cancer and different sites in the axillary lymph nodes

Liao N, Li C, Cao L, Chen Y, Ren C, Chen X, Mok H, Wen L, Li K, Wang Y, Zhang Y, Li y, Lv J, Cao F, Luo Y, Li H, Wu W, Balch CM, Giuliano AE

P5-01-07 Recruitment, clinical equipoise, patient acceptance and compliance in the UK-ANZ POSNOC trial

Goyal A, Bruce C, Sadiq S, Lewis M, Montgomery A, Mann GB, Badger H, Monson K, Jenkins V, Fallowfield L, Reed M, Dodwell D, Fairbrother P, Homer T, Vale L, Butt R, Miles E, Dowe S, Matthews L, Jarrett H, Jackson J, Ali A

P5-01-08 Steps toward noninvasive lymph node staging (NILS) in clinically node negative patients: Artificial neural network model to preoperatively predict lymphovascular invasion

Hjartström M, Dihge L, Bendahl P-O, Ohlsson M, Rydén L

P5-01-09 Evaluation of the efficacy of using fluorescence-associated indocyanine green in sentinel lymph node biopsies from breast cancer patients

Sá R, Nazário A, Sanvido VM, Giordano R, Rodrigues R, Bugalho L, Silva S

P5-01-10 Is the Indian population ready for ACOSOG Z0011 protocol?

Nadarajan AR, Bhargavan R, Augustine P, Cherian K, Mathews A, Krishna J

P5-01-11 Utility of 18F-FDG PET/CT for the prediction of pathologic complete response in axilla to neoadjuvant chemotherapy in breast cancer

Michel E, Beltjens F, Cochet A, Alberini JL, Coutant C, Jankowski C

Prognostic and Predictive Factors: Biomarkers Predicting Tx Response: For Targeted Therapies

P5-02-01 Moved to HER2 Session

P5-02-02 Genomic landscape of ER+/HER2- metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor

Chica-Parrado MR, Lin C-C, Mahoney T, Mauer E, Hanker AB, Arteaga CL

P5-02-03 Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial

Graeser M, Kuemmel S, Gluz O, Feuerhake F, Volk V, Ulbrich-Gebauer D, Biehl C, Reinisch M, Kostara A, Scheffen I, Luedtke-Heckenkamp K, Hartkopf A, Hilpert F, Kentsch A, Ziske C, Deppenbusch R, Braun M, Blohmer J-U, zu Eulenburg C, Christgen M, Kates R, Bartels S, Kreipe H-H, Pelz E, Schmid P, Harbeck N

P5-02-04 Immune signatures display subtype-specific activation in breast cancer

Munkacsy G, Santarpia L, Gyorffy B

P5-02-05 Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative breast cancer in Japan

Futamura M, Nakayama T, Yoshinami T, Oshiro C, Ishihara M, Morita M, Watanabe A, Taniguchi A, Tsukabe M, Shimoda M, Mitta K, Chihara Y, Yasojima H, Ouchi Y, Tokumaru Y, Ishihara T, Masuda N

P5-02-06 Constitutively active HER2 signaling, ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulation of tumor microenvironment and breast cancer response to neoadjuvant therapy

Attalla SS, Pupa S, Boucher J, Pizzamiglio S, Dall-Proud H, Triulzi T, Castagnoli L, Cappelletti V, Izquierdo M, Rosa DD, de Azambuja E, Ciniselli CM, Roux P, De Santis MC, Colombo MP, Pruneri G, Tagliabue E, Verderio P, Muller W, Di Cosimo S

P5-02-07 Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis

Medford AJ, Velimirovic M, Niemierko A, Hensing WL, Davis AA, Clifton KK, Keenan JC, Dai CS, Kiedrowski LA, Shah AN, Gerratana L, Spring LM, Ellisen LW, Doebele RC, Cristofanilli M, Bardia A

P5-02-08 Biomarker associated with response to CDK4/6 inhibitors in metastatic hormone receptor positive breast cancer

Witkiewicz A

P5-02-09 Quantitative analysis of fiber-level collagen features in H&E whole-slide images predicts neoadjuvant therapy response in patients with HER2+ breast cancer

Nguyen TH, Mirzadeh M, Prakash A, Krause EL, Zhang J, Pyle M, Ogayo ER, Cramer III HC, Binboga Kurt B, Brosnan-Cashman J, Drage MG, Schnitt S, Beck AH, Montalto M, Wapinski I, Chambre L, Tolaney SM, Waks A, Lee J, Mittendorf EA

P5-02-10 In-silico approaches that detect immune contexture to trastuzumab response in neo-adjuvant studies

AlSultan D, Eustace AJ, Madden SF, Crown J

P5-02-11 Immune cell profile of tumors from patients with metastatic (met) HER2+ breast cancer (BC) with < 30 months overall survival (OS)

Collins DM, McCormack J, Ivers LP, Berenguer Pina JJ, Ballot J, Quinn C, Skrobo D, Dustace AJ, Walsh N, Fabre A, Crown J

P5-02-12 Prognostic relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy

Zhou Y, Zhou J, Shi H, Hu Z, Yang Y, Jiang Z, Wang T

P5-02-13 TRK inhibitor in a patient with metastatic triple negative breast cancer and NTRK fusions identified via cell-free DNA analysis

Keenan JC, Medford AJ, Oshry LJ, Boyraz B, Dai CS, Kiedrowski LA, Menshikova S, Butusova A, Gogakos T, Occhiogrosso R, Ryan P, Lennerz J, Spring LM, Moy B, Ellisen LW, Bardia A

P5-02-14 Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials

Andre F, Solovieff N, Su F, Bardia A, Neven P, Yap Y-S, Tripathy D, Lu Y-S, Slamon D, Chia SK, Joshi M, Chakravarty A, Lteif A, Taran T, Arteaga CL

P5-02-15 Withdrawn

P5-02-16 SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2- breast cancer

van Geelen CT, Teo ZL, Savas P, Luen SJ, Clarke KA, Sant S, Cowley KJ, Caramia F, Simpson KJ, Andre F, Dawson S-J, Pearson R, Loi S

P5-02-17 Prognostic and predictive role of RBSig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials

Malorni L, Benelli M, Liu Y, Deng S, Zhang Z, Guarducci C, Leo A, Nardone A, Galardi F, Risi E, Moretti E, Romagnoli D, Biagioni C, Paoli M, Biganzoli L, Migliaccio I

P5-02-18 HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome

Bottosso M, Sandoval RL, Verret B, Polidorio N, Caron O, Gennari A, Bychkovsky B, Hyman S, Achatz MI, Guarneri V, Andre F, Garber J

P5-02-19 ctDNA as dynamic marker of response to fulvestrant and everolimus in CDK4/6 inhibitor-pretreated ER+ HER2- metastatic breast cancer patients: a prospective study

Vasseur A, Hego C, Taka W, Trabelsi-Grati O, Lerebours F, Pierga J-Y, Loirat D, Brain E, Cottu P, Sablin M-P, Cabel L, Renouf B, Renault S, Bidard F-C

P5-02-20 Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial

Wang K, Zhu Y, Zerdes I, Matikas A, Sifakis e, Salgkamis D, Bjöhle J, Elinder E, Margolin S, Bosch Campos A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Johansson H, Hellström M, Azavedo E, Hartman J, Bergh J, Hatschek T, Foukakis T

P5-02-21 RAB5 is a generic biomarker for ADC efficacy

Engebraaten O, Medhus A, Longva A, Weyergang A, Berg K

P5-02-22 Circulating tumor DNA genotyping of intrinsic and acquired gene alterations in patients with advanced breast cancer receiving the cyclin-dependent Kinase 4/6 inhibitor Palbociclib: Biomarker results from POLARIS

Tripathy D, Blum JL, Deng S, McCune SL, Patel K, Wang Y, Lakhanpal S, Karuturi MS, Zhang Z, Deshpande C, Montelongo MZ, Gauthier E, Liu Y, Rocque GB, Bardia A

P5-02-23 Association of neutrophil-to-lymphocyte ratio and absolute lymphocyte count with clinical outcomes for patients with advanced breast cancer in the MONARCH 2 Trial

Tokunaga E, Miyoshi Y, Dozono K, Kawaguchi T, Toi M

P5-02-24 Whole genome sequencing of long-term, never relapse exceptional responders HER2+ advanced metastatic breast cancer

Andrieu C, Ivers LP, Berenguer Pina JJ, Skrobo D, Ballot J, Eustace AJ, Quinn C, Gullo G, Walsh N, Crown JP

P5-02-25 Transcriptional profiling of CTCs in metastatic breast cancer patients in the course of CDK4/6 inhibition

Kasimir-Bauer S, Gruber C, Moukas S, Tewes M, Kolberg H-C, Kimmig R, Keup C

P5-02-26 The 27-gene IO score is associated with pathologic complete response (pCR) in HR+/HER2- breast cancer patients treated with pembrolizumab in the I-SPY2 Trial

Seitz RS, Nielsen TJ, Ring B, Cronister CT, Varga MG, Bailey D, Dugo M, Bianchini G, Ross DT

P5-02-27 Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial

McCartney A, Biagioni C, Chen B, Shepherd L, Gelmon K, Joy AA, Parulekar W, Bergqvist M, Migliaccio I, Leo A, Benelli M, Risi E, Moretti E, Livraghi L, Biganzoli L, Malorni L

P5-02-28 P27Kip1 V109G single-nucleotide polymorphism (SNP): pinpointing the hormone-receptor positive breast cancer subpopulation that requires CDK4/6 inhibitors in addition to endocrine therapy

Quintela-Fandino M, Mouron S, Bueno MJ, Muñoz M, Torres R, Rodriguez S, Sánchez-Bayona R, Manso L, Silva J, Malumbres M

P5-02-29 Withdrawn

P5-02-30 Histology-based survival outcomes in HR+/HER2- metastatic breast cancer treated with targeted therapies plus endocrine therapy based on HER2 expression

Mouabbi J, Singareeka Raghavendra A, Bassett R, Hassan A, Tripathy D, Layman RM

P5-02-31 Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLT1 TOT-HER3 trial

Brasó-Maristany F, Falato C, Martínez-Sáez O, Cejalvo JM, Margelí M, Tolosa P, Salvador Bofill FJ, Cruz J, González-Farré B, Sanfeliu E, Arumí M, Villacampa G, Ciruelos E, Espinosa-Bravo M, Izaruzaga Y, Galván P, Matito J, Pernas S, Santhanagopal A, Esker S, Patel P, Fan P-D, Ferrero-Cafiero JM, Vivancos A, Pascual T, Prat A, Oliveira M

P5-02-32 Differential gene mutation landscape in patients With PIK3CA-altered and non-altered hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the SOLAR-1 clinical study

Juric D, Rugo HS, Reising A, Ma C, Ciruelos E, Loibl S, Singer CF, Sohn JH, Campone M, Conte P, Iwata H, Ghaznawi F, Miller M, Taran T, Su F, Andre F

P5-02-33 Deep learning-based assessment of HER2-low expression on breast cancer H&E digital whole slide images

Oakley III G, Reis-Filho J, Klimstra D, Goldfinger M, Wang Y, Marra A

P5-02-34 Single-cell analysis of KN026 in combination with KN046 in treating patients with advanced HER2-positive breast cancer

Liu J, Liao J, Tian Z, Wang J, Song C

P5-02-35 Radiomic biomarkers to predict the efficacy of anti-PD-1 immunotherapy-based combinational treatment in advanced breast cancer: a multi-center study

Liu J, Zhao J, Sun Z, Yu Y, Yuan Z, Yao H, Wang Y

P5-02-36 Proteogenomic profiling of fresh frozen core biopsies from CALGB 40601

Jaehnig EJ, Fernandez-Martinez A, Vashist T, Holt MV, Williams L, Lei J, Kim B-J, Dou Y, Korchina V, Gibbs R, Muzny D, Doddapaneni H, Rodriguez H, Robles A, Hiltke T, Mani D, Gillette M, Hyslop T, Wen Y, McCart L, Miles G, Carr S, Zhang B, Satpathy S, Ellis M, Anurag M

P5-02-37 Multi-omics approach to identify markers of resistance to endocrine therapy + CDK4/6 inhibitors in first line HR+/HER2- metastatic breast cancer (MBC) patients

Frenel JS, Ben Azzouz F, Bigot F, Dauve J, Heymann MF, Gouraud W, Guette C, Lasla H, Michel B, Morel A, Patsouris A, Robert M, Siekaniec G, Colombie M, Jézéquel P, Campone M

P5-02-38 Leptin receptor (Ob-R)/leptin axis significantly modulates tumour-infiltrating lymphocytes (TILs) and PD-1 expression in early HER2+ breast cancer (BC) emerging as a new surrogate marker for immunotherapy

García-Estévez L, Fernández A, Palacios J, Sampayo M, Calvo I, Díaz E, González M, Pérez-Mías B, González S, Pérez-García JM, Cortés J, Moreno-Bueno G

P5-02-39 Efficacy of fulvestrant-based therapies in treating HR-positive, HER2-negative breast cancer with liver metastasis

Chien C, Madak-Erdogan Z, Goel M, Gangidi S, Tripathy D, Singareeka Raghavendra A

P5-02-40 Anthracycline improves the outcome of neoadjuvant trastuzumab-treated breast cancer patients with FcyRIIIA F/F genotype by decreasing the ratios of CD8+PD1+ and CD68+PDL1+ cells

Lee K, Luo R, Lu Q, Wang S, Xu F

P5-02-41 UBE2E3 promotes the progression of HER2-positive breast cancer and influences the efficacy of targeted therapy via EGFR stabilization

Li P, Chi W-R, Xiu B, Zhang Q, Zhang L, Chen M, Xue J, Huang X, Chi Y, Wu J

P5-02-42 Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR)

Mukohara T, Ozaki Y, Kitano S, Yamashita M, Ikarashi D, Tsurutani J, Iwasa T, Takahashi M, Masuda N, Futamura M, Minami H, Matsumoto K, Tanabe Y, Kawabata H, Yoshimura K, Takano T

P5-02-43 Incidence of HER2-low expression in HR-positive/HER2-negative and triple-negative breast cancers in the integra connect database

Fares M, Gart M, Blanc S, Zheng J, Saunders W, Smith R, Vasudevan A, English S

P5-02-44 Efficacy analysis of CDK4/6 inhibitors in combination with endocrine therapy treatment in HR+/HER2- breast cancer according to PAM50 intrinsic subtype: primary results of SOLTI-1801_CDK-PREDICT study

Tolosa P, Pascual T, Hernando C, Servitja S, Fernández A, Brasó-Maristany F, Benitez J, Lema L, Ruano Y, Parrilla L, Roncero AM, Sánchez-Bayona R, Alva M, Villacampa G, Moreno-Villa MR, Canes J, Salvador F, Prat A, Ciruelos E

P5-02-45 An HRD scoring system based on long-focal copy number alterations predictive of PARP inhibitor response

Gurileva M, Kotlov N, Love A, Melnikova A, Nomie K, Fowler N, Bagaev A

P5-02-46 Targeted capture sequencing allows sensitive genomic profiling of circulating tumor DNA in advanced HR+/HER- breast cancer patients

Dandachi N, Graf R, Potocnik N, Pancheri L, Klocker E, Suppan C, Jost P, Gerritsmann H, Heitzer E, Balic M

P5-02-47 Quantitative proteomic analysis of plasma exosomes from patients with advanced hormone receptor-positive/HER2-negative breast cancer receiving palbociclib and tamoxifen

Zhang Z, Ma X, Ekiert J, Mohapatra G, Coleman L, Truica CI, Blaes A, Rana J, Pavankumar T, Green L, Yu M, Toppmeyer D, O'Regan R, Wisinski KB, Danciu OC, Hoskins K, Gao Y

P5-02-48 Identifying immune-related predictive factors for paclitaxel + bevacizumab therapy in patients with HER2-negative advanced breast cancer- A multicenter retrospective study

Watanabe J, Sugino T, Muramatsu K, Morita S, Hidaka Y, Nakamoto S, Ito M, Ohtani S, Ikeda M

P5-02-49 Efficacy of subsequent-abemaciclib treatment after disease progression on palbociclib combined with endocrine therapy in patients with ER-positive HER2-negative metastatic breast cancer

Seki H, Nakai T, Shimizu K

P5-02-50 Do thymidine kinase 1 (TK1) plasma concentration and activity play a role in therapy management of metastatic breast cancer patients treated with CDK4/6 inhibitors?

Moukas S, Dohn M, Kimmig R, Tewes M, Kolberg H-C, Kasimir-Bauer S, Keup C

P5-02-51 Single-cell transcriptome reveals distinct peripheral blood immune landscapes associated with sensitivity to anti-HER2 treatment in HER2-positive metastatic breast cancer patients

Lee J, Choi J, Park IH

P5-02-52 Predictive and prognosis value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors (TKIs): a systemic review and meta-analysis

Shi Q, Xuhong J, Tian H, Zhang Y, Jiang J, Qi X

P5-02-53 P95HER2 expression in HER2-positive breast cancer

Goh CW, Zhang L, Chi W-R, Xiu B, Chen J, Yang W, Ao C, Tang J, Xue J, Chi Y, Wu J

P5-02-54 Application of low-pass whole genome sequencing for the detection of homologous recombination deficiency in breast cancer

Belbin G, An J, Mazur C, Pickrell J, Li J, Metzger D, Gao S, Van Roey E, Seager R, Pabla S, Dash DP, Conroy JM

P5-02-55 Withdrawn

Epidemiology, Risk, and Prevention: Epidemiology - Genetic and Molecular

P5-03-01 Long-term oncologic outcome of unselected triple-negative breast cancer patients according to BRCA1/2 mutations: a comprehensive single institution study

Chung SY, Ryu JM, Jung YJ, Kim YJ, Kim HJ, Nam SJ, Kim SW, Yu J, Chae BJ, Lee JE, Lee SK, Kim S-W, Kim EY

P5-03-02 Adiposity and immune-related gene expression in the breast tumor microenvironment

Cespedes Feliciano EM, Zimbalist A, Cheng E, Caan BJ, Chen WY, Mittendorf EA, Pimenta Peixoto RB, Domingos TA, Taneja K, Patel A, Dillon DA

P5-03-03 Variant classification discordance: A real-world experience of genetic test results in a community-based setting

Cummings S, Mundt E, Miller AM, Bauman T, Slavin T, Maganini R

P5-03-04 PIK3CA mutation prevalence in hormone receptor positive breast cancer patients in United Arab Emirates

Azribi F, Hourani M, Magdub S, Alawadhi A, Yousif A, Dawoud E, Al Qawasmeh K, Al Ameri M, Trad D, Bennini N, Ahmed M, Ansari J

P5-03-05 Distinct molecular differences between African American/Black and White women with triple negative breast cancer

Park SH, Khalife R, White E, Magliocco A

P5-03-06 Effect of sleep traits on subtype specific breast cancer survival: A Mendelian randomization analysis

Hayes B, Martin R, Lawlor D, Richmond R, Robinson T

P5-03-07 Prevalence of pathogenic variants in cancer predisposition genes in women with young onset breast cancer

Metcalfe K, Quan ML, Narod S, Warner E, Friedenreich C, Baxter N, Poll AJ, Akbari M

P5-03-08 Joint associations of mammographic breast density and obesity on the presence of crown-like structures in the breast adipose tissue of breast cancer patients

Maliniak ML, Seidel RL, Bertrand K, McCullough LE

P5-03-09 Cell composition changes in healthy breast tissue is associated with advancing age and epigenetic age acceleration

Sehl ME, Guo W, Farrell C, Marino N, Henry J, Storniolo AM, Papp J, Li J, Horvath S, Pellegrini M, Granz PA

P5-03-10 Moved to HER2 Session

P5-03-11 The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer

Hjorth C, Damkier P, Stage TB, Feddersen S, Hamilton-Dutoit S, Ejlersen B, Lash TL, Bøggild H, Sørensen H, Cronin-Fenton D

P5-03-12 DNA repair genes are more frequently mutated in non-white populations of metastatic breast cancer (MBC) patients

Hilley S, Dunetz R, Blais E, Pierobon M, Petricoin EF, Baldelli E

P5-03-13 Circular RNAs express heterogeneously across different breast cancer subtypes and correlate with invasive disease-free survival

Li JL, Yoshimatsu TF, McClellan JC, Zhao F, Zheng Y, Olopade OI, Huo D

P5-03-14 Prevalence of germline BRCA mutations in unselected Korean patients with HER2-negative breast cancer: A Prospective cohort study

Ahn HK, Kim JH, Kim M, Park S, Koh S-J, Sohn JH, Kang MJ, Jung KH, Lee KE, Lee J, Koh SA, Chae YS, Byun JH, Park IH, Kim H-J, Kim JH, Kim HJ, Jung JY, Lee JL, Cho YY, Park KH, Kim J-Y, Im S-A, Park YH

P5-03-15 Application of 21-gene Breast Recurrence Score® assay to evaluate prognosis and benefit of adjuvant chemotherapy in BRCA1 and BRCA2 pathogenic variant carriers with early stage, estrogen receptor positive breast cancer

Saha P, Aller A, Deliere A, Hulick P, Yao K, Kuchta K, Sullivan M, DePersia A

P5-03-16 Changes in preferences for ovarian cancer prevention strategies during the COVID-19 pandemic: Results of a discrete choice experiment

Egleston B, Daly M, Lew K, Bealin L, Husband A, Stopfer J, Przybysz P, Tchuvatkina O, Wong Y-N, Garber J

P5-03-17 BRCA1/2 gene mutations in patients with high-risk breast cancer in a tertiary-level hospital in Guatemala

Alvarado-Muñoz J, Reyes-Morales A, Chivalan M, Torselli S, Valenzuela H, Yalibat G, Ordoñez M, León R, Alvarez E

P5-03-18 Co-occurring alterations in PALB2 germline carriers identified by liquid biopsy in patients with advanced breast cancer

Chen N, Nanda R, Howard FM, Vidula N, Yen J, Drusbosky LM, Bucheit L

P5-03-19 Frequency of germline TP53 p.R337H variant among women at risk of hereditary breast cancer in a public health system of Central-West of Brazil

Correa TS, Sandoval RL, Oliveira ES, Leite ACR, Nardin Weis L, Achatz MI, Oliveira CP, Asprino PF, Barroso-Sousa R

P5-03-20 Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations

Kim J, Jeong K, Jun H, Kim K, Kim T-Y, Lee D-W, Woo G-u, Park S, Yi H, Lee K-H, Im S-A

P5-03-21 A comparison of breast cancer survival across different tumour biology in young women: A multicentric database study in Klang Valley, Malaysia

See MH, Rajehgopal P, Teh MS, Lai LL, Yahya A

P5-03-22 BRCA1/2 germline pathogenic variants in triple negative breast cancer patients according to age and family history: The Cancer Genetic Centre experience of Pisa University Hospital (AOUP)

Sidoti D, Fratini B, Roncella M, Michelotti A, Ghilli M, Landucci E, Caligo MA

Detection and Diagnosis - Imaging and Screening: Screening

P5-04-01 Screening patterns of mammography and breast magnetic resonance imaging following cancer genetic testing in an integrated health care system

Guo B, Knerr S, Wernli K, Mittendorf K, Feigelson H, Gilmore M, Jarvik G, Kauffman T, Keast E, Liles B, Lynch F, Muessig K, Sasaki S, Veenstra D, Zepp J, Wilfond B, Goddard K, Devine B

P5-04-02 Comparative analysis between screening mammography performed in patients at usual risk and patients at high risk for breast cancer in the early detection program for breast cancer in Brazil

Antonini M, Pannain GD, ferraro O, Coelho Lopes RG, Mattar A, Real JM

P5-04-03 Analyzing the performance of Thermalytix, an AI-based breast cancer screening solution, in a community setting

Manjunath G, Krishnan L, Deshpande G, Madhivanan P, Krupp KF

P5-04-04 Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?

Beltran-Bless A-A, Alshamsan BI, Alzahrani M, Hilton J, Baines K-A, Samuel V, Pond GR, Vandermeer L, Clemons M, Larocque G

P5-04-05 Predictors of guideline-incongruent breast cancer screening in an urban comprehensive cancer center

Wehbe A, Gonte M, O'Neill S, Amit-Yousif A, Purrington K, Manning M, Simon M

P5-04-06 Breast imaging recommendations for females < 40 years of age with #20% lifetime breast cancer risk: Practice patterns at a specialized clinic

Wehbe A, Laws A, Katlin F, Sharma E, Hans M, Graichen M, Bychkovsky B, Scheib R, Garber J, Pace L, King T

P5-04-07 Comparison of performance metrics of prevalence versus incidence screening contrast enhanced mammograms

Fruchtman Brot H, Keating D, D'Alessio D, Jochelson MS, Dixon L, Comstock C, Sung J

P5-04-08 Breast cancer screening using ultrasound increases recall, biopsy, and cancer detection rates

Staub J, Soonavala R, Dacosta Byfield S, Badal K, Catlett K, Maffey L, Kim M-O, Wimmer K, Shieh Y, Esserman LJ

P5-04-09 Analysis of an update to a novel breast cancer screening web-app

Muñoz Lozano JF, Zayas Villanueva O, Abundis Marquez E, Alcorta Nuñez F, Noriega MF, Salazar Mejia C, Gonzalez Alcorta CB, Pérez Ibave DC, Oyervides Juarez V, Renteria Garcia LM, Alcorta Garza A, Gonzalez Guerrero JF, Hernandez D, Piñeiro Retif R, Vidal Gutiérrez O

P5-04-10 Consensus guidelines for breast cancer staging during pregnancy. A Delphi Study

Herbison HR, Miller A, Shnier D, Greenberg S, Devitt B

Detection/Diagnosis - Pathology: Circulating BioMarkers and ctDNA

P5-05-01 Personalized Cancer Monitoring (PCM): A novel ctDNA tool to detect molecular residual disease in patients with early-stage breast cancer

Garcia-Murillas I, Walsh-Crestani G, Phillips E, Cutts R, Hrebien S, Dunne K, Sidhu K, Daber R, Carter AC, De La Peña L, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N

P5-05-02 Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study

Damodaran S, Moore H, O'Sullivan CC, Plourde pv, Riordan G, Sloan HS, Tripathy D, Carroll D, Portman DJ

P5-05-03 Characterization of the genomic landscape of breast carcinoma patients with NF1 alterations using comprehensive cell-free tumor DNA next-generation sequencing

Chang E, Tsai J, Lim B

P5-05-04 Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene or fulvestrant in the ELAINE 1 study

Goetz MP, Gal-Yam E, Stover DG, Sammons SL, Graff SL, Wang G, Cristofanilli M, Riordan G, Sloane HS, Carroll D, Plourde PV, Portman DJ

P5-05-05 Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing

Magbanua MJM, Rugo HS, Brown Swigart LA, Ahmed Z, Hirst GL, Wolf DM, Lu R, Kalashnikova E, Renner D, Rodriguez A, Liu MC, Yau C, Esserman LJ, Van 't Veer L, DeMichele A

P5-05-06 ctDNA detection in seven different types of body liquids in patients with metastatic breast cancer

Richard F, Geukens T, De Schepper M, Mahdami A, Van Baelen K, Maetens M, Nguyen H-L, Pabba A, Leduc S, Isnaldi E, Hajipirloo M, Vanden Berghe E, Bachir I, Hatse S, Vermeulen P, Vanderheyden E, Boeckx B, Lambrechts D, Smeets A, Nevelsteen I, Punie K, Neven P, Wildiers H, Van Den Bogaert W, Biganzoli E, Floris G, Desmedt C

P5-05-07 Assessment of immune checkpoint expression on the peripheral blood mononuclear cells (PBMCs) of patients with breast cancer (BC)

Papadaki MA, Monastirioti A, Apostolopoulou CA, Agelaki S, Mavroudis D

P5-05-08 Dual ctDNA and tissue sequencing improves detection of actionable variants in breast cancer patients

Mackay M, Manghnani K, Hockenberry A, Drews J, Chen J, Ben-Shachar R, Guinney J

P5-05-09 Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer

Shishido S, Kuhn P, Mason J, Hicks J, Nevarez R, Matsumoto N, Kolatkar A, Ruiz Velasco C, Anderson A, Kidd M, Wilkinson K, Hwang ES, Lu J, Nieva J, Higa N, Naghdloo A, Hart O, Setayesh SM

Detection/Diagnosis - Pathology: Circulating Tumor Cells

P5-06-01 A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the Parsortix® PC1 System in support of FDA clearance

Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang JE, Khoury J, Press MF, McBride H, Kim KK, Khazan N, Zhang Q, Zhang Y, Guzman R, Miller MC, Reuben J, Ueno NT

P5-06-02 Circulating tumor cells in metastatic breast cancer highlight potential role of copy number evolution in late-stage cancer mutational profile

Chong W, Luo R, Zhang Z, Abu-Khalaf M, Silver D, Fellin F, Jaslow R, Lopez A, Cescon T, Myers R, Becker M, Wei Q, Li B, Wang C, Yang H

P5-06-03 Analyzing the results of liquid biopsy in the identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: comparison and combination of cell and cell-free platforms

Di Caro G, Lam ET, Slade MM, Lundberg A, Blankfard M, Dharajiya N, Tubbs A, Wenstrup R, Schwartzberg L

P5-06-04 The prognostic value of c-MET monitoring by using c-MET-enriched circulating tumor cells in HR-positive HER2-negative metastatic breast cancer

Park J, Chang ES, Kim J-Y, Chelakkot C, Sung M, Song J-Y, Jung K, Kim NY, Lee H, Kang M-R, Park YH, Shin YK, Choi Y-L

P5-06-05 Whole-genome bisulfite sequencing of single circulating tumor cells identifies cellular methylation heterogeneity in metastatic breast cancer

Luo R, Chong W, Zhang Z, Abu-Khalaf M, Silver D, Fellin F, Jaslow R, Lopez A, Cescon T, Ip K, Myers R, Wei Q, Li B, Wang C, Yang H

P5-06-06 TROP2 and HER2 expression by liquid biopsy in women with mTNBC

Bourdon D, Cunsolo A, Guillory B, Slade MM, Di Caro G, Tubbs A, Iwase T, Ueno NT

Psychosocial, QOL, and Educational Aspects - Quality of Life Issues: QOL - Supportive Care

P5-07-01 Outcomes of multidisciplinary team approach and intensive patient education in young women with breast cancer to improve the rate of fertility preservation

Lee YJ, Han H, Kim HJ

P5-07-02 Embryo utilization in young breast cancer patients who have undergone egg harvesting for fertility preservation

Weltz C, Nevid D, Pruzan A, Port E, Couri R

P5-07-03 The association between symptom severity and physical function among participants in I-SPY2

Basu A, Umashankar S, Blevins K, Northrop A, Christofferson A, Olunuga E, Cha J, Mittal A, Molina-Vega J, Sit L, Brown T, Parker B, Heditsian D, Brain S, Simmons C, Taboada A, Hieken TJ, Ruddy KJ, Salvador C, Mainor C, Afghahi A, Tevis S, Blaes A, Kang IM, Perlmutter J, Rugo HS, Kanaparthi S, Peterson G, Weiss LT, Asare A, Esserman LJ, Melisko M, Hershman DL

P5-07-04 Evaluation of treatment choices at baseline among breast cancer patients based on the frailty status of the patients

Kaur J, Galaznik A

P5-07-05 Improving health-related quality of life with outpatient high-dose Methotrexate regimen among solid tumor oncology patients with intracranial metastases: A qualitative study

Min H, Weil E, Nelson M, Charlson J, Conroy M, Powell M, Cheng YC, Chaudhary LN, Burfeind J, Retseck J, Sriram D, Kamaraju S

P5-07-06 Prospective cohort of breast cancer patients exposed to a navigation program for timely access to referral services in Mexico

Mesa-Chavez F, Rochelle-Palacios E, Canavati-Marcos M, Villarreal-Garza C

P5-07-07 Feasibility of a whole-food, plant-based intervention among women with metastatic breast cancer and its effect on patient-reported outcomes

Campbell T, Campbell E, Culkova E, Wixom N, Guido J, Blanchard L, Janelsins M, Mustian K, Fettes J, Peppone L

P5-07-08 Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer

Farooq F, Cason D, Ohri N, Kumar S, Grann A, Litvak A, Ganesan S, Haffty BG, Toppmeyer D, Omene C, George MA

P5-07-09 Fatigue in patients with locally advanced or metastatic breast cancer undergoing single-agent taxane-based chemotherapy: de novo versus relapsed

Blaes A, Gavioli EM, Wakade R, Miracle S, DiTuri G, DePizzolo M, Ruffini PA, Sergio F, Leone M, Mantelli F, Allegrretti M, Fabi A

P5-07-10 Symptom and functional status for individuals with triple negative breast cancer and palliative care utilization: Findings from the Cancer Experience Registry

Popalios ML, Badt H, Doughtie K, Lawrence C, Miller MF

P5-07-11 Referral patterns of metastatic breast cancer patients to palliative care team at a cancer center in Brazil

Gomes SA, Silva DN, Passarini T, Petrocchi JA, de Paula MM, de Sá JS, Costa e Silva M, Coelho TA, de Aquino RL, Sorice FS, Santos P, Madureira D, Martins E, Cruz H, Ferrari BL

P5-07-12 Patient-reported symptom burden in women undergoing treatment for early stage and metastatic breast cancer

Kaufmann T, Galaznik A, Coombs N, Rocque GB

P5-07-13 Effect of a 12 week virtual supervised exercise program on cardiorespiratory fitness in breast cancer patients undergoing chemotherapy: Results from the STRENGTH Trial

Teplinsky E, Podolski A, Bessada K, Rutledge J, Burke B, Christoudias M, Klein L, Abbate K

P5-07-14 A pilot study of novel approach of intraneural facilitation versus standard physical therapy for prevention of chemotherapy induced peripheral neuropathy

Ran Castillo D, Jeon WJ, Luceno CF, Bussell M, Coleman R, Pieters K, Hankins J, Boggs A, Garcia L, Dehom S, D'Errico E, Nagaraj G

P5-07-15 Impact of integrative therapies on patients with metastatic breast cancer

Andac-Jones E, Gonzalo MB, Kelly G, Weldon S

Psychosocial, QOL, and Educational Aspects - Quality of Life Issues: Survivorship Research

P5-08-01 Pilot study of a patient-reported outcome (PRO) measurement strategy to determine impact of screening for minimal residual disease (MRD) in high-risk breast cancer survivors

Kaufmann T, Chang P, Rosenberg SM, Frank E, Hobbs B, Bayne LJ, Nivar I, Goodspeed BL, Rohn KM, Kugler EM, Fox K, Domchek SM, Bradbury A, Shah PD, Knollman h, Jankowitz RC, Makhlin I, Clark AS, Chodosh LA, DeMichele A

P5-08-02 Withdrawn

P5-08-03 Sexual health in long-term breast cancer survivors - a comparative study

Smedsland SK, Vandraas K, Falk R, Kiserud C, Brekke M, Dahl A, Reidunsdatter R, Horn J, Reinertsen K

P5-08-04 Mammo-50: Mammographic surveillance in early breast cancer patients aged over 50 years – patient reported outcomes 3 years post diagnosis

Campbell AF, Marshall A, Dunn JA, Donnelly PK, Evans AJ, Elbeltagi NI, Cameron DA, Audisio RA, Turner L, Watson E, Gasson SJ, Young AM, Thompson AM, Mammo-50 Trial Management Group

P5-08-05 Conception and pregnancy among young breast cancer survivors

Sorouri K, Sella T, Rosenberg SM, Loucks M, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Partridge AH

P5-08-06 Breastfeeding in survivors of early breast cancer

Sella T, Sorouri K, Rosenberg S, Loucks M, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Warner E, Partridge AH

P5-08-07 Dietary patterns among women with early-stage breast cancer from the Healthy Living Program

Liu B, Shen S, Salehi E, Chen Y, Toumbacaris N, Allsop J, Anselmo C, Corcoran S, Kelly B, Magnoli R, Smith A, Emerzian M, Brockway-Marchello J, Bacotti D, Robson ME, Iyengar NM

P5-08-08 Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with sub-acromion-deltoid bursitis: a pilot randomized clinical study

Lippi L, De Sire A, Folli A, D'Abrosca F, Turco A, Bonizzi G, Fusco N, Invernizzi M

P5-08-09 Does breast inflammation contribute to lymphedema risk in patients treated with axillary lymph node dissection?

Barrio AV, Montagna G, Sevilimedu V, Gomez E, Giri D, Mehrara B, Morrow M

P5-08-10 Safety and tolerability of Paxman scalp cooling at lower temperatures to improve efficacy with Anthracycline chemotherapy

Goldfarb SB, Blinder V, Gajria D, Chang C, Dacunto A, Park J, Fournier M, Lacouture M

P5-08-11 Objective comparison of post-operative activity after sentinel lymph node biopsy versus axillary lymph node dissection using wearable activity monitors – The 'BRACELET' Study

Che Bakri NA, Kwasnicki R, Tenang L, Giannas E, Dhillon K, Darzi A, Leff D

P5-08-12 Lifestyle factors and patient-reported outcome measures using the European Organisation for Research and Treatment of Cancer survivorship questionnaire in early breast cancer patients attending for surveillance imaging

Waterhouse JV, Pattarakuzhyil Jose J, Snuggs N, White A, Harper K, van Leeuwen M, Ring A

P5-08-13 Frequency of low bone mineral density in young women with breast cancer and associated factors

Mesa-Chavez F, Chavarri-Guerra Y, Ruiz-Cruz S, Cabrera-Galeana P, del Rio-Martinez CJ, Bermudez-Barrientos CG, Moreno-Jaime B, Samayoa-Mateos A, Vega-Morales D, Villarreal-Garza C

P5-08-14 Blockade of CD47/Thrombospondin-1 signaling increases glycolytic metabolism as a protective mechanism against chemotherapy-associated cardiac injury in a model of triple-negative breast cancer

Bronson SM, Mackert JD, Kooshki M, Wilson AS, Cruz-Diaz N, Triozzi PL, Thomas A, Cook KL, Soto-Pantoja DR

P5-08-15 Reducing rates of chronic breast cancer related lymphedema with screening & early intervention: An update of recent data

Whitworth P, Vicini F, Valente S, Brownson K, Dupree B, Kohli M, Lawson L, Shah C

P5-08-16 "It's like Coming Home": A qualitative evaluation of project life a virtual wellness community for people living with metastatic breast cancer

Roberson M, Woods J, Glenn L, James D, Maues J

P5-08-17 Monitoring for cardiotoxicity in early breast cancer: an Australian experience

Kirwin B, Pugliano L, Baron Hay S

P5-08-18 A novel free-to-use software for upper limb volume quantification in breast cancer related lymphedema: implementing cutting-edge technology in the individualized therapeutic approaches of breast cancer survivors

Lippi L, Nascimben M, de Sire A, Folli A, Fusco N, Rimondini L, Invernizzi M

Treatment - Therapeutic Strategies: Neoadjuvant Endocrine Therapy

P5-09-01 Neoadjuvant hormonal therapy plus palbociclib versus hormonal therapy plus placebo in women with operable, hormone sensitive and HER2-negative primary breast cancer

Ueno T, Chow LWC, Han W, Huang CS, Mann GB, Morita S, Haga H, Fakhrejehani E, Kobayashi T, Bando H, Inoue K, Tokiwa M, Suwa H, Aruga T, Minamiguchi S, Yamada Y, Tanabe Y, Takada M, Yamashita T, Iwata H, Chung C-F, Takahara S, Tokunaga E, Imoto S, Lee ES, Sagara Y, Kim JH, DeBoer RH, Kim H-A, Lai HW, Hou M-F, White M, Umeyama Y, Toi M

P5-09-02 Impact of neoadjuvant endocrine therapy on tumor transcriptome in patients with early-stage breast cancer from the FLEX trial

Habibi M, Jelovac D, Couzi R, Augusto Santa-Maria C, Klein C, White M, Naik N, Wei J, Huynh Y, Ellappalayam A, Blumencranz LE, Yoder EB, Dauer P, van der Baan B, Audeh W

P5-09-03 Real world data on neoadjuvant endocrine treatment and Ki67 assessment in ER+/HER2- breast cancer. results from a single-institution prospective cohort study

Marti C, Frias L, Loayza A, Moreno E, Meléndez M, Sanchez-Mendez JJ

P5-09-04 Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with hormone-responsive and HER2-negative, lymph node-negative breast cancer

Gu C, He Y, Li J, Wang T, Fan Z, Ouyang T

P5-09-05 A phase II, single-arm study of histone deacetylases inhibitor Tucidinosat and Exemestane as neoadjuvant therapy in patients with hormone receptor positive HER2 negative breast cancer (NeoTEE trial)

Shan Z, Shao N, Zhang X, Shi H, Zheng Y, Luo J, Zhen T, Chen R, Lin Y

Treatment: Therapeutic Strategies - Antiangiogenic Therapy (Adjuvant and Metastatic)

P5-10-01 Phase 2 study of anlotinib combined with taxanes and lobaplatin in the neoadjuvant treatment of triple-negative breast cancer: efficacy, safety and biomarker analysis from the SWH-B006 (neoALTALL) trial

Liang Y, Liu J, Luo T, Ge J, Tian H, Zhang G, Fan L, Ren L, Chen L, Tang P, Zhu K, Bian X, Jiang J, Zhang Y, Qi X

Tumor Cell and Molecular Biology: Epithelial-Mesenchymal Transition

P5-11-01 Epithelial-mesenchymal plasticity is regulated by inflammatory signaling networks coupled to cell morphology

Yin Z

P5-11-02 Withdrawn

P5-11-03 Knockdown of TMEM45A regulates malignant progression of triple-negative breast cancer by inhibiting TGF- β /Smad signaling pathway-mediated EMT

Xu Y, Liu S

P5-11-04 Differentially expressed genes and their pathways in breast cancer patients with mesenchymal CTC

Mego M, Hadzega D, Minarik G, Soltysova A, Nemcova P, Kalavska K, Karaba M, Benca J, Sedlackova T, Pindak D, Klucar L

Tumor Cell and Molecular Biology: Genetics - Germline Changes

P5-12-01 MUTYH in a cancer population

Smith LA

P5-12-02 Germline variants detected by next-generation sequencing-based multigene panel testing in patients with suspected hereditary breast cancer at a University Hospital in Japan

Atake Y, Nagahashi M, Kanaoka H, Hattori A, Bun A, Fukui R, Ozawa H, Fujimoto Y, Higuchi T, Imamura M, Murase K, Takatsuka Y, Kashima M, Okada C, Kinjo C, Miyata M, Miyazaki A, Ueda M, Tsubamoto H, Sawai H, Miyoshi Y

P5-12-03 Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers

Batalini F, Gulhan DC, Katopodi XL, Kalavros N, Tran A, Karagkouni D, Stern-Gatof E, Schnitt S, Garber JE, Wulf GM, Park PJ, Vlachos I, Tung N

P5-12-04 Withdrawn

P5-12-05 Gestation and breast cancer in women with mutations in DNA repair genes: Is there any relationship?

López-herrero López M, Morales Estévez C, Armenta Triviño A, Contreras MJ, Gómez Aguilera M, Rodríguez Alonso B, Porras I, de la Haba-Rodríguez; Arranda Aguilar E

Tumor Cell and Molecular Biology: Genetics - Germline Changes

P5-12-06 Comprehensive analysis of DNA damage repair gene germline mutations in Chinese breast cancer patients

Liao N, Cao L, Zhang G, Wang J, Yang A, Wang Y, Li K, Wen I, Ren C, Jia M, Li C, Mok H, Chen B, Lai J, Xiao W

P5-12-07 Polygenic Risk Score in a cohort of 105 breast cancer patients previously tested with a multi gene panel for hereditary cancer

Tsoulos N, Agiannitopoulos K, Goga H, Troupis T, Markopoulos C

Tumor Cell and Molecular Biology: Genetics - Somatic Changes

P5-13-01 Tumor progression model in breast cancer with brain metastasis

Varuzza MB, Evangelista AF, Souza CP, Marques MC.

P5-13-02 Moved to HER2 Session

P5-13-03 Real-world clinico-genomic data reveal differences in genomic landscape associated with CDK4/6 inhibitors in HR+/HER2- breast cancer

Chaudhary N, Mecalfe C, Hafner M

P5-13-04 Clonal evolution of mammary epithelial cells into breast cancers

Nishimura T, Kakiuchi N, Yoshida K, Sakurai T, Kataoka TR, Kondoh E, Chigusa Y, Kawai M, Sawada M, Inoue T, Takeuchi Y, Maeda H, Baba S, Shiozawa Y, Saiki R, Nakagawa MM, Nannya Y, Ochi Y, Hirano T, Inagaki-Kawata Y, Aoki K, Hirata M, Suzuki E, Takada M, Kawashima M, Kawaguchi K, Chiba K, Shiraishi Y, Miyano S, Mandai M, Takeuchi K, Haga H, Toi M, Ogawa S

P5-13-05 Profiling of APOBEC3 dysregulation in breast cancer

Hamidi H, Khosh A, Rahimi H, Ebrahimi D

P5-13-06 Overexpression of somatic mutation in NSDHL promotes breast cancer cell migration and tumor growth

Baek M, Kim HS, Yoon S-H, Ryu S, Lee S, Park K, Lee H-B, Han W

Tumor Cell and Molecular Biology: Genomics

P5-14-01 Transcriptomic insights into lobular breast cancer biology: a retrospective analysis of the MINDACT clinical trial

Desmedt C, Nguyen H-L, Richard F, Linn S, Metzger O, Poncet C, Wesseling J, Hilbers F, Aalders K, Delorenzi M, Delaloge S, Pierga JOY, Brain E, Vrijaldenhoven S, Neijenhuis PA, Van Baelen K, Maetens M, Rutgers E, Piccart M, Van 't Veer L, Viale G, Cardoso F

P5-14-02 Identifying oncogenic enhancer elements in TNBC of the Basal-like subtype using single-cell ATAC-seq and RNA-seq

Regner MJ, Thennavan A, Wisniewska K, Garcia-Recio S, Mendez-Giraldez R, Spanheimer P, Perou CM, Franco HL

P5-14-03 Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study

Morganti S, Jin Q, Santos K, Gibson C, Patel A, Wilson A, Merrill M, Vincuilla J, Stokes S, Lipsyc-Sharf M, Parker T, King T, Mittendorf EA, Curigliano G, Hughes ME, Tayob N, Lin NU, Miller P, Tolaney SM, Garber J, Parsons HA

P5-14-04 Genomic characterization of hormone receptor-positive advanced breast cancer with high tumor mutational burden: fresh-frozen tissue genomic analysis from MUTATION-1 study (KCSG BR17-04)

Kim MH, Yang Y, Kim E, Moon YW, Kim GM, Kim S-G, Chae YS, Lee J, Jeong JH, Lee K-H, Kim HJ, Jung JY, Koh S-J, Lee KE, Kim H-J, Park KH, Lim S, Park YH, Kim S, Sohn JH

P5-14-05 Moved to HER2 Session

P5-14-06 Tumor genomic landscape in older women with metastatic breast cancer (MBC)

Gupta HV, Freedman R, Hughes ME, Li YY, Kirkner G, Files JL, Strauss S, Garrido-Castro, Buckley L, Barroso-Sousa, Bychkovsky B, Tolaney SM, MacConaill L, Lindeman N, Johnson B, Myerson M, Winer EP, Dillon DA, Cherniack A, Lin NU

P5-14-07 Somatic mutations of ER and HER2 subtypes exhibit divergent evolutionary trajectories determined by selective epistasis revealed in phylogenetic reconstruction and stage-specific analyses

Dasari K, Fisk JN, Townsend J

P5-14-08 Machine learning based histopathology images analysis reveals cancer stemness in TNBC patient with 17p loss

Dong T, Liu J, Fang Y, Liu Z, Lu X, Huang K

P5-14-09 Comparison of cell-free DNA genomics of breast cancer associated-chest wall disease vs. age & subtype matched controls with metastatic breast cancer not involving the chest wall

Vidula N, Ryan L, Niemierko A, Juric D, Isakoff SJ, Verdial F, Azin M, Petrillo LA, Moy B, Ellisen LW, Demehri S, Bardia A

P5-14-10 Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases

Giannoudis A, Sokol E, Ramkissoon S, Bhogal T, Ross J, McGregor K, Razis E, Bartsch R, Huang RS, Palmieri C

P5-14-11 Rearrangements in CDH1, ESR1, and ERBB2 are commonly observed in breast cancer and may influence diagnosis and treatment

Sokol E, Jin D, Ross JS, Lee AV, Oesterreich S

P5-14-12 ESR1-alterations in HR+HER2- breast cancer patients

Basu G, Udhane SS, Dombrowski S, Hong L, Alyaqoub F, Barbi de Moura M, Chandrasekaran T, Dogruluk T, Driscoll D, Jalkanen A, Noel P, Szelinger S, Wang M, Hall D, Hoag J, Lobello J, Baehner F, Thakkar S, O'Shaughnessy J

P5-14-13 Benefits of Oncotype DX genomic screening in a geriatric vs. non-geriatric cohort. Analyzing key factors in therapy decision making process

Chiru ED, Grasic Kuhar C, Oseledchyk A, Kurzeder C, Vetter M

Tumor Cell and Molecular Biology: Mammary Development and Differentiation

P5-15-01 Rediscovering IRF5: A prognostic indicator with novel roles in mammary gland development, ribosome biogenesis, tumor initiation, and metastasis

Barnes B, Brune Z, Rice M, Somerville C

COMING SOON!

 **ORSERDU**[™]
elacestrant

GET UPDATES
AT ORSERDU.COM



ONGOING CLINICAL TRIALS POSTER SESSION 3

**THURSDAY, DECEMBER 8, 2022: 5:00 PM – 6:15 PM
HALL 1**

Ongoing Clinical Trials: Nonsurgical Treatment of Early Breast Cancer

OT3-01-01 A single-arm confirmatory study to evaluate the efficacy of non-surgical therapy for HER2 positive early breast cancer with clinical complete response after primary

Fujisawa T, Shigematsu H, Shien T, Iwata H, Sasaki K, Shibata T

Ongoing Clinical Trials: Novel Targets

OT3-02-01 Efficacy and safety of Larotrectinib in patients With Tropomyosin Receptor Kinase (TRK) fusion-positive breast cancer

Rosen EY, Italiano A, Chung HC, Orbach D, Lin JJ, De Miguel M, Norenberg R, Burcoveanu D-I, Mussi CE, Shen L, Drilon A

Ongoing Clinical Trials: Oncolytic Virus Therapy

OT3-03-01 Phase I study of intratumoral administration of CF33-hNIS-antiPD-L1 (CHECKvacc) in patients with metastatic triple negative breast cancer

Yuan Y, Rand JG, Zhang J, Kessler J, Modi B, Pillai R, Egelston CA, Chaurasiya S, Murga M, Tang A, Martinez N, Meisen H, Yamauchi D, Yost SE, Chong L, Seiz A, Nixon B, Ede N, Waisman J, Stewart D, Sedrak MS, Fong Y

Ongoing Clinical Trials: Ovarian Suppression

OT3-04-01 A Phase 3 study evaluating ovarian suppression following three-month leuprolide acetate in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA)

Turncliff R, Hamilton E, Lynch K, Atkinson SN

Ongoing Clinical Trials: PARPi Resistance Markers

OT3-05-01 Adaptive multi-drug treatment of evolving cancers (AMTEC): A phase II, open-label, study of Olaparib in combination with either Durvalumab, Selumetinib or Capivasertib, or Ceralasertib monotherapy in patients with metastatic TNBC

Hobbs E, Mills G, Lim J, Klinger M, Siex K, Huszti S, Yang A, Galipeau D, Zheng C, Murray L, Goodford B, Marter-Sanders N, Olson A, Stommel J, Johnson B, Keck J, Kong B, Solanki A, Goodyear S, Corless C, Gray J, Zahi M

Ongoing Clinical Trials: Patient Education

OT3-06-01 Diminishing chemotherapy related side effects through patient education

Labe S, Vasekar M, Mikhail D, Jones G, Bhasker J, Singh P, Kanwar R, Hafiz S, Zhu J, Dailey H

Ongoing Clinical Trials: Patterns of Care - Brazil

OT3-07-01 Real-world data on first-line treatment of HR-positive, HER2-negative, metastatic breast cancer in Brazil (BRAVE Study / LACOG 0221)

Werutsky G, Reinert T, Rosa DD, Barroso-Sousa R, Resende H, Signorini PA, Martins Fagundes JG, Figueiredo JMB, Cronemberger E, Vieira AC, Santos Leal JH, Nardin Weis L, Thommen L, Jesus RG, Gössling G, Bines J

Ongoing Clinical Trials: PI3K Mutants

OT3-08-01 A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3K α H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress)

Juric D, Jhaveri K, Beeram M, Hamilton E, Chau V, Hanley MP, Liu S, Smyth LM, Meric-Bernstam F

Ongoing Clinical Trials: PI3K Mutants - Overcoming Resistance

OT3-09-01 Clinical trial of Alpelisib and Tucatinib in patients with PIK3CA-mutant HER2-positive metastatic breast cancer

Shagisultanova E, Wisinski KB, Gawryletz CD, Datko FM, Medgyesy D, Diamond JR, Borges VF, Kabos P

Ongoing Clinical Trials: Post-progression Treatment

OT3-10-01 Moved to **P4-01-42**

Ongoing Clinical Trials: Predictive Biomarkers

OT3-11-01 TK IMPACT: Treatment monitoring of hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients receiving CDK 4/6 inhibitors (CDK4/6i) with DiviTum® thymidine kinase 1 activity

Bagegni NA, Grigsby I, Nehring L, Luo J, Powers Carson J, Gibson DW, Horvath M, Clifton KK, Ademuyiwa FO, Suresh R, Frith A, Davis AA, Peterson LL, Bose R, Williams A, Bergqvist M, Ma CX

OT3-11-02 SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL

Balmaña J, Pascual T, Llop-Guevara A, Tolosa P, Blancas I, Perez-Lopez M-E, Adamo B, Teruel I, Ponce J, Gonzalez M, Viñas G, Lema L, Salvador FJ, Martinez MT, Espinosa A, Prat A, Serra V

OT3-11-03 The PREDICT Registry Australia: A prospective registry to evaluate the clinical utility of a 7-gene predictive biosignature on treatment decisions in patients with ductal carcinoma in situ

Zissiadis Y, Mann GB, Speakman D, Saunders C, Pyke C, De Viana D, Bochner M, French JR, Dreosti M, Baron-Hay S, Feetham A, Kirkham K, Ryan S, Mittal K, Shivers SC, Bremer T

Ongoing Clinical Trials: Predictors of Axillary Nodal Response

OT3-12-01 Immunological predictors of nodal response in breast cancer patients undergoing neoadjuvant therapy

Gasparri ML, Ruscito I, Bellati F, Corsi F, Di Micco R, Gentilini OD, Kuehn T, Papadia A, Caserta D, Rossi L, Calcinotto A

Ongoing Clinical Trials: Progranulin/GP88

OT3-13-01 First in Human Study of AG01 a chimerized monoclonal antibody to Progranulin/Glycoprotein 88 (GP88)

Tkaczuk K, Rosenblatt P, Mehra R, Scilla K, Tait N, Yue B, Serrero G

Ongoing Clinical Trials: Racial Disparities

OT3-14-01 A longitudinal investigation of sociocultural and behavioral influences on symptom management, biological response, and functioning among Chinese American and White female breast cancer survivors

Kwa M, Schwartz M, Crew KD, Genkinger JM, Brown RL, Hilakivi-Clarke L, Kitlinska J, Roblin DW, Antoni M, Adams S, Joseph K-A, Chen L-S, Wang JH-y

Ongoing Clinical Trials - Radiotherapy

OT3-15-01 TBCRC-053: P-RAD: A randomized study of preoperative chemotherapy, Pembrolizumab and no, low or high dose rAdiation in node-positive, HER2-negative breast cancer

Connolly JJ, Spring LM, Taghian AG, Gadd M, Warren L, Garrido-Castro AC, King T, Mittendorf EA, Leone JP, Casey DL, Carey LA, Traina TA, Abdou Y, Khan A, Plitas G, Wright J, Santa-Maria CA, Jacobs L, Blitza R, Hwang ES, Anders C, Krop I, Wolff AC, Thompson AM, Denault E, Gupta G, Ho A

OT3-15-02 A phase II study evaluating the combination of radiotherapy with chemotherapy and Pembrolizumab in patients with PD-L1-positive metastatic triple-negative breast cancer

Schreiber AR, Kagihara J, Nicklawsky A, Gao D, Afghani A, Elias A, Kabos P, Shagisultanova E, Pitts T, Lang J, Karam S, Borges VF, Wood M, Fisher CM, Diamond JR

OT3-15-03 The ARETTA trial experience: Radiotherapy quality assurance in an international breast cancer trial

Balogun O, Sowunmi A, Ntekim A, Alabi A, Olopade OI

Ongoing Clinical Trials: Response Markers

OT3-16-01 On-going prospective study to measure serum progranulin/GP88 levels in metastatic breast cancer patients in association with disease status

Serrero G, Rosenblatt P, Tait N, Rector B, Latteri JA, Yue B, Tkaczuk K

Ongoing Clinical Trials: Screening

OT3-18-01 Electronic health record patient portal (MyChart) research study recruiting methods and results: the WISDOM study

Petruse A, Ryu RH, Lewis T, Stover Fiscalini A, Hogarth MA, Wernisch J, Park HL, Fors S, Rocha AN, Johansen L, Sabacan L, Soonavala R, Choy P, Leggat-Barr K, Palmeri M, Herrera M, Goodman S, Van 't Veer L, Shieh Y, Madlensky L, Tice J, Ziv E, Eklund M, Blanco A, Tong B, Goodman D, Risty L, Hiatt RA, Wenger N, Lee V, Heditsian D, Brain S, Kaplan C, Morrehead D, Parker B, Borowsky A, Anton-Culver H, Kaster A, LaCroix AZ, Olopade OI, Garcia A, Lancaster RB, WISDOM Study and Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ, Naeim A

OT3-18-02 Clinical validation of “TriNetra™-Breast” test for breast cancer screening in a prospective, observational, case-cohort study

Vaishampayan U, Patil D, Rahman W, Patterson S, Mitrikeska E, Dib J

OT3-18-03 The PRAIM study: A prospective multicenter observational study of an integrated Artificial Intelligence system with live monitoring

Byng D, Eisemann N, Schüller D, Bunk S, Leibig C, Brehmer M, Elsner S, Katalinic A

OT3-18-04 Personalized breast cancer screening in a population-based study: Women informed to screen depending on measures of risk (WISDOM)

Choy P, Soonavala R, Lewis T, Leggat-Barr K, Sabacan L, Stover Fiscalini A, Van 't Veer L, Herrera M, Goodman S, Scheuner M, Sales P, Shieh Y, Madlensky L, Tice J, Ziv E, Edlund M, Blanco A, Tong B, Goodman D, Park HL, Palmieri M, Petruse A, Wernisch J, Risty L, James J, Kaplan C, Hiatt RA, Rhoads K, Wenger N, Lee V, Heditsian DM, Brain S, Parker B, Borowsky A, Anton-Culver H, Naeim A, Kaster A, LaCroix AZ, Olopade OI, Garcia A, Lancaster RB, Plaza M, Moorehead D, WISDOM Study and Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ, Rao S

Ongoing Clinical Trials: Screening - Brain MRIs

OT3-19-01 Phase II study of screening brain MRIs in stage IV breast cancer

Ahmed KA, Kim Y, Armaghani A, Arrington J, Costa R, Czerniecki BJ, Diaz R, Forsyth PA, Khong H, Lee K, Loftus L, Rosa M, Soliman HH, Washington I, Soyano A, Han HS

Ongoing Clinical Trials: Surgery

OT3-20-01 Ketamine analgesia for long lasting pain relief after surgery (KALPAS) study

Doan L, Perez R, Chun J, Cuevas R, Miah P, Guth A, Hiotis K, Schnabel F, Curatolo M, Edwards R, Park H, Rotrosen J, Axelrod D, Wang J

OT3-20-02 SMALL: Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a UK phase III randomised multi-centre trial

McIntosh SA, Coles CE, Dodwell D, Elder K, Foster J, Gaunt C, Kirkham A, Lyburn I, Morgan J, Paramasivan S, Pinder SE, Pirrie S, Potter S, Roberts T, Sharma N, Stobart H, Southgate E, Taylor-Phillips S, Wallis M, Rea D

OT3-20-03 Refusal of breast surgery in breast cancer patients With cCR after neoadjuvant systemic therapy and vacuum-assisted biopsy (VAB) and SLNB confirmed pCR. An interim report of the prospective non-randomized trial. NCT04293796

Krivorotko P, Yerechshenko S, Emelyanov A, Busko E, Tabagua T, Mortada V, Zernov K, Komyakhov A, Nikolaev K, Zhiltsova E, Gigolaeva L, Pesotsky R, Enaldieva D, Bondarchuk Y, Amirov N Channov V, Novikov S, Bryantseva Z, Artemyeva A, Smirnova V, Semiglazova T, Belyaev A, Semiglazov V

OT3-20-04 SerMa – Seroma formations of the Mammary gland in breast cancer patients after mastectomy and implant-based reconstruction (EUBREAST 5)

Ditsch N, Pochert N, Jeschke U, Schneider M, Koepke M, Banys-Paluchowski M, Traidl-Hoffmann C, Dannecker C, Kühn T

Ongoing Clinical Trials: Surgery - Reconstruction

OT3-21-01 A pilot study of robot-assisted nipple-sparing mastectomy followed by immediate breast reconstruction using da Vinci SP® single-port system

Kuo W-L, Chu C-H, Huang J-j

Ongoing Clinical Trials: Targeted Agents

OT3-22-01 First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3K α inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer

Varkaris A, Hamilton E, Henry J, Spira AI, Schram AM, McGuinness JE, Tan G, Li X, Hunter T, Samadani R, Timm A, Karanovic D, Subbiah V, Perez CA

Ongoing Clinical Trials: Targeted-CDKs

OT3-23-01 VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Patel MR, Juric D, Henick BS, Moore KN, Do D, Chapman J, Zhang H, Roche M, Newberry KJ, Rinne M, Yap TA

Ongoing Clinical Trials: Targeted-FGFR

OT3-24-01 ReFocus: A phase 1/2 study of the highly selective FGFR2 inhibitor, RLY-4008, in patients with advanced solid tumors including breast cancer

Kamath S, Tai D, Moreno I, Babiker H, Jin Z, Yoo C, Ricard F, Jen KY, Coward J, Liu J, Opdam F, Millward M, Ponz-Sarvise M, Yachnin J, Kim R, Park JO, Subbiah V, Schram AM

Ongoing Clinical Trials: Targeted-HER2

OT3-25-01 Neoadjuvant HER2-targeted therapy +/- Immunotherapy with Pembrolizumab (neoHIP): An open label randomized phase II trial

McArthur H, Santos Leal JH, DiLauro Abaya C, Reddy SM, Carter M, Basho R, Phillips M, Chan D, Hool H, Park D, El-Masry M, McAndrew P, Sikaria S, Spring LM, Bardia A, Tighiouart M, Dadmanesh F, Giuliano A, Shiao S, Page DB

OT3-25-02 Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer a single arm multicenter phase II clinical trial

Zhao J, Cai Y, Ding L, Yang Y, Zou G, Yao H, Wang Y

Ongoing Clinical Trials: Targeting PI3K/mTOR

OT3-26-01 CCTG MA40: Double-blind placebo controlled phase III trial of Fulvestrant and lpatasertib for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer post first line CDK 4/6 and aromatase inhibitor therapy (FINER)

Chia SK, Cescon DW, Redfern AD, Rodin D, Simmons C, Ayoub J-P, Chalchal HI, Rayson D, Rushton-Marovac M, Hay T, Gallinaro L, Chen B, Parulekar W

OT3-26-02 A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+ /HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Hurvitz SA, Andre F, Cristofanilli M, Curigliano G, Giordano A, Han HS, Martín M, Pistilli B, Rugo HS, Wesolowski R, Suzuki S, Mutka SC, Gorbachevsky I, Loibl S

Ongoing Clinical Trials: TNBC Subtyping

OT3-27-01 Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial

Shao Z-M, Wang Z-H, Jiang Y-Z, Liu Y, Zhu X-Z, Xiao Y, Wu S-Y, Zuo W-J, Yu Q, Cao A-Y, Li J-J, Yu K-D, Liu G-Y, Wu J, Sun T, Cui J, Lv Z, Li H-P, Zhu X-Y

Ongoing Clinical Trials: Topoisomerase-1 Inhibitors

OT3-28-01 A dose-escalation study of the safety and pharmacology of DAN-222 in subjects with metastatic breast cancer NCT05261269

Wright AP, Wyatt EA, Hagerty T.

Ongoing Clinical Trials: Tyrosine Kinase Inhibitors

OT3-29-01 A Phase Ib/II Study of anlotinib combined with pyrotinib and capecitabine for HER2-positive metastatic breast cancer

Luo T, Zhong X, Chen J

Ongoing Clinical Trials: Treatment Side Effects

OT3-30-01 A randomized double-blind placebo controlled phase 3 trial on the effect of Salovum™ and SPC-Flakes™ on abemaciclib-induced gastrointestinal toxicity in early breast cancer – the ASF-BC study

Lindman H, Nygren P, Valachis A

Ongoing Clinical Trials: Treatment-induced Hyperglycemia

OT3-31-01 The Amelia-1 Study: A phase 1b/2 trial of evexomostat (SDX-7320) plus fulvestrant (Faslodex®) and alpelisib (Piqray®) in patients with advanced breast cancer at risk for alpelisib (Piqray)-induced hyperglycemia

Cornelius P, Salomon N, Browning D, Gill S, Mayes B, Dufour P, Shanahan J, Carver B, Rugo HS

Ongoing Clinical Trials: Tumor Gene Expression Assays

OT3-32-01 OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer

Stein R, Makris A, Macpherson I, Hughes-Davies L, Marshall A, Dotchin G, Cameron DA, Kiely BE, Wilson C, Armstrong A, Earl HM, Poole CJ, Tsang J, Naume B, Rea D, Ohnstad H, Hall PS, McIntosh SA, Shinkins B, McCabe C, Morgan A, Bartlett JMS, Dunn JA

Ongoing Clinical Trials: Artificial Intelligence

OT3-33-01 Prospective, multi-center, artificial intelligence study for early prediction of serious events under treatment is now open for recruitment in breast cancer – OMCAT trial in progress

Schinköthe T, Tonk CH, Kates R, Küemmel S, Cardoso F, Harbeck N, Staib P, Schmidt A

POSTER SESSION 6

**FRIDAY, DECEMBER 9, 2022: 7:00 AM – 8:15 AM
HALL 1**

Prognostic and Predictive Factors-Biomarkers Predicting Tx Response: Predictive Biomarkers for Chemo

P6-01-01 Validation of an optical imaging platform to identify metabolic vulnerabilities in chemo-resistant and sensitive tumors

Sunassee ED, Maydew E, Crouch B, Madonna M, Palmer GM, Ramanujam N

P6-01-02 Using MammaPrint on core needle biopsy to guide neoadjuvant chemotherapy for invasive breast carcinoma

Drapalik LM, Singh R, Simpson A, Rock L, Shenk R, Amin AL, Miller ME

P6-01-03 Tumor-infiltrating lymphocytes (TILs) and 21-gene recurrence score in 1,883 patients with ER+/HER2- breast cancer

Ahn SG, Jang JS, Kook Y, Baek SH, Lee SB, Bae SJ, Jeong J

P6-01-04 The hierarchy of biomarkers

Eltoum N, Thannickal H, Henderson NL, Wagner LI, Wallner LP, Wolff AC, Rocque GB

P6-01-05 Platelet-derived growth factor-CC expression in primary triple-negative breast cancer is associated with the basal-like molecular subtype and increased immune infiltrate

Lehn S, Pekar G, Bolivar Balbas P, Staaf J, Möller C, Lövgren K, Ehinger A, Bosch Campos A, Borg Å, Pietras K

P6-01-06 Multi-parametric MRI-based radiomics models from tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant systemic therapy in triple negative breast cancer patients

Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K-P, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Ma J, Rauch G

P6-01-07 Withdrawn

P6-01-08 Gene signatures provide independent prognostic information in elderly breast cancer patients

Castresana Aguirre M, Johansson A, Lindström LS, Tobin N

P6-01-09 Efficacy of platinum-based chemotherapy and germline mutational status in early-stage triple-negative breast cancer: a unicenter retrospective analysis with long-term follow-up

Rodríguez Hernández A, Conte B, Fernández L, Brasó-Maristany F, Pastor B, Potrony M, Moreno L, Grau E, Puig-Butillé JA, Sánchez A, González-Farré B, Sanfeliu E, Martínez-Sáez O, Falato C, Vidal M, Chic N, Pascual T, Schettini F, Muñoz M, Balaguer F, Prat A, Adamo B

P6-01-10 Conventional immunohistochemistry-based tools predict satisfactory response to neoadjuvant chemotherapy in HR+/HER2- breast cancer patients

Oprea A-L, Georgescu R, Aytin YE, Eren ÖC, Aral C, Taştekin E, Szekely T-B, Kaya H, Bademler S, Karanlik H, Sezer AY, Ugurlu MU, Turdean SG, Marginean C, Gulluoglu BM

P6-01-11 A UK prospective multicenter decision impact, decision conflict and economic evaluation of the use of Oncotype DX® to guide chemotherapy in 680 women with hormone receptor positive, HER2 negative breast cancer and 1 to 3 nodes involved

Holt SD, Sai-Giridhar P, Verrill M, Pettit L, Rigg A, Hickish T, Archer CD, Wadhawan A, Dillon M, Dent J, Nathan MR, Barthelmes L, Rehman S, Innis P, Khawaja S

P6-01-12 Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery

Zhu Y

P6-01-13 Identification of protein biomarkers for early detection and stratification of triple negative breast cancer

Metwali E, Pennington S

P6-01-14 Genomic characterization and oncology outcomes of a locally advanced ER+/HER2- breast cancer cohort treated with neoadjuvant chemotherapy

Abrea M, Furlan L, Ma Y, Chen H, Ferreira C, Fares A, Constantino E, Nora GR, Lucio G, Colombo T, Liu R, Wu X, Ou Q, Araujo DV

P6-01-15 Breast cancer patients with different hormone receptor subtypes receiving neoadjuvant chemotherapy (NAC) experience differential overall survival according to their resistance to NAC

Prabhakaran S, Pankratz VS, McNicoll C, Falk N, Nemunaitis J, Zhou J, Sandoval-Belt P

P6-01-16 Circulating tumour DNA (ctDNA) detection and dynamics in patients with early breast cancer (EBC): Results of the neoadjuvant TRACER cohort

Elliott MJ, Veitch Z, Bedard P, Amir E, Dou A, Fuentes Antras J, Nadler M, Meti N, Gregorio N, Shah E, Chow H, Campbell N, Terrell S, Knape C, Howarth K, Siu L, Berman H, Cescon DW

P6-01-17 A single-center prospective cohort study to evaluate circulating tumor cells as a monitoring tool in women with breast cancer treated with neoadjuvant chemotherapy

Chegade R, Jain A, Moravan V, Di Caro G, Anderson A, Slade MM, Wenstrup R, Lohmann AE, Jerzak K

P6-01-18 Predicting response of triple negative breast cancer to neoadjuvant chemotherapy using a deep convolutional neural network-based artificial intelligence tool
Krishnamurthy S, Jain P, Tripathy d, Muhammad H, Huang W, Yang H, Kummar S, Wilding G, Roy R, Randhawa R

P6-01-19 Multiparametric MRI-based longitudinal-radiomics analysis for early prediction of treatment response of breast cancers to neoadjuvant chemotherapy: A multicenter study

Li W, Huang Y, Zhu T, Wu Z, Lin Y, Ye G, Wang K

P6-01-20 Luminal androgen receptor subtype and M2 macrophage signatures strongly associate with low pathological complete response rates and poor outcomes in patients with triple negative breast cancer receiving neoadjuvant chemotherapy

Meisel J, Douglass E, Kalinsky K, Griffiths LM, Li Z, Li X

P6-01-21 Moved to HER2 Session

P6-01-22 Age, Ki-67, Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer

Moldoveanu D, Goetz MP, Hoskin TL, Day CN, Boughey JC

P6-01-23 Role of tumor infiltrating lymphocytes and PD-L1 expression in the response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial

Kearney M, Guo H, Vanguri R, Wang Q, Garlin M, Connelly C, Kalinsky K, Connolly EP

P6-01-24 Long-term outcome data using Endopredict® as risk stratification and chemotherapy decision biomarker in hormone receptor positive, HER2-negative early breast cancer

Klein E, Josipovic A, Noske A, Anders S, Mogler C, Weichert W, Hapfelmeier A, Kiechle M, Ettl J

P6-01-25 Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

Freeman JQ, Shubeck S, Howard FM, Chen N, Nanda R, Huo D

P6-01-26 YAP1 predicts pathological complete response to neoadjuvant chemotherapy in luminal breast cancer patients

Park NJ-Y, Lee J, Lee SJ, Lee IH, Kang J, Kim EA, Park J-Y, Jung JH, Park HY, Chae YS

P6-01-27 Utilization of the oncotype Dx assay for young patients with early stage, hormone-receptor positive, HER2-negative breast cancer in an integrated health system

Aller A, Darbinian JA, Liu R, Kuehner G, Savitz A, Odele P, Habel L, Vuong B

P6-01-28 Tangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers

Alblihy A, Shoqafi A

P6-01-29 Serial genomic analysis of circulating tumor cells, circulating free DNA and change of immune-related gene signature in triple negative and HER2 positive advanced, metastatic breast cancer

Lee J, Shin K, Joe SY, Lee H, Jeon BH, Lee A

P6-01-30 PgR levels and Ki67 expression of lobular carcinomas of the breast might indicate OncotypeDX testing to evaluate chemotherapy benefit

Markopoulos C, Sariyanni M, Karamargiou A, Antonopoulou Z, Tsoulos N

P6-01-31 Lactate dehydrogenase as a surrogate marker for both and survival in breast cancer patients who underwent neoadjuvant chemotherapy

Lee IH, Lee SJ, Lee J, Park HY, Jung JH, Park NJ-Y, Park J-Y, Kang J, Kim EA, Chae YS

P6-01-32 Evaluation of pathologic response and residual tumor cellularity following neoadjuvant chemotherapy predict prognosis in breast cancer patients

Gentile D, Sagona A, De Carlo C, Fernandes B, Di Maria Grimaldi S, Barbieri E, Gatzemeier W, Scardina L, Biondi E, Jacobs F, Vatteroni G, Tinterri C

P6-01-33 Diffusion-weighted magnetic resonance imaging for subtype-specific prediction of pathologic complete response in neoadjuvant chemotherapy

Zimmermann J, Carmona-Bozo J, Le NN, Onishi N, Wilmes LJ, Gibbs JE, Liang J, Newitt DC, Partridge S, Bolan P, Joe BN, Price ER, LeStage B, Hylton NM, Li W

P6-01-34 Longitudinal DCE-MRI radiomic models for early prediction of response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC) patients

Panthi B, Mohamed RM, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K-P, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, Lane DL, Moseley T, Perez F, White J, Ravenberg E, Clayborn A, Pagel M, Chen H, Sun J, Wei P, Thompson AM, Moulder S, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yam C, Rauch G

P6-01-35 A pre-operative dynamic contrast enhanced MRI-based radiomics models as predictors of treatment response after neoadjuvant systemic therapy in triple negative breast cancer patients

Mohamed RM, Panthi B, Adrada B, Candelaria R, Guirguis MS, Yang W, Boge M, Patel M, Elshafeey N, Pashapoor S, Zhou Z, Son JB, Hwang K-P, Le-Petross HTC, Leung J, Scoggins ME, Whitman GJ, Xu Z, lane DL, Moseley T, Perez F, White J, Chen H, Sun J, Wei P, Litton JK, Valero V, Yam C, Pagel M, Ma J, Rauch G

P6-01-36 Validation of prognostic platform to further refine identification high risk patients indicated for chemotherapy free treatment in early-stage breast cancer

Peterson J, Rubio-Romera J, Giakoumis Spear G, Britto M, Hack B, Pandey T, Saha P

P6-01-37 Tumor microenvironment subtype influence the response of neoadjuvant chemotherapy in breast cancer

Kim j-Y, Park K, Park w-Y, Lee JE, Kim SW, Nam SJ, Lee SK, Park YH

P6-01-38 Predictive efficacy biomarker for chemotherapy agents against triple-negative breast cancer bioprinted organoid tumors (BOTs) using solid tumor biopsy-on-a-chip

Bollenbecker S, Patel Z, Punjani Z, Charania A, Patel H, Abbott A, Kunkle K, Sewell-Loftin MK, Grossman G, Budhwani K

P6-01-39 The impact of the 21-gene Recurrence Score® assay upon physician treatment recommendations in the neoadjuvant setting in lymph node-negative breast cancer patients in a multicenter prospective study in Quebec

Yordanova M, Sideris L, Dubé P, Boileau J-F, Lemieux J, Mihalciou C, Levesque S, Guertin M-C, Patocskai E, Younan R, Robidoux A, Hassan S

P6-01-40 Integrative transcriptomic analysis and cohort validation identify key genes in chemotherapy treatment response in Latino breast cancer patients

Guevara-Nieto HM, Parra-Medina R, Mejia-Henao JC, López-Correa P, Diaz S, Gerai J, Zabaleta J, López-Kleine L, Combita AL

P6-01-41 Influence of HER2 expression status in the distribution of recurrence score from the OncotypeDx assay among women with early-stage estrogen-receptor-positive/HER2-negative breast cancer

Shah A, Budhathoki P, Gaire S, Joshi U, Yadav S

P6-01-42 Baseline 18FDG-PET metabolic tumour volume (MTV) as a potential predictive factor of response to metronomic chemotherapy (mCHT) in HR+/HER2- metastatic breast cancer (MBC) patients (pts). Preliminary results of the Metro-PET Study

Meazza Prina M, Gotuzzo I, Cazzaniga ME, De Bernardi E, Cafaro P, Capici S, Cogliati V, Pepe FF, Cicchiello F, Riva F, Cordani N, Cerrito MG, Turolla EA, Landoni C, Elisei F, Crivellaro C, Virdone L, Monaco L, Guidi A, Guerra L

P6-01-43 Predictors of response to neoadjuvant chemotherapy in breast cancer: OncotypeDX versus MammaPrint versus liquid biopsy

Bilani N, Itani M, Mohanna M, Debnath N Dominguez B, Liang H, Nahleh Z

P6-01-44 Alteration of DNA methylation landscape in breast patients treated with adjuvant chemotherapy

Ho PJ, Khng AJ, Tan BKT, Tan EY, Lim Gh, Tan S-M, Tan VKM, Lim EH, Hartman M, Li J

P6-01-45 Correlation of an immune-related 8-gene panel with the efficacy of neoadjuvant chemotherapy for breast cancer

Liu C-Y, Huang C-C, Tsai Y-F, Chao T-C, Lin Y-S, Feng C-J, Lai J-I, Chen J-L, Chen Y-J, Chiu J-H, Hsu C-Y, Tseng L-M

Epidemiology, Risk, and Prevention: Familial Breast Cancer - Genetic Testing

P6-02-01 Frequency of pathogenic germline mutations beyond Germline BRCA gene mutations among Saudi patients with breast cancer

Alolayan A, Sabatin F, Algarni M, Mabsout N, Zaher H, Shehata H, Alturki S, Alshalhoub A, Alturki F, Abdelhafiz N, Alfayea T, Alshammari K, Albalwi M

P6-02-02 Challenges and dilemmas following a traceback approach for genetic counseling and genetic testing for pathogenic germline mutations among high-risk patients previously diagnosed with breast cancer

Tamimi F, Sharaf B, Salama O, Edaily S, Khater S, AlKyam M, Abujamous L, Azzam K, Abu-Fares H, Abaza H, Abdel-Razeq H

P6-02-03 Breast Health Assessment: A family health history tool using the electronic health record and clinical decision support to facilitate guidelines-driven hereditary breast cancer genetic testing at the time of screening

DePersia A, Choi S, Yao K, Dunnenberger H, Hulick P

P6-02-04 Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes

Makhnoon S, Chen M, Levin B, Ensinger M, Mattie K, Grana G, Shete S, Arun BK, Peterson SK

P6-02-05 Prevalence of non-BRCA germline pathogenic variants in Mexican women with breast cancer referred for genetic cancer risk assessment

Chavarri-Guerra Y, Villarreal-Garza C, Rodriguez-Olivares JL, Aguilar-y Mendez D, Quintero-Beulo G, Gutierrez-Delgado F, Herzog J, Gruber S

P6-02-06 Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging center

Miltenburg D, Westbrook L, Souter V, Maisenbacher MK, Howard KL, Sha Y, Yavari M, Kypraios N, Hurtado S, Rodas M, Weitzel JN

P6-02-07 Uptake of breast cancer MRI screening in patients after multiplex gene panel testing

Naghi LA, Ricker CN, Sturgeon D, Culver J, Kingham K, Hodan R, Chun NM, Kidd J, Bonner J, Hong C, Mills M, Lindsey SS, McDonnell K, Ladabaum U, Ford JM, Gruber S, Kurian AW, Idos GE

P6-02-08 Identifying preferences that may motivate choice of ovarian cancer risk prevention strategies using a discrete choice experiment

Daly M, Egleston B, Lew K, Bealin L, Husband A, Stopfer J, Przybysz P, Tchuvatkina O, Wong Y-N, Garber J, Rebbeck T

P6-02-09 Racial/ethnic groups have different rates of pathogenic variants in common cancer genes

Beitsch P, Wernecke C, Patel R, Rosen B, Compagnoni G, Grady I, Brown e, Gold L, Whitworth P, Smith LA, Wirga M, Reitherman R, Cai S, Nguyen T, Traina V, Holmes D, Baron P, Krauthem B, Peled A, Taylor W, Bontempo K, Bentley B, Ortega K, Ahmadi P

P6-02-10 Prevalence of breast cancer predisposing variants in patients with breast carcinoma in situ

Fostira F, Nasikas D, Apostolou P, Dellatola V, Fokianou A, Kontogianni P, Alevizou R, Filippidou S, Maniatis D, Papadopoulos L, Pavlakis E, Ntasiou P, Karageorgopoulou S; Xepapadakis G

P6-02-11 Implementation of multigene panel testing in triple-negative breast cancer. The PERSONA-breast trial

Kahler Ribeiro Fontana SK, Bonetti E, Bernard I, Calvello M, Bonanni B, Bonizzi G, Veronesi P, Mazzarella L, Galimberti V, Sangalli C

P6-02-12 Underutilization and disparities in germline genetic testing for breast cancer patients diagnosed in Chile

Acevedo F, Walbaum B, Medina L, Merino T, Reyes P, Petric M, Dominguez F, Gonzalez P, Sanchez C

P6-02-13 Expanding the reach of germline genetic testing: Use of web-based risk assessment to inform medical management amongst patients at breast and imaging centers

Fecteau H, Keller H, Horton C, Milliard C, Pilarski R, Lyon L, Hoang L, Kieran S

P6-02-14 Contralateral breast cancer risk in patients with or without BRCA mutation

Kang E, Jung J-J, Yeoh H Lim C, Kim J-i, Chun JW, Kim H-K, Lee H-B, Han W, Moon H-G

P6-02-15 Don't get lost in translation: Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) recommendations for reporting germline cancer susceptibility gene variants in 19 languages – breast cancer as a model

De Nicolo A, Eccles DM, Ariansen SL, Biancolella M, de la Hoya M, Diez O, Ehrencrona H, Fostira F, Hassan T, Imoto I, Kowalik A, Lesueur F, Mensenkamp AR, Nevanlinna H, Ngeow J, Palmero EI, Pedersen IS, Que F, Soukupová J, Tan Y, vega A, Spurdle AB, Radice P

P6-02-16 Breast cancer prognosis of germline BRCA1/BRCA2 mutation carriers of young women: a retrospective hospital-based cohort

Hego F, Barthoulot M, Pierard C, Mailliez A

P6-02-17 A real-world study of BRCA1 and BRCA2 germline mutations among high hereditary risk subjects and patients with breast and ovarian cancer in Lebanon

El Saghir N, Safi N, Masri A, Kreidieh F, Mukherji D, Assaf N, Mahfouz R, Moukadem H

Epidemiology, Risk, and Prevention: Risk Factors and Modeling

P6-03-01 The MERIT Cohort: An MD Anderson initiative to integrate blood and imaging biomarkers to personalize breast cancer risk

Leung J, Weaver O, Hanash S, Dennison J

P6-03-02 Social determinants, food deserts, and their combined contribution to breast cancer mortality

McCormack K

P6-03-03 Persistence and compliance of the French metastatic breast cancer population

Rinder P, Marcille T, Sinel-Boucher P, Hornus P, Heudel PE, Bernard-Marty C, Levy C, Teixeira L, Kanoun D

P6-03-04 Ipsilateral infusions are not associated with increased risk of breast cancer-related lymphedema in patients enrolled in a prospective screening program

Brunelle CL, Jung AW, Smith LH, Daniell K, Asdourian MS, Bucci LK, Juhel B, Hausman EK, Naoum GE, Taghian AG

P6-03-05 Clinico-pathological co-variates define a predictive model of breast cancer related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer

Tang CC, Timbres J, Ramsey K, Mera A, Irshad S, Sawyer E, Khan A

P6-03-06 Determining prognostic factors and optimal surgical intervention for young patients with triple-negative breast cancer

Zhen Y-Z, Liu Y, Deng Z-H, Liu G-W, Xie N

P6-03-07 Development of an at-home breast health assessment test, to increase compliance with screening mammography using proteins from tears

Daily A, Ravishankar P, Klimberg VS, Harms S

P6-03-08 Trained artificial intelligence (AI) for predicting treatment termination based on patient observations in advanced breast cancer

Schinköthe T, Kates R, Sprecher B, Meyer S, Tonk CH, Harbeck N, Schmidt A

Detection and Diagnosis: Diagnostic Pathology

P6-04-01 Withdrawn

P6-04-02 Ki67 Assessment Protocol: Companion Diagnostic Biomarker for LUMINA Prospective Cohort Study

Nielsen T, Leung S, Riaz N, Kos Z, Bane A, Whelan TJ

P6-04-03 Computational pathology based HER2 expression quantification in HER2-low breast cancer

Spitzmüller A, Kapil A, Shumilov A, Chan J, Konstantinidou L, Hassan Z, Gustavson M, Carroll D, Varghese D, James GD; Moh A, Livingston A, de Giorgio-Miller V

P6-04-04 Clinical relevance of PD-L1 and CD8 expression in triple negative breast cancer
Bago-Horvath Z, Marhold M, Heber U, Bartsch R, Fitzal F, Singer CF, Filipits M

P6-04-05 A fully automatic artificial intelligence system for accurate and reproducible HER2 IHC scoring in breast cancer

Globerson Y, Bien L, Harel J, Malle G, Sebag G, Vandenberghe M, Barker C, Matsuo T, Garrido C, Sandbank J, Linhart C

P6-04-06 Moved to HER2 Session

P6-04-07 Primary diagnosis of breast biopsies supported by AI versus microscope: Multi-site clinical reader study

Salomon A, Nudelman A, Cyrta J, Maklakovski M, Albrecht Shach A, Sebag G, Malle G, Krasnitsky I, Feinberg T, Vecsler M, Sandbank J

P6-04-08 Machine learning-based characterization of the breast cancer tumor microenvironment for assessment of neoadjuvant-treatment response

Kirkup C, Vasudevan S, Kos F, Trotter B, Resnick M, Beck AH, Montalto M, Wapinski I, Glass B, Lin M, Hennek S, Khosla A, Drage MG, Chambre L

P6-04-09 Variations in diagnostic practice of Ki67 scoring suggest standard guidelines needed for pathological assessment: survey results of global Ki67 testing methods

Moore HM, Lin WW, Fernando TM, Lopez C, Kent E, Ellouk K, Giltneane JM

P6-04-10 Recurrence prediction in ductal carcinoma in situ (DCIS) patients from tissue microarrays (TMAs)

Soumya G, Gokmen-Polar Y, Cho S, McDonough E, Davis C, Mitra J, Zhang Z, Ginty F, Badve S

P6-04-11 Improved quantitative fibrosis indices reveal diverse survivals of triple negative breast cancer patients

Ren Y, Tai D, Zhao Y, Tan PH

P6-04-12 Differential diagnoses of breast biopsies by spatial parametric modeling of histological structures and explainable AI

Tosun AB, Chennubhotla SC

P6-04-13 Centralized adequacy assessment of ductal carcinoma in situ samples for the COMET study (AFT-25)

Factor R, Schnitt S, West R, Hyslop T, Lynch T, Collyar D, Basila D, Grimm L, King L, Marks J, Badve S, watson M, Ryser M, Weiss A, Rapperport A, McCall L, Le-Petross HTC, Partridge AH, Hwang ES, Thompson AM

P6-04-14 Comparison of next-generation sequencing and real-time PCR for PIK3CA testing in hormone receptor-positive/HER2-negative breast cancer on metastatic and matched primary tumor samples

Venetis K, Pepe F, Sajjadi E, Bonizzi G, Ivanova M, Vacirca D, Rappa A, Barberis M, Viale G, Guerini-Rocco E, Munzone E, Malapelle U, Fusco N

P6-04-15 AI-based prediction of tertiary lymphoid structures and lymphocyte immune infiltration in breast carcinomas

Kushnarev V, Dymov D, Lukashevich N, Popyvanov L, Belozerova A, Shamsutdinova D, Akaeva A, Popov Y, Khorkova S, Valiev I, Zotova A, Brown JH, Love A, Bagaev A, Postovalova E, Fowler N

P6-04-16 ART: Automated Region segmentation of Tumor on HER2-stained breast cancer tissue

Kapil A, Shumilov A, Wortmann P, Khelifa S, Chan J, Vandenberghe M, Barker C, Gustavson M, Carroll D, Sade H, Schmidt G

P6-04-17 High Intra- and Inter-block concordance of HER2 immunohistochemistry (IHC) scores across breast cancer samples and impact of decalcification procedures

Tsirka A, Garrido C, Scott M, Scorer P, Boothman A-M, Matsuo T, Barker C

P6-04-18 Rapid diagnosis of breast biopsies with open-top light-sheet microscopy

Olin Pope BE, Dintzis S, Parker EU, Alvarez R, Alvarsson A, Rahbar H, Reder N

Psychosocial, Quality of Life and Educational Aspects: Psychosocial, QOL & Educational Aspects-Other

P6-05-01 Employment status patterns in a cohort of young women with breast cancer in Mexico

Villarreal-Garza C, Ferrigno A, Enriquez LF, Fonseca A, Platas A, Cruz-Ramos M, Miaja M, Vaca-Cartagena B, Becerril-Gaitan A, Mesa-Chavez F, Bargallo-Rocha E, Mohar A

P6-05-02 Presence of BRCA mutations and pre-chemotherapy serum anti-mullerian hormone levels predict risk of amenorrhea in women with breast cancer

Goldfarb SB, Turan V, Bedoschi G, Abdo N, Chang C, Bang H, Oktay KH

P6-05-03 Post-mastectomy implant complications in a Hispanic breast cancer patient population

Conte B, Shermoen C, Cerbon D, Kesmodel S, Fiser C, Liu S, Takita C, Meshman J, Oeltjen J, Wang L

P6-05-04 Patterns in palliative care use and their impact on survival in the elderly metastatic breast cancer (MBC) population: a National Cancer Database (NCDB) analysis

Patel R, Kwon D, Hovstadius M, Tiersten A

P6-05-05 Patient-reported outcomes, perceptions, and knowledge about recurrence in women with high-risk hormone receptor-positive (HR+) breast cancer (BC)

Rosenberg SM, Zheng Y, Santos K, Riley E, Meadows H, Snow C, Hughes ME, Frank E, Lin NU, Partridge AH, Winer EP, Parsons HA

P6-05-06 Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status

Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow WE, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K, Henry NL

P6-05-07 Oncologic outcomes of pregnancy after surgical treatment of breast cancer 35 years old or under

Kim JH, Woo SU, Lee JB, Kim WY, Chung JH, Kim YY

P6-05-08 Distress screening for family caregivers of metastatic breast cancer patients

Buchanan A, Sarfo A, Badr H

P6-05-09 Cardiovascular risk evaluation for breast cancer survivors: A pilot study

Schlam I, Debnath D, Gallagher C, Dilawari AA, Tiwari SR, Aschalew M, Guebre-Xabiher H, Malloy S, Graves K, Barac A, Chitalia A

P6-05-10 An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas

Oesterreich S, Pate L, Lee AV, Jankowitz RC, Derksen P, Mukhtar R, Otzger O, Sikora MJ, Li C, Sotiriou C, Ulaner G, Reis-Filho J, Davidson NE, Van Baelen K, Hutcherson L, Freeney S, Migyanka F, Turner C, Bear T, Desmedt C

P6-05-11 Active surveillance versus conventional treatment in low-risk DCIS; women's preferences in the LORD trial

Schmitz RS, Engelhardt EG, Gerritsma MA, Sondermeijer CM, Alaeikhanehshir S, Verschuur E, van Oirsouw M, Houtzager J, Griffioen R, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker E

P6-05-12 Understanding patient perspectives on window of opportunity clinical trial participation in breast cancer

Lopez Ozuna V, Pond GR, Bartlett JMS, Radvanyi L, Spears M, Petrocelli T, Gordon C, Rose RJ, Arnaout A

P6-05-13 The psychological impacts of COVID-19 on breast cancer patients in China

Wang Y, Yang Y, Yan C, Yang J, Wei H, Ma W, Li N

P6-05-14 The association of sleep quality with anxiety, depression and social support in breast cancer patients with chemotherapy

Zhu W, Li W, Yang H, Wang L, Guo J, Gao J

P6-05-15 Standard of care for HR+/HER2- breast cancer: Integrating the "Yale Model Shared Decision-Making Multidisciplinary Team Solution" into the practice setting

Rudell E, Agrawal T, Peterson P, Fallon Ingram M, Oliver B, Adelson K

P6-05-16 Social isolation induces gut dysbiosis, mitochondrial metabolic dysfunction, and infiltration of tumor immunosuppressive cells: do they explain enhanced mammary tumorigenesis?

De Oliveira Andrade F, Jin L, Verma V, McDermott M, Staley C, Hilakivi-Clarke L

P6-05-17 Recruitment challenges in a UK surgical de-escalation study: preliminary qualitative research findings from the SMALL trial

McIntosh SA, Coles CE, Dodwell D, elder K, Foster J, Gaunt C, Kirkham A, Lyburn I, Morgan J, Pinder SE, Pirrie S, Potter S, Roberts T, Sharma N, Stobart H, Southgate E, Taylor-Phillips S, Wallis M, Rea D, Paramasivan S

P6-05-18 Reasons for delay in Indian women presenting with primary stage III or IV breast cancer: An observational study

Khare S, Doda V, Irrinki RNNS

P6-05-19 Racial disparities in the quality of life and vaccination of breast cancer survivors during COVID-19: A longitudinal study

Zhao F, Copley BL, Birch SH, Nanda R, Olopade OI, Huo D

P6-05-20 Quitxt mobile cessation service for cancer patients: Development and implementation process

Chalela P, Cortez V, Flores A, Sivak S, Lew Y, Munoz E, Despres C, Ruiz S, Cancino R, Kitano M, Mundlamuri R, Gunnam G, Akopian D, Mesa R, Ramirez A

P6-05-21 Quality of life and perspectives of older adults with early & locally advanced breast cancers undergoing pre-operative therapy

Ma J, Zhang Z, Tan JYT, Ong WS, Kamis S, Tan BKT, Tan VKM, Kanesvaran R, Tan TJY

P6-05-22 Multilevel, multicomponent intervention to improve informed decision-making about clinical trial participation among cancer patients

Chalela P, Cortez V, Flores A, Sivak S, Lew Y, Munoz E, Despres C, Rainosek C, Gonzalez A, Ali A, Mesa R, Ramirez A

P6-05-23 Lifestyle interventions and complementary care use among oncology patients: a survey in a large teaching hospital population

Honkoop A, Bakkar J, Noorda E

P6-05-24 Implementing system solutions for survivorship care plans

Alnabulsi D, Jackson GL Lopez A

P6-05-25 HT Helper: A mobile app to promote hormone therapy adherence among breast cancer patients

Cortez V, Chalela P, Flores A, Sivak S, Munoz E, Lew Y, Kaklamani V, Lathrop KI, Inupakutika D, Akopian D, Ramirez A

P6-05-26 Financial toxicity and intersectionality among socially and economically marginalized women with breast cancer

Shiu-Yee K, Lee S, Blevins T, Rush L, Tarver W, Pawlik TM, Paskett E, Andersen BL, McAlearney A, Carson III WE, Obeng-Gyasi S

P6-05-27 Feasibility, safety and efficacy of a combined supervised physical exercise and nutritional program in a selected population of luminal metastatic breast cancer patients: Oncare-01 Pilot Study

Cortés A, Riquelme A, Ferrero G, Longo F, Garví M, Lamas L, Morales Á, García L, Cortez-Castedo P, Gión M, Saavedra C, Martínez-Jáñez N, Fernández-Abad M

P6-05-28 Withdrawn

P6-05-29 Experience of financial toxicity and distress among individuals diagnosed with triple negative breast cancer: Findings from the cancer experience registry

Doughtie K, Fortune EE, Badt H, Lawrence C, Popalis ML, Miller MF

P6-05-30 Effects of a 12-week exercise program on breast cancer survivors' quality of life

Imai L, Baron K, Toyama M, Pagano I, Yamada P, Teranishi-Hashimoto C, Fukui J

P6-05-31 Early integrated rehabilitation helps smoking cessation in 467 breast cancer patients – a comparison between the intervention and control group in a prospective study

Besic N, Mavric Z, Mozetic A, Zagar T, Homar V, Kopcavar Gucek N, Skufca Smrdel AC, Knific J, Borstnar S, Kurir Borovcic M, Zadravec Zaletel L, Kos N, Strazisar B, Mastnak Mlakar, Kovacevic N, hadzic V, Pelhan B, Sremec M, Rozman T, Cencelj-Arnez R

P6-05-32 Does aggregation hide place of death disparities for Asians with breast cancer?

Lall N, Noveihed A, Hussaini QS, Blackford AL, Gupta A, Sedhom R

P6-05-33 Distress reduction and physical activity enhancement by mobile support group in breast cancer survivors: A randomized controlled study

Chung I-Y, Jung M, Lee SB, Lee JW, Ahn SH, Chung H

P6-05-34 Depression and psychological distress in breast cancer patients

Cotchett KR, Kelly AH, Szabo A, Cheng YC, Kamaraju S, Chitambar C, Wallace L, Chaudhary LN, Burfeind J

P6-05-35 Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in Panama

Castillo-Fernandez OO, Lim M, Montano L

P6-05-36 Cost-effectiveness of CDK4/6 inhibitors as a first line therapy for metastatic breast cancer. A Mexican cohort

Ramos-Ramírez M, Guzman-vazquez S, Dominguez-Esquivel V, Espinosa-Fernandez JR, Ruiz-Cruz S, Cabrera-Galeana P, Garcilazo A, Cabrera-Miranda LA, Arce Salinas CH

P6-05-37 Comparing changes in depression and anxiety levels of breast cancer patients throughout a course of radiation therapy

Beiner C, Zhao J, Mustafa M, Hirsch A

P6-05-38 Breast Density Notification: Impact on anxiety, breast cancer worry, and self-perceived risk among Latinas at a federally qualified medical center

Ghosh K, Jenkins S, Ridgeway J, Austin JD, Borah B, Patel BK, Rhodes D, Norman A, Ramos EP, Jewett M, Gonzalez C, Hernandez V, Singh D, Suman V, Vachon C

P6-05-39 Black breast cancer survivors' sociocultural perspectives of beauty, and use of personal care products containing endocrine disrupting chemicals

Bailey J, Ericson M, Tomlin-Harris T, Galloway D, Dawkins-Moultin L, Llanos A, Treviño L, Montgomery SB, Teteh D

P6-05-40 Aqua polo: Preliminary feasibility and efficacy study of a programme of adapted, supervised water polo to reduce fatigue and improve women's psychological and social recovery after breast cancer treatment. A mixed-method design

Cuvelier S, Goetgheluck-Villaron C, Cohen M, Tallet A, Lopez Almeida L, Boher J-M, Jowett S, Justafre S, Dantin P, Viens P, Calvin S

P6-05-41 Advocate-BREAST: Advocates and patients' advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025

O'Sullivan CC, Larson NL, Vierkant RA, Smith ML, Chauhan C, Couch FJ, Olson JE, Ruddy KJ

P6-05-42 (Fluoroscopy-guided) Manual lymphatic drainage does not substantially improve the effect of decongestive lymphatic therapy in people with breast cancer-related lymphoedema (EFforT-BCRL trial): a multicentre randomised trial

De Vrieze T, Gebruers N, Nevelsteen I, Fieuws S, Thomis S, De Groef A, Tjalma W, Belgrado J-P, Vandermeeren L, Monten C, Hanssens M, Devoogdt N

P6-05-43 Validity of EQ-5D-5L for women with breast cancer

Torres S, Trudeau M, Liu G, Mitsakakis N, Bayoumi A

P6-05-44 Reasons for choosing delayed rather than immediate contralateral prophylactic mastectomy in patients with unilateral breast cancer

Soh CL, Muktar S, Malata CM, Benson JR

P6-05-45 Providing educational resources during the pandemic for advanced breast cancer patients

Kirklín GT, Kaler AJ, Tripathy D

P6-05-46 Project SOAR (Speaking Our African American Realities): A qualitative study of the Strong Black Woman schema in the breast cancer context

Denyse T, Martin KJ, Pageot YK de Luz D, Owoyemi P, Stanton AI, Kim JH

P6-05-47 Preimplantation genetic testing for BRCA gene mutation carriers - the future of health care in Poland?

Kufel-Grabowska J, Podolak A, Bartoszkiewicz M, Maliszewski D, Ossowska D, Spaczynski R

P6-05-48 Perceptions about breast cancer in North Africa: A social listening project

Ladjeroud A, El Ghoul A, Mohamed M

P6-05-49 Modeling a public-private grant initiative to address breast cancer care disparities at the community level

Marlow EC, Wehling K, Wysocki K, Waldrop J, Brumlow A

P6-05-50 Lobular Breast Cancer Alliance Inc. Survey of Individuals with Metastatic Invasive Lobular Carcinoma

Hutcheson LB, Axelrod J, Camden A, Charlevoix DJ, Cushing TA, Jochelson MS, Kruse ML, Langdon T, Levine JK, McKay C, Metzger O, Mitchell-Daniels M, Mouabbi J, Neilsen BF

P6-05-51 Best Quality of Care from a Distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, patient participation and satisfaction with the program

Kimmick G, Divakaran S, Moore H, Rose C, Gentry P, Willis M, Dent S, Sammons SL, Force J, Westbrook K, Anders C, Shelby R

P6-05-52 Addressing healthcare gaps and disparities in electronic medical record messages: A quality improvement project among breast cancer patients

Conroy M, Powell M, Nagavally S, Dawson A, Beckius A, Min H, Sweeney M, Weil E, Hallbach A, Chaudhary LN, Cheng YC, Deiinger J, Burfeind J, Retseck J, Wright T, Charlson J, Kamaraju S

P6-05-53 "Andean Caravam" & "Mauchis Platform": 1st mobile clinic and 1st artificial intelligence platform against cancer in Peru

León Rivera M, Gonzalez Bocanegra SK

P6-05-54 "Clinical Trials are Space Travel": Moderators of recurrence stress among breast cancer oncologists

Henderson NL, Courtney A, Valerie L, Ingram SA, Zubkoff L, Tung N, Wagner L, Wallner LP, Wolff AC, Rocque GB

P6-05-55 Financial toxicity outcomes on a phase I 5-fraction partial breast irradiation protocol for early stage breast cancer

Simmons A, Sher D, Kim DWN, Leitch M, Wooldridge R, Goudreau S, Seiler S, Neufeld S, Stein M, Albuquerque K, Spangler A, Heinzerling J, Gardwood D, Stevenson S, Ahn C, Ding C, Timmerman R, Rahimi A

P6-05-56 Current status and focus of breast reconstruction research in China and abroad-A bibliometric study

Ren H, Hao S, Chen J, Shao Z, Liu G, Cao A-Y, Wu J

P6-05-57 Developing and feasibility testing a web-based intervention (ePainQ) to support post-operative pain and symptom self-management following surgery for breast cancer

Hartup SM, Ashley L, Briggs M, Velikova G, Johnson M

P6-05-58 Comparing patient-reported outcomes for same-day discharge and inpatient admission after mastectomy

Vemuru S, Colborn K, Leonard L, Huynh V, Kaoutzanis C, Cohen J, Mathes D, Christian N, Ahrendt GM, Fisher CM, Kim S, Tevis S

P6-05-59 Developing a Community Standard of Care for Individuals Diagnosed with Breast Cancer Patients Across Oregon

Stearns S, Williams T, Peters L, Trytko S

Psychosocial, QOL, and Educational Aspects- Social and Education Issues: Advocacy

P6-06-01 Development of a patient advocate training at UNC's Lineberger Comprehensive Cancer Center

Kennedy KL, Mejia AM, Walton EK, Freeman J, Lu A, Potter JA, Spears PA

Psychosocial, QOL, and Educational Aspects: Social and Education Issues - Cost-Effectiveness

P6-07-01 Costs of breast cancer recurrence after initial treatment for high risk early breast cancer using SEER-Medicare linked data

Vitko AS, Martin PA, Zhang S, Johnston AF, Ohsfeldt RL, Zheng S, Liepa AM

Psychosocial, QOL, and Educational Aspects: Social and Ed Issues-Disparities and Barriers to Care

P6-08-01 A cost-consequence analysis of pertuzumab in the neoadjuvant treatment of high-risk HER2+ Early-Stage Breast Cancer (EBC): health-economic considerations for drug availability in Italy

Zambelli A, Cazzaniga ME, La Verde N, Munzone E, Antonazzo IC, Mantovani LG, Mancuso A, Generali DG, Cortesi PA

P6-08-02 Developing a patient-centered video intervention to improve uptake of genetic testing for cancer among black Americans: The stakeholder's perspective

Smith KC, Grob R, Connor A, Matchette AS, Fasaye G-A, May BJ, McCollough M, Warne E, Roth J, Visvanathan K

P6-08-03 Barriers to enrolling in observational trials for patients with stage IV breast cancer

Machado Heredia ML, Kuriakose A, Menegaz BA, Thompson AM, Lim B, Javaid H

P6-08-04 Geographical variation of social deprivation, cardiovascular and other comorbidities in 226,516 patients with early breast cancer in England: results from a National Registry Dataset Analysis

Waterhouse JV, Welch CA, Battisti NML, Adlam D, Sweeting MJ, Paley L, Lambert P, Deanfield JE, de Belder M, Peake MD, Ring A

P6-08-05 Racial and economic disparities in social support and symptom distress among women diagnosed with early-stage breast cancer

Abujaradeh H, Mazanec S, Sereika SM, Brufsky AM, Bender CM, Connolly MC, Rosenzweig MQ

P6-08-06 Uncovering gaps in patient-provider perceptions of triple-negative breast cancer care: Addressing disparities through education-advocacy partnerships

Ackbarali T, Fairley R, Traina TA

P6-08-07 Reasons for reduced willingness to participate in clinical trials during the COVID-19 pandemic: The Translational Breast Cancer Research Consortium (TBCRC) 057 Survey

Smith KL, Mead-Harvey C, Mazza GL, Holler AE, Shinn E, Frank E, Melisko M, Eaton C, Salamone JM, Pollastro T, Spears P, Wolff AC, Rocque GB

P6-08-08 Withdrawn

P6-08-09 Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival

Kaur M, Patterson A, Molina-Vega J, Rothschild HT, Clelland E, Abel MK, Esserman LJ, Olopade OI, Mukhtar R

P6-08-10 Cash, Commercial Negotiated Prices, and Correlations with Neighborhood Poverty Levels for Shoppable Breast Cancer Services

Noveihed A, Lall N, Hussaini Q, Elias R, Gupta A, Sedhom R

P6-08-11 Hyperglycemia in Hispanic MBC patients treated with alpelisib: single institution retrospective study

Chamorro Y, Mahtani R, Monestime S, Ahluwalia M, Rubens M, Harpalani N, Sandoval-Leon A

P6-08-12 Toward comprehensive cancer prevention for women experiencing homelessness: Demonstrating the need for onsite mammography, education, navigation, and cross cancer screenings

Combs P, Hurwitz HM, Mariner M, Anderson N, Mccaffrey K, Jackson R, Kilic S, Onger T, Sanders K, Stimpert T, Suwarna J, Weleff J, Shah C

P6-08-13 Home-based treatment with subcutaneous (SC) trastuzumab - only a pandemic solution? Real world evidence (RWE) analysis

Radecka B, Joanna H-K, Sawka D, Sarga J, Noworolska B, Sawicka J, Duda E, Obrušnik N, Zajęc P.

P6-08-14 Breast cancer treatment choices and results in Hispanic women without funding for radiation

Leon-Camarena MDL, Reddy N, Ellison K, Goodgame B

Psychosocial, QOL, and Educational Aspects: Social and Education Issues - Dr-Pt Communication

P6-09-01 Treatment goals and quality of life (QOL) in a survey of patients with ER+/HER2-metastatic breast cancer (mBC)

Sammons SL, Meisel J, Shanahan K, Pluard T, Kozlowski M, Carroll D, Attias E

P6-09-02 Knowledge of tumor/blood genomic testing (NGS) and ESR1 mutations in a survey of patients with ER+/HER2- metastatic breast cancer (mBC)

Meisel J, Sammons SL, Shanahan K, Pluard T, Kozlowski M, Carroll D, Attias E

P6-09-03 Examining recollections of Black women with breast cancer who participated in clinical trials: A grounded practical theory study of patient-provider communication

Ridley-Merriweather KE

P6-09-04 Oncologist-reported Barriers and Facilitators to enrolling patients in optimization trials that test less intense cancer treatment

Rocque GB, Courtney A, Frazier RM, Valerie L, Ingram SA, Smith ML, Wagner LI, Zubkoff L, Tung N, Wallner LP, Wolff AC

P6-09-05 Using mixed methods to examine clinician and patient use of terminology to describe Trastuzumab biosimilars

Papautsky E, Salunke D, Montague H, Carlson M, Johnson S, Attai D, Lustberg M

Treatment: Therapeutic Strategies - Novel Targets and Targeted Agents

P6-10-01 The executioner protein for immunogenic anticancer drug-induced necrosis in ER positive breast cancer is transient receptor potential Melastatin Member 4

Ghosh S, Yang R, Duraki D, Kim JE, Zhu J, Livezey M, Boudreau M, Park BH, Fan T, Nelson ER, Hergenrother PJ, Shapiro DJ

P6-10-02 Self-assembled nano drugs of pyrozinib and indocyanine green based on photothermal photodynamic therapy

Xuhong J, Deng J, Jiang J, Qi X

P6-10-03 Datopotamab Deruxtecan (Dato-DXd) in advanced triple-negative breast cancer (TNBC): Updated results from the Phase 1 TROPION-PanTumor01 Study

Bardia A, Krop I, Meric-Bernstam, Tolcher AW, Mukohara T, Lisberg A, Shimizu T, Hamilton Ep, Spira AI, Papadopoulos KP, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Kogawa T

P6-10-04 Homologous recombination deficiency across subtypes of primary breast cancer

Engebretsen C, Yndestad S, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestøl RK, Minsaas L, Leirvaag B, Iversen G, Gilje B, Blix E, Espelid H, Lundgren S, Geisler J, Vassbotn LJ, Aase HS, Aas T, Llop-Guevara A, Serra V, Lønning PE, Knappskog S, Eikesdal HP

P6-10-05 Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition

Bland P, Saville H, Read A, Wai P, Muirhead G, Curnow L, Nieminuszczy J, Ravindran N, John M, Hedayat S, Barker H, Wright J, Yu L, Mavrommati I, Peck B, Allen M, Gazinska P, Pemberton H, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Barlow S, Kalirai H, Coupland S, Broderick R, Alsafadi S, Houy A, Stern M-H, Pettit S, Choudhary J, Haider S, Niedzwiedz W, Lord C, Natrajan R

P6-10-06 A preoperative window-of-opportunity study of imlunestrant in estrogen receptor-positive, HER2-negative early breast cancer: Results from the EMBER-2 study

Neven P, Stahl N, Vidal M, Martín M, Harbeck N, Kaufman PA, Bidard F-C, Fasching PA, Aftimos P, Hamilton EP, Carter S, Schmid P, Wheatley D, Bhave M, Hunt KK, Kulkarni SA, Ismail-Khan R, Karacsonyi C, Estrem ST, Ozbek U, Ciruelos E

P6-10-07 CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer

Brown v, House N, Ramsden P, Ho K, Wu H-J, Wilker E, Guo J, Chen M, Wilson D, Bifulco N, Wenglowsky S, Choi YJ, Faia K

P6-10-08 Evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers

Mughees M, Tacam Jr M, Tan A, Gonzalez H, Villodre ES, Debeb B, Tripathy D, Bartholomeusz G, Lee J, Dalby K, Bartholomeusz C

P6-10-09 Mutational landscape of breast cancer patients in ROME trial: preliminary results

Botticelli A, Scagnoli S, Conte P, Cremolini C, Ascierto PA, Cappuzzo F, Aglietta M, Mazza F, Capoluongo E, Blandino G, Malapelle U, Nuti M, D'Amati G, Cerbelli B, Pruneri G, Biffoni M, Giannini G, Cognetti F, Curigliano G, Marchetti P

P6-10-10 Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan

Bidard F-C, Bello Roufai D, Medford AJ, Tirunagaru V, Doebele RC, Bardia A

P6-10-11 Engineered neoantigen-specific T cell receptors to treat metastatic breast cancer

Shafer P, Leung WK, Woods ML, Rodriguez-Plata C, Ali A, Nalawade S, Kelley LM, Joubert J, Manliguez A, Vasileiou S, Fuqua SA, Lulla P, Rooney C, Leen A, Hoyos V

P6-10-12 Discovery and development of next-generation estrogen receptor mutant inhibitors using DNA-encoded chemical library screening

Palaniappan M, Bohren KM, Wang Y, Young DW, Fuqua SA, Matzuk MM

P6-10-13 An update to a Phase I trial of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors with HER2-negative breast cancer expansion cohorts

Hilton J, Renouf D, Cescon DW, Hansen A, Abdul Razak A, Stayner LOA, Denny TA, Roberts-Thomson E, Chen D-Y, Bray M, Bedard P

P6-10-14 Lysosomal acid lipase (LIPA) as a novel therapeutic vulnerability for treating TNBC

Viswanadhapalli S, Liu X, Pratap U, Sareddy GR, Weintraub ST, Raj GV, Ahn J-M, Vadlamudi RK

P6-10-15 Targeting MARCKS in inflammatory breast cancer increased paclitaxel sensitivity

Manai M, Bini I, Finetti P, Bichiou F, Reduzzi C, Ben Hamida N, Lopez M, Rahal K, Mrad K, Manai M, Cristofanilli M, Boussem H, Doghri R, Kharrat M, Bertucci F

P6-10-16 Restoring the efficacy of standard of care in treatment-refractory ER+ breast cancer

Saatci O, Cetin M, Tokat UM, Marrangoni E, Sahin O

P6-10-17 Pharmacological strategies to target circadian clock genes in TNBC

Pan Y, Jayachandran P, Roussos Torres ET, Kay SA

P6-10-18 Developing novel lysyl oxidase (LOX) inhibitors to overcome chemotherapy resistance in triple negative breast cancer

Cetin M, Saatci O, Akbulut O, Beneker C, Rezaeian A-H, Chernov M, McInnes C, Sahin O

P6-10-19 Screening of GPCR-targeting drugs for repositioning in breast cancer

Abdulkareem N, Bhat Raksha, Powell R, Chikermane S, Yande S, Trinh L, Abdelnasser H, Ruiz A, Sobieski M, Nguyen N, Johnson C, Johnson M, Stephan C, Trivedi M

Tumor Cell and Molecular Biology: Metabolism and Breast Cancer

P6-11-01 Scaffold attachment factor B1 modulates cholesterol pathways in triple-negative breast cancer

Ghidey M, Murthy D, Yang S, Ahn S, Park JH, Kaiparettu B

P6-11-02 Mitochondria-nuclear crosstalk regulates the WNT pathway in triple-negative breast cancer

Yang S, Park JH, Kim S, Ghidey M, Kaiparettu B

P6-11-03 Lipid-rich environment induces epigenetic reprogramming in non-transformed breast epithelial cells enhancing a mammary cell plasticity

Bustamante Eduardo M, Cottone G, Khan S, Clare S

P6-11-04 Novel roles of Inosine Monophosphate Dehydrogenase 2 (IMPDH2) in TNBC doxorubicin resistance

da Silva Fernandes T, Bianchi-Smiraglia A

P6-11-05 Carnitine palmitoyltransferase 1A (CPT1A) mediates therapeutic response to endocrine therapy in estrogen receptor positive breast cancer

Hussein S, Gatza ML, Ganesan S

P6-11-06 Capecitabine, eribulin and paclitaxel differentially impact the metabolite pool in metastatic breast cancer patients

Gandhi S, Roy AM, Takabe K, Rosario S

P6-11-07 Role of insulin resistance in HR+ mammary carcinogenesis

Buque A, Picatoste MB, Bloy N, Yammine L, Leahey R, Sato A, Johnson E, McGraw TE, Galluzzi L

P6-11-08 Non-transformed breast epithelial cells show neural-like gene signature after lipid exposure

Cottone G, Bustamante Eduardo M, Yadav S, Khan S, Clare S

P6-11-09 Effects of a 12 Week breast cancer exercise program on the Mitochondrial Derived Peptide MOTS-c

Shen C, Baron K, Toyama M, Cohen P, Wan J, Kumagai H, Pagano I, Yamada P, Teranishi-Hashimoto C, Fukui J

P6-11-10 Investigating the role of mitochondrial protein translation in the metabolic adaptation of chemoresistant triple negative breast cancer

Berner MJ, Baek L, Lee J, Lorenzi PL, Leng M, Saltzman AB, Malovannaya A, Dobrolecki LE, Sallas C, Lewis MT, Echeverria GV

P6-11-11 Breast cancer stem cell marker, CD24 regulates metabolic reprogramming in triple negative breast cancer

Murthy D, Dutta D, Yang S, Park J, Kaiparettu B

P6-11-12 Withdrawn

P6-11-13 Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

Yang F, Xiao Y, Ding J-H, Jiang Y-Z, Shao Z-M

P6-11-14 Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment

Baek L, Lee J, Pendleton KE, Berner MJ, Goff E, Tan L, Martinez S, Mahmud I, Arriojas A, Zhurkevich A, Wang T, Meyer M, Lim B, Barrish JP, Porter W, Zarringhalam K, Lorenzi PL, Echeverria GV

P6-11-15 Lipid accumulation in residual triple negative breast cancer cells surviving chemotherapy treatment

Pendleton KE, Baek ML, Lee J, Tan L, Johnson HL, Dobrolecki LE, Barrish JP, Lewis MT, Lorenzi PL, Stossi F, Echeverria G

P6-11-16 Withaferin A induces metabolic crisis in breast cancer cell lines via decreasing c-myc expression: potential therapeutic implication

Khan A, Siddiqui S, Massey S, Saluja D, Husain SA, Iqbal, MA

Tumor Cell and Molecular Biology: Signaling Pathways

P6-12-01 ALCAM (Activated Leukocyte Cell Adhesion Molecule) is associated with HGF/MET signalling pathway in different subtypes of breast cancer

Yang Y, Sanders AJ, Jiang WG

P6-12-02 Connecting fluctuations in estrogen production, release, and action with hormone-dependent gene expression in breast cancers

Kim HB, Kraus WL

P6-12-03 Proinflammatory and estrogen signaling modulates the chemoresistance and metastasis of breast cancer cells through post-translational modifications of pioneering factor FOXA1

Li S, Franco HL, Kim H, Plagens RN, Mendez-Giraldez R, Tubbs C, Malladi V, Garay J

P6-12-04 An inducible lineage tracing system for the identification of tumor-initiating cells

Souto EP, Lewis MT

P6-12-05 The role of endothelial-specific AXL and its associated signaling pathways in the tumor microenvironment

Lalonde A, Côté J-F

P6-12-06 Neratinib vs. Trastuzumab plus Ribociclib in ERBB2-positive breast cancer: Preclinical mechanistic efficacy study

Koirala N, Aske J, Lin X, Dey N, De P

P6-12-07 Cooperative NF- κ B and Notch1 signaling promotes expression of the dissemination promoting protein, MenalNV in breast cancer

Duran C, Karagiannis G, Chen X, Sharma V, Enterberg D, Oktay M, Condeelis J

P6-12-08 Identifying FOXA1 binding partners using proximity labeling

Plagens RN, Li S, Mills CA, Herring L, Franco HL. University of North Carolina Chapel Hill.

P6-12-09 Retinoic acid receptor (RAR) signalling plays a role in neratinib (NER) resistance in HER2+ breast cancer (BC) cell lines

O'Reilly D, Eli LD, Wong A, Crown J, Collins DM

Tumor Cell and Molecular Biology: Stem/Progenitor Cells

P6-13-01 Epithelial-Mesenchymal transition and tumor stem cells network identification in breast carcinomas: In Silico study

Dybal V, Cavalcante BR, Rocha RV, Gurgel C

Tumor Cell and Molecular Biology: Tumor Progression, Invasion, and Metastasis

P6-14-01 Invasively distinct subpopulations cooperate via a laminin-332/Rac1 axis in triple-negative breast cancer

Yoon SB, Mouw J, Chen L, Wu H, Marcus A

P6-14-02 Hope for OTHERS – An organ donation program for metastatic breast cancer research

Oesterreich S, Miller L, Rosenzweig MQ, Bartholow TL, Yates M, Elangovan A, Savariau L, Casey AN, Priedigkeit N, Ding K, Wedn A, Liu JB, Brown DD, Hyder T, Pecar G, Carleton N, Trejo Bittar H, Geisler D, Lopez-Nunez O, Clark AM, Wells A, Roy P, Puhalla S, Howard N, Needles C, Trent S, Walker S, Hodgdon C, Bhargava R, Atkinson JM, Lee AV

P6-14-03 Oestrogen represses Noggin expression by interfering BMP/Smad signalling in ER positive breast cancer cells

Liu M, Ye L, Jiang WG

P6-14-04 HIF1's promotion of FASN-dependent palmitoylation of sonic hedgehog

Engbretson H, McClellan B, deGraffenried L

P6-14-05 Regulation of cellular identity and spatial organization during collective breast cancer invasion

Doak AE, Cheung KJ

P6-14-06 Histopathological and immune characterization of liver metastases from patients with breast cancer

Leduc S, De Schepper M, Vermeulen P, Floris G, Biganzoli E, Donckier V, Bohlok A, Gerling M, Richard F, Maetens M, Jaekers J, Topal B, Latacz E, Van Baelen K, Geukens T, Nguyen HL, Dirix L, Larsimont D, Van Kerckhove S, Caetano Oliveira R, Kulka J, Lucidi V, Meyer Y, Verhoef C, Santos E, Salamon F, Madaras L, Szasz AM, Borbála S, Dede K, Engstrand J, Moro CF, Desmedt C

P6-14-07 Genetic ablation of ACF7, a member of the +TIP family of microtubule-binding proteins, impairs metastasis of HER2-positive breast cancer

Cusseddu R, Côté J-F

P6-14-08 Epithelial/stromal cross talks that induce malignant transition of human ductal carcinoma in situ

Rastogi A, Behbod F, Navin N, Lin J, Li L, Li H, Godwin AK, Thompson AM, Fields T, Hong Y

P6-14-09 Non-canonical Wnt/Ror2 signaling regulates tumor cell invasion and dissemination in breast cancer through cell-matrix crosstalk

Si H, Zhao N, Pedroza A, Creighton C, Rosen J, Roarty K

P6-14-10 Jagged-1 promotes breast cancer metastasis through the lymphatic system

Gordon B, Swaminathan B, Naiche L, Kitajewski J

P6-14-11 Exosome-mediated Circ-CRSP1 promotes tumor proliferation and metastasis through stabilizing ELAVL1 protein and suppresses anti-tumor immune response in regulating the progression of triple-negative breast cancer

Yang S, Tang J

P6-14-12 Evaluation of changes in sequencing quality and transcriptomic profiles with increasing post-mortem interval: results from an optimization experiment within the UPTIDER tissue donation program

Richard F, Geukens T, Marano G, Van Den Bogaert, De Schepper M, Maetens M, Mahdami A, Van Baelen K, Nguyen H-L, Pabba A, Leduc S, Isnaldi E, Hajjirloo M, Bachir I, Vanderheyden E, Boeckx B, Lambrechts D, Smeets A, Nevelsteen I, Punie K, Neven P, Wildiers H, Biganzoli E, Floris G, Desmedt C

P6-14-13 Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type

Vuoti S, Saari M, Narasimha K, Reinikainen K

P6-14-14 Advancing research on metastatic breast cancer: the UPTIDER post-mortem tissue donation program

Geukens T, De Schepper M, Van Baelen K, Richard F, Maetens M, Mahdami A, Nguyen H-L, Isnaldi E, Pabba A, Leduc S, Bachir I, Hajjirloo M, Vanden Berghe E, Hatse S, Leucci E, Baietti MF, Sflomos G, Brisken C, Derksen P, Scheele C, Vandecaveye V, Smeets A, Nevelsteen I, Punie K, Neven P, Biganzoli E, Wildiers H, Van Den Bogaert W, Floris G, Desmedt C

P6-14-15 PD-L1 expression regulated by JAK/STAT signaling pathway contributes to cell migration and invasion in breast cancer

Chen J

P6-14-16 Claudin-9 and its subcoat anchorage proteins ZO-1 and ZO-3 in breast cancer, the clinical and therapeutic significance

Zhuang X, Jiang WG, Davies E, Xu B, Martin TA

P6-14-17 Endomucins and their expression in breast cancer and the cellular and therapeutic impact

Li AX, Martin TA, Ye L, Sanders AJ, Ruge F, Lane J, Davies E, Jiang WG

P6-14-18 Effect of 3q oncogene SEC62 on migration and proliferation of triple-negative breast cancer cells

Zimmermann JSM, Cullmann A, Kaya A, Doerk M, Linxweiler M, Radosa MP, Lang S, Jung M, Solomayer EF, Radosa JC

2022 AWARD RECIPIENTS

William L. McGuire Memorial Lecture

Wednesday, December 7, 2022, 8:30 AM

The McGuire Award was established in 1992 to honor William L. McGuire, MD, who co-founded the San Antonio Breast Cancer Symposium in 1977 along with Charles A. Coltman, MD.

Leveraging Preclinical Models for Translational Breast Cancer Research

Recipient: Jeffrey Rosen, PhD

Baylor College of Medicine
Houston, TX

Susan G. Komen Brinker Award For Scientific Distinction In Basic Science

Thursday, December 8, 2022, 12:30 PM

Recipient: Norman Wolmark, MD, FACS, FRCSC

University of Pittsburgh
Pittsburgh, PA

Susan G. Komen Brinker Award For Scientific Distinction In Clinical Research

Friday, December 9, 2022, 11:30 AM

Recipient: Norman Wolmark, MD, FACS, FRCSC

University of Pittsburgh
Pittsburgh, PA

AACR Distinguished Lectureship In Breast Cancer Research

Wednesday, December 7, 2022, 12:30 PM

TBA

AACR Outstanding Investigator Award For Breast Cancer Research

Friday, December 9, 2022 8:30 AM

TBA

SABCS Basic Science Scholar Award Recipients

For laboratory-based investigators-in-training whose work focuses on the biology of breast cancer and preclinical models of its development and progression.

Potentiating Alpelisib in PI3K Pathway Overactive Triple Negative Breast Cancers

P1-13-04 Tuesday, December 6, 2022, 5:00 PM

David C. Boyd, BS, Virginia Commonwealth University, Richmond, VA

Hepatic Leukemia Factor (HLF), a potential therapeutic target in triple negative breast cancer

PD5-07 Wednesday, December 7, 2022, 7:00 AM

Ibrahim Bouakka, MS, Gustave Roussy Cancer Campus, Villejuif, France

DAPK3 modulates migration and invasion of triple negative breast cancers

PD5-05 Wednesday, December 7, 2022, 7:00 AM

Junkai Wang, B.Sc, Baylor College of Medicine, Houston, TX

Unravelling the clinicopathological and functional significance of Replication Protein A (RPA) heterotrimeric complex in sporadic breast cancers

P3-05-18 Wednesday, December 7, 2022, 5:00 PM

Mashaël Algethami, MSc, BSc, Biodiscovery Institute, University of Nottingham

Stromal mediators of lymphocyte exclusion and dysfunction in triple negative breast cancer

PD9-01 Wednesday, December 7, 2022, 5:00 PM

Julia Yu Jia Chen, MBBS, FRACP, Kinghorn Cancer Centre/Garvan Institute of Medical Research, Australia

Role of immunosuppressive JNK pathway in the tumor microenvironment among Triple Negative Breast Cancer subtypes in IBCSG Trial 22-00

PD9-07 Wednesday, December 7, 2022, 5:00 PM

Andrea Joaquin Garcia, MA, Institut Jules Bordet, Brussels, Belgium

NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer.

P4-08-05 Thursday, December 8, 2022, 7:00 AM

Tejaswini Reddy, BA, Houston Methodist Research Institute, Houston, TX

SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2- breast cancer

P5-02-16 Thursday, December 8, 2022, 5:00 PM

Courtney T. van Geelen, BSc, Peter MacCallum Cancer Centre, Australia

Non-canonical Wnt/Ror2 signaling regulates tumor cell invasion and dissemination in breast cancer through cell-matrix crosstalk

P6-14-09 Friday, December 9, 2022, 7:00 AM

Hongjiang Si, PhD, Baylor College of Medicine, Houston, TX

ZNF689 deficiency promotes intratumor heterogeneity and resistance to immune checkpoint blockade in triple-negative breast cancer

GS5-05 Friday, December 9, 2022, 12:00 PM

Li-Ping Ge, BS, Fudan University Shanghai Cancer Center, Shanghai, China

SABCS Clinical Scholar Award Recipients

For clinical scientists-in-training who are actively pursuing clinical or clinical/translational research in breast cancer.

The Impact of Structural Racism on Breast Cancer Stage at Presentation

PD1-01 Tuesday, December 6, 2022, 5:00 PM

Alexandra Hernandez, MD, MPH, University of Miami Miller School of Medicine, Miami, FL

Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with HR+/HER2- early breast cancer: a systematic review and meta-analysis

P1-07-01 Tuesday, December 6, 2022, 5:00 PM

Diogo Martins Branco, Institut Jules Bordet, MD, MSc, Institut Jules Bordet, Anderlecht, Belgium

Virtual molecular and precision medicine (vMAP) clinic to improve access to clinical trials for patients with metastatic breast cancer: an academic-community collaboration

P1-08-01 Tuesday, December 6, 2022, 5:00 PM

Lindsey Mortensen, BS, University of Minnesota Medical School, Minneapolis, MN

HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy

P2-11-04 Wednesday, December 7, 2022, 7:00 AM

Emma Zattarin, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Risk of breast cancer after false-positive mammography recalls: a matched cohort study

P4-03-09 Thursday, December 8, 2022, 7:00 AM

Xinhe Mao, MSc, Karolinska Institutet, Sweden

Low-dose aspirin prescriptions and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up

P4-03-02 Thursday, December 8, 2022, 7:00 AM

Elisabeth Solmunde, BSc, Aarhus University and Aarhus University Hospital, Denmark

Brazilian Randomized Study - BREAST-MRI Trial - Impact of Preoperative Magnetic Resonance in the Evaluation for Breast Cancer Conservative Surgery: Local recurrence and surgical outcomes

PD15-08 Thursday, December 8, 2022, 5:00 PM

Bruna Salani Mota, PhD, ICESP/USP, São Paulo

Racial Disparities in the Use of Preoperative Breast MRI after Breast Cancer Diagnosis

PD16-01 Friday, December 9, 2022, 7:00 AM

Sara Ginzberg, MD, University of Pennsylvania Health System, Philadelphia, PA

Histopathological and immune characterization of liver metastases from patients with breast cancer

P6-14-06 Friday, December 9, 2022, 7:00 AM

Sophia Leduc, M.Sc, KU Leuven, Belgium

InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas

GS5-06 Friday, December 9, 2022, 12:00 PM

Lily Xu, B.S., University of Texas Southwestern Medical School, Dallas, TX

Coltman Scholar Award Recipients

In memory of Dr. Charles A. Coltman, co-founder of SABCS, to commemorate the significant contributions he made to oncology medicine. For clinical scientists-in-training.

Evaluation of the Sensitivity to Endocrine Therapy Index (SET_{2,3}) in Early Male Breast Cancer: Results from an analysis in the EORTC 10085/TBCRC/BIG/NCTN International Male Breast Cancer Program

PD6-11 Wednesday, December 7, 2022, 7:00 AM

Danielle B. Zakon, MD, The University of Texas MD Anderson Cancer Center, Houston, TX

Deconstructing the molecular characteristics of ER+ HER2+ early breast cancer in the POETIC trial using multiplex immunofluorescence and gene expression profiles

P2-03-08 Wednesday, December 7, 2022, 7:00 AM

Xixuan Zhu, MRes, The Institute of Cancer Research, United Kingdom

Depression and breast cancer recurrence among female veterans in the United States: a retrospective cohort study

P3-03-08 Wednesday, December 7, 2022, 5:00 PM

Maya Aboumrad, MPH, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Obesity is associated with poor breast cancer prognosis, particularly among women with low socioeconomic position

PD12-02 Thursday, December 8, 2022, 7:00 AM

Sixten Harborg, BSc. med, Aarhus University Hospital, Aarhus, Denmark

Does reducing the frequency of regularly scheduled physical examinations affect recurrence detection in patients with early breast cancer?

P5-04-04 Thursday, December 8, 2022, 5:00 PM

Ana-Alicia Beltran-Bless, MD, Ottawa Hospital Cancer Centre, Ottawa, ON

AACR Associate Member Award Recipients

For presenters of meritorious abstracts who are Associate Members of the American Association for Cancer Research (AACR).

Racial disparity in tumor microenvironment and outcomes in residual breast cancer treated with neoadjuvant chemotherapy

GS1-02 Tuesday, December 6, 2022, 2:00 PM

Burcu Karadal, MD, Albert Einstein College of Medicine, Bronx, NY

Racial disparities in neoadjuvant chemosensitivity and survival in early breast cancer: A national database study.

PD1-07 Tuesday, December 6, 2022, 5:00 PM

Arya Mariam Roy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Spatial transcriptomics reveals a substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications

PD4-01 Wednesday, December 7, 2022, 7:00 AM

Xiaoxiao Wang, MD, Institut Jules Bordet, Brussels, Belgium

Comedications at Breast Cancer diagnosis impact overall survival: results from the ADRENALINE (Atlas for DRug and brEast caNcer survivAl INtErAction) study (n=235,368)

P3-07-06 Wednesday, December 7, 2022, 5:00 PM

Elise Dumas, MSc, Institut Curie, Paris

Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort

PD9-06 Wednesday, December 7, 2022, 5:00 PM

Holly Tovey, MSc, The Institute of Cancer Research, Surrey, United Kingdom

Population-based survival outcomes of pure vs mixed invasive lobular breast carcinoma in Ontario, Canada

P4-03-11 Thursday, December 8, 2022, 7:00 AM

David W. Lim, MDCM, MEd, PhD, Women's College Research Institute, Toronto, ON

Characterization and validation of biologically-driven HER2-positive breast cancer subgroups in the ALTTO and NeoALTTO clinical trials

P4-09-05 Thursday, December 8, 2022, 7:00 AM

Mattia Rediti, MD, Institut Jules Bordet, Université Libre de Bruxelles, Belgium

Proinflammatory Dietary Patterns and Risk of Total and Subtypes of Breast Cancer Among US Women

P4-03-14 Thursday, December 8, 2022, 7:00 AM

Andrea Romanos-Nanclares, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Clonal hematopoiesis of indeterminate potential after (neo)adjuvant chemotherapy versus endocrine therapy for early breast cancer: the CIRCE-eBC prospective cohort study

P5-14-03 Thursday, December 8, 2022, 5:00 PM

Stefania Morganti, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Adjuvant Trastuzumab Emtansine Versus Paclitaxel plus Trastuzumab for Stage I HER2+ Breast Cancer: 5-year results and correlative analyses from ATEMPT (TBCRC033)

PD18-01 Friday, December 9, 2022, 7:00 AM

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA

Arti Hurria Award Recipients

Association between the CARG-BC score and clinical decline after adjuvant chemotherapy in fit older adults with breast cancer: Results from the Hurria Older Patients (HOPE) Prospective Study.

PD6-01 Wednesday, December 7, 2022, 7:00 AM

Jingran Ji, City of Hope

Serum methylmalonic acid concentrations at breast cancer diagnosis strongly correlate with frailty: a retrospective cross-sectional study

PD6-03 Wednesday, December 7, 2022, 7:00 AM

Qi Wu, KU Leuven

EXECUTIVE COMMITTEE

Carlos L. Arteaga

UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX

Angela DeMichele

University of Pennsylvania, Philadelphia, PA

Margaret Foti

American Association for Cancer Research, Philadelphia, PA

David Gius

UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Sharon Hill

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)

Virginia G. Kaklamani

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

Kate Lathrop

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)

Ruben A. Mesa

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

PROGRAM PLANNING COMMITTEE

Fabrice Andre

Gustave Roussy, Ile de France, France

Carlos L. Arteaga

AACR (Co-Chair), UT Southwestern, Harold C. Simmons Cancer Center, Dallas, TX

Andrea Barrio

Memorial Sloan Kettering Cancer Center, New York, NY

Thelma Brown

University of Alabama at Birmingham, Birmingham, AL

Carlos Caldás

University of Cambridge, Cambridge, United Kingdom

Christina Curtis

Stanford University, Stanford, CA

Gary C. Chamness

Baylor College of Medicine, Houston, TX (ex-officio)

Angela DeMichele

University of Pennsylvania, Philadelphia, PA

Rebecca Dent

National Cancer Center, Singapore

Margaret Foti

American Association for Cancer Research, Philadelphia, PA

David Gius

UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Shom Goel

Peter MacCallum Cancer Centre, Melbourne, Australia

Virginia G. Kaklamani (Co-Chair)

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX

Seema A. Khan

Northwestern University, Chicago, IL

Celina Kleer

University of Michigan Medical School, Ann Arbor, MI

Kate Lathrop

Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, TX (ex-officio)

Sibylle Loibl

GBG Forschungs GmbH, Neu-Isenburg, Germany

Ann Partridge

Dana-Farber Cancer Institute, Boston, MA

Charles M. Perou

University of North Carolina, Chapel Hill, NC

Manjeet Rao

UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Mothaffar Rimawi

Baylor College of Medicine, Houston, TX

Peter Schmid

Bart's Cancer Institute Queen Mary University of London, London, United Kingdom

Kalliopi Siziopikou

Northwestern University, Chicago, IL

Patty Spears

UNC Lineberger Comprehensive Cancer Center, Shanghai, China

Melinda Telli

Stanford University, Stanford, CA

Alana Welm

University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Wendy Woodward

UT MD Anderson Cancer Center, Houston, TX

Richard Zellars

Indiana University School of Medicine, Indianapolis, IN

ABSTRACT REVIEW COMMITTEE

Kathy S. Albain

Loyola University Chicago, Maywood, IL

Carey Anders

Duke Cancer Center, Durham, NC

Fabrice André

Institut Gustave Roussy, Villejuif, France

Banu Arun

University of Texas MD Anderson Cancer Center,
Houston, TX

Hoda Badr

Baylor College of Medicine, Houston, TX

Justin Balko

Vanderbilt University Medical Center, Nashville, TN

Andrea Barrio

Memorial Sloan Kettering Cancer
Center, New York, NY

John Bartlett

Ontario Institute for Cancer
Research, Ontario, Canada

Philippe Bedard

Princess Margaret Cancer Centre,
Toronto, Ontario, Canada

Jennifer Bellon

Dana Farber Cancer Institute, Boston, MA

Alexander Bishop

UT Health San Antonio San Antonio, TX

Anne Blaes

University of Minnesota, Minneapolis, MN

Melissa L. Bondy

Stanford Medicine Stanford, CA

Judy Boughey

Mayo Clinic Rochester, MN

Andrew Brenner

UT Health San Antonio, San Antonio, TX

Adam Brufsky

University of Pittsburgh, Pittsburgh, PA

Mark E Burkard

University of Wisconsin Madison, Madison, WI

Erin Burke

University of Kentucky, Lexington, KY

Jenny Chang

Houston Methodist Hospital, Houston, TX

Robert Coleman

University of Sheffield, Sheffield, United Kingdom

Richard Crownover

University of Arkansas for Medical
Science, Little Rock, AR

David Danforth, Jr.

NIH, Bethesda, MD

Angela DeMichele

University of Pennsylvania, Philadelphia, PA

Carsten Denkert, MD

Institut für Pathologie Marburg, Germany

Christine Desmedt

KU Leuven, Leuven, Belgium

Nora Disis

University of Washington, Seattle, WA

Susan Domchek

University of Pennsylvania, Philadelphia PA

Heide Ford

University of Colorado, Aurora, CO

Prue Francis

Peter MacCullum Cancer Centre,
Melbourne, Australia

Sarah Friedewald

Northwestern Medicine, Lake Forest, IL

Patricia A. Ganz

UCLA Jonsson Comprehensive
Cancer Center, Los Angeles, CA

Judy E. Garber

Dana Farber Cancer Institute, Boston, MA

David Gius

UT Health San Antonio, San Antonio, TX

Shom Goel

Peter MacCallum Cancer Centre,
Melbourne, Australia

Matthew P. Goetz

Mayo Clinic Rochester, MN,

William J. Gradishar

Northwestern University, Chicago, IL

Joe Gray

OHSU, Lake Oswego, OR

Valentina Guarneri

University of Padova, Padova, Italy

Nadia Harbeck

University of Munich, Munich, Germany

Norah Henry

University of Michigan, Ann Arbor, MI

Dawn Hershman

Columbia University Medical Center, New York, NY

Sara A. Hurvitz

UCLA Jonsson Comprehensive Cancer Center, Santa Monica, CA

James Ingle

Mayo Clinic Rochester, MN

Claudine Isaacs

Georgetown University, Washington, DC

Reshma Jagsi

University of Michigan, Ann Arbor, MI

Stephen Johnston

Royal Marsden Hospital, London, United Kingdom

Kevin Kalinsky

Emory University, Atlanta, GA

Seema Khan

Northwestern University, Chicago, IL

Ian Krop

Yale University, New Haven, CT

Allison Kurian

Stanford University School of Medicine, Stanford, CA

Matteo Lambertini

University of Genova, Genova, Italy

Adrian Lee

University of Pittsburgh, Pittsburgh, PA

A. Marilyn Leitch

UT Southwestern Medical Center, Dallas, TX

Nancy Lin

Dana Farber Institute, Boston, MA

Hannah Linden

Seattle Cancer Care Alliance, Seattle, WA

Sherene Loi

Peter MacCallum Cancer Centre Melbourne, Australia

Sibylle Loibl

German Breast Group and University Frankfurt, Neu-Isenburg, Germany

Maryam Lustberg

Yale University, New Haven, CT

Fiona MacNeill

Royal Marsden, London, United Kingdom

David Mankoff

University of Pennsylvania, Philadelphia, PA

Suleiman Massarweh

MyDoctorM, Palo Alto, CA

Kandace McGuire

VCU, Massey Cancer Center, Richmond, VA

Todd Miller

Geisel School of Medicine at Dartmouth, Lebanon, NH

Elizabeth A. Mittendorf

Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

Julie R. Nangia

Baylor College of Medicine, Houston, TX

Ruth O'Regan

University of Wisconsin, Madison, WI

Tolga Ozmen

University of Miami, Miller School of Medicine, Miami, FL

Ann H. Partridge

Dana Farber Institute, Boston, MA

Electra D. Paskett

Ohio State University College of Medicine, Columbus, OH

Sujata Patil

Cleveland Clinic, Cleveland, OH

Frederique Penault-Llorca

Centre Jean Perrin, Clermont-Ferrand, France

Charles M. Perou

University of North Carolina, Chapel Hill, NC

Lajos Pusztai

Yale University, New Haven, CT

Jorge Reis-Filho

Memorial Sloan Kettering Cancer Center, New York, NY

David Rimm

Yale University School of Medicine, New Haven, CT

Mark E. Robson

Memorial Sloan Kettering Cancer Center, New York, NY

Hope S Rugo

University of California, San Francisco, San Francisco, CA

Rachel Schiff

Baylor College of Medicine Houston, TX

Robert J. Schneider

NYU School of Medicine, New York, NY

Stuart J. Schnitt

Brigham and Womens Hospital, Dana Farber Cancer Institute, Boston, MA

Karla Sepulveda

Baylor College of Medicine, Houston, TX

Ivana Sestak

Queen Mary University of London, London, United Kingdom

Dennis C. Sgroi

Massachusetts General Hospital and Harvard Medical School, Boston, MA

Priyanka Sharma

University of Kansas Medical Center, Westwood, KS

Shayna Showalter

University of Virginia, Charlottesville, VA

William Sikov

Women and Infants Hospital of Rhode Island, Providence, RI

Kalliopi P. Siziopikou

Northwestern University, Chicago, IL

George W. Sledge, Jr.

Stanford, Stanford, CA

Anna Sorace

University of Alabama at Birmingham, Birmingham, AL

Christos Sotiriou

Institut Jules Bordet, Brussels, Belgium

Joseph Sparano

Montefiore Medical Center Albert Einstein College of Medicine New York, NY

Sandi Stanford

Alamo Breast Cancer Foundation, San Antonio, TX

Patrick Sung

UT Health San Antonio, San Antonio, TX

W Fraser Symmans

UT MD Anderson Cancer Center, Houston, TX

Shou-Ching Tang

University of Mississippi, Madison, MS

Melinda Telli

Stanford University School of Medicine, Stanford, CA

Mary Beth Terry

Columbia University, New York, NY

Alastair M. Thompson

Baylor College of Medicine, Houston, TX

Sara M. Tolaney

Dana Farber Cancer Institute, Boston, MA

Debasish (Debu) Tripathy

UT MD Anderson Cancer Center, Houston, TX

Nicholas Turner

The Royal Marsden Hospital, London, United Kingdom

Naoto Ueno

UT MD Anderson Cancer Center, Houston, TX

Ratna Vadlamudi

UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX

Ines-Maria Vaz-Duarte-Luis

Institut Gustave Roussy, Villejuif, France

Nikhil Wagle

Dana Farber Cancer Institute, Boston, MA

Wendy A. Woodward

UT MD Anderson Cancer Center, Houston, TX

Douglas Yee

Masonic Cancer Center, Minneapolis, MN

Richard Zellars

Indiana University School of Medicine, Indianapolis, IN

Xiang Zhang


Baylor College of Medicine, Houston, TX

2022 SABCS EXHIBITORS

2Unstoppable	T8	Merck & Co., Inc.	734, 907
American Association for Cancer Research.	1011	Merit Oncology	1016
Aarnet Pty	635	Metavivor Research and Support, Inc.	T9
Alamo Breast Cancer Foundation	920	Mylan Institutional LLC, A Viatris Company.	1020
Agendia, Inc	513	Myriad Genetics.	1001
Agilent Technologies.	733	Natera	629
Angle Europe Limited	929	Nejm Group	103
Arvinas, Inc	1031	NeoGenomics Laboratories	816
AstraZeneca	607	Novartis	521, 601, 723
Biocept	T11	OBI Pharma USA, Inc.	822
Biofluidica	426	Olink Proteomics, Inc.	906
Biotheranostics, A Hologic Company.	801	OPIS.	922
Bostongene	107	Organon & Co..	729
Caris Life Sciences	901	Outcomes4me	T7
Daiichi Sankyo	100	Oxford University Press	430
DAVA Oncology.	1032	Paige	814
Delphinus Medical Technologies Inc	T2	Paxman USA Inc	720
Dignitana	429	Pfizer	501, 507
Dilon Technologies	830	Physicians' Education Resource	825
Eisai	406, 422	Pillar Biosciences	821
Elsevier	T6	The Pink Fund	T10
Encore Medical Education LLC	1007	Pink Warrior Advocates	T12
Epic Sciences	529	Preludedx	105
Exact Sciences	613	Puma Biotechnology.	1027
Fresenius Kabi USA, LLC	915	Seagen Inc.	102, 421
GE Healthcare.	701	Sermonix Pharmaceuticals.	307
Gencove	828	Simbiosys, Inc.	823
Genentech	815	SiParadigm	T13
Gilead Sciences.	407, 401	Society of Surgical Oncology (SSO)	1028
Global Breast Cancer Conference.	924	Spectrum Pharmaceuticals, Inc.	1014
Guardant Health	921	StatLab	732
Harborside Press	T3	Survivingbreastcancer.org	433
Labcorp Oncology	T4	Tempus.	807
Lilly	201, 207, 301, 715	Tersera Therapeutics	428
Lumicell, Inc	625	The Pink Fund	T10
MacroGenics, Inc.	832	Translational Research in Oncology	717
MD Anderson Cancer Center.	621	Varis Health	T14
Medidata	633	Veracyte	724
Memorial Healthcare System	T5	Veru Inc.	829
Menarini Silicon Biosystems	722	Zeiss	431
Menarini Stemline	414	Zero Gravity	910



2022 SABCS EXHIBITORS FLOORPLAN



2022 INDUSTRY, FOUNDATION AND AGENCY SUPPORT

We are proud to acknowledge the following for their contributions to and generous support of our program.

Executive



Premier



Angel



Patron



Major Supporters

Caris Life Sciences
 Clinical Care Options, LLC
 Epic Sciences
 GE Healthcare
 Myriad Genetics
 Natera
 Puma Biotechnology
 Research To Practice
 Tempus
 Veru Inc.

Contributors

Angle Europe Limited
 Arvinas, Inc.
 Eisai
 Fresenius Kabi USA, LLC
 Guardant Health
 Lumicell, Inc.
 Mylan Institutional, A
 Viatris Company
 NeoGenomics Laboratories
 OBI Pharma USA, Inc.
 Oxford University Press
 Physicians' Education
 Resource

Donors

Aarnet Pty
 Agilent Technologies
 American Association
 for Cancer Research
 Biofluidica

Bostongene
 DAVA Oncology
 Digniatana
 Dilon Technologies
 Gencove
 Global Breast Cancer
 Conference
 Greenwich Lifesciences, Inc.
 MacroGenics, Inc.
 MD Anderson Cancer Center
 Medidata
 Menarini Silicon Biosystems
 Merit Oncology
 NEJM Group
 Olink Proteomics, Inc.
 OPIS
 Organon & Co.
 Oxford University Press
 Paige
 Paxman USA Inc.
 PVI, PeerView Institute
 for Medical Education
 Pillar Biosciences
 Preludedx
 Sermonix Pharmaceuticals
 Simbiosys, Inc.
 Society of Nuclear Medicine
 and Molecular Imaging
 Spectrum
 Pharmaceuticals, Inc.
 StatLab
 Survivingbreastcancer.org

Tersera Therapeutics
 Translational Research
 in Oncology
 Veracyte
 Zeiss
 Zero Gravity

Friend

2Unstoppable
 Alamo Breast Cancer
 Foundation
 Biocept
 Blueprint Medicines
 Certis Oncology Solutions
 Delphinus Medical
 Technologies Inc
 Elsevier
 Encore Medical Education, LLC
 Greenwich LifeSciences, Inc.
 Harborside Press
 Labcorp Oncology
 LECANCER.FR
 Mersana Therapeutics, Inc.
 Metavivor Research
 and Support, Inc
 Outcomes4me
 The Pink Fund
 Pink Warrior Advocates
 SiParadigm
 Society of Surgical Oncology
 Survivingbreastcancer.org
 Varis Health

SABCS gratefully acknowledges

Lilly for support of the **Patient Advocate Lounge**.

This activity is supported by education grants provided by

AstraZeneca
Daiichi-Sankyo
Eisai
Genentech
Gilead
Lilly
Novartis

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

NOW APPROVED ACROSS MULTIPLE INDICATIONS

See how ENHERTU is transforming the treatment landscape

Explore the latest data at
booths 100 & 607 and [ENHERTUhcp.com](https://www.enherthu.com)



Please see Important Safety Information and full Prescribing Information, including Boxed WARNINGS for Interstitial Lung Disease/Pneumonitis and Embryo-Fetal Toxicity, and Medication Guide at booths 100 & 607, at [ENHERTUhcp.com](https://www.enherthu.com), or by scanning here.

 **ENHERTU**[®]
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE

 Daiichi-Sankyo

| AstraZeneca 

ENHERTU[®] is a registered trademark of Daiichi Sankyo Company, Limited.
© 2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-ENB-2049 10/22

